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Zusammenfassung 
 
Im Rahmen dieser Dissertation sollten Naturstoffe und davon abgeleitete Derivate synthetisiert und 
im Hinblick auf ihre biologische Aktivität als Protease-Inhibitoren untersucht werden. 
Für die Naturstoffklasse der 3-Amino-6-Hydroxy-2-piperidon(Ahp)-Cyclodepsipeptide, die als nicht-
kovalente Serin-Protease-Inhibitoren bekannt sind, konnte eine Festphasensynthese basierend auf 
einem allgemeinen Ahp-Vorläufermolekül entwickelt werden. Für den Ahp-Vorläufer wurde eine 
Lösungssynthese entwickelt. Die Festphasenstrategie ermöglicht die Synthese maßgeschneiderter 
Ahp-Cyclodepsipeptide; sie beinhaltet eine Veresterung an der festen Phase, sowie eine Festphasen-
Macrolaktamisierung und etabliert ein neues Protokoll zur Generierung eines Aldehyds bei 
Abspaltung von der festen Phase. Zur Überprüfung der neu-entwickelten Strategie wurde der 
Chymotrypsin-Inhibitor Symplocamide A erfolgreich an der festen Phase synthetisiert und im 
Anschluss auf seine biologische Aktivität hin untersucht. 
Mit Symplocamide A als der Leitstruktur wurden vereinfachte Analoga von Ahp-Cyclodepsipeptiden 
synthetisiert, um zu überprüfen ob diese Analoga, wie die Ahp-Cyclodepsipeptide auch, die 
sogenannte kanonische Konformation einnehmen. Die kanonische Konformation wurde zuerst in 
proteinogenen Serinprotease-Inhibitoren beobachtet und studiert. Kürzlich wurden auch peptidische 
Analoga dieser Inhibitoren untersucht und ein Zusammenhang mit den Ahp-Cyclodepsipeptiden 
erkannt, welche ebenfalls durch die Einnahme der kanonischen Konformation inhibieren.  
Im Rahmen dieser Dissertation war es möglich zu zeigen, dass die Ahp-Einheit unter Retention der 
biologischen Aktivität durch kommerziell erhältliche Aminosäuren ersetzt werden kann. Mittels 
Struktur-Wirkungsuntersuchungen konnten zudem die kritischen Determinanten zur Einnahme der 
kanonischen Konformation bestimmt, sowie ein Einblick in die molekulare Grundlage einer 
effizienten Inhibition gewonnen werden. 
Für den Naturstoff Symplostatin 4 wurde eine konvergente Lösungssynthese entwickelt, die einen 
flexiblen Zugang zu modifizierten Derivaten ermöglichte. Speziell die Synthese von Sonden für die 
Untersuchung von Symplostatin 4 mittels aktivitätsbasiertem Proteinprofiling war durch eine 1,3-
dipolare Huisgen-Cycloaddition von propargyl-modifizierten Spezies mit Azid-modifizierten 
Reportermolekülen vereinfacht möglich.  
Durch aktivitätsbasiertes Profiling konnten mit den Cystein-Proteasen RD21A und RD21B die 
Zielenzyme von Symplostatin 4 in der Modellpflanze Arabidopsis thaliana identifiziert werden. 
Desweiteren wurde die anti-Malaria-Aktivität, die für das chemisch identische Gallinamide A 
publiziert worden war, für Symplostatin 4 und seine Derivate studiert. Im Rahmen von 
Untersuchungen mit dem Malariaerreger Plasmodium falciparum konnte festgestellt werden, dass 
Symplostatin 4 ein nanomolarer Inhibitor der Cystein-Proteasen Falcipain 2 und 3 ist, die für den 
Hemoglobinverdau zuständig sind und als wichtige Zielenzyme einer alternativen Malaria-
Chemotherapie betrachtet werden. 
 i 
Diese Arbeit wurde in der Zeit von Oktober 2007 bis Juni 2011 am Chemical Genomics 
Centre der Max-Planck-Gesellschaft und in der Zeit von Juni 2011 bis März 2012 am Zentrum 
für Medizinische Biotechnologie der Universität Duisburg-Essen angefertigt.  
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1 Introduction 
 
Bioactive substances isolated from natural sources have a long history as therapeutic 
agents[1] In the search for new pharmacophores, natural products have been and still are a 
rich inspirational source, contributing to the development of new drugs.[2] Their significance 
stems from their biologically pre-validated structures owing to their natural origin: during 
their biosynthesis, natural products are required to interact with different enzymes along an 
assembly line; the functionalities or molecular structures used for these interactions 
potentially also address other protein domains regarding the limited number of protein 
folds. Furthermore, the structures of natural products have evolved to display potent 
bioactivities either within their originating species or across species.[3,4] Consequently, these 
properties turn natural products into ideal lead structures for medicinal chemistry research.  
 
In chemical biology, natural products and natural product-derived compounds are valuable 
tools for the investigation of biomolecules and their biological function. Alternatively, the 
identification of the molecular basis (i. e. elucidation of the direct binding target of a small 
molecule) for a bioactivity is a challenging question. Both aspects have been addressed in 
the present dissertation. 
1.1 Proteases and protease inhibitors 
 
Proteolytic enzymes, also referred to as peptidases, proteases or proteinases, are important 
enzymes that are involved in innumerable vital processes. They belong to the superfamily of 
hydrolases and their biological function is to catalyze the hydrolysis or the formation of 
peptide bonds. The breakdown of a peptide bond is the major function of proteases, 
although the reverse reaction, i. e. the formation of a peptide bond, is catalyzed as well. The 
cleavage of a peptide bond is effected by the addition of water to the peptide bond, 
resulting in the hydrolysis of the peptide or protein into an acid and an amine part.  
Although the hydrolysis of a peptide bond is favored thermodynamically, the partial double 
bond character of a peptide bond lowers the electrophilic character of the carbonyl group 
and thereby prevents hydrolysis under physiological conditions. Instead, enzyme catalysis is 
required to achieve peptide bond hydrolysis.[5] The enzyme-mediated cleavage is achieved 
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by a nucleophilic attack on the carbonyl carbon of the scissile bond, either from the active 
site residue of the protease or from an enzymatically-activated water molecule.[6,7] 
The molecular interaction of a protease with a substrate or inhibitor is described by the 
Schechter-Berger nomenclature[8]. The subsites of the protease N-terminal to the scissile 
bond (non-primed side) are numbered S1 to Sn; on the C-terminal side (primed side) they are 
numbered S1’ to Sn’. The corresponding amino acid residues of the substrate are numbered 
P1 to Pn and P1’ to Pn’ respectively (Fig. 1). The specificity as well as the strength of the 
interaction are different for every protease; they are determined by the interaction of the 
subsites with the substrate.[9] 
 
 
 
Figure 1 (adapted from [9]): Schematic representation of the interaction of a protease with a peptidic substrate 
or an inhibitor. 
 
Proteases were initially classified into endopeptidases, targeting internal peptide bonds, and 
exopeptidases with either carboxypeptidase (i. e. cleavage from the C-terminus of their 
substrate) or aminopeptidase (i. e. cleavage from the N-terminus of their substrate) activity. 
This classification is complemented by an alternative classification based on structural and 
mechanistic considerations. As a result, proteases are subdivided by their catalytically active 
amino acids and nowadays six classes of proteases are known: aspartic, glutamic and 
metalloproteases as well as cysteine, threonine and serine proteases; glutamic proteases 
have so far not been found in mammals. In cysteine, threonine and serine proteases, the 
eponymous active site amino acid is directly involved in the nucleophilic attack on the 
carbonyl group. Consequently, these proteases act via a covalent catalysis mechanism. 
Aspartic, glutamic and metalloproteases on the other hand mediate hydrolysis by a general 
acid-base catalysis mechanism, causing the nucleophilic attack by an activated water 
molecule (Fig. 2).[7,10] 
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Figure 2[10]: Different tetrahedral intermediates formed during the cleavage of a peptide bond via covalent 
catalysis or general acid-base catalysis.  
 
In the MEROPS classification of proteases, protease classes are further divided into different 
families on the basis of bioinformatic comparison of their amino acid sequences; this 
alignment results in a categorization of proteases into clans and families based on 
similarities in their three-dimensional structure and the order of the catalytic residues as 
well as phylogenetic similarities.[11] 
Originally, research on proteases focused mainly on their digestive function where they act 
as non-specific protein-degrading enzymes to supply an organism with amino acids.[7] This 
restricted view has however changed dramatically in the last decades when proteases were 
recognized as key players in numerous vital processes. For example, protease signaling 
pathways are crucial elements in various physiological processes and are therefore strictly 
regulated. Moreover, many pathogenic states have been traced back to the dysfunction or 
misregulation of proteases, leading to a wide range of diseases such as cardiovascular or 
inflammatory disorders, osteoporosis, metastasis formation in cancer and even neurological 
pathologies such as Alzheimer´s disease. Due to the critical role of proteases in these vital 
processes, proteases have consequently been recognized as important drug targets.[7,9]  
The important role of proteases in biology is further emphasized by genomic analyses of 
various organisms. These studies have revealed that 2-4% of a genome generally encodes 
proteolytic enzymes. In humans, around 2% of the genome encodes for proteases, 
corresponding to a total number of 500 to 600 proteases.[9,12] To date, the MEROPS database 
as the central inventory of known proteases lists 686 different proteases for Homo sapiens 
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and 423 homologs that have been characterized biochemically (December 2011).[11] Of note, 
approximately 14% of the known human proteases were under investigation as drug targets 
in 2001 and recent estimations testify that 5 to 10% of all pharmaceutical targets pursued 
for drug discovery are indeed proteases.[10,13] 
  
Introduction 
5 
1.2 Serine proteases and the S1 family 
 
Among the different classes of proteolytic enzymes, the serine proteases play the most 
prominent role as over one third of all known proteases are serine proteases. To date, over 
26000 serine proteases grouped into 13 different clans and 40 families are represented in 
the MEROPS database (for an overview, see Table 1). 
 
Table 1: general properties of serine proteases (adapted from [12,14]) 
Clan Number  
of families 
Representative member Fold Catalytic residues 
PA(S) 12* trypsin Greek-key β-barrels His, Asp, Ser 
SB 2 subtilisin 3-layer sandwich Asp, His, Ser 
SC 2 prolyl oligopeptidase α/β hydrolase Ser, Asp, His 
SE 6 D-Ala-D-Ala carboxypeptidase α-helical bundle Ser, Lys 
SF 3 LexA peptidase all β Ser, Lys/His 
SH 2 cytomegalovirus assemblin α/β barrel His, Ser, His 
SJ 1 Lon peptidase α + β Ser, Lys 
SK 2 Clp peptidase αβ Ser, His, Asp 
SP 3 nucleoporin all β His, Ser 
SQ 1 aminopeptidase DmpA 4-layer sandwich Ser 
SR 1 lactoferrin 3-layer sandwich Lys, Ser 
SS 14 L,D-carboxypeptidase β-sheet + β-barrel Ser, Glu, His 
ST 5 rhomboid α-barrel His, Ser 
* 7 additional families of viral origin in clan PA use a catalytic Cys 
 
In serine proteases, the eponymous serine residue acts as nucleophile during the hydrolysis 
reaction. The nucleophilicity of the catalytically active serine is enhanced by an interaction 
with one or two additional amino acids. These specific arrangements are known as catalytic 
triads (in case of two other amino acids) or dyads (if only one other amino acid is directly 
involved). The most prominent catalytic triad is the Asp, His, Ser combination, which is also 
referred to as the charge relay system. Four different three-dimensional folds have been 
found to exhibit this identical arrangement of catalytic residues. Remarkably, these folds 
have originated from four different evolutionary pathways yielding exactly the same 
mechanism of catalysis which is an astonishing example for a convergent evolution. The 
prominent examples for the four different folds are: trypsin, subtilisin, prolyl oligopeptidase 
and Clp peptidase.[12,14] 
The underlying catalysis mechanism of the catalytic triad was first elucidated for 
chymotrypsin (clan PA, Fig. 3), but could later also be confirmed in other proteases by 
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crystallographic analyses. In the first step of the cleavage reaction the carbonyl carbon of the 
cleavable peptide bond is attacked by the activated Ser-195 residue, resulting in the 
formation of a covalent tetrahedral intermediate (1). This instable intermediate then forms 
an acyl-enzyme intermediate under cleavage of the peptide bond. This reaction is mediated 
by the Asp-102-polarized His-57, which acts as an acid in this step (2). Subsequently, the 
amine cleavage product associated with His-57 is exchanged for a water molecule. His-57 
now acts as a base and activates the water molecule for the nucleophilic attack of the acyl-
Ser-195 intermediate, which results in the formation of a second tetrahedral intermediate 
(3). The final step of the catalysis cycle is the liberation of the C-terminal cleavage product 
along with the recovery of the active enzyme (4) (Fig. 3). It should be noted that serine 
proteases not only mediate catalysis via the described covalent catalysis mechanism. 
Moreover, also transition state catalysis plays a major role. To this end, the backbone 
hydrogens of Ser-195 and the adjacent Gly-193 form an oxyanion hole which stabilizes the 
tetrahedral intermediate (and thus lowers the corresponding transition state 
energetically).[15] 
  
Introduction 
7 
 
 
Figure 3 (adapted from[15]): Schematic representation of the peptide cleavage mediated by the Asp-His-Ser 
catalytic triad.  
 
Besides the described catalytic triad, other serine proteases achieve hydrolysis  by using 
simpler catalytic dyad system, in which the active site serine is accompanied by a lysine or a 
histidine residue. Additionally, recent investigations have identified catalytic triads that 
feature unconventional arrangements of active site residues. For example, a pair of 
histidines along with the active site serine has been found as a catalytic triad system in some 
proteases (Table 1).  
Among the serine proteases, the S1 family (serine proteases with the “classical” 
chymotrypsin fold) of clan PA (MEROPS classification, also sometimes referred to as “S”), 
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plays by far the most prominent role in eukaryotic organisms. In fact, of the 699 known 
human proteases, 178 are serine proteases and 138 of those are S1 proteases (Fig. 4).[12,14] 
 
 
 
Figure 4[14]: Overview on the diversity of proteases in the human degradome. Only 4 families of proteases 
underwent a significant gene duplication and diversification. The S1 family represents the largest homologous 
group. 
 
A comparison of the diversity of proteases from different organisms reveals that the S1 
proteases have obviously emerged from the evolutionary selection process to become key 
players in intra- and extracellular processes as their diversity strongly increases with 
evolutionary development. While lower organisms seem to have reacted to natural selection 
by developing novel mechanisms of proteolysis resulting in a wide variety of protease 
families and novel catalytic mechanisms, this variation is much lower in higher metazoa. 
Instead, the diversity of proteases increased, in particular for S1 serine proteases. (Fig. 5) 
This pinpoints that S1 serine proteases are evolutionary validated to overtake a wide range 
of biological functions. As a consequence, S1 serine proteases display an unusually high 
proteolytic diversity.[16] 
In fact, the high abundance of S1 proteases, alongside with the key roles they have taken in 
eukaryotic organisms, implies a selective advantage of the chymotrypsin-fold compared to 
other protease folds. The trypsin-like proteases have emerged from the evolutionary process 
as chief proteases, most probably due to their efficient catalytic activity, substrate selectivity 
and the efficient interaction with auxiliary protein modules to achieve a regulation of the 
proteolytic activity.[12]  
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Figure 5[16]: Landscape representation of protease diversity in eukaryotic, eubacterial and archeal genomes. 
The distribution of 154 peptidase families from the different catalytic classes (aspartic (A), cysteine (C), metallo 
(M), threonine (T), serine (S) and mixed (P); x-axis)) was quantified for 128 complete genomes. Over 2 million 
protein sequences from eubacteria (Bac), archaea (Arc), plants (Pla), lower eukarya (Euk), yeasts (Yea), 
protostomes (Pro) and deuterostomes (Deu) (ordered along the z-axis) contained more than 38000 proteases.  
 
On a structural level, all S1 serine proteases adopt the so-called chymotrypsin fold. A 
remarkable feature of this fold is the even distribution of the catalytically active amino acids 
over the peptide sequence. The two β-barrels constituting the fold host the active pocket at 
their interface. Asp-102 and His-57 are located within the N-terminal β-barrel, Ser-195 and 
the oxyanion hole (Ser-195, Gly-193) are found within the C-terminal β-barrel.  
The substrate specificity of the S1 proteases is determined mainly by the S1 subsite, other 
sites do not enhance selectivity in a significant manner. The trypsin-like proteases have a 
preference for the basic amino acids Lys and Arg in the P1 position, whereas chymotrypsin 
preferentially digest substrates with larger hydrophobic residues such as Phe, Trp or Tyr. 
Although the molecular origin of these different preferences was determined to be a single 
exchange of amino acids within the primary specificity pocket (Asp-189 in trypsins, Ser-189 
in chymotrypsins), attempts to engineer a trypsin into a chymotrypsin protease by carrying 
out this single exchange did not suffice. To obtain at least the desired selectivity, further 
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alterations in loop regions that are not in contact with the substrate are necessary. However, 
despite these additional replacements, a full conversion and comparable enzyme efficiency 
has not been achieved. For the conversions of chymotrypsin to trypsin or of trypsin to 
elastase this strategy to date even failed completely. Consequently, these results indicate 
that the structure-function relation of the trypsin selectivity is not as straightforward as 
often perceived and still requires further investigation.[12] 
The proteases of the chymotrypsin fold (S1) are further classified into two subfamilies: S1A 
(trypsin-like) and S1B: Despite representing two phylogenetically distinct families, both 
subfamilies nevertheless share the common two β-barrel structure. The S1B proteases are 
found ubiquitously and their function usually lies in the intracellular protein turnover. In 
contrast, the S1A proteases often act in the extracellular space, mediating many processes 
crucial to the persistence of an organism. The genomic distribution of the S1A proteases is 
uneven as they are underrepresented in plants, prokarya and archaea; in higher eukarya, 
however, they underwent a significant expansion and overtake innumerous functions. For 
example, the S1A proteases trypsin, chymotrypsin and elastase are endopeptidases heavily 
involved in food digestion. In contrast, the tryptases are the main components in the 
secretory granules of mast cells, being important components of the immune system. The 
matriptases are a family of membrane-bound enzymes with a substrate specificity similar to 
that of trypsin. High expression levels of these enzymes are a hallmark in some cancer types, 
although the biological function of matriptases is still largely unknown. The kallikrein family 
has attracted interest also due to its overexpression in various cancer types; kallikreins are 
involved in the blood coagulation, representing essential elements of the kinin system. 
Finally, granzymes play a role in the defense against viral infection by mediating directed 
apoptosis through natural killer cells and cytotoxic T cells. As a unique feature, granzymes 
have a preference for acidic amino acids in the P1 position.[14] 
A unique trait of trypsin-like proteases is that they are biosynthesized as inactive zymogens 
and are activated by cleavage of a proprotein precursor. Upon cleavage of the propeptide, 
the active conformation is adopted, thereby resulting in an active protease.[9,12] 
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1.3 Proteinaceous serine protease inhibitors and the canonical conformation  
 
Serine proteases represent crucial factors in the maintenance and vitality of eukaryotic 
organisms. Consequently, their enzymatic activity in living organisms is strictly regulated via 
several different control mechanisms. Among them, the secretion of proteinaceous serine 
protease inhibitors plays an important role and several classes of these factors have been 
identified so far.  
The so-called canonical inhibitors are a subclass of these proteinaceous serine protease 
inhibitors. They are usually relatively small proteins ranging from 29 to about 180 amino 
acids in size and their mode of action has been extensively studied in the last decades. Their 
primary feature is an exposed binding loop that binds to the target protease in a substrate-
like manner. The resulting backbone conformation of the binding loop is the eponymous 
canonical conformation and represents the structural basis for protease inhibition. At least 
18 non-homologous families of serine protease inhibitors adopting this conformation have 
been identified so far, thereby representing an outstanding example of convergent 
evolution.[17,18] 
Besides this common feature, the canonical inhibitors are quite diverse in their structure as 
they do not rely on a common folding motif. In fact, extensive studies of different canonical-
conformation inhibitors have revealed that except for the common conformation of the 
binding loop, the inhibitors display quite different folding motifs. Additional, distinct 
structural elements in the vicinity of the binding loops are not required for the interaction 
with the protease.  
On a molecular level, the association of the inhibitor with the protease is effected by binding 
of the reactive-site loops to the enzyme’s catalytic residues in an analogous manner to the 
productive binding of a substrate. To this end, the protein portion on the N-terminal part of 
the protein (in relation to the scissile bond) binds to the enzyme in the form of an 
antiparallel β-strand with main-chain interaction hydrogen bonds forming between the two 
different proteins. On the C-terminal side, other hydrogen bond can be formed (for example 
on position P2’). The reactive site of the inhibitor is positioned closely to the catalytically 
active residues of the protease so that the P1 carbonyl carbon is fixed to the Ser-195-γ-O and 
projects into the oxyanion hole formed by Ser-195 and Gly-193. Interestingly, the scissile 
bond is not cleaved, although for some inhibitor complexes a slight out-of-plane 
deformation of the carbonyl-carbon was observed.  
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Although several of the exposed side chains of the loop regions around the active site (P9 to 
P4’) also interact with the protease, mainly by hydrophobic interactions, the primary 
determinant of binding is the interaction of P1 with the S1 subsite for chymotrypsin-like 
proteases. Alongside, the interactions of the P2, P1’ and P2’ residues with the corresponding, 
more shallow subsites also contribute to specificity, but to a lesser extent. 
The packing at the interface of the complex is very dense, both for the protease as well as 
for the inhibitor and is comparable to the packing in the inside of a protein. In shape, the 
contact areas between native inhibitors and their target proteases are highly 
complementary. Consequently, the formation of the enzyme-inhibitor complex requires only 
slight changes in the conformation of the inhibitor. The high complementarity furthermore 
contributes to a fast association of the inhibitor with the protease to form a tight substrate-
like complex. Overall, the substrate-like binding structure is defined by intra- and 
intermolecular interactions between the inhibitor’s primary binding loop with its core and 
with the enzyme’s binding site; the mutual stabilization of these interactions results in an 
extremely tight binding, so that a cleavage of the inhibitor and subsequent decomposition of 
the complex rarely occurs.[17,19] 
 
1.3.1 Small-molecule analogs of canonical inhibitors 
 
In contrast to the abundant and well-studied proteinaceous serine protease inhibitors, small 
molecule peptidic inhibitors that act via a similar mechanism are rather rare. Some peptidic 
natural product inhibitors of serine proteases have been elucidated as “canonical inhibitors”. 
Moreover, some synthetic peptides have been designed that also act in a similar manner. 
Interestingly, all small molecule “canonical inhibitors” described so far are macrocycles.  
For example, synthetic peptides derived from the reactive site loop of Bowman-Birk type 
inhibitors were developed. These compounds are macrocycles with an average of 11 amino 
acid residues that were arranged via an internal disulfide bridge into a fold that resembles a 
canonical conformation (Fig. 6). Consequently, these synthetic compounds not only retained 
the three-dimensional structure of the active site loop of Bowman-Birk inhibitors but also 
the biological potency of the original proteinaceous structure.[18,20] Investigations were able 
to reveal that the required 9 amino acid core structure (Fig. 6) can be stabilized by 
introduction of one additional amino acid at each terminus of the peptide; resulting in an 
increased potency for these 11-mer peptides.[20] Interestingly, a naturally occurring cyclic 
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peptide inhibitor from sunflower seeds known as sunflower trypsin inhibitor 1 (SFTI-1) also 
incorporates a similar inhibitory motif and has been identified as a canonical inhibitor.  
 
 
Figure 6 (adapted from[20]): The 9-mer core sequence of disulfide-linked peptidic inhibitors derived from BBI. 
Xaa represents any amino acid.  
 
The disulfide bridge formed between the cysteines at P3 and P6’ could also be replaced by a 
D-Pro-L-Pro linkage as enclosure of the core loop structure, yet the activity of these 
derivatives is reduced, due to the loss of potential contacts with the target protease.[20,21] 
The variation of single amino acids within the core structure revealed important structure-
function relations. As expected, the P1 amino acid determines the specificity towards a 
target protease, for instance, inhibitors with a Lys or Arg at this position selectively inhibit 
trypsin. For the 11-mer sequence SCXFSIPPQCY (with F being P1), Thr was found to be the 
optimal P2 amino acid in terms of chymotrypsin inhibition. In a study with trypsin inhibitors 
of the sequence SCTKSXPPQCY (with K being P1), Ile could be determined as optimal P2’ 
residue.  
In a large, combinatorial synthesis-based approach the same consensus sequence for 
chymotrypsin inhibitors could be obtained, additionally, Tyr in P1 position and Nle in the P2’ 
position were selected.[20] 
In conclusion, the P1 residue is the crucial residue in terms of protease selectivity. In the 
canonical conformation it is hyper-exposed for the primary interaction with the target 
protease, this interaction is supposed to be responsible for up to 50% of the total 
intermolecular contacts. In the P2 position, Thr is conserved among the peptidic BBI-derived 
inhibitors, it enhances the stability of the peptide against hydrolysis by forming a hydrogen 
bond with a backbone amide using its side chain hydroxyl group. In the P2’ position Ile is 
widely conserved, contributing to the affinity and also to the hydrolytic stability.[18,22] 
The location of the putative scissile bond for the peptidic inhibitors described before is yet 
determined neither by the primary sequence of the inhibitor nor by the enzyme’s selectivity 
but by the canonical conformation of the backbone which is an inherent feature of this class 
of inhibitors. The pre-arranged backbone is the part of the peptide that is complementary to 
the enzyme’s active site and hyper-exposes the P1 residue to establish the primary contact to 
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the protease. The backbone conformation is enforced by the conserved P3’ Pro and further 
enhanced by another Pro in P4’ position leading to the formation of a cis-amide bond that 
resembles the native-like structure found in BBIs. Although the P4’ Pro has a trans 
conformation, it enhances the formation of a cis-amide bond for the preceding P3’ Pro 
residue. This hypothesis was verified by replacing the P4’ Pro with Ala, which resulted in the 
formation of a 1:1 mixture of slowly exchanging and structurally diverse cis/trans 
isomers.[18,23] Furthermore, the covalent cyclization by a disulfide bridge is required for a 
potent inhibition. 
Interestingly, Leatherbarrow and coworkers found that despite its stubborn conservation 
among the BBI-derived inhibitors the P1’ Ser is not an essential element for the integrity of 
the reactive site loop, although there is an indication from crystal structures, that the side 
chain hydrogen bond is involved in a transannular hydrogen bond with the backbone. An 
NMR study, in which either the P1’ Ser or the putative bonding partner, P5’ Gln, was replaced 
by Ala, indicated clearly that the hydrogen bond formed between P1’ and P5’ is dispensable 
in terms of the overall structure and that the loss of this bond reduces the inhibitory potency 
only marginally.[22] 
Besides the natural product SFTI-1 and the described small molecule inhibitors, some 
depsipeptide inhibitors of bacterial origin are another class of small molecule analogs of 
proteinaceous canonical conformation inhibitors. In these compounds, macrocycles are 
formed via lactonization of the hydroxyl group of the Thr side chain with the acid function of 
another amino acid residue. The overall fold of results in a canonical conformation and 
represents another remarkable example of convergent evolution. A comparison of the 
binding structures of a proteinaceous canonical Bowman-Bork inhibitor (BBI), the designed 
small molecule Bowman-Birk inhibitor mimics, the sunflower-derived small molecule natural 
product inhibitor SFTI-1 and the bacterial cyclodepsipeptides scyptolin A and A90720A 
clearly illustrates the global concept of the canonical conformation as a motif for efficient 
inhibition of serine proteases. Although the “fixation” of the canonical conformation is 
realized in different ways, the same three-dimensional structure is adopted by all compound 
classes (Fig. 7).[18] 
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Figure 7 (adapted from[18]): Structural comparison of plant-derived (A, B) and bacterial macrocyclic (C, D) 
inhibitors isolated from different cyanobacteria. 
A: NMR structure of the synthetic BBI-derived cyclic peptidic elastase inhibitor NleCTTSIPPQCY superimposed 
onto reactive side loop of the Lima bean Bowman-Birk-Inhibitor (black sticks; 1H34); B: NMR structure of SFTI-1 
superimposed onto its binding structure in complex with bovine trypsin (black sticks; 1SFI, 1JBL); C: crystal 
structure (1OKX) of the elastase inhibitor scyptolin A from Scytonema hofmanni in complex with porcine 
pancreatic elastase; D: crystal structure (1TPS) of the trypsin inhibitor A90720A from Microchaete loktakensis in 
complex with bovine trypsin.[18] 
 
1.3.2 The natural product class of 3-amino-6-hydroxy-2-piperidone (Ahp) 
cyclodepsipeptides as protease inhibitors 
 
The cyanobacterial macrocyclic inhibitors containing the unusual 3-amino-6-hydroxy-2-
piperidone (Ahp) unit are a class of natural products that represent potent serine protease 
inhibition. They comprise a growing class of non-toxic, secondary metabolites isolated from 
diverse cyanobacteria such as Microcystis, Anabaena, Oscillatoria, Nostoc, Lyngbya, or 
Symploca spp. and have the remarkable feature of selectively and potently inhibiting S1 
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serine proteases in a non-covalent mode of action. Regarding these remarkable properties it 
is not surprising that this class of natural products has been suggested as a lead for serine 
protease inhibitor design.[24,25] 
To date, two x-ray structures of Ahp cyclodepsipeptides with serine proteases are available. 
In their co-crystallization study of the depsipeptide A90720A with bovine trypsin Clardy and 
coworkers were able to observe the expected substrate-like binding of the inhibitor 
molecule to its target protease trypsin. The substrate-like binding is achieved by steric 
complementarity and hydrophobic interactions; it is further enhanced by the formation of 
hydrogen bonds. The Ahp residue thereby forms two hydrogen bonds within the macrocycle; 
one bond is formed between the Ahp-NH and the lactone carbonyl, the other one is formed 
by the hydroxyl group of the Ahp ring and the valine amide. These two hydrogen bonds are 
proposed to be responsible for the elliptical shape that enables the molecule to adopt the 
canonical conformation and the high rigidity of the inhibitor that further enhances 
binding.[25,26] Rigidity and decreased rotational and conformational degrees of freedom are 
general strategies for efficient enzyme inhibition: an inhibitor that is already restricted in its 
binding conformation does not lose as much entropy upon binding as a comparable 
structure with more degrees of freedom. In these terms, the Ahp unit plays a central role in 
the efficient inhibition mechanism displayed by the Ahp depsipeptides.  
On the non-primed side of the inhibitor, ranging from the P1 residue Arg to the P4 residue 
glyceryl sulfate, several hydrogen bonds are formed with the protease. The P1 arginine 
moiety deeply penetrates into the narrow S1 pocket, where the guanidinium unit forms an 
ion bond/hydrogen bond with the Asp-189 at the bottom of the catalytic site as well as one 
hydrogen bond with the hydroxyl group of Ser-190. In a natural substrate, the carbonyl 
carbon of the arginine that is directly located in the active site would be attacked by the 
hydroxyl group of the catalytically active Ser-195. In the co-crystal structure, however, the 
distance of the arginine carbonyl carbon and the Ser-195 hydroxyl group is extended, 
thereby excluding a nucleophilic attack. The arginine carbonyl oxygen nevertheless is 
hydrogen-bonded to the backbone amides of Gly-193 and Ser-195, thus creating the 
oxyanion hole, just as expected for a natural substrate. Finally, the hydrophobic region of 
A90720A, represented by P2’ Leu and P3’ NMeTyr binds into a hydrophobic pocket of the 
protease. 
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Overall, these interactions lead to a tight, substrate-like binding of the inhibitor. The binding 
interactions are so strong that no dissociation of the inhibitor can occur. The highly 
complementary interaction of the inhibitor and the protease thereby leads to a deep energy 
minimum for the complex, resulting in an elevated activation barrier for the hydrolysis. Even 
if a hydrolysis occurred, the inhibitor fragments cannot dissociate and are held in place by 
the cyclic nature of the molecule and the transannular hydrogen bonds of the Ahp residue. 
Consequently, a restoration of the macrocyclic structure would occur.[26] 
 
 
 
 
Figure 7: The cyanobacterial inhibitor A90720A in complex with bovine trypsin (1TPS).[26] 
Top: Representation of the X-ray structure of A90720A with bovine trypsin, the side chains of the residues 
forming the catalytic triad are shown in pink. Bottom: chemical structure of A90720A; the transannular 
hydrogen bonds formed by the Ahp unit are indicated by dashed bonds.  
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The comparison of the A90720A-trypsin complex with a complex formed by the 
cyanopeptolin scyptolin A[27,28] with elastase pinpoints that all Ahp cyclodepsipeptides share 
a universal mode-of-action. In fact, the structure of scyptolin A with its target protease 
elastase is highly similar and well superimposable to the one observed for the A90720A-
trypsin complex. The different specificity is determined by a leucine residue at the P1 
position instead of the arginine found in A90720A. Besides the interactions of the non-
primed side of the inhibitor with the S1 to S4 subsites of elastase that form an antiparallel β-
sheet structure by main chain hydrogen bonds and the interaction of the P1 leucine carbonyl 
oxygen with the residues forming the oxyanion hole, further hydrogen bonds of the P4 
alanine carbonyl oxygen as well as the P2’ threonine hydroxyl with the protease could be 
observed. In addition, the authors however furthermore noted a conspicuous water 
molecule bound in a perfect tetrahedral conformation by three residues of the inhibitor (i. e. 
the carbonyl oxygen of the S2 threonine, the side chain hydroxyl of P3 threonine and the 
hydroxyl group of the P3’ cmTyr) and the guanidinium amide of Gln-200 from elastase. It has 
been proposed that the binding of this water molecule enhances the overall rigidity of the 
complex. Finally, a further contribution to the overall binding and complementarity of the 
inhibitor with the protease is provided by the accommodation of the butyroyl group as well 
as the chlorine substituent in a hydrophobic environment.  
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Figure 8: The cyanobacterial inhibitor scyptolin A in complex with porcine pancreatic elastase (1OKX).[28] 
Top: Representation of the X-ray structure of scyptolin A with porcine pancreatic elastase, the side chains of 
the residues forming the catalytic triad are shown in pink. Bottom: chemical structure of scyptolin A; the 
transannular hydrogen bonds formed by the Ahp unit are indicated by dashed bonds. 
 
After comparing the overall structure of the scyptolin A-elastase complex (Fig. 8) to other 
inhibitor-elastase complexes, Schulz and coworkers however became aware of another 
striking feature of Ahp cyclodepsipeptides. They recognized that the Ahp unit occupies the 
space within the catalytic pocket in which, in other structures, the water molecule required 
for hydrolysis is located. This emphasizes yet again the crucial contribution of the Ahp 
residue for the inhibitory potency of the Ahp depsipeptides.[28] 
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A superimposition of the scyptolin A complex with the A90720A complex reveals highly 
similar conformations for the 19-membered macrocycles, including the Ahp residue as well 
as the transannular hydrogen bonds (Fig. 9).[29] 
 
 
 
Figure 9: Comparison of the binding structures of A90720A[26] (top) and scyptolin A[28] (bottom) with their 
target proteases.  
The inhibitors as well as the catalytic triad (pink) display a nearly identical conformation for both inhibitor 
molecules.  
 
In summary, analysis of the mode-of-action of Ahp cyclodepsipeptides has revealed that 
they act as canonical conformation inhibitors. The Ahp unit is thereby of particular interest 
and is located in the P1’ position where it overtakes special functions. First, the Ahp residue 
plays a central role for the bioactivity of this inhibitor class by stabilizing the canonical 
conformation via formation of two stabilizing transannular hydrogen bonds. Second, the Ahp 
residue also enhances the potency and selectivity towards distinct proteases by 
accommodation to the S1’ subsite.[18,29] Finally, x-ray analyses have suggested that the Ahp 
unit might play another interesting role. It seems as this residue occupies the space of the 
“catalytic” water molecule that during the enzymatic mechanism mediates the hydrolysis of 
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the acyl-enzyme complex. Consequently, the hydrolytic water is excluded from the enzyme 
which provides an additional protection against a hydrolysis of the inhibitor.[28,29] 
As a consequence of their selective and potent inhibition of S1 serine proteases by a 
remarkable non-covalent mechanism, the Ahp cyclodepsipeptides and have been suggested 
for further investigations in terms of structure-activity relationships and also the wish to 
enable access to modifiable templates has been expressed.[29] Both aspects have indeed 
been part of the work presented in this thesis.  
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1.4 Malaria - a persisting global burden 
 
The complex and devastating disease malaria is still a heavy burden on global population, 
affecting especially the weakest members in the poorest countries of the world. In the year 
2008, 3.3 billion people in 109 countries and territories worldwide were still threatened by a 
malaria infection. It is most devastating in Africa, where malaria represents the second most 
frequent cause of death from an infective disease after HIV/AIDS. In contrast, malaria ranges 
in fifth place worldwide. After abortion of the Global Malaria Eradication campaign (1950s to 
1970s), the interest in this disease has dropped dramatically, despite its enduring presence. 
Only in 1998, after the numbers of malaria cases and deaths had multiplied, the Roll Back 
Malaria partnership was initiated by the World Health Organization (WHO), the United 
Nations Children´s Emergency Fund (UNICEF), the United Nations Development Programme 
(UNDP) and the World Bank to coordinate malaria control and treatment globally.[30] As a 
consequence of this concerted action the number of malaria cases worldwide could be 
reduced from 233 million in 2000 to 225 million (176 million in Africa) in 2009. The number 
of deaths was also reduced from nearly one million in 2000 to 781000 in 2009.  
The primary measure to take control of malaria and in long-term eliminate malaria 
completely is vector control, i. e. elimination of the mosquitos transmitting the parasite, and 
thereby preventing the infection and reinfection with malaria. The individual protection 
against mosquito bites is in this circumstance the first line of defense, enforced by 
distribution of insecticide-treated nets (ITNs) under which, in the ideal case, every individual 
in high-risk areas should sleep every night. Besides providing these safety measures, it is of 
course also of great importance to instruct the local population to a correct and most 
importantly regular use of the provided nets.  
The second approach to prevent transmission is indoor residual spraying (IRS) with 
insecticides, a measure which enables rapid elimination of transmission. The full potential of 
IRS is achieved when 80% or more of all households and animal shelters within a community 
are treated.  
Another measure that is undertaken to prevent the transmission of malaria is the 
intermittent preventive treatment of pregnant women at risk in sub-Saharan Africa, as well 
as preventive treatment of infants at risk in sub-Saharan Africa.[31,32] 
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Despite these protective measures, an infection with malaria currently cannot be prevented 
completely. Consequently, chemotherapeutics for treatment of malaria disease represent 
another important component to reduce the global burden of malaria.  
 
1.4.1 Plasmodium species as the causing agents of malaria in humans 
 
Malaria in humans is caused by 5 different species of Plasmodium parasites which are 
transmitted by the bites of female Anopheles mosquitos, the so-called malaria vectors. 
Plasmodium falciparum, which is spread in tropical regions, is by far the most common and 
also most deadly of the five species. It is responsible for the majority of malaria-related 
fatalities in sub-Saharan Africa and thereby the main target of malaria control. Infections 
with Plasmodium vivax, common in most of Asia, the Eastern Mediterranean and the 
endemic countries in the Americas, are responsible for 25 to 40% of worldwide malaria 
cases, although the infection usually does not progress as severe as by P. falciparum 
infection; on the other hand, P. vivax infection can cause relapses and a treatment of the 
infection should therefore also focus on preventing relapses. Additionally, it has been 
reported that the host inflammatory response upon P. vivax infection is higher than upon 
P. falciparum infection at comparable levels of parasitemia.[33] The number of infections 
caused by P. malariae and P. ovale are rather small and these infections also progress in an 
uncomplicated manner, comparable to P. vivax in most cases. Only recently a fifth species, 
P. knowlesi, known to cause malaria in monkeys, has also been reported to cause human 
malaria. [30,32] 
All Plasmodium species have complex life cycles that differ slightly between the different 
species. The parasite is transmitted in the sporozoite form to the human blood cycle with 
the saliva of female Anopheles mosquitos. From there, the sporozoites are rapidly taken up 
by the liver where they infect the hepatocytes. At this stage differences between the 
different Plasmodium species occur. P. falciparum and P. malariae progress rapidly through 
the hepatocytes, replicating asexually via a schizont state and re-enter the blood cycle after 
the rupture of the hepatocytes as haploid merozoites. In the case of P. vivax or P. ovale 
infections, a certain part of the infected hepatocytes become dormant hypnozoites which 
can be reactivated without a repeated infection after different time periods ranging from 3 
weeks to several years, causing a relapse of the disease. In all cases, the merozoites then 
infect red blood cells (RBCs), progressing from the ring-stage via the trophozoite stage that 
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exhibits a nucleus and a digestive vacuole and then entering asexual replication within the 
erythrocytes until the rupture of the schizont. The egress from the schizont sets free a large 
number of merozoites which can again invade RBCs and increase the parasite´s biomass with 
every replication cycle (Fig. 10). 
 
 
 
Figure 10 (adapted from[33]): The life cycle of the malaria parasite. The major differences between the different 
Plasmodium spp. are indicated by red boxes. 
 
During the replication in the RBCs, the parasites process hemoglobin in an acidic food 
vacuole to nurture from the amino acids and peptides originating from this digestion. The 
digestion of hemoglobin also produces heme, a toxic side product, which is on the one hand 
related to symptoms caused during a malaria infection, but on the other hand also an entry 
to the treatment of malaria; this point will be discussed in the following section.  
The rupture of the red blood cells and the liberation of parasital toxins and the host’s 
inflammatory response then cause the typical symptoms of malaria such as fever, headache 
and chills, more severe infections can also result in anemia or cerebral malaria in the case of 
P. falciparum infection. The times between these febrile paroxysms can vary between the 
Plasmodium spp. and represent the replication times of the parasites. The replication time of 
P. falciparum and P. vivax is 48 hours, whereas the cycle of P. malariae is longer (72 hours). 
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The newly discovered P. knowlesi has a very low replication time of only 24 hours and could 
progress to a life-threating infection even at low parasitemia rates if it remains untreated.[33] 
To progress the parasites’ development, some of the merozoites differentiate and develop 
into male and female gametocytes which are able to undergo a sexual replication cycle once 
taken up by a mosquito during a blood meal. The point of time at which gametocytes appear 
is yet another key difference between P. falciparum and P. vivax. In a P. vivax infection, 
gametocytes can appear simultaneously with the asexual stages or even before those. In 
contrast to this, for a P. falciparum infection gametocytes are observed only at late stages of 
the infection (Fig. 10).  
Once taken up by the mosquito during a blood meal, the male gametocytes are activated to 
form gametes which then fuse with the female gametocytes thereby forming diploid 
ookinetes. The ookinetes can then migrate to the midgut of the mosquito and, after passing 
the cell wall, form into oocysts. By meiotic division sporozoites are formed which, after 
liberation, migrate to the salivary glands of the mosquito to be transmitted to a host again 
during a blood meal (Fig.10).[33] 
Finally, it should be noted that when treating P. falciparum or P. vivax infections the 
differences between the species should be considered. A P. vivax infection rather demands 
for an elimination of the gametocytes rather than an inhibition of differentiation. 
Although P. falciparum malaria is often accounted for as the form of malaria causing more 
severe cases of infection; P. vivax can also cause severe disease progressions that become 
life-threatening.[34,35] Severe P. falciparum malaria shows various clinical symptoms ranging 
from an initial high fever, over progressing anemia to multiorgan dysfunction and 
unconsciousness or coma which is a sign of cerebral malaria. This severe etiopathology is 
determined by various factors that originate from the parasite itself as well as from the host 
organism. Overall, a malaria infection is a complex process with many different events 
cumulating to a severe outcome of the infection.[34,36]  
When comparing P. falciparum and P. vivax malaria infections, a greater inflammatory 
response is observed for the P. vivax infection. This infection has been found to cause higher 
fevers at comparable levels of parasitemia; i. e. the pyrogenic threshold of P. vivax is higher 
than that of P. falciparum. In general, a P. vivax infection does not lead to as high 
parasitemia as observed for P. falciparum; nevertheless at comparable or even higher levels 
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of P. falciparum, a P. vivax infection causes a greater inflammatory response, related to a 
higher level of cytokines.[35] 
 
1.4.2 Antimalarial drugs and their mode of action 
 
The first drug that was used to treat malaria was quinine, which could be isolated from the 
bark of Cinchona calisaya as early as 1632. Until the 19th century it was the only drug known 
to cure malaria. After World War I, synthetic derivatives of quinine were developed. First, 
primaquine and quinacrine came to the market and finally chloroquine was introduced in 
1934. By 1946, chloroquine had become the preferred anti-malarial drug, overcoming the 
undesired adverse effects of quinine.[33,37] 
Quinine and its derivatives are potent schizonticides, eliminating exclusively the asexual 
blood stages of the parasite. Their mode of action is the interference in the deposition of the 
toxic heme to insoluble hemozoin. The parasites dispose of the toxic metabolite formed 
upon hemoglobin digestion by polymerizing the heme to form crystalline hemozoin, which is 
also referred to as malaria pigment and can be visualized by simple microscopy. By 
interfering with this process, the parasite is intoxicated and killed by its own metabolic 
products. Evidence for the proposed interference in heme detoxification is provided by the 
finding that chloroquine and related drugs act stage-specific, killing only those parasites that 
digest hemoglobin. Morphologically, the effect of a quinoline therapy is accompanied by a 
significant swelling of the food vacuole (food vacuole defect) caused by the 
hyperconcentration of heme.[38,39] Interestingly, the mechanism of this heme detoxification 
is still unclear and different polymerization scenarios have been discussed.[40,41] 
On the other hand the formation of hemozoin by a crystallization process in a hydrophobic 
environment by a biomineralization process has been suggested and is accepted today as 
the most probable mechanism for heme detoxification.[39] 
Mutations of the parasite however lead to chloroquine resistance due to reduced take-up of 
the drug to the digestive food vacuole. The underlying mechanism of resistance is not yet 
fully understood, although there is strong evidence that mutations in the gene encoding for 
Plasmodium falciparum chloroquine resistance-related transporter protein (PfCRT) as well as 
mutations in the Plasmodium falciparum multidrug resistance (pfmdr1) gene are key 
players.[37] For P. vivax, a resistance to chloroquine was reported as late as 1989, compared 
to the first evidence for resistant P. falciparum in 1957.[42] 
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Figure 11: Antimalarial drugs currently in use to treat malaria infections (selection from[33]). A: Artemisinin and 
derivatives; B: Quinine and quinine derivatives, some of the drugs are used for ACT; C: combination drugs used 
mostly as preventive therapy; D: drugs recommended for treatment of P. vivax, effective in hypnozoite 
elimination. 
 
In another approach, rational design of inhibitors targeting the essential folate production of 
the parasite is pursued. The malaria parasites are not able to salvage folate and depend on 
synthesizing it de novo, as it is required for the synthesis of tetrahydrofolate, the co-factor 
needed for methylation reactions. The two drugs emerging from this design were 
sulfadoxine, inhibiting dihydropteroate synthetase (DHPS) and pyrimethamine which inhibits 
dihydrofolate reductase (DHFR). Both drugs interfere effectively in the synthesis of 
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dihydrofolate, an important intermediate in the synthesis of tetrahydrofolate. The best 
effect is achieved when they are used as sulfadoxine-pyrimethamine (SP) combination. In 
the second half of the 20th century, SP was used as second line treatment following 
chloroquine treatment for acute, uncomplicated infections caused by all 4 Plasmodium 
spp..[33,40] With evolving chloroquine resistance, SP replaced the former as first-line 
treatment in Thailand and 10 African countries.[43] Today, SP therapy is used and 
recommended for intermittent preventive treatment of pregnant women and infants in 
moderate to high risk regions of sub-Saharan Africa.[31] Unfortunately, SP resistance occurred 
very quickly after its introduction, the mutations leading to the drug resistance are well 
described.[43] 
Especially the appearance of chloroquine resistant strains was a major drawback in the 
battle against malaria. Intensive research was conducted to find replacements for 
chloroquine, which lead to the discovery of the chloroquine-derived drugs such as 
piperaquine, mefloquine, amodiaquine and lumefantrine that were all active against the 
chloroquine-resistant strains and acted by the same mechanism as chloroquine. 
Unfortunately, resistances to these new drugs appeared rapidly after their introduction and 
their utilization as first line treatment. 
A new era of malaria treatment commenced with the (re)discovery of artemisinin 
(Quinghaosu) by Chinese researchers in 1972. Artemisinin is isolated from the leaves of 
Artemisia annua and has been known to traditional Chinese medicine for over 2000 years; its 
use as antimalarial agent was described in the fourth century for the first time. Chemically, 
artemisinin is a sesquiterpene featuring an unusual endoperoxide bridge. The main 
metabolite of artemisinin is the lactole dihydroartemisinin (DHA); derivatives like 
arthemether, artemotil and artesunate are esterified derivatives of DHA. Artemisinin as well 
as its derivatives are active against all drug-resistant strains of P. falciparum, killing all blood 
stages of the parasite, thereby leading to the shortest fever clearance times of all 
antimalarials. Besides the broad range against all blood stages of the parasite, the synthetic 
derivatives also possess an excellent safety profile. Furthermore, artemisinins help to reduce 
transmission as they are also active against the gametocytes, both immature and 
developing.[33,44] 
There is no consensus on the mode of action of artemisinins. It has been reported that the 
toxicity to the parasite at nanomolar concentrations is based on an enhanced uptake of the 
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metabolite DHA in infected RBCs. Indeed, infected RBCs seem to take up more than 100-fold 
higher concentrations of DHA than uninfected RBCs. Concerning their mode of action, there 
is strong evidence that the artemisinins act by generating free radicals that damage the 
parasite cells. The alkylation of proteins by the electrophilic species generated in artemisinin 
decomposition most probably accounts for the potency of the drug. Besides the effects in 
the food vacuole, other cell organelles of the parasites are damaged as well by artemisinins: 
effects on the mitochondria, rough endoplasmatic reticulum and the nuclear envelope have 
been observed.[45] The very effective two-way mechanism of artemisinin proceeding via an 
activation within the parasite to free radical species that specifically target parasital enzymes 
and alkylate them, has rendered the artemisinins the drug of choice for the treatment of 
uncomplicated P. falciparum malaria.  
To overcome a potential drug resistance and to retain the desperately required activity of 
artemisinin derivatives, artemisinin monotherapies have been replaced by artemisinin 
combination therapies (ACT), in which an artemisinin derivative is combined with a partner 
antimalarial drug. The artemisinin component of the ACT is supposed to kill off the bulk 
parasite loading, while the partner drug with a longer half-life eliminates residual parasites. 
The combination of two drugs minimizes the selective window for either drug, thereby 
protecting their antimalarial potency and suppressing the emergence of resistant strains.[44] 
Despite the efforts undertaken to preserve artemisinin activity, first indications of an 
emerging artemisinin resistance were reported from the Cambodian side of the Cambodia-
Thailand border region in 2004. The region of Western Cambodia had already been in focus 
after the emergence of chloroquine and SP resistances, underlining the urgency to 
encounter the newly reported resistance with all measures available.[44] 
Consequently, artemisinin resistance has to be monitored constantly, as new cases of 
reduced efficacy have been reported from the Thailand-Myanmar border region, the China-
Myanmar border region as well as from one Vietnamese province.[31] 
Unlike P. falciparum, P. vivax can still be treated with chloroquine, which is recommended by 
the WHO as first-line treatment in regions with no chloroquine-resistant strains. For the 
regions in which P. vivax has become resistant to chloroquine, an adequate ACT is 
recommended. For the elimination of hypnozoites pamaquine and primaquine are 
recommended as oral medication.[31,33]  
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Currently, the different types of malaria infections can be treated effectively with the drugs 
described above. Nevertheless, the parasites themselves as well as the malaria vectors 
quickly adapt to drug pressure which results in the emergence of resistances. This calls for 
research efforts to identify alternative possible targets for a safe and more specific 
chemotherapy as well as the rational design of drugs addressing these targets.[40] Although 
the identification of a molecular target is tedious work, it is advantageous to identify the 
molecular target and mechanism of a potential drug candidate before entering the clinical 
phase of drug development.[33] 
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1.5 Cysteine proteases and their inhibitors 
 
Cysteine proteases, also referred to as thiol proteases, are another large group of proteases 
that are widely distributed in viruses, bacteria, protozoa, plants, mammals and also fungi.[46] 
In the MEROPS database, the cysteine proteases are divided into 8 clans and about 60 
different families (of which some so far have not been assigned to a protease clan). 
Furthermore, the four clans of mixed mechanism (P) proteases include cysteine proteases as 
well. An overview of cysteine protease clans along with prominent family members is given 
in Table 2 (based on: MEROPS database[11], January, 2012) 
 
Table 2: Representation of the cysteine protease clans and examples for unassigned families currently listed in 
the MEROPS database (January, 2012). 
Clan Number of families  Representative member(s) Family  
CA 27 papain 
calpain-2 
C1 
C2 
 
CD 6 clostripain 
caspase-1 
C11 
C14 
 
CE 6 adenain C5  
CF 1 pyroglutamyl-peptidase I C15  
CL 2 sortase A C60  
CM 1 hepatitis C virus peptidase 2 C18  
CN 1 sindbis virus nsP2 peptidase C9  
CO 1 dipeptidyl peptidase VI C40  
unassigned 
 
 
 
13 chestnut blight fungus virus p29 peptidase 
RvrRpt2 peptidase 
C7 
C70 
 
 
PA 6 poliovirus-type picornain 3C C3  
PB 5 amidophosphoribosyl transferase precursor C44  
PC 2 gamma glutamyl hydrolase C26  
PD 1 hedgehog protein C46  
 
The clan CA represents the most populated clan of cysteine proteases, followed by the clan 
CD. A look on the different cysteine protease families reveals that the C1 family of papain-
like cysteine proteases is most often found. The most prominent member of this family is the 
name-giving protease papain isolated from papaya. Other important representatives are the 
related plant proteases bromelain or chymopain, the lysosomal cathepsins, proteases from 
parasitic protozoa such as cruzipain from Trypanosoma cruzi, the parasite causing Chagas’ 
disease, or the falcipains from the malaria parasite Plasmodium falciparum.[47] 
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In humans, the most important cysteine proteases of the C1 family of papain-like proteases 
are the cathepsins. They comprise a class of enzymes found in the intracellular space that 
are mostly localized in the lysosomes. In total, 11 cysteine protease cathepsins (B, H, L, S, C, 
K O, F, V, X and W) were so far identified in humans. With the exception of cathepsin S, the 
cathepsins were found to be expressed in various cell types and their major role was 
believed to be the non-specific degradation of proteins inside the lysosomes. Under special 
conditions, often related to pathogenic states, cathepsins can also be found outside of the 
lysosomes. Moreover, the development of new microbiology techniques enabled the 
identification of tissue-specific cathepsins, cathepsin K for example is expressed almost 
exclusively in osteoclasts. The lysosomal cysteine proteases require a reducing and slightly 
acidic environment for optimal function. They are mostly endopeptidases, cathepsin B also 
acts as a dipeptidyl carboxypeptidase and cathepsin H is an aminopeptidase. Cathepsin C is 
an exception, being a dipeptidyl aminopeptidase. 
Besides their appointed role inside the lysosomes, the cathepsins also degrade proteins 
outside the lysosomes and are involved in the processing of proteins. Other important 
cellular processes such as the antigen presentation or bone resorption are closely related to 
lysosomal proteases. Furthermore, it has been observed that the secretion of lysosomal 
cysteine proteases can be very harmful and has been related to various disorders. 
Consequently, their inhibition can represent an important strategy for the development of 
novel chemotherapeutics. Their unwanted inhibition however can cause serious side effects 
due to their important role in various cellular processes.  
In protozoic parasites, cysteine proteases are also key players, ensuring the “well-being” of 
the parasital species. Despite the high diversity of pathogenic, protozoan species, the vast 
majority of proteases isolated from these species are in fact cysteine proteases. Some of 
these proteases are key players in the parasitic life cycle, ensuring the nutrition of the 
parasite as well as the invasion of the host cells. A full example for a parasitic protozoan 
species with a description of its crucial cysteine proteases is given in the following section on 
the falcipains from the malaria parasite P. falciparum. 
Additional examples for essential parasital cysteine proteases are cruzipain from 
Trypanosoma cruzi, the pathogen causing Chagas’ disease or cysteine proteases from 
Schistosoma mansonia, the parasite responsible for intestinal bilharzia that, similar to P. 
falciparum, also nourishes on hemoglobin digested by cysteine proteases.[46]  
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The currently best investigated cysteine protease is papain, for which the full sequence as 
well as the three-dimensional structure is known.[46] The papain-like proteases consist of two 
domains, the L and the R domain (left and right, the names originate from the orientation of 
the domains in the common view) that interact through a large, planar interaction surface, 
opening at one side to form a V-shaped active site cleft. The main feature of the L domain is 
a helix motif; the catalytically active Cys-25 is located at the N-terminus of the helix. The key 
feature of the R domain is a β-barrel structure incorporating His-159, the second component 
needed in the mechanism of catalysis.[47] Activation of the active site cysteine is thereby 
achieved by a catalytic dyad between cysteine and a histidine residue.  
The binding of substrates to cysteine proteases has been studied with different proteases 
and protease inhibitors and showed that the principles observed for the model protease 
papain can be extended to other papain-like cysteine proteases. In fact, crystallographic 
analyses of the co-complex structures of papain with different inhibitors revealed that the 
interaction of papain-like proteases with a substrate or an inhibitor usually only spans the S2 
to S2’ subsites (in contrast to the seven binding subsites (S4 to S3’) postulated by Schechter 
and Berger[8]). This has led to the definition of the term “substrate binding site” for binding 
to the S2 to S2’ subsites, while the additional sites are termed as “binding area” because the 
experimental data does enable a clear definition of these binding sites. The individual 
binding sites are formed by loops originating from the core of the two domains (Fig. 12).[47] 
 
 
 
Figure 12[47]: Schematic representation of the substrate binding sites of papain-like cysteine proteases. The 
different binding sites are formed by various loops and one disulfide bridge. Some key amino acids are 
represented in the figure.   
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Just as for all other proteases, a strict control of cysteine protease activity is necessary. One 
important means of control and regulation of cysteine protease activity are thereby 
endogenous cysteine protease inhibitors. 
To this end, mammals express a number of proteinaceous cysteine protease inhibitors, the 
cystatin superfamily. This superfamily can be further grouped into three families on the basis 
of sequence homologies: a) the stefin family, b) the cystatin family and c) the kininogen 
family.[46,48] 
In addition to these proteinaceous cysteine protease inhibitors, also small molecule 
inhibitors, either derived from natural sources or synthetic compounds, are known. In 
general, these small molecule inhibitors are based on the incorporation of an electrophilic 
element in a peptide sequence. The electrophilic warhead is attacked by the nucleophilic 
thiol, leading to a covalent modification of the target enzyme. A representation of different 
cysteine protease inhibitors is given in the following section on falcipains. The principles 
presented for the inhibition of falcipains can also be adapted to other cysteine proteases. 
 
1.5.1 Falcipains - possible new targets for malaria chemotherapy 
 
The completion of the genome sequencing of P. falciparum in 2002 lead to the identification 
of 92 putative proteases encoded within the genome. As already discussed, proteases are 
excellent drug targets; the inhibition of parasital proteases may provide access to a more 
specific and effective therapy of malaria infections.[49] 
In the search for antimalarial drugs, the parasital proteases have been suggested as very 
promising drug targets, as they are involved in numerous processes essential to parasite 
survival. Among them, the cysteine proteases are regarded as most auspicious candidates. 
The best characterized cysteine proteases in P. falciparum are the four falcipains, belonging 
to the family of papain-like cysteine proteases.  
From inhibitory studies, an essential role in hemoglobin digestion was appointed to these 
cysteine proteases. Inhibitors applied to different life-cycle stages maximally affected the 
mature trophozoite and schizont stages. Additionally, further roles were suggested on the 
basis of the observation that all developmental stages of the parasite were affected after a 
long term treatment with cysteine protease inhibitors. 
The best characterized function of cysteine proteases within the parasite is the degradation 
of hemoglobin, providing the parasite with amino acids for the biosynthesis of proteins. It 
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has been suggested that the hydrolysis of hemoglobin is a cooperative process mediated by 
cysteine, aspartic and metallo proteases, although the participation of cysteine proteases 
was found to be the essential element: The distinct food vacuole swelling related to a 
disturbed hemoglobin hydrolysis could only be observed when cysteine proteases were 
inhibited by compounds such as leupeptin or E-64, which are well-known inhibitors of 
cysteine proteases. Besides this direct involvement of falcipain-2 and falcipain-3, they also 
indirectly influence the hemoglobin hydrolysis in an indirect manner by processing aspartic 
proteases involved in the hydrolysis process.  
Inhibitory studies alongside with gene disruption experiments revealed a certain redundancy 
among the proteases involved in hemoglobin processing. This allows the parasite to react to 
a temporary loss of one or more proteases from different classes involved in this essential 
process. Nevertheless, this redundancy is not complete and so the inhibition of falcipains is 
detrimental to the parasite. A synergistic effect in antimalarial activity, when inhibiting 
cysteine as well as aspartic proteases, could also be observed.  
The falcipains are four cysteine proteases of P. falciparum belonging to the family of papain-
like cysteine proteases (clan CA, family C1) and are denoted as falcipain-1 (FP-1), falcipain-2 
(FP-2), falcipain-2’ (FP-2’ or -2B), which is 99% homologous to FP-2 in the catalytic domain, 
and falcipain-3. FP-1 is only 40% homologous to the other falcipains that share 68% of their 
sequences, so the falcipains are subdivided into FP-1 and the FP-2/3 subfamilies. In P. vivax a 
homolog of FP-1 could be identified, showing 72% homology; for FP-2/3, three homologs 
with 60 to 70% identity were characterized.[50]  
FP-2 and FP-3 are expressed at different points of time in the parasite life-cycle: FP-2 is 
expressed in early trophozoites, the maximum expression of FP-3 can be found in late 
trophozoites. FP-2 has been found to be responsible for 90% of the cysteine protease activity 
with standard peptidyl substrates, whereas FP-3 is relatively unreactive against these 
peptidyl substrates. Both proteases prefer hydrophobic residues at the P2 position, 
characterizing them as cathepsin L-like.[50,51]  
From the expression profiles at different points of time as well as from knock-out studies for 
FP-2 and FP-3 it could be determined that FP-3 is the critical falcipain expressed at a later 
stage of parasital development.[52,53] These studies attempted the knock-out of all four 
falcipains in erythrocytic stage parasites using the 3D7 strain. The mutants carrying the FP-1 
and FP-2’ knock-outs could not be distinguished from wild-type parasites, indicating that FP-
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1 as well as FP-2’ does not play a role in erythrocytic development. The overall role of FP-2’ 
remains uncertain, taking into account that it shares 99% identity with FP-2 in the catalytic 
domain but obviously does not seem to play a role in the erythrocytic development of the 
parasite. The FP-2 knock-out mutants showed the distinct swollen food vacuole, related to a 
disturbed hemoglobin digestion. The same phenotype was observed when treating the 
parasite culture with the cysteine protease inhibitor E-64 (Fig. 13).  
 
 
Figure 13[53]: Trophozoite morphologies: WT: synchronized wild-type, WT+E-64: wild-type treated with E-64 (10 
μM), FP-2, FP-2’ and FP-1 knock-out. All cells were cultured for 22 h, then the smears were stained with Giemsa 
and the morphologies were evaluated under a bright field microscope.  WT+E-64 and FP-2KO show the distinct 
swelling of the food vacuole.  
 
Furthermore, the FP-2 knock-out mutants showed a twice increased sensitivity to cysteine 
protease inhibitors as well as a 1000-fold increase in sensitivity towards an aspartic protease 
inhibitor. This result resembles well the postulated synergistic effect of cysteine and aspartic 
proteases in hemoglobin digestion. Nevertheless, FP-2 knock-out mutants remain viable and 
progress to schizont stage, where the observed altered morphology resolves, leading to a 
phenotype not distinguishable from the wild-type. The same effect was observed for the FP-
1 and FP-2’ knock-out mutants.  
All attempts to generate a FP-3 knock-out mutant failed. The mutants were not viable, 
indicating a crucial role for FP-3 in the erythrocytic development of the parasite. To rule out 
a mutation-resistance of the FP-3 locus, the gene was replaced readily by a tagged version, 
affording viable mutants, expressing FP-3. This finding underlines the essential role of FP-3 in 
the development and progression of the trophozoites.  
The results of the knock-out studies were able to emphasize the essential roles of FP-2 and 
FP-3 in the erythrocytic development of P. falciparum. In the early developmental stage of 
the trophozoites, FP-2 is responsible for the hydrolysis of hemoglobin. In late trophozoites 
the expression level of FP-2 is lower, here FP-3 expression is maximal and FP-3 ensures 
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hemoglobin hydrolysis and proliferation to the schizont stage. The FP-2 knock-out mutants 
are most probably rescued by FP-3, which is expressed in the late trophozoite stage and in 
the schizont stage. The lethality of a FP-3 knockout further supports such a rescue-
mechanism. Consequently, FP-2 and FP-3 seem to have very similar roles, but are expressed 
at different points of time within the erythrocytic development, pinpointing for a stage-
dependent activity rather than a redundant activity of these two proteases. For antimalaria 
research, the results clearly indicate that a focus should be put on FP-2 and FP-3 inhibitors. 
Furthermore, a combined strategy with cysteine and aspartic protease inhibitors should 
represent a viable approach as indicated by the increased sensitivity of the FP-2 knock-out 
mutants.[53] 
When compared biochemically, FP-2 and FP-3 show similar but not identical features. Both 
proteases have a low pH optimum consistent with their location in the acidic food vacuole. 
Moreover, a reducing environment is required for the maximum activity. Like most members 
of the papain-family, FP-2 and FP-3 specificity towards a substrate is determined by the P2 
residue and both proteases prefer substrates with leucine at this position. FP-2 shows a high 
affinity for peptidyl substrates, represented in vivo by globin peptides, whereas FP-3 shows a 
higher affinity for native hemoglobin. In a study with recombinant enzymes, FP-3 was found 
to hydrolyze native hemoglobin with a greater activity than FP-2. The reaction rate of both 
enzymes in globin digestion was significantly higher than the digestion rate for native 
hemoglobin, both enzymes hydrolyzed globin at comparable rates.  
The different substrate affinities enable an optimal digestion and recycling of native 
hemoglobin as well as denatured globin proteins. Another difference between the proteases 
was found concerning their pH stability: both proteases are stable at acidic pH, but FP-2 is 
also stable at neutral pH and is additionally able to undergo autohydrolysis to the mature 
protease at this pH. The different stabilities as well as substrate preferences may stem from 
different roles of the two enzymes. After expression as membrane-bound preforms both 
enzymes need to be processed to an active, mature form and relocated to the food vacuole. 
FP-2 is processed more quickly and undergoes autohydrolysis at neutral pH, which provides 
evidence for an additional role of FP-2 outside the food vacuole. FP-2 was found to hydrolyze 
the erythrocyte cytoskeletal proteins band 4.1 and ankyrin at neutral pH, indicating a role in 
destabilization of the erythrocyte membrane before the rupture and liberation of the 
merozoites.   
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FP-3 is on the other hand more stable and active at acidic pH and is most probably located 
only in the acidic food vacuole, where it is the more potent hemoglobinase, hydrolyzing 
native hemoglobin as well as denatured globin proteins.[50,54] 
Recently, the crystal structures of FP-2 with E-64 and of FP-3 with leupeptin were solved. 
These studies revealed – as expected – that both proteases are highly homologous to other 
members of the papain-like cysteine protease family (Fig. 14). They exhibit a clear 
preference for hydrophobic residues at the P2 position and the preference of FP-2 and FP-3 
for a leucine residue on this position can be explained by the co-complex structure. It has 
been recognized previously that FP-3 seems to be more difficult to address with peptide-
based inhibitors. The co-crystallization of the proteases with small molecule inhibitors 
revealed subtle differences in the actives sites of the two proteases that may be the 
molecular basis of the observed different substrate preferences. The overall secondary 
structure of the two enzyme-inhibitor complexes was found to be highly similar, with no 
notable movements in the backbone or loop regions. The superimposition of the respective 
substrate-specificity determining S2 subsites, however, revealed two amino acid 
substitutions that slightly alter the nature of the subsite.[51] 
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Figure 14 (adapted from[51]): Close-up on the structures of FP-2 and FP-3 active sites in complex with small 
molecule inhibitors. A: left: surface representation of FP-2 in complex with E-64, the inhibitor is shown in gray, 
right: surface representation of FP-3 with leupeptin, the inhibitor is represented in gray; B: chemical structures 
of E-64 (left) and leupeptin (right), the putative attack of the catalytic cysteine is indicated; C: superimposition 
of the S2 subsites, color in accordance with A. 
 
The first substitution is the replacement of Asp-234 in FP-2 for Glu-243 in FP-3. This position 
is generally non-conserved throughout the clan CA enzymes. The amino acid is located at the 
base of the S2 subsite; but as both inhibitors used in the co-crystallization experiment 
contain a leucine at the P2 position, a hydrogen bond with the carboxylic acid functionality 
can be excluded. In the FP2-E-64 crystal structure, the Asp-234 is rotated away from the 
inhibitor, but is prevented from pointing toward the solvent. In the FP-3-leupeptin crystal 
structure, Glu-243 is also rotated away from the inhibitor; in this case, however, it points 
outward into the solvent and forms an additional hydrogen bond to Tyr-245. Overall, the 
base of the S2 subsite in FP-3 is more exposed to the solvent allowing additional stabilization. 
Glu-243 in comparison to Asp-234 is more bulky and due to the additional carbon-carbon-
bond more flexible, thereby altering the base of the subsite. The second amino acid 
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substitution is the replacement of Leu-84 to Tyr-93 in FP-3, resulting in an overall narrowing 
and thereby restricted accessibility of the S2 subsite. The position of Tyr-93 has been 
suggested as one of two gatekeeper residues in a FP-3 homology model, pinpointing that 
this residue together with the Asp-234 to Glu-243 modification contributes to the different 
preferences of FP-2 and FP-3.[51] 
The similar activities of FP-2 and FP-3 have resulted in the development of compounds that 
inhibit both proteases, although most inhibitors are developed for FP-2. The peptidic 
inhibitors developed for FP-2 and FP-3 are based on a leucine or an alternative hydrophobic 
residue in the P2 position and incorporate a reactive group in the P1’ position that is known 
for the interaction with cysteine proteases. Variation can be included in the P3 position to 
enhance selectivity and pharmacological parameters. 
Fluoromethyl ketone inhibitors (Fig. 15) are known as highly reactive, selective and 
irreversible inhibitors for cysteine proteases. A number of fluoromethyl ketone-based FP-2 
inhibitors was tested, among them, (Z)-Phe-Arg-CH2F was distinguished as the most potent 
inhibitor of FP-2 (IC50 = 0.36 nM). The inhibitor furthermore blocked hemoglobin hydrolysis 
and inhibited the growth of cultured parasites, both at nanomolar concentrations (IC50 = 
0.10 μM for hemoglobin hydrolysis; IC50 = 64 nM for malaria parasite development) and was 
active at nanomolar concentrations in four different P. falciparum strains while being non-
toxic in four human cell lines. Other fluoromethyl ketone inhibitors incorporating a 
morpholine urea (Mu) moiety at P3 were able to inhibit FP-2 at nanomolar or even picomolar 
concentrations. The inhibitor Mu-Phe-HomoPhe-CH2F was not only an effective inhibitor of 
FP-2 (IC50 = 3 nM), but also inhibited the rodent P. vinckei cysteine protease most effectively 
(IC50 = 5.1 nM). The P. vinckei cysteine protease is biochemically very similar to FP-2 in terms 
of molecular weight, pH preferences, substrate specificity and inhibitor sensitivity and can 
be tested in vivo in a murine malaria model. Of the P. vinckei infected mice treated 
parenterally with the inhibitor (four doses / day, four day treatment), 80% were cured by 
inducing a long-lasting immunity.[55] 
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Figure 15: Examples of highly effective FP-2 fluoromethyl ketone inhibitors: IC50((Z)-Phe-Arg-CH2F) = 0.36 nM; 
IC50(Mu-Phe-HomoPhe-CH2F) = 3 nM; IC50(Mu-Leu-HomoPhe-CH2F) = 0.42 nM.
[55] 
 
Another class of irreversible covalent inhibitors are the peptidyl vinyl sulfones. They act by 
the addition of the reactive cysteine thiol to the Michael acceptor system. The generally-
accepted mechanism includes the polarization of one of the sulfone oxygens by a 
protonated histidine present in the proximity of the active site which should enhance the 
nucleophilic attack on the β-carbon. The resulting negative charge on the α-carbon is then 
eliminated by deprotonation of the participating histidine (Fig. 16).[55] 
 
 
 
Figure 16 (adapted from[55]): Proposed reaction mechanism for the vinyl sulfone inhibitors. 
 
Vinyl sulfones are highly specific inhibitors of cysteine proteases, being unreactive to other 
protease classes (despite the proteasome) as well as to non-active site cysteines or free 
thiols such as glutathione. Extensive SAR studies have been carried out for the vinyl sulfones 
starting from peptidyl vinyl sulfones analogous to the fluoromethyl ketones described before 
(Fig. 17).[55] 
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Figure 17: Vinylsulfone inhibitors incorporating a morpholine urea.[55] 
 
These first inhibitors were tested against FP-2 and its P. vinckei analog, showing similar 
inhibitory effects against both targets. Mu-Phe-HomoPhe-VSPh was evaluated as a mid-
nanomolar inhibitor of both proteases (IC50 (FP-2) = 0.08 μM; IC50 (P. vinckei) = 0.1 μM). The 
homologous Mu-Leu-HomoPhe-VSPh inhibitor however showed an increased activity against 
FP-2, but a decreased activity against the homologous P. vinckei protease (IC50 (FP-2) = 0.003 
μM; IC50 (P. vinckei) = 0.2 μM), indicating a critical role of the inhibitor peptide portion for 
specificity towards the different target enzymes.  
To improve the bioavailability as well as the solubility, the morpholine urea was replaced by 
an N-methyl piperazyl urea (N-Pipu) (Fig. 18) which resulted in a slightly increased IC50 of 
8.7 nM, but this new analog showed a decreased IC50 against P. falciparum (IC50(Mu-Leu-
HomoPhe-VSPh) = 22 nM vs. IC50(N-Pipu-Leu-HomoPhe-VSPh) = 4.5 nM). A further 
improvement in the activity against P. falciparum could be achieved by replacing the original 
morpholine urea by a 4-pyrrole-piperidine urea (4-Py-Pipu) moiety. (IC50(Mu-Leu-HomoPhe-
VSPh) = 22 nM vs. IC50(4-Py-Pipu-Leu-HomoPhe-VSPh) = 1.6 nM); this compound also 
inhibited FP-2 at low nanomolar concentrations (IC50 = 6.7 nM).[55] 
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Figure 18: Improved vinyl sulfone inhibitors. The compounds showed an improved inhibition of P. falciparum 
(IC50 = 4.5 nM for N-Pipu-Leu-HomoPhe-VSPh and IC50 = 1.6 nM for 4-Py-Pipu-Leu-HomoPhe-VSPh) in comparison 
to the original Mu-Leu-HomoPhe-VSPh (IC50 = 22 nM). The inhibition of FP-2 was slightly increased for the new 
compounds (IC50 = 8.7 nM for N-Pipu-Leu-HomoPhe-VSPh and IC50 = 6.7 nM for 4-Py-Pipu-Leu-HomoPhe-VSPh) 
compared to Mu-Leu-HomoPhe-VSPh (IC50 = 3.0 nM).
[55] 
 
In another series of inhibitors, a sulfonamide moiety was used instead of a sulfone residue, 
resulting in a higher potency (FP-2 inhibition: IC50 = 2.3 nM) while the excellent inhibition of 
P. falciparum growth was maintained (IC50 = 4.4 nM) (Fig. 19).[55] 
 
 
 
Figure 19: Comparison of vinyl sulfone and vinyl sulfonamide inhibitors of FP-2. The inhibition of FP-2 was 
improved (IC50 = 8.7 nM for N-Pipu-Leu-HomoPhe-VSPh and IC50 = 2.3 nM for 4-Py-Pipu-Leu-HomoPhe-VSA-OPh) 
while the excellent inhibition of P. falciparum growth was maintained (IC50 = 4.5 nM for N-Pipu-Leu-HomoPhe-
VSPh and IC50 = 4.4 nM for 4-Py-Pipu-Leu-HomoPhe-VSPh).
[55] 
 
In contrast to the previously described fluoromethyl ketone and vinylsulfone inhibitors, 
peptide aldehyde and α-ketoamides inhibit cysteine proteases in a covalent but reversible 
manner. So far, they are the most potent inhibitors of FP-2 and show also activity against 
FP-3. Mu-Leu-HomoPhe-al as well as Mu-Leu-HomoPhe-(CO)-Phe-NH2 exhibit potent 
inhibitory activity against FP-2 (IC50 = 1 nM for both inhibitors) and are potent anti-
plasmodial agents against different strains of P. falciparum (low nanomolar IC50 values) 
(Fig. 20). However, the inhibitors were less potent in the mouse model of P. vinckei malaria, 
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emphasizing once more the difference between the falcipain targets in P. falciparum and 
P. vinckei that represents a serious problem in malaria drug research for compound 
validation in rodent models.[55] This issue might be overcome by the introduction of 
recombinant rodent parasites expressing the human P. falciparum proteases or by the 
introduction of a P. falciparum mouse model.[50] 
 
 
 
Figure 20: Peptide aldehyde and α-ketoamide inhibitors based on potent peptidic core structures.[55] 
 
The major drawbacks of peptidic inhibitors in terms of drug development are their low 
bioavailability as well as their susceptibility towards degradation by endogenous proteases. 
To overcome this weakness and to improve pharmacokinetic and -dynamic parameters, a 
common strategy is the replacement of peptidic structures by rigid scaffolds locking a 
defined conformation and mimicking the secondary structure motif. The β-turn motif has in 
this context been suggested as for a suitable motif for enhancing bioactivity. 1,4-
benzodiazepines have been reported as β-turn mimetics with favorable pharmacodynamics. 
Consequently, FP-2 inhibitors based on the 1,4-benzodiazepine core in the P2 position (as 
replacement for leucine) have been developed. For example, the peptidomimetic 1 (Fig. 21) 
showed a potent inhibition of FP-2A and B (IC50 = 8.7 μM for FP-2A; IC50 = 25.9 μM for FP-2B). 
The peptidomimetic 2 (Fig. 21), in which the masked aspartyl aldehyde functionality from 
peptidomimetic-1 was replaced by a classical Michael acceptor displayed a low dissociation 
constant for FP-2 (kinac (min-1) / Kinac (μM) = 0.10/0.32)and potent inhibition of P. falciparum 
growth (IC50 = 9.1 μM). [49,55] 
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Figure 21: Peptidomimetic FP-2 inhibitors based on the 1,4-benzodiazepine scaffold. [49,55] 
 
Besides the 1,4-benzodiazepine core, other peptidomimetic scaffolds that lock the peptide 
backbone conformation have been examined as potential replacements for the P2 amino 
acid. For example the use of the 5-aminopyridone (peptidomimetic 3), a pyridone 
(peptidomimetic 4) or a pyrrolidone (peptidomimetic 5) motif with different electrophilic 
warheads (Fig. 22) also resulted in potent anti-plasmodial inhibitors.[49] 
 
 
 
Figure 22: Structurally diverse peptidomimetic inhibitors with potent anti-plasmodial activities against different 
strains of P. falciparum and/or potent FP-2/FP-3 inhibition. Peptidomimetic 3: IC50 = 0.016 μM against D6, IC50 = 
0.018 μM against W2; peptidomimetic 4: IC50 = 5.7 μM against 3D7, IC50 = 9.0 μM against TM6; peptidomimetic 5: 
IC50 = 0.05 μM against FP-2/FP-3.
[49] 
 
Further research has been conducted in the field of non-peptidic inhibitors of falcipains. 
Several potent inhibitors have been synthesized based on the chalcone natural product 
licochalcone A, which was the first compound from this class reported to exhibit antimalarial 
activity. Furthermore, the inhibitory potential of isoquinoline and thiosemicarbazone 
inhibitors has been investigated (Fig. 23). So far, no enzyme inhibition mechanism for the 
non-peptidic inhibitors could be determined, only few docking experiments have revealed 
putative structure-activity relations.[55] 
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Figure 23: Structures of non-peptidic falcipain inhibitors.[55] 
 
Considering all potential drug targets in anti-malaria therapy, the falcipains seem to 
represent an appropriate class of target enzymes. FP-2 and FP-3 are crucial 
(hemo)globinases of the malaria-causing pathogens, ensuring the nutritious supply of the 
parasite in the erythrocytic stages as well as the progression of the life cycle. Consequently, 
FP-3 activity is essential for the survival at late developmental stages. Attempts to disrupt 
FP-3 expression genetically failed, emphasizing the crucial role of this protease.  
Nevertheless, inhibitors targeting falcipains usually are designed to inhibit FP-2. So far, no 
inhibitor explicitly targeting FP-3 has been reported. In the past decades, resistances against 
the “classical” antimalarial drugs have evolved, thereby underlining the requirement for new 
therapeutic targets and new chemotherapeutics. Studies of parasital resistance against a 
vinylsulfone falcipain inhibitor have revealed a very slow selection of resistant mutants and a 
complex mechanism of drug resistance, holding the promise that falcipain inhibitors may not 
be as prone to development of resistances as other substance classes have been. Hence, the 
falcipains remain an interesting and sensible target for the investigation of antimalarial 
compounds.[50] 
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1.6 Proteomics as a technique for analyzing the mode-of-action of small molecules 
 
The term “proteome” was used for the first time in 1995 to describe the total complement 
of proteins encoded by a genome. [56] The individual proteome expressed in a distinct cell or 
tissue type is subject to fluctuations that are caused by internal influences such as the 
developmental stage and mutation or external influences such as stress response, drug 
perturbation or pathogens. The research area of proteomics is nowadays defined as the 
systematic study of the many and highly diverse properties of proteins on a large scale. This 
includes expression levels, post-translational modifications and interactions with other 
proteins. The goal is to gain comprehensive insights on the structure, function and control of 
biological systems in healthy and diseased organisms.[57,58] 
The proteomics approach emerged originally from the genome sequencing projects that had 
set out to map and sequence complete genomes and resulted in the finding that many gene 
products did not have an assigned function.[58] Moreover, the relatively small number of 
genes identified for the human genome compared to the larger number of proteins 
expressed in the different cells and tissues emphasizes the need of an alternative technique 
to mRNA expression level analysis and the requirement to reconsider traditional concepts 
such as the “one gene - one protein” hypothesis.[59] In both cases, proteomics can serve as a 
powerful tool to identify proteins, assign them a function and determine their role in a 
network of protein-protein interactions.  
As a consequence of the genome sequencing projects and the advent of proteomics, the 
systems biology approach has recently emerged aiming at the determination of the 
spatiotemporal distribution of biomolecules and their organization into networks and 
pathways. To reach this highly ambitious (and potentially even unattainable) goal, 
proteomics is regarded as a rich source of information because proteins are involved in 
almost all biological processes. An understanding of their diverse function will provide access 
to an elaborate understanding of physiological processes.  
In the early days of proteomic research, the goal was to rapidly identify the full set of 
proteins expressed in an organism which has so far not been achieved for any organism. The 
goals of proteomics have however shifted nowadays towards a systematic determination of 
selected processes in which the diverse properties of proteins are studied, including their 
sequence, structure and state of modification, the quantity and cellular distribution, their 
activity and the interactions with one another.[58] The ultimate goal of proteomics is not only 
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to reveal all proteins of an organism and assign their individual functions, but also to identify 
all isoforms and modifications of those proteins, the interactions between the proteins and 
higher-order complexes; in other words, proteomics studies proteins “post-genomic”.[60] In 
general, the experimental set-up required for proteomics is by far more complex than the 
one required for genomics. Nevertheless, proteomics has been impressively successful in a 
relatively short period of time and has provided insights into the gene expression of different 
cell and tissue types in healthy and diseased states. Furthermore is has helped to dissect 
cellular pathways and led to a deeper understanding of molecular physiology. In terms of 
technological development, proteomics is supplied with mature tools that are, nevertheless, 
under constant refinement.[58,60] Consequently, proteomics has been provided with 
elaborate instrumentation and has conceptually become the method of choice for the 
analysis of biological systems, yet there are still some challenges that have to be met. 
 
As an analytical method for proteomics research, mass spectrometry has become the most 
essential technique. To be able to analyze a molecule by mass spectrometry, the molecule of 
interest first needs to be ionized, enabling its transfer to the gas phase, in which it is then 
analyzed within the mass spectrometer. The mass of the analyte is measured as the mass-to-
charge ratio, m/z. Initial attempts to ionize proteins or peptides with the given ionization 
techniques proved difficult, leading to massive fragmentation of the sensitive molecules. The 
development of mild ionization techniques for biomolecules was a major breakthrough in 
the field, enabling a rapid analysis and identification of proteins and pushing forward all 
research concerned with proteins. The relevance of this advance in technology is 
demonstrated by the recognition with the Nobel prize in 2002.[61] 
The two techniques for mildly ionizing protein molecules and thereby enable their transfer 
to the high vacuum system of the spectrometer are electrospray ionization (ESI) and matrix-
assisted laser desorption ionization (MALDI). Both methodologies quickly penetrated into 
protein research once they had been combined with commercial mass spectrometers.  
The MALDI-type ion sources (Fig. 24) are usually combined with time-of-flight (TOF) 
analyzers, in which the ionized molecules are accelerated and separated by their different 
velocities. Since all ions are accelerated with the same energy, the lighter ions reach a higher 
velocity than heavier ions with the time of flight being proportional to �𝑚/𝑧.  
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Figure 24 (adapted from[61]): Set-up of a MALDI ion source (top), MALDI-TOF instrument set-up (bottom) 
 
MALDI allows the determination of the mass of a peptide or protein with high accuracy and 
a broad spectrum of masses can be addressed. The mass of a protein is, however, not a 
uniquely identifying feature, so further measurements are necessary to determine the 
identity of a protein. In the so-called peptide mass fingerprinting a protein of interest is 
digested with an enzyme with known cleavage specificity to generate smaller peptide 
fragments that are then analyzed by mass spectrometry. The fragments generated by 
proteolysis are unique for each protein and can therefore be used to identify the protein by 
comparison of the fragments identified by mass spectrometry with a sequence database. 
The accuracy of this method depends on the specificity of the enzyme used in the digest 
(usually trypsin), on the number of fragments identified and on the accuracy of the mass 
spectrometer. Owing to the highly increased accuracy of MALDI, the peptide mass 
fingerprinting using MALDI-TOF has become the method of choice to identify proteins that 
were separated by 2D electrophoresis and then individually digested to obtain the peptide 
fragments.[61] 
The ESI ion sources (Fig. 25) are usually combined with triple-quadrupole or ion trap 
instruments, a more recent combination includes hybrid-quadrupole TOF MS/MS 
spectrometers. All of the instruments mentioned are not only able to measure a peptide 
mass, they are also able to isolate selected ions according to their m/z ratio and fragment 
the ions in the gas phase for recording of MS/MS spectra.  
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Figure 25 (adapted from[61]): Set-up of an ESI ion source (top), mass analyzers typically combined with ESI: 
triple-quadrupole/linear ion trap (middle) or ion trap (bottom) 
 
This fragmentation is specific and also sequence-dependent, the MS/MS spectrum of a 
protein can, in principle, be used to determine the sequence. The MS/MS spectrum can 
uniquely identify a protein by matching the fragments to a database and the accuracy of this 
type of identification is often higher than for peptide mass fingerprinting. A further 
advantage of ESI-MS/MS set-ups is their facile incorporation into existing protein purification 
systems such as HPLC, as both systems can be operated using the same solvents. Nanospray-
ESI allows the direct injection of unseparated peptide mixtures into the mass spectrometer 
at very low flow rates and is able to reach much higher sensitivity than traditional ESI-MS. 
This method consumes only very small amounts of sample and owing to the low flow rate, it 
is possible to record fragment ion spectra of several precursor ions that can be observed. 
The precursor ions can either be selected manually by an operator or by computer-
controlled software that allows the automatic measurement of MS/MS spectra for multiple 
peptide ions without operator intervention. These automatized analyses are mainly used in 
systems that are supplied online by an HPLC system and this approach is referred to as LC-
MS/MS.[58,61] 
A gel-independent alternative is the shotgun proteomics approach based on a LC-MS/MS 
methodology. This approach uses the combination of LC-MS/MS analysis with sequence 
database searches and is applied to the analysis of complex mixtures of peptides generated 
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by proteolysis of a sample containing several proteins. It provides the opportunity to catalog 
hundreds to thousands of compounds from samples obtained from different sources.[58] 
Besides the identification of proteins in complex protein mixtures, also the quantification of 
distinct proteins is of interest. Unfortunately, a regular mass spectrometric analysis does not 
provide quantitative information for mixtures of proteins because the signal intensity 
depends on the chemical composition of the peptide and the matrix and not on the 
abundance of a peptide in the mixture. A loophole to this dilemma is a technique known as 
isotope-tagging: Two peptides of identical chemical composition that nevertheless differ in 
their masses due to a different isotopic composition give identical and specific signals in a 
mass spectrometer based on the theory of stable isotope dilution.[58] 
One technique following this methodology involves the use of isotope-coded affinity tags 
(ICATs). The reagents contain a linker region that incorporates either hydrogens or 
deuteriums to achieve the isotope dilution, a reactive group that chemically modifies the 
peptides and a biotin tag for the affinity purification of the tagged peptides. In a typical 
experiment, two samples are treated with one of the ICAT reagents, combined and digested. 
The tagged peptides are then selected by affinity purification and submitted to mass 
analysis. For each peptide two signals will then be obtained corresponding to the light and 
the heavy version, respectively. The signal intensities can in this case be used to quantify the 
amount of peptide. Furthermore, the sequences of the individual peptides can be 
determined from the MS/MS spectra (Fig. 26).[58,62] 
 
 
 
Figure 26 (adapted from[62]): Schematic representation of the ICAT experimental set-up. 
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Not surprisingly, proteomics has also become the major tool to investigate the mode-of-
action of bioactive small molecules via elucidation of their direct protein targets. Moreover, 
chemical tools have been invented to reduce the data set in proteomics studies. Such 
approaches belong to the evolving field of chemical proteomics.[60] The most prominent 
chemical proteomics technology thereby is an approach known as activity-based protein 
profiling (ABPP). In the present PhD thesis, ABPP has been used to determine the direct 
target of synthesized bioactive small molecules and will therefore be described explicitly in 
the next section.  
 
1.6.1 Activity-based protein profiling - ABPP 
 
The assignment of protein functions is one of the central aims of proteomics research. After 
the completion of numerous sequencing projects it became clear that a large part of the 
identified gene products did not have an assigned function. Activity-based protein profiling 
(ABPP) has become the key technology in the field of chemical proteomics that set out to 
assign the function of active enzymes. It has emerged into a powerful tool for analyzing 
samples isolated from all types of cells and tissues and recent advances allow an application 
even in native biological systems.[63] 
In ABPP, activity-based probes (ABPs) are used to selectively label active enzymes. To this 
end, an activity-based probe consists of several subunits: First, an ABP features a reactive 
group or “warhead” that is supposed to react with the active site of a distinct subset of 
enzymes. Ideally, the reactive group labels a distinct number of enzymes belonging to the 
same class and shows little cross-reactivity with enzymes of other classes. Generally, there 
are two types of reactive groups: one type is represented by electrophilic groups that react 
with the active center nucleophiles, the second group are photoreactive moieties that react 
with residues in the proximity of the reactive site upon UV irradiation.  
The second part of an activity-based probe is the tag which is connected to the reactive 
group by a variable linker region. The linker region is not only required to connect the 
reactive group and the tag, it also ensures an adequate distance between the two groups to 
prevent an interference of the tag with the reactive group’s reactivity.  
Finally, ABPs feature reporter tags. These can for example be fluorescent dyes such as 
rhodamine for direct visualization. Also biotin can be used that has a dual function: it can be 
used as a reporter in a Western blot, but it can also be used to purify the labeled proteins by 
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affinity chromatography. A further possibility is the use of alkyne or azide tags that enable 
the attachment of a reporter group after the actual labeling reaction by a copper-mediated 
1,3-dipolar Huisgen cycloaddition (click reaction). The advantage of using activity-based 
probes with click tags is the reduced size of the tag that does not interfere with the labeling 
reaction. Due to the bioorthogonality of the click reaction the reaction can even be carried 
out in vivo if desired. The respective tags require different read-out or work-up procedures 
after the labeling experiment and the used reporter tag dictates the options for the read-
out.[63] Enhancements to the “traditional” reporter tags are trifunctional activity-based 
probes that consist of a reactive group and two tags, for example a biotin for purification 
and visualization in a Western blot and a rhodamine for the direct in-gel detection by 
fluorescence.[64] 
 
 
 
Figure 27 (adapted from[63]): Schematic set-up of a typical ABPP experiment.  
 
As indicated in Figure 27, the most important experimental platform for the analysis of ABPP 
experiments is in-gel visualization. After the labeling experiment the labeled proteins are 
separated by gel electrophoresis, in most cases a standard 1D-SDS-PAGE is sufficient. The 
visualization then depends on the reporter that was used. After having visualized the 
proteins, their identity can be determined by mass spectrometry. The gel-based methods for 
ABPP are still the most widely used method for the rapid and comparative analysis of 
proteomes.[63] 
In addition, gel-independent methods based on LC-MS have been developed for ABPP. Such 
mass spectrometry-based ABPP approaches (Fig. 28) can be performed in two different 
manners: on the one hand, the target protein of a probe can be determined; on the other 
hand, peptides derived from the labeled protein can be identified. The first approach 
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represents a combination of ABPP and multidimensional protein identification technology 
(ABPP-MudPIT) and uses biotin probes. After the labeling with the probe, the labeled 
enzymes are enriched by using streptavidin beads, followed by on-bead digestion with 
trypsin and analysis of the resulting peptides by LC-MS. This method has the capacity to 
identify 50 to 100 enzymes from one proteome (Fig. 28, A).  
 
 
 
Figure 28[63]: Gel-independent ABPP experiments based on LC-MS. 
A: Experimental set-up for the ABPP-MudPIT approach; B experimental set-up for the ASPP approach. 
 
The shortcoming of the ABPP-MudPIT approach is that it cannot directly identify the probe-
labeled peptide from each target and therefore the active site of the enzyme. This can 
however be achieved by the so-called active site peptide profiling(ASPP)-approach in which 
the labeled proteins are first digested with trypsin and then only the labeled peptides are 
enriched using streptavidin beads (Fig. 28, B). This allows identification and assignment of 
only the peptides that are directly labeled by a probe. One has to note that MudPIT and 
ASPP are complementary methods. MudPIT is however far more sensitive than ASPP 
because it is able to identify more enzymes as multiple peptides originating from one protein 
are analyzed in contrast to single peptides in the ASPP approach. On the other hand ASPP 
provides the possibility to determine if a protein was really targeted at its active site or if the 
labeling occurred at another site.[63] 
In general, two different ABPP approaches can be differentiated. Comparative ABPP is the 
method of choice to compare differentially perturbed proteomes and to identify the targets 
of an activity-based probe. In comparison to the more classical genomics-proteomics 
approaches, ABPP has some advantages. First of all, ABPP addresses active enzymes and is 
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thereby able to enable access to proteins that are just activated by post-translational 
modifications, making ABPP a method to identify post-translational modifications and to 
study their functional effect. Moreover, in ABPP, enzymes are labeled in relation to their 
activity and not due to their abundance. This allows to target enzymes with a low abundance 
that normally fall through the grid of traditional profiling. 
Besides the comparative ABPP, a competitive ABPP set-up is possible as well. This approach 
enables the identification of enzyme inhibitors and is therefore a powerful tool for drug 
discovery. In a general set-up, the proteome of interest is pre-incubated with an inhibitor of 
interest and then treated with the activity-based probe. If an enzyme is inhibited, the 
protein band visible in an untreated sample decreases in intensity or (in the case of a very 
potent inhibition) vanishes completely. By treating a proteome with different inhibitors a 
reactivity profile of the inhibitors for distinct members of the proteome can be established 
(Fig. 29).[63] 
 
 
 
Figure 29 (adapted from[63]): Schematic experimental set-up of a competitive ABPP experiment. 
 
Once an inhibitor for a certain enzyme has been identified, it is also possible to determine 
the inhibitory potency quantitatively, for example, an IC50 can be determined. To achieve 
this, the comparative assay is repeated using a fixed excess amount of the activity-based 
probe and different concentrations of the inhibitor. By monitoring the appearance or 
disappearance of the labeled enzyme in the gel at the different concentrations of inhibitor, 
its inhibitory potency can be determined. The concentration experiments can be carried out 
either with the whole proteome sample or with isolated enzymes obtained for example by 
recombinant expression. 
ABPP can address a great variety of different enzymes, depending on the respective activity- 
based probe. The most prominent examples of enzyme classes that are studied by ABPP are 
the highly important and ubiquitously abundant serine and cysteine proteases. The most 
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prominent activity-based probes for serine proteases are based on phosphonate residues, 
such as fluorophosphonates or aryl-phosphonates (Fig. 30). They represent very selective 
serine protease probes owing to the high oxophily of the phosphorus.[63] 
 
 
 
Figure 30 (adapted from[63]): Examples of phosphonate-based activity-based probes for serine proteases. A: a 
fluorophosphonate probe with an alkyl linker; B: a fluorophosphonate probe with a polyethylenglycol linker; C: 
an aryl-phosphonate probe. 
 
Activity-based probes directed against cysteine proteases contain highly reactive 
electrophiles such as epoxides, halomethyl ketones or unsaturated systems that can be 
attacked by the nucleophilic thiol of the active center cysteine. Many activity-based probes 
for cysteine proteases are based on the broad band cathepsin inhibitor E-64; modified 
versions of E-64, for example, a fluorescently-tagged version has found broad applications 
(Fig. 31).[63] 
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Figure 31 (adapted from[63]): Examples of activity-based probes for cysteine proteases. A: the cathepsin 
inhibitor E-64, a basis for various activity-based probes for cysteine proteases; B: a halomethyl ketone-based 
probe for cysteine proteases. 
 
Besides using well-known probes as a basis for activity-based protein profiling, it is also 
possible and reasonable to convert putative inhibitors into activity-based probes and 
investigate their activity. The possibility to incorporate for example an azide or an alkyne tag 
into an existing inhibitor, derived for example from a natural product, makes the conversion 
to an activity-based probe a task that can readily be incorporated into an existing synthesis. 
Such an approach has for example been followed in the present PhD work. 
In summary, activity-based protein profiling has evolved to become a fundamental 
technology platform in proteomics. It enables the rapid and experimentally facile analysis of 
highly differential proteomic samples in a comparative manner. It can be used to identify 
targets, determine enzyme functions and activities and help to gain insights into complex 
biological systems. ABPP is used on a broad basis, its applications range from fundamental 
research in biology to highly versatile profiling in a clinical environment to applications in 
drug discovery.[63] 
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1.7 Synthesis of peptidic natural products 
 
The total synthesis of natural products is until today regarded as the flagship of organic 
chemistry. Natural products have always been a challenge to be met; their complex nature 
has inspired, improved and pushed forward efforts towards new or improved synthetic 
methods or synthesis strategies. The application of new concepts to the total synthesis of a 
natural product can demonstrate the scopes and limitations of a novel method and bridge 
the gap between a model reaction and the application on a level of higher molecular 
complexity.  
The motivations for a chemist to enter the field of natural product synthesis can be diverse: 
the complex molecular structure, representing an intellectual challenge and the prospect of 
developing novel synthetic strategies may be one. Then again, another motivation could be 
the wish to synthetically generate a larger amount of a substance so far available only in 
minute amounts by isolation from natural sources. This motivation is usually accompanied 
by the wish to gain insight into the biomolecular activity of a natural product and the desire 
to elucidate its mode-of-action. This can contribute not only to medicinal research, but also 
to the fields of chemical ecology, biosynthesis studies or chemical biology. The biological 
investigation of natural products and the evaluation of their bioactivities are closely related 
to the wish and, in cases of medicinal research, the requirement to modify an existing 
structure in order to amend desired properties or to eliminate undesired features. An 
existing total synthesis is a valuable starting point for such investigations. Finally, the total 
synthesis of a natural product and the comparison of synthetic and natural material is the 
ultimate means to validate a proposed structure.[65,66] 
Peptidic natural products represent a class of natural products of diverging levels of 
complexity, ranging from linear peptide sequences originating from a simple ribosomal 
assembly to highly complex architectures that represent a daunting challenge to any organic 
chemist. Different features of a peptidic natural product can contribute to the molecule’s 
overall complexity: unusually modified or built up from unnatural amino acids, polyketide 
fragments, rearranged elements that do not reveal the peptidic origin at first glance or 
highly complex stereochemical settings are only a few examples.  
Peptidic natural products usually present a high density of functionalities and can be 
regarded as biologically pre-validated structures owing to their natural origin.[1] Just as any 
given natural product, a peptidic natural product is synthesized in the respective organism 
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by different enzymes and is hence required to interact with different binding partners during 
the assembly; the functionalities or molecular structures needed for these interactions can 
serve as tools for the investigation of molecular interactions and biological function. Peptidic 
natural products may be used as lead structures for medicinal chemistry research, yet they 
are also important tools in chemical biology, helping to gain in-depth insight into 
biomolecular mechanisms of action.[3] 
In the medicinal chemistry field, peptidic natural products may bridge the gap arising from 
the limited size of small molecules: some protein-protein interactions that are regarded as 
potential drug targets cannot be addressed by small molecules because the interaction 
surface is too large for a small molecule effector.[67] 
The desire to use peptidic natural products in research implies the necessity to synthesize 
the molecule of interest in larger amounts and/or in modified forms. In over 100 years of 
research on peptide synthesis and on the development of new synthetic strategies, reliable 
methodologies have been developed for the synthesis of peptides of varying complexities. 
Different protecting group strategies that enable flexible approaches to a synthetic problem 
have been developed. Still, the most important protecting groups are the Boc/t-Bu groups 
and the Fmoc group, although the arsenal has been expanded to highly specialized groups 
meeting different requirements. The development of solid-phase peptide synthesis by 
Merrifield marks a major breakthrough for the field, enabling a quick and facilitated 
approach to the assembly of peptides. The use of an insoluble solid support not only enables 
a quick access to the desired structures, the process can be automated and combinatorial 
methods open the gate to highly diverse products. In addition to the original Merrifield resin, 
numerous solid supports have been developed that enable the attachment and the cleavage 
of diverse functional groups and converting solid-phase synthesis to a general method in 
organic chemistry beyond the assembly of peptides.[68] 
The development of different coupling reagents meeting the requirements of peptide 
synthesis such as highly efficient and racemization-free coupling of sterically hindered or 
unreactive building blocks further enhanced the possibilities in peptide synthesis and 
opened the gateway to the synthesis of more complex molecules. Nowadays, innumerous 
methods and reagents for the formation of the crucial amide bond are available, 
guaranteeing high yields for this important reaction step.[69] 
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Naturally, methods developed for other fields of synthetic organic chemistry have found 
entrance into the syllabus of peptide synthesis which has evolved from the belittled “just 
amide bond formation” to a field of highly elaborate chemistry addressing highly complex 
structures.  
Some structures that have until recently failed a proper addressing have now been 
synthesized successfully and their total syntheses demonstrate beautifully the status-quo of 
peptide syntheses.  
An example for a natural product that includes highly racemization-prone amino acids that 
are extremely difficult to integrate into in an efficient synthesis is feglymycin. In their total 
synthesis of feglymycin, Süssmuth and coworkers have demonstrated how to chemically 
handle such delicate building blocks.[70] Another example are supplementary intramolecular 
linkages that often contribute to the complexity of the molecule and are another challenge 
to encounter in a total synthesis. Centers of atropisomerism that are created by certain side 
chain macrocyclizations represent a significant challenge in a total synthesis. The syntheses 
of the structurally related [71,72] natural products chloropeptin I and isocomplestatin by 
Hoveyda and coworkers [73-75] or the synthesis of complestatin by Boger et. al.[76,77] illustrate 
the difficulties provided by strained structures along with the handling of racemization prone 
phenylglycine derivatives. A very recent example illustrating the high complexity that can be 
displayed by a natural product with a peptidic core structure is the product class of 
kapakahines. Total syntheses have now been accomplished by the Baran group [78,79] as well 
as by Rainier and Espejo.[80,81] 
Exemplary for structurally highly elaborate molecules with a peptidic core structure is the 
antibiotic vancomycin that has kept a number of research groups busy for several years until 
Evans and coworkers as well as Nicolaou and coworkers were able to present individual total 
syntheses.[82] The syntheses presented by these two groups have become classics of organic 
synthesis and will be presented here as examples for the state of the art in the synthesis of 
highly complex peptidic natural products in solution phase synthesis.  
Nowadays, a peptide chemist can revert to a large number of methods to synthesize amino 
acid building blocks, choose from a wide variety of commercially available coupling reagents 
and methods, apply different orthogonal protecting group strategies and decide between a 
solution and a solid-phase strategy. Despite the enormous number of tools available for the 
synthesis of peptidic natural products, also the synthesis of less complex peptidic natural 
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products can be a challenge, requiring precise synthesis planning and development of new 
methods. For example, some amino acids seem not to be compatible to the “standard” 
coupling procedures and require a different handling as demonstrated for example in the 
synthesis of tubulysin D by Ellman and coworkers.[83] Another challenge also in, on a first 
sight, less complex architectures are cyclization reactions. The syntheses of FK228 by 
Simon[84] and Williams[85] that are based on a macrolactonization strategy and the 
alternative approach by Ganesan[86] who applied a macrolactamization strategy, however, 
demonstrated how a “simple” condensation can hamper the accomplishment of a total 
synthesis. Some natural products also call for different ring closing strategies, if for example 
a double bond is featured in a macrocyclic core. Waldmann and coworkers as well as Kaiser 
and coworkers have demonstrated the incorporation of a ring closing metathesis in their 
syntheses of chondramide C[87] and syringolin A[88,89], respectively. 
Solid-phase peptide synthesis has indeed revolutionized peptide chemistry and the 
syntheses of simple linear or also (cyclo)depsipeptides have become routine work. Still, a 
solid phase approach is only feasible if the reactions can be conducted with high yields and 
minimized racemization. The incorporation of non-standard amino acids into a solid-phase 
peptide synthesis is still a challenge that requires a precise strategic planning and 
preliminary studies in order to establish a fruitful synthesis. The synthesis of oxathiocoraline 
by Albericio et. al [90] is such an example for a solid-phase synthesis that has emerged from 
tedious preliminary studies.[91] In the present PhD thesis, synthetic methodologies for the 
synthesis of natural products on solid phase have been developed.  
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1.7.1 A total synthesis “classic”: vancomycin 
 
Vancomycin was first isolated in 1956 from Streptomyces orientalis and is considered as the 
prototypical member of a family of antibiotics that possess an aryl-glycine rich heptapeptide 
core (the aglycon) decorated with different sugar residues (Fig. 32).  
 
 
 
Figure 32: Structure of vancomycin and the vancomycin aglycon. 
 
The structural diversity within this natural product class is created by variation of amino 
acids in the aglycon as well as by differing positions, numbers and natures of the sugar 
residues attached to the aglycon. Vancomycin has found a clinical application as a potent 
antibiotic reagent acting against Gram-positive bacteria. Most importantly, it is also active 
against methicillin-resistant Staphylococcus aureus and has therefore become the antibiotic 
of last resort against this fatal pathogen.[92] 
Vancomycin has long attracted chemists not only because of its potent bioactivity but mainly 
due to its unusual molecular architecture. Efforts driven towards the total synthesis of 
vancomycin have resulted in the development of a number of new synthetic methods.[93] 
The most daunting synthetic challenge posed by the vancomycin molecular architecture are 
for sure the three stereochemical elements of atropisomerism occurring due to a hindered 
rotation within each of the cyclic tripeptide subunits.  
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1.7.1.1 Evans’ synthesis of the vancomycin aglycon 
 
In their considerations towards the synthesis of the vancomycin aglycon, Evans and 
coworkers envisioned a strategy that would enable them to control the formation of each of 
these elements of atropisomerism individually during the assembly of the target structure.  
 
 
 
Figure 33: Retrosynthesis for Evans’ synthesis of the vancomycin aglycon.[92] 
 
Extensive studies were carried out to achieve conditions that would deliver the desired 
stereochemistry of these crucial architectural features. Ultimately, the reactions developed 
dictated the overall synthesis plan and the individual strategy for each of the cyclic 
tripeptide units that were designated as M(2-4), M(4-6) and M(5-7) (Fig.33). The amino acids 
required to synthesize the 4-7 tetrapeptide were synthesized using the chiral auxiliary 
methods developed by the Evans group.  
Initially, two analogs of amino acid 6 were envisioned and investigated, a chloro and a 
dechloro derivative. With these two analogs in hand, the desired M(4-6) chlorine 
atropisomer would be possible to obtain from either stereochemical outcome of the 
envisioned SNAr-based macrocyclization due to the possibilities provided by the Sandmeyer 
reaction that would enable a NO2→H as well as an NO2→Cl transformation. In the end, the 
chloro analog delivered the desired atropisomer.  
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The synthesis of amino acid 6 starts with an (isothiocyanoacetyl)oxazolidinone-assisted 
asymmetric Aldol reaction affording the syn-Aldol product. In the following conversions the 
products had to be handled delicately to prevent SNAr-type reactions due to a fluoride 
displacement. After the Boc protection of the thioamide, the directing oxazolidinone was 
cleaved to afford the carboxylic acid, simultaneously the thiooxazolidinone was converted to 
the oxazolidinone. In the next step, amino acid 7 could be coupled to the free acid using 
EDC/HOBt activation and affording the dipeptide. Subsequently, the oxazolidinone was 
cleaved under mild basic conditions (Li2CO3) to afford a Boc-protected amino alcohol 
element. After removal of this Boc protection, amino acid 5 could be coupled to the resulting 
amine. The Boc protection on amino acid 5 was then replaced by a trifluoroacetamide, 
thereby setting the stage for the first macrocyclization reaction. The oxidative biaryl coupling 
was carried out using VOF3 and afforded the desired R atropisomer with a high 
diastereoselectivity. The reductive quenching had to be adjusted to prevent the reduction of 
the nitro group. Simultaneously, the benzyl ether protection on ring 5 was also removed 
during the coupling reaction.  
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Figure 34: Synthesis of the 4-7 tetrapeptide.[92] 
 
After the removal of the trifluoroacetamide protection, amino acid 4 was coupled with 
HATU/HOAt activation. The removal of the phenolic TBS ether on ring 4 then set the stage 
for the second macrocyclization reaction, the M(4-6) biaryl ether coupling (Fig. 34).  
At this point, various strategies using the two different amino acid 6 analog-derived 
tetrapeptides, were examined. The optimal conditions delivering the desired 
stereochemistry with the chloro analog of amino acid 6 were the application of basic 
conditions (Na2CO3) at room temperature. Due to an enhanced electrophilicity, the reaction 
of the chloro analog was much quicker compared to the dechloro analog (1.5 h vs. 66 h) for a 
full conversion. The desired atropisomer could be obtained with a dr of 5:1 in a yield of 79%. 
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After the removal of the nitro group by a two-step reduction/diazotation-reduction process, 
the monochloride with the desired R configuration, as confirmed by NMR, could be 
obtained. The Pd-mediated removal of the allyl ether on ring 4 and the aryltriflate on ring 5, 
as well as the adjustment of the protecting groups at the N-terminus and on ring 4 then and 
the cleavage of the methyl ethers on ring 7 set stage for the M(5-7) atropisomerization. The 
isomerization reaction proceeded under very mild conditions (55 °C, MeOH) to afford the 
desired S biaryl configuration with an excellent selectivity (dr >95:5). For the following final 
assembly of the vancomycin aglycon, the phenols on ring 5 and 7 were benzylated and the 
Piv protection on ring 4 was exchanged for an allyl ether again. Additionally, the Ms group 
on ring 4 was removed as well as the trifluoroacetamide protection. To the free amide, a 
pre-synthesized tripeptide was coupled using EDC/HOAt activation and affording the 
heptapeptide in 86% yield with no detectable epimerization (Fig. 35). 
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Figure 35: Synthesis of the heptapeptide intermediate and establishment of the M(4-6) and M(5-7) centers of 
atropisomerism.[92] 
 
The final SNAr macrocyclization provided the full tricyclic vancomycin core, the M(2-4) 
atropisomer with the desired R stereochemistry was obtained with a dr of 5:1 in an overall 
yield of 95%. After reduction of the diastereomeric mixture, the resulting diastereomeric 
anilines could be separated chromatographically. The following Sandmeyer transformation 
then installed the chlorine on ring 2 and provided the fully assembled protected vancomycin 
aglycon. Conversion of the methyl amide to the free acid by nitrosation/oxidation and 
careful removal of the remaining protecting groups finally afforded the vancomycin aglycon 
from a sequence of 40 steps (longest linear sequence) from 3,5-dimethoxy alcohol, the 
starting material for amino acid 7 (Fig. 36).[92] 
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Figure 36: Final transformations yielding the vancomycin aglycon.[92]  
 
 
1.7.1.2 Nicolaou’s total synthesis of vancomycin 
 
When planning the total synthesis of the vancomycin aglycon and subsequently vancomycin, 
Nicolaou and coworkers envisioned a strategy similar to the one of Evans et. al. concerning 
the order of establishment of the centers of atropisomerism. First the M(5-7) center should 
be established, followed by the M(4-6) center. Instead of an individual control of the single 
centers of atropisomerism, the building block of amino acid 4 was designed in a fashion that 
it would have the intrinsic ability to control the formation of both biaryl ethers (M(4-6) and 
M(4-2)). To achieve this, a triazene-mediated biaryl coupling method, based on the 
complexation of copper by triazene, was developed in the course of the efforts towards the 
synthesis of vancomycin in the Nicolaou group. For the M(5-7) linkage, a Suzuki-coupling 
approach was envisioned.[93] 
The synthesis of the individual amino acids required for the vancomycin framework was 
established by using well-established methods. Instead of auxiliary methods as used in the 
Evans approach, Sharpless asymmetric dihydroxylation or aminohydroxylation reactions 
were preferred. The synthesis of the amino acids 4 to 7 is summarized in Figure 37. 
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Figure 37: Syntheses of the building blocks for amino acids 4 to 7 (summarized).[93] 
 
To establish the first center of atropisomerism, the amino acids 5 and 7 were coupled in a 
Suzuki reaction that yielded 84% of a 2:1 mixture of atropisomers. Further investigation 
proved the major isomer to be one desired for the further synthesis.  
After conversion of the hydroxyl group to the azide as well as the hydrolysis of the methyl 
ester, the dipeptide was coupled with amino acid 6 using EDC/HOAt activation, affording the 
tripeptide in 85% yield (dr = 13:1). After removal of the Boc protection, the central amino 
acid 4 was coupled, yielding the tetrapeptide in 76% yield. The tetrapeptide was then 
subjected to the first triazene-based biaryl coupling that was carried out using CuBr∙SMe2 for 
the coupling and yielded the two possible atropisomers in an equal mixture with an overall 
yield of 60%. (Figure. 38 shows only the atropisomer relevant for the further synthesis.) The 
two atropisomers were easily be distinguished by their distinct NMR spectra. To establish 
the bicyclic 4-7 vancomycin framework, a macrolactamization reaction was carried out after 
the desilylation of the TBS ether, the conversion of the azide to the amine and the hydrolysis 
of the ethyl ester. An FDPP-mediated coupling reaction then provided the bicyclic system; 
the correct stereochemistry could be assigned by NMR analysis.[93] 
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Figure 38: Establishment of the 4-7 vancomycin framework.[93,94] 
 
The synthesis was then continued by preparing the molecule for the attachment of the N-
terminal tripeptide portion. First, the free hydroxyl function of amino acid 6 was reprotected 
as a silyl ether, and then the N-terminal Boc group was removed (Fig. 38).  
The N-terminal tripeptide was pre-synthesized from amino acids prepared by well-
established methods. The heptapeptide was obtained by an EDC/HOAt-mediated coupling in 
a yield of 81%. This set the stage for the second triazene-mediated biaryl ether coupling, 
which was carried out using the previously established conditions, yielding a 1:3 mixture of 
atropisomers in an overall yield of 72%. Unfortunately, the minor isomer was required for 
further synthesis but the yield could be enhanced by heating the chromatographically 
separated atropisomers in 1,2-dichlorobenzene which resulted in the formation of a 1:1 
mixture of separable atropisomers (Fig. 39).[94] 
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The final steps for the total synthesis of the vancomycin aglycon required the removal of the 
triazene, the oxidation of the homobenzylic alcohol as well as the removal of the remaining 
protecting groups. 
 
 
 
Figure 39: Final steps in the synthesis of the vancomycin aglycon.[94,95] 
 
Especially the removal of the triazene residue proved to be a greater challenge than 
expected. Initial attempts using standard conditions for the removal could not provide the 
desired phenol but resulted in a fully reduced product (X = H, refer to Figure 39). The 
successful sequence leading finally to the desired phenol started with the conversion to an 
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aniline by a Raney-Ni reduction. This also effected a partial cleavage of the benzyl ether, 
which was completed by a Pd(OH)2/C-reduction. Next, the aniline was converted to the 
diazonium salt, which was treated with potassium iodide to establish the iodide, this 
reductive procedure also resulted in the formation of the previously observed reduction 
product (X = H) which could not be separated from the iodide at this stage. Instead, the 
mixture was subjected to boronation conditions and on the boronate stage the reduced 
product could be removed by chromatography. The boronate was formed by deprotonation 
of all NH groups followed by metal-halogen-exchange with MeMgBr and iPrMgBr and 
quenching of the aryl-Grignard species with an excess of B(OMe)3. The peroxide-mediated 
oxidation of the boronate then finally provided the desired phenol derivative along with a 
reduced product which could be separated by preparative thin layer chromatography. 
Consequently, the overall yield for the phenol was only 50% from the aniline. Surprisingly, all 
of these manipulations did not affect the stereochemistry in the natural product. In 
preparation of the final oxidation, the phenol was protected with a methyl group. A 
sequential treatment with Dess-Martin periodinane, potassium permanganate and finally 
diazomethane established the methyl ester. Removal of the remaining protection groups 
with AlBr3/EtSH finally provided the desired vancomycin aglycon (Fig. 39).[95] 
To complete the synthesis of vancomycin, the sugar moieties still had to be coupled to the 
aglycon. First the aglycon had to be protected properly: persilylation and methyl ester 
formation followed by a selective desilylation of the central phenol provided the desired 
glycosyl acceptor. The development of a proper strategy for the glycosyl donors was again 
tedious work and resulted in the use of a trichloroacetimidate as the glucosyl donor and a 
fluoridated vancosamine donor. To complete the synthesis, the glucosyl building block was 
coupled to the deprotected vancomycin aglycon, providing a mono-glycosylated 
intermediate. After removal of the Alloc protection, the second sugar moiety was 
introduced, providing a protected vancomycin derivative. A sequential removal of the silyl 
groups and the acetate groups followed by the hydrolysis of the methyl ester and the 
reductive cleavage of the Cbz groups then finally yielded the complete natural product 
vancomycin (Fig. 40).[96] 
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Figure 40: Synthesis of vancomycin from the vancomycin aglycon.[96] 
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1.7.1.3 Synthesis planning, solid-phase peptide synthesis: oxathiocoraline 
 
Although solid-phase strategies are highly elaborated and offer solutions to a great number 
of synthetic problems, contributions to this field are still to be made. An alternative cleavage 
strategy meeting the requirements of a total synthesis is one innovation to solid-phase 
peptide chemistry that was investigated throughout the project presented in this 
dissertation. Another contribution to the field is represented by the synthesis of 
oxathiocoraline by Albericio and coworkers that is an example of efficient synthesis planning 
and development [90,91]. It also pinpoints that the transfer of synthetic strategies to the solid 
support requires complex considerations, a wise choice of protecting groups, the will to use a 
higher number of protecting groups and carefully planned transformations. Then, a 
successful and robust solid-phase strategy paves the road to a quick and simplified access to 
analogs and derivatives of the original compound.  
Oxathiocoraline is a C2-symmetrical compound belonging to a family of anti-tumoral bicyclic 
peptide antibiotics that are known bisintercalators to DNA.[97] Oxathiocoraline itself is not a 
natural product, it is a pharmacokinetically more stable derivative of the potent natural 
product thiocoraline[98,99] It contains a high density of non-proteinogenic amino acids, in this 
case N-methylated and D-amino acids, in addition it features a central disulfide bridge that is 
flanked by two ester bonds that establish the bicyclic core structure of the molecule (Fig. 
41). 
The total synthesis presented by Albericio and coworkers is highly elaborated and extensive 
preliminary studies were carried out to optimize the conditions for this challenging 
synthesis. The studies included the evaluation of the optimal starting amino acid, the 
investigation of alternative resins, coupling reagents and optimization of the protecting 
group strategy. One of the major difficulties to encounter in this synthesis is the lower 
reactivity of a hydroxyl group compared to an amine which is accompanied by a lower 
stability of the resulting ester bond and the formation of diketopiperazines. Cysteines are a 
challenge in the assembly of peptides as they are prone to racemization when they are part 
of an ester, additionally N-methylated cysteines are also known to eliminate under basic 
conditions and can easily undergo oxidation. This stands of course in stark contrast to the 
harsh conditions that are required for the coupling to N-methylated amino acids. 
In the successful synthesis route, glycine was chosen as the anchoring point to the solid 
phase, as no racemization can occur with this amino acid during the attachment to the resin 
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and further racemization is also suppressed. After removal of the Fmoc protection, Fmoc-
Ser(Trt)-OH was coupled to glycine using HATU/HOAt activation. The N-terminal Fmoc 
protection was then replaced by a p-nitrobenzyloxycarbonyl (pNZ) group that showed a 
better compatibility with the ester bond and serves on the other hand as a placeholder for 
the aromatic heterocyclic moiety. After removal of the trityl protection, the hydroxyl group 
was esterified with Alloc-NMe-Cys(Acm)-OH using DIPCDI and DMAP for the activation. The 
Alloc protection was then removed in a Pd-mediated isomerization and Boc-NMe-Cys(Acm)-
OH was coupled using HATU/HOAt activation and a reduced amount of base to minimize 
side reactions. By using this strategy the tetradepsipeptide could be obtained in 89% purity. 
The next step was the on-resin formation of the central disulfide bridge which was achieved 
by oxidation with iodine in methanol. The subsequent cleavage from the resin was 
performed in the presence of water to prevent the formation of sulfoxides. The cleavage 
conditions also removed the remaining Boc groups, providing the precursor for the final 
cyclizations. Without a purification step, the lyophilized crude peptide was pre-activated 
with HOAt at a slightly basic pH and PyBOP was used as the coupling reagent to establish the 
bicyclic structure. In this manner, the bicycle could be obtained without notable 
diketopiperazine formation. After a reductive removal of the pNZ groups, 3-hydroxyquinaldic 
acid was coupled using mild EDC/HOSu activation to finally yield oxathiocoraline in an overall 
yield of 7%. This synthesis is an example of a highly optimized solid-phase approach; the 
optimization nevertheless holds promise for a quick access to modified analogs of 
oxathiocoraline.[90] 
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Figure 41: Solid-phase synthesis of oxathiocoraline.[90] 
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2 Aims of the PhD project 
 
The main focus of this dissertation was set on the development of a general solid-phase 
approach to the natural product class of 3-amino-6-hydroxy-2-piperidone (Ahp) containing 
cyclodepsipeptides. This natural product class is, as described already, known for its potent 
and most intriguingly non-covalent inhibition of S1 serine proteases. The potent inhibition is 
achieved by adapting the so-called canonical conformation which has been recognized as a 
structural motif in proteins and peptides of natural and synthetic sources mediating a non-
covalent inhibition of serine proteases. [17-20] At the beginning of the project, solution-phase 
syntheses of two Ahp containing cyclodepsipeptides, micropeptin T-20 and somamide A, had 
been published.[100-102] Although these syntheses finally attained the synthesis of the 
respective natural product, they are highly specialized and require multi-step solution phase 
syntheses. Nevertheless, Yokokawa et. al. could prove in their syntheses that the crucial Ahp 
hemiaminal residue can readily be generated from a precursor aldehyde macrolactam at a 
late stage of the peptide synthesis. In fact, the Ahp hemiaminal forms spontaneously from 
the precursor aldehyde.[100-102] 
 
 
 
Figure 42: General structure of the Ahp containing depsipeptides. The Ahp hemiaminal is formed 
spontaneously from a precursor aldehyde macrocycle, with the equilibrium being on the side of the 
hemiaminal structure. 
 
Accordingly, the synthetic outline for a solid-phase approach to the class of Ahp containing 
cyclodepsipeptides envisioned the development a suitable precursor unit that can be 
coupled to solid support and, after the assembly of the peptide sequence, can be converted 
to an aldehyde residue (and thus ultimately to the Ahp unit). This approach was envisaged to 
pave the way to tailor-made Ahp cyclodepsipeptides because the unifying element of the 
substance class (i. e. the Ahp unit) was chosen as the anchoring point to the solid phase. As a 
proof of principle for this approach, a solid phase synthesis of the natural product Ahp 
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cyclodepsipeptide symplocamide A was chosen. Symplocamide A was only discovered 
recently[24] and no synthesis of this natural product had been reported before this PhD 
project.  
 
 
 
Figure 43: Symplocamide A, an Ahp cyclodepsipeptide isolated from a Symploca sp. from Papua New Guinea.[24] 
The natural product was chosen as the synthetic target for the validation of the newly developed solid-phase 
strategy. 
 
In a second step after its synthesis, a validation of its reported biological activity and 
investigation of further bioactivities were planned.  
After the successful development of a solid phase-based synthesis of Ahp containing 
cyclodepsipeptides, the follow-up question of the significance of the Ahp moiety in Ahp 
cyclodepsipeptides was to be addressed. The contribution of the Ahp moiety to the 
induction of a canonical conformation in the cyclodepsipeptide is well-described in 
literature. As the synthesis of such Ahp-containing cyclodepsipeptides is however rather 
laborious, the development of peptidic analogs of the Ahp containing cyclodepsipeptides 
that could retain the canonical conformation and thereby the biological activity was an aim 
in this PhD thesis.  
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To this end, analogs in which the Ahp unit was replaced by other amino acids were 
investigated for their biological activity. The elucidation of suitable Ahp mimics would enable 
a quick and if necessary combinatorial access to canonical conformation inhibitors and 
therefore represent valuable tools for chemical biology investigations of serine proteases.  
 
 
 
Figure 44: General structure of structure-activity analogs derived from symplocamide A. The amino acids 
envisioned to be investigated are indicated.  
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In a second project, the synthesis of the natural product symplostatin 4 and derivatives that 
would enable the biological investigation as well as the identification of the molecular target 
of symplostatin 4 by the means of an activity-based approach was planned.  
Symplostatin 4 is a linear peptide isolated from a cyanobacterium of the Symploca genus and 
shows a structural similarity to the potent cytotoxic agents dolastatin 10 and 15 which are 
lead compounds in cancer therapy. As dolastatin 10 and 15 are potent disruptors of 
microtubule polymers, symplostatin was also tested on microtubule interaction, displaying 
an effect significantly lower than dolastatins 10 and 15, but leading to the same cellular 
phenotypes.[103] 
Interestingly, the natural product gallinamide A isolated from a Schyzothryx sp., was 
published just shortly before symplostatin 4 was disclosed and later studies demonstrated 
that both natural products have the same structure.[103,104] However, gallinamide A emerged 
from a screen of compounds isolated from marine cyanobacteria and displayed a promising 
antimalarial activity.[104] Symplostatin 4 initially attracted interest as a target structure for 
this dissertation owing to the prominent Michael acceptor system that is accompanied by 
the rather unusual methyl-methoxypyrrolinone. In an activity-based approach, a probe 
generated on the basis of symplostatin 4 could be a valuable tool for the investigation of 
proteases that are known targets of α,β-unsaturated carbonyls. Moreover, the methyl-
methoxypyrrolinone unit could be studied in terms of its influence on the activity and 
selectivity of the natural product once a target is identified.  
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Figure 45: Symplostatin 4 and derivatives for biological studies. A: The natural product symplostatin 4, a natural 
product isolated from a Symploca sp. from Key Largo.[103] B: Derivatives of symplostatin 4 for biological studies. 
Differentially tagged derivatives should be accessible by the reaction of alkyne-modified analogs with 
differentially tagged azides using click chemistry. 
 
In addition, some chemical biology studies with symplostatin 4 such as a target identification 
in different organisms were envisaged. To this end, two collaborations with groups from 
different research fields were established. First, in collaboration with the van der Hoorn 
group (MPI Cologne), the effect of symplostatin 4 in the model plant Arabidopsis thaliana 
was to be investigated and the targets of symplostatin 4 and its analogs were to be 
identified. In addition, the molecular basis of the antimalarial activity of Symplostatin 4 
should be investigated. To this end, a collaboration with the Bogyo group (Stanford 
University) was initiated; this studies aimed at the determination of the potency of the 
antimalarial effect of symplostatin 4 as well as the target identification of this compound in 
Plasmodium falciparum using the newly generated derivatives of symplostatin 4.  
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3 Results and Discussion 
 
3.1 Chemistry and Biology of Ahp cyclodepsipeptides  
3.1.1 Retrosynthetic analysis of Ahp cyclodepsipeptides: Development of a synthetic 
strategy for a general solid-phase approach to this natural product class 
 
The Ahp cyclodepsipeptides are an interesting natural product class due to their potent 
biological activity directed against S1 serine proteases and their non-covalent mode of 
inhibition. Consequently, the substance class has been suggested as a potential lead for the 
rational design of drugs.[25] 
For investigating the interaction of an inhibitor with its target, a certain amount of inhibitor 
is required for the biological experiments. The isolation from natural sources, however, is 
usually laborious and yields mostly only minute amounts of the pure natural substance. 
Often, this amount does not suffice to initiate an elaborate evaluation of the biological 
activities of a natural substance. Moreover, for in-depth insights into the mode-of-action of a 
natural product, as well as for the development of new natural product-derived drugs, 
derivatives or analogs of the original substances are desired. The modified compounds can 
be used as tools in chemical biology approaches to investigate the structural determinants of 
inhibition. For the development of a bioactive small molecule into a drug, a derivatization of 
a lead structure is often required to enhance its efficacy and to minimize potential side 
effects as well pharmacological parameters such as the solubility or the uptake of a drug. 
The chemical synthesis of natural products and derivatives therefore provides a powerful 
platform that enables researchers to overcome the limited material supply and also offers a 
multitude of possibilities to the modification of natural products for different applications.  
So far, no general approach to the synthesis of Ahp cyclodepsipeptides has been established. 
Yokokawa and coworkers however reported the synthesis of the Ahp containing 
cyclodepsipeptides somamide A and micropeptin T-20. In these syntheses, they 
demonstrated that the crucial hemiaminal constituting the Ahp unit can be formed from a 
precursor aldehyde macrocycle at a late stage of the peptide synthesis. Both syntheses were 
based on a tedious multi-step solution-phase assembly of different peptide fragments to 
finally obtain the desired natural products.[100-102] 
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In contrast to this laborious solution synthesis, a more straightforward solid-phase strategy 
that could be applied to the synthesis of various Ahp cyclodepsipeptides was envisioned. To 
this end, the development of a general Ahp precursor molecule that could be used in solid 
phase synthesis was envisaged. Consequently, the whole Ahp cyclodepsipeptide could be 
assembled on solid phase, using standard peptide couplings as well as an on-resin 
esterification to the depsipeptide residue. 
To achieve this aim, the following retrosynthetic strategy was pursued (Fig. 46): The target 
Ahp cyclodepsipeptide structure should form spontaneously from a precursor aldehyde that 
could be generated upon liberation from the solid phase (A). To this end, the aldehyde 
functionality could be introduced via oxidative cleavage of a suitable masked glutamic 
aldehyde equivalent. The ring closure to the macrocycle from a linear precursor was planned 
as an on-resin macrolactamization. Prior to the macrolactamization, the attachment of the 
final amino acid to the sterically hindered and less reactive methylated amino acid needed to 
be achieved in an efficient manner. The esterification of the unreactive threonine side chain 
hydroxyl group was regarded as another crucial step in the synthesis, due to the low reaction 
rates of an esterification reaction compared to the formation of an amide bond (B). A further 
breakdown of the peptidic structure then leads to the Ahp precursor coupled to the solid 
phase (C). Finally, a synthesis of the Ahp precursor is required which could be achieved by 
solution-phase chemistry.  
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Figure 46: Retrosynthetic analysis for a solid-phase approach towards Ahp cyclodepsipeptides. 
 
Besides the incorporation of the masked glutamic aldehyde equivalent, the Ahp precursor 
needs to be equipped with adequate protection groups at both termini. Especially the 
protection of the C-terminus is critical for the synthesis strategy as it has to be stable under 
the different peptide synthesis conditions that are required for the assembly but also has to 
be removed under mild conditions at a late stage of the peptide synthesis. Consequently, an 
allyl ester protection seems to be a wise choice in this place because it is stable under the 
peptide synthesis conditions and can be cleaved under very mild conditions on the solid 
phase using palladium catalysis.[105] 
The choice of a double bond as the masked glutamic aldehyde equivalent was based on 
previous works by the Meldal group. This group has demonstrated that the oxidative 
cleavage of double bonds by a dihydroxylation-glycol cleavage protocol cleanly generates 
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aldehydes on solid phase.[105-108] Accordingly, an adapted dihydroxylation-glycol cleavage 
protocol should represent a feasible method to generate an aldehyde upon cleavage from 
the solid phase.  
 
3.1.1.1 Development of a suitable Ahp precursor - Synthesis of the Ahp precursor in 
solution 
 
The first Ahp precursor (1, Ahp precursor I) that was tested for the development of a solid-
phase approach featured a Fmoc protecting group for the N-terminus as well as an allyl ester 
protection of the C-terminus. The allyl ester represents an orthogonal protecting group that 
can be removed prior to the cyclization. As a masked glutamic aldehyde, an α,β-unsaturated 
carboxylic acid moiety was envisaged as the acid function can be coupled to the solid phase 
– for example onto a 2-chlorotrityl chloride resin. 
 
 
 
Figure 47: Ahp precursor I 
 
The synthesis of 1 started from the commercially available Boc-protected glutamic acid 
benzyl ester (Fig. 48). First, the glutamic acid side chain was reduced to the alcohol using 
Shioiri’s protocol from the synthesis of micropeptin T-20.[101] In this procedure, the acid 
functionality was first converted to a more reactive mixed anhydride which is then reduced 
to the alcohol using sodium borohydride. A subsequent Dess-Martin oxidation to the 
aldehyde however resulted in the preferential formation of a hemiaminal and only a small 
amount of the aldehyde was formed. However, due to the equilibrium between the 
aldehyde and hemiaminal form, a subsequent conversion of the mixture of hemiaminal and 
aldehyde to the corresponding α,β-unsaturated acid derivative was attempted. Despite 
several trials for example via Wittig reactions, all attempts to obtain this derivative failed, 
The formation of such undesired hemiaminals that represent intramolecular traps has been 
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described in literature.[109] The formation of these unwanted hemiaminals can however be 
prevented by the introduction of a second Boc protecting group on the amine.[110,111] 
 
 
 
Figure 48: First steps towards the synthesis of Ahp precursor I. Reagents and conditions: (a) i. EtOCOCl, Et3N, 
THF, -15 °C, 1 h; ii. NaBH4, THF/H2O (1:1), -15 °C, 1 h, then rt, 6 h (84%). 
 
As a consequence, the synthesis plan was reconsidered and a bis-Boc-protection of the 
amine residue was pursued (Fig. 49). To this end, Boc glutamic acid benzyl ester was first 
converted to the methyl ester 3. The second Boc group was introduced using Appela’s 
protocol which yielded the di-Boc-protected methyl ester 4.[112] The following mild DIBAL-H 
reduction of the methyl ester led to the respective aldehyde 5 in however only 27% yield as 
an overreduction to the alcohol could not be prevented in the tested reaction conditions. 
Nevertheless, in order to test the feasibility of the overall synthesis strategy, the synthesis 
was continued and the aldehyde 5 was converted smoothly to the α,β-unsaturated tert-butyl 
carboxylic ester 6 with a Wittig reaction. After this successful installation of the masked 
glutamic aldehyde equivalent, a change of the benzyl ester protecting group to an allyl ester 
protection was envisaged. This however, required a removal of the benzyl group without 
affecting the double bond of the α,β-unsaturated system. A selective hydrogenation 
protocol described by Shah et. al. that uses palladium(II) acetate as a catalyst and 
triethylsilane as an in situ source of hydrogen enabled the selective cleavage of the benzyl 
group in the presence of the double bond, affording the free carboxylic acid 7 in 62% 
yield.[113] The reaction however turned out to be more delicate than first expected. It turned 
out that the yields of this reaction depended on the batch size. Especially large reaction 
batches led to unsatisfying yields. Nonetheless, the carboxylic acid 7 was converted to the 
respective allyl ester using the well-established protocol by Kunz et. al. (i. e. allylation of the 
cesium salt of the carboxylic acid with allyl bromide).[114] The simultaneous removal of the 
tert-butyl ester and the Boc protection using trifluoroacetic acid then set the stage for the 
introduction of the Fmoc protection at the N-terminus to finally yield the desired Ahp 
precursor I (1). The reaction of the free amine 9 with Fmoc-Cl at a basic pH in a dioxane-
Results and Discussion 
87 
water mixture however provided the desired product 1 only in 49% yield and turned out to 
be rather irreproducible if larger reaction batch sizes were used.[115] 
 
 
 
Figure 49: Alternative pathway to the generation of the Ahp precursor I (1). Reagents and conditions: (a) 
methyl iodide, K2CO3, acetone, reflux, 4 h (quant.); (b) Boc2O, DMAP, CH3CN, rt, 20 h (98%); (c) DIBAL-H, 
toluene, -78 °C, 5 h (27%); (d) i. Ph3P
+CH2COO(CH3)3Cl,  2 M NaOH/toluene (1:1); ii. 5, ylide, CH2Cl2, rt, o/n (84%); 
(e) Pd(OAc)2, Et3SiH, Et3N, CH2Cl2, rt, o/n (62%); (f) i. Cs2CO3, MeOH; ii. allylbromide, DMF, rt, o/n (76%); (g) 
TFA/CH2Cl2 (1:1), rt, 4 h; (h) FmocCl, NaHCO3 (sat. solution), pH>8, dioxane/H2O (1:1), 40 °C, rt, o/n (max. 
49%).[115] 
 
This discouraging result, along with the only moderate yields for the reduction of the methyl 
ester to the aldehyde, called for yet another reconsideration of the synthetic strategy. 
Consequently, the initial synthesis strategy was picked up again: In contrast to the first 
attempt, the aldehyde should however be generated at a later stage of the synthesis. 
Consequently, the alcohol 2 was converted to the silyl ether intermediate 10 before the 
second Boc group was introduced in order to obtain the fully protected amino acid 11 in an 
excellent yield. The next step in the synthesis was the exchange of the protection at the 
carboxylic acid functionality. Next, the benzyl ester was removed by hydrogenation. The 
reaction conditions for this hydrogenation reaction required some adjustment as the 
standard conditions using ethanol or methanol as the solvent resulted in a significant 
cleavage of the silyl ether protection. This circumstance was overcome by using ethyl 
acetate as the solvent for the hydrogenation reaction as described by Hirota and 
coworkers.[98] Using this procedure, the free acid 12 was obtained on a large scale in 
quantitative yields. The conversion of the free acid 12 to the allyl ester-protected 
intermediate 13 then proceeded smoothly using the previously established reaction 
Results and Discussion 
88 
conditions, providing the fully protected intermediate 13 in 95% yield. The cleavage of the 
silyl ether protecting group required some investigations again. The standard conditions 
using TBAF resulted instead of the formation of the desired alcohol in the formation of an 
undesired lactone species. A method using phosphomolybdic acid that was immobilized on 
silica gel was however able to cleave the silyl ether selectively. [116]  Unfortunately, during 
chromatographic purification, one of the two Boc protecting groups was cleaved as well. 
Finally, a very mild CuII-mediated reaction provided the desired alcohol 14 in a high yield 
without any by-products.[117] The aldehyde 15 was then obtained by Dess-Martin oxidation 
and the subsequent Wittig reaction provided again the α,β-unsaturated, fully protected 
species 8. After the simultaneous removal of the Boc groups and the tert-butyl ester, the 
conversion of 9 to the Ahp precursor I (1) was reinvestigated (Fig. 50). For the introduction 
of the Fmoc group, different reaction conditions were explored: Fmoc-Cl and Fmoc-OSu 
were compared alongside with different inorganic (NaHCO3) and organic bases (Et3N, DIEA), 
different solvent mixtures were also investigated such as a dioxane-water mixture or pure 
organic solvent. Unfortunately none of the conditions explored could provide the desired 
Fmoc-protected species.  
 
 
 
Figure 50: A new attempt to the synthesis of Ahp precursor I (1). Reagents and conditions: (a) TBDMSCl, 
imidazole, CH2Cl2, 0 °C to rt, o/n (95%); (b) Boc2O, DMAP, CH3CN, rt, 24 h (81%, b.r.s.m.); (c) 10% Pd/C, H2, 
EtOAc, rt, 2.5 h (99%); (d) i. Cs2CO3, MeOH; ii. allylbromide, DMF, rt, o/n (95%); (e) CuCl2*2H2O, acetone/H2O 
(95:5), reflux, 1 h (92%); (f) Dess-Martin periodinane, CH2Cl2, rt, 1 h (84%); (g) i. Ph3P
+CH2COO(CH3)3Cl, 2 M 
NaOH/toluene (1:1); ii. 15, ylide, CH2Cl2, rt, o/n (94%); (h) TFA/CH2Cl2 (1:1), rt, 4 h.
[115,118] 
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As an alternative, several methods to cleave the Boc groups selectively and leave the tert-
butyl ester protection intact were then investigated. Depending on the reagents that were 
used, the cleavage of a single Boc group could be observed but also a complete 
decomposition of the material, most likely due to a Michael addition to the α,β-unsaturated 
system. The attempts to introduce a TMSE group as an alternative protection did not 
succeed; neither did the attempted exchange of the amine for an azide group.  
An even more discouraging result was then obtained when the little amount of Ahp 
precursor I that had been obtained by the former reaction strategy was coupled to the solid 
phase: the synthesis of a model peptide could not be carried out successfully as the cleavage 
of the Fmoc group already resulted in the formation of unwanted side products, rendering 
the precursor not suitable for a use in solid-phase synthesis. The source of the undesired 
side reactions as well as the difficulties in the installation of any protecting group at the N-
terminus is most likely the α,β-unsaturated system that is prone to nucleophilic attack, for 
example by the intramolecular amine group.  
These findings consequently required a reconsideration of the design of the Ahp precursor 
structure. Hence, it was necessary to omit the conjugated double bond and investigate a 
strategy for the incorporation of an isolated double bond as the masked glutamic aldehyde 
equivalent alongside with a group that would allow the attachment to the solid phase. 
Owing to the difficulties experienced previously for the introduction of the Fmoc protecting 
group, an alternative strategy was to maintain the bis-Boc protection and explore alternative 
resins that would be stable under the acidic conditions required for the removal of the Boc 
groups as well as under the basic conditions required for the removal of Fmoc protecting 
groups.  
In a first study towards such a system, a precursor with a terminal vinyl iodide which could 
be coupled to a borylated resin in a Suzuki reaction was investigated. This approach required 
in addition an exchange of the permanent allyl ester protection to a protecting group that is 
stable under the cross-coupling conditions as well as under the conditions required for the 
removal of the Boc and the Fmoc protection. These features are provided by the 2-
(pyridyl)ethyl ester (Pet) protecting group that was introduced by Kunz and Kessler and can 
be removed after alkylation with mild base.[119,120] The application of this protecting group in 
solid-phase peptide synthesis has been demonstrated by Taylor et. al..[121] 
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Furthermore, the new synthetic route envisaged the ring opening of a hemiaminal derived 
from pyroglutamic acid by a Wittig reaction, thereby completely avoiding the formation of a 
highly reactive intermediate aldehyde. Hence, the synthesis started from pyroglutamic acid 
which could readily be esterified with 2-(pyridyl)ethyl alcohol and protected with a Boc 
group at the amide position. The DIBAL-H reduction of the 2-pyrrolidone then yielded the 
hemiaminal that could be ring-opened by a Wittig reaction with Ph3PCH2I (Fig. 51). 
 
 
 
Figure 51: An alternative Ahp precursor suitable for the coupling to a borylated resin. 
 
With this alternative precursor in hand, a Suzuki coupling to two different borylated resins 
was investigated (Fig.52).  
 
 
 
Figure 52: Attempted attachment of the vinyl iodide precursor to borylated resins. 
  
Results and Discussion 
91 
The first resin was a boronic ester-modified resin that was generated by the reaction of 4-
bromopolystyrene with bispinacolatodiboron. The reaction with the alternative Ahp 
precursor was monitored by Fmoc determination after the attachment of the second amino 
acid. For this combination of resin and precursor, only very low coupling yields were 
achieved, with a maximal loading of 2.5%.[122] As an alternative, a boronic acid-modified 
resin was also investigated; however, again only very low coupling yields could be achieved 
(4.7%) (Fig. 52).[123,124] Due to these disappointing results, the Suzuki-cross-coupling 
approach was not pursued further. 
The final solution towards the synthesis of a suitable Ahp precursor II resulted from a 
reinvestigation of the second synthesis approach of Ahp precursor I. The idea was to use an 
alternative Wittig reagent that could provide on the one hand the free acid required for the 
attachment to a suitable resin and could on the other hand introduce an isolated (and no 
longer a conjugated) double bond, if aldehyde 15 was used. To set this into practice, a Wittig 
reagent derived from butyric acid was used and Ahp precursor II (16) could readily be 
synthesized from the aldehyde 15 (Fig. 53). For the Wittig reaction, different bases 
(NaHMDS, KHMDS, LHMDS), an addition of DMPU and different reaction conditions (-78 °C 
to rt) were explored. The best results were obtained with LHMDS without any additive and a 
slow warming of the reaction mixture from 0 °C to ambient temperature. The 
chromatographic purification of the free acid product required some effort to find an 
optimal solvent mixture and an adequate flow rate to ensure a pure product.[115,118]  
 
 
 
Figure 53: The final modification yielding Ahp precursor II (16). Reagents and conditions: a) i. Ph3P
+(CH2)3CO2H 
Br-, LHMDS,THF, 0 °C, 55 min; ii. 15, THF, 0 °C to rt, o/n (64%).[115,118] 
  
Results and Discussion 
92 
3.1.1.2 Development of a solid-phase strategy with Ahp precursor II 
 
With the Ahp precursor II (16) in hands, a solid-phase synthesis strategy using this building 
block could finally be investigated. To this end, a synthesis of the natural product 
symplocamide A was envisaged. This natural product was isolated in 2007 and elucidated as 
a potent chymotrypsin inhibitor.[24] Furthermore, at the beginning of this dissertation no 
synthesis of symplocamide A had been reported.  
Initially, first model studies on a symplocamide derivative in which the 3-bromo-4-methyl N-
methyl tyrosine was replaced by an N-methyl phenylalanine moiety were performed. To this 
end, the Ahp precursor was coupled to amino-methylated polystyrene resin and the peptide 
sequence was assembled solely with standard conditions (HOBt/HBTU peptide coupling; 
DIC/DMAP esterification; PyBrOP coupling to mPhe) to test for general problems in the 
synthesis route. The conditions for the oxidative cleavage from the solid phase were adapted 
from the protocol provided by Meldal and coworkers, using OsO4 and NaIO4 in a one-pot 
reaction and adding DABCO to suppress the formation of hydroxymethyl ketones 
(Fig.54).[108]  
 
 
 
Figure 54: Synthesis of a first model peptide on amino-methylated polystyrene. Reagents and conditions: (a) i. 
amino-methylpolystyrene (0.9 mmol/g), 16 (1.2 eq.), HOBt, DIC, CH2Cl2/DMF (9:1), rt, 24 h; ii. CH2Cl2/DIEA/Ac2O 
(3:1:1), 3h; (b) i. TFA/CH2Cl2 (1:1) 1 h; ii. Et3N/CH2Cl2 (1:9), 2x 10 min; iii. Fmoc-Cit-OH, HOBt, HBTU, DIEA, DMF, 
2 h (55%, by Fmoc determination, 2 steps).[115] 
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The peptide was cleaved from the resin and the crude peptide was purified by HPLC. A 
putatively pure peptide fraction was obtained by HPLC purification. The subsequent analysis 
of this fraction by LC-MS revealed however that the fraction still contained a large quantity 
of impurities.[115]  
The extent of impurities found after resin cleavage gave rise to the suspicion that the 
polystyrene core of the resin used in the synthesis was not stable under the cleavage 
conditions. This hypothesis was reinforced by a simple test reaction in which the amino-
methylated polystyrene was acylated with acetic anhydride and base. The resin was then 
subjected to the reaction conditions for the oxidative cleavage. A LC-MS analysis of the 
cleaved material showed clearly the same impurities that had been observed after the 
cleavage of the model peptide, proving that the polystyrene core is indeed instable under 
the cleavage conditions.  
To overcome this obstacle, two alternative resins (NovaPEG amino resin and aminoPEGA 
resin, both from Novabiochem) that consist of a polyethylene-glycol core instead of a 
polystyrene core were investigated under the same conditions as the amino-methylated 
resin. For both resins, no impurities were observed after the cleavage. For practical reasons, 
NovaPEG amino resin was therefore chosen as the solid support in subsequent syntheses.  
In a first study the model peptide that had previously been synthesized on the amino-
methylated polystyrene was re-synthesized on the NovaPEG amino resin. Consequently, 
reaction conditions adapted to the different handling of the polyethylene-glycol-based resin 
had to be developed. For example, this resin shows a swelling behavior that is significantly 
different from the behavior of customary polystyrene-based resins and is especially difficult 
to dry to a constant weight. Therefore, tedious washings with anhydrous solvents and 
prolonged drying under high vacuum were performed prior to reactions that required a dry 
resin (for example an Fmoc determination). Furthermore, the coupling time for a regular 
peptide coupling was extended to four hours or sometimes even overnight to achieve 
complete conversions.  
The coupling of the Ahp precursor to the NovaPEG amino resin was achieved with DIC/HOBt 
activation, followed by a capping step to block the remaining free amines. The removal of 
the Boc groups from the Ahp precursor was achieved by using a mixture of 50% TFA in 
dichloromethane. This was followed by a neutralization step with 10% triethylamine in 
dichloromethane. For the regular peptide couplings HOBt/HBTU activation was applied after 
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the deprotection of the N-terminus. For the removal of the Fmoc protection a mixture of 
20% piperidine in DMF was used.  
After the coupling of the P1 amino acid citrulline, the resin was dried thoroughly to enable 
the determination of the initial loading by an Fmoc determination. A full loading of the resin 
was not intended to prevent side-reactions during the on-resin macrolactamization reaction. 
Instead, a lower loading to ensure pseudo-dilution conditions similar to the conditions used 
for cyclization reactions in solution was envisaged. This was achieved by using 
2.4 equivalents of the Ahp precursor 16 in the loading reaction which resulted in an initial 
loading of efficiency of 30% (0.20 mmol/g resin). 
Next, a threonine building block was incorporated that did not feature a protecting group on 
the side chain hydroxyl function. The secondary alcohol of the threonine side chain is much 
less reactive than a primary amine in coupling reactions and therefore no laborious 
protection/deprotection sequence prior to the esterification on this moiety is therefore 
required. In the next steps, Fmoc-Gln(Trt)-OH was coupled, followed by butyric acid. 
The subsequent esterification needed different activating reagents and a higher excess of 
reagents than a standard peptide coupling. To this end, the conditions for the esterification 
of the threonine side chain with valine were optimized. The best protocol consisted of four 
repetitive short-time (2 hours) couplings, using 10 equivalents of Fmoc-Val-OH and the 
coupling reagent (DIC) but only 1 equivalent of coupling additive (DMAP) in a mixture of 
dichloromethane and dimethylformamide. This procedure provided excellent coupling yields 
that were superior compared to the yields obtained for example by a single 24 hour coupling 
as determined by resin loading determination after the esterification (Fig. 55).  
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Figure 55: First steps in the synthesis of a symplocamide A model peptide on amino NovaPEG resin. Reagents 
and conditions: (a) i. amino NovaPEG resin (0.66 mmol/g), 16 (2.4 eq.), HOBt, DIC, CH2Cl2/DMF (9:1), 24 h; ii. 
CH2Cl2/DIEA/Ac2O (3:1:1), 3 h (b) i. TFA/CH2Cl2 (1:1), 1 h; ii. Et3N/CH2Cl2 (1:9), 2x 10 min; iii. Fmoc-Cit-OH, HOBt, 
HBTU, DIEA, DMF, 5 h (30%, by Fmoc determination, 2 steps); (c) i. piperidine/DMF (1:4), 2x 15 min; ii. Fmoc-
Thr-OH, HOBT, HBTU, DIEA, DMF, 2 h; iii. piperidine/DMF (1:4), 2x 15 min; iv. Fmoc-Gln(Trt)-OH, HOBT, HBTU, 
DIEA, DMF, 2 h (88% by Fmoc determination, 2 couplings); (d) i. piperidine/DMF (1:4), 2x 15 min; ii. butyric 
acid, HOBT, HBTU, DIEA, DMF, 2 h; iii. Fmoc-Val-OH, DIC, DMAP, CH2Cl2/DMF (9:1), 4 x 2 h (79% by Fmoc 
determination, 2 couplings).[115] 
 
Next, Fmoc-N-methyl phenylalanine was coupled, followed by cleavage of the Fmoc group. 
The coupling of Fmoc-Ile-OH to the N-methylated phenylalanine required harsher coupling 
conditions and was achieved by using PyBrOP as the coupling reagent and prolonging the 
reaction time to 24 hours. PyBrOP is the coupling reagent of choice for the difficult coupling 
to sterically hindered and less reactive amino acids such as N-methylated amino acids. After 
the attachment of the final amino acid isoleucine, the Fmoc protection on this amino acid as 
well as the allyl protection on the Ahp precursor needed to be removed to set the stage for 
the cyclization reaction. The Fmoc group was cleaved using the standard protocol, the 
regular washing protocol was supplemented by a tedious washing protocol and thorough 
drying in order to prepare the resin for the removal of the allyl protection. The removal of 
the allyl group was carried out using the protocol established by Vaz, using Pd(PPh3)4 as 
catalyst and morpholine as the scavenger and conducting the reaction in degassed 
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solvent.[105] In order to remove residual catalyst, a tedious washing protocol was again 
required after the cleavage reaction. 
For the on-resin macrolactamization, the conditions established during the first synthesis on 
the amino-methylated polystyrene resin were employed. Consequently, PyBOP as the 
coupling reagent along with the additive HOBt and the base DIEA were used and the reaction 
time was extended to 24 hours to ensure a complete conversion. As a further optimization, 
first HOBt and DIEA were added as a solution in DMF to the resin for the pre-activation of 
the free acid, followed by addition of PyBOP dissolved in DMF; the resulting suspension was 
then shaken for 24 hours. After the customary washing of the resin, a Kaiser test was carried 
out to check for full conversion, revealing a complete reaction after 24 hours. In addition, no 
intermolecular coupling products could be observed by LC-MS analysis after the cleavage 
from the resin, indicating the applicability of the found reaction conditions (Fig. 56).  
In the first attempt to synthesize a symplocamide A model peptide, cleavage of the crude 
peptide from the resin was achieved by using the reaction conditions reported by the Meldal 
group.[108] In this procedure, a precipitation of sodium periodate and DABCO from the water-
THF mixture was, however, observed. To prevent the precipitation as well as to account for 
the different swelling properties of the PEG-based resin, the cleavage conditions were 
adjusted. Sodium periodate and DABCO were dissolved individually in water, using 
ultrasonication to promote dissolution of the reagents. The reagent solutions were then 
added to the dry resin, which was subsequently allowed to swell in this mixture for 10 
minutes. After this time, THF was added to obtain a 1:1 solvent mixture and the resin was 
shaken for 2 minutes. After this time, a solution of osmium tetroxide in t-BuOH was carefully 
added and the resin was shaken for 20 hours. For work-up, the highly toxic osmium tetroxide 
was quenched with sodium metabisulfite. The extraction of the resulting aqueous solution 
with organic solvents turned out to be rather tedious and best results were obtained with 
ethyl acetate. 
In order to investigate the efficiency of the cleavage protocol, the cleavage of the crude 
peptide from the resin was carried out twice. The resulting crude mixtures were analyzed 
separately to investigate the impact of a double cleavage procedure on the yield of the solid-
phase synthesis. As the second cleavage contained only traces of the desired peptide, only a 
single cleavage reaction was used in later Ahp cyclodepsipeptide syntheses. After the 
cleavage from the resin, the crude peptide with the trityl protecting group on the glutamine 
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side chain was purified by HPLC, yielding the desired Ahp cyclodepsipeptide in 1.2% overall 
yield (based on 18).[115] 
Next, a cleavage of the trityl protecting of the glutamine side chain was attempted. To this 
end, a solution containing 95% trifluoroacetic acid and 2.5% water and TIS, respectively, was 
used. However, when the Ahp cyclodepsipeptide 24 was submitted to these conditions, a 
rapid and almost complete decomposition of the peptide was observed, owing most 
probably to the strong acidic conditions (Fig. 56).[115] This finding indicates that Ahp 
cyclodepsipeptides are not stable to strongly acidic conditions, calling for an adjustment of 
the synthetic route (via the use of alternative building blocks with differently cleavable 
protecting groups).  
 
 
 
Figure 56: Synthesis of a symplocamide A model peptide on amino NovaPEG resin (continued). Reagents and 
conditions: (a) i. piperidine/DMF (1:4), 2x 15 min; ii. Fmoc-NMePhe-OH, HOBT, HBTU, DIEA, DMF, 2 h; iii. 
piperidine/DMF (1:4), 2x 15 min; iv. Fmoc-Ile-OH, PyBrOP, DIEA, DMF, 24 h (60%, by Fmoc determination, 2 
couplings); (b) i. piperidine/DMF (1:4), 2x 15 min; ii. Pd(PPh3)4, morpholine, CH2Cl2, 30 min; (c). PyBOP, HOBt, 
DIEA, DMF, 24 h; (d) i. NaIO4, OsO4 (0.1 M in t-BuOH), DABCO, H2O/THF (1:1), 20 h; ii. HPLC purification (1.2 % 
overall yield); (e) TFA/TIS/H2O (95:2.5:2.5).
[115] 
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Thus, in later syntheses of Ahp cyclodepsipeptides, protecting groups requiring strong acid 
for their removal should be avoided or cleaved before the formation of the Ahp moiety. 
Fortunately, the overall strategy for the synthesis of the Ahp cyclodepsipeptides however 
proved to be feasible.  
 
3.1.2 Solid-phase total synthesis of symplocamide A 
 
Consequently, to achieve a total synthesis of symplocamide A, an introduction of the 
glutamine moiety was by coupling of Boc-Gln-OH was envisaged, thereby leaving the side 
chain unprotected and rendering a later deprotection obsolete. An unprotected glutamine 
side chain is however always prone to form pyroglutamates under weak acidic conditions. 
The cleavage of the Boc group is however performed under strong acidic conditions. As the 
neutralization is carried out directly after the cleavage, the formation of pyroglutamates 
seemed rather unlikely in this case. In contrast, the possibility to use Boc-protected amino 
acid building blocks as an alternative to Fmoc-protected species also offered the opportunity 
to a simplified solution phase synthesis of amino acid building blocks. For example, the 
required unnatural tyrosine derivative 3-bromo-4-methyl-N-methyl tyrosine was synthesized 
as a Boc-protected derivative (Fig. 57). This building block was synthesized in a 
straightforward manner from (L)-tyrosine using a literature procedure for the first steps of 
the synthesis. To this end, a bromination of the aromatic moiety was performed, followed by 
introduction of the Boc group. Then, the ester as well as phenol moiety were methylated, 
followed by N-methylation with sodium hydride and methyl iodide in DMF. A fine-tuning of 
the conditions of the N-methylation was required to prevent a racemization of the amino 
acid building block; consequently, no racemization was detected when the reaction time was 
limited to one hour. Finally, the methyl ester was saponified, leading to the building block 29 
for solid phase synthesis.[118,125]  
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Figure 57: Synthesis of the N-methylated (3-Br,4-OMe) tyrosine building block for the symplocamide A 
synthesis. Reagents and conditions: (a) HBr in HOAc (33%), Br2, HOAc, rt, 27 h (96%); (b) Boc2O, 2 M NaOH, pH 
9, t-BuOH/H2O (9:1), rt, 1 h (93%); (c) i. 29, Cs2CO3 (aq.), MeOH/H2O (11:1); ii. Cs salt of 29, CH3I, DMF, rt, 18 h 
(70%)[125]; (d) NaH, CH3I, DMF, rt, 1 h; (90%); (e) LiOH, THF/MeOH/H2O (1.67:1:0.67), rt, 5 h (78%)
[118]. 
 
With this tyrosine building block 29 in hands, the synthesis of symplocamide A was initiated. 
The loading of the resin with the Ahp precursor was adjusted slightly for this synthesis by 
using the coupling reagents HBTU/HOBt activation instead of the previously applied 
DIC/HOBt activation, leading to an enhanced coupling yield of 36%. In the other reaction 
steps, the reaction conditions of the model peptide synthesis were employed. Importantly, 
the reactions as well as their yields proved to be fully reproducible and were verified by 
intermediate loading determinations. The natural product symplocamide A could finally be 
obtained after the oxidative cleavage from the resin and a subsequent HPLC purification of 
the crude peptide in an overall yield of 3% (based on 31) (Fig. 58). [115,118] 
The spectroscopic data (NMR analysis, mass spectra, optical rotation) of the synthetic 
symplocamide A derivative thereby corresponded well to the data published for the isolated 
natural product symplocamide A[24], proving a successful synthesis of this natural product.  
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Figure 58: Solid-phase synthesis of symplocamide A. Reagents and conditions: (a) i. amino NovaPEG resin (0.66 
mmol/g), 16 (2.5 eq.), HOBt, HBTU, DIEA, CH2Cl2/DMF (9:1), 24 h; ii. CH2Cl2/DIEA/Ac2O (3:1:1), 2x 2h; (b) i. 
TFA/CH2Cl2 (1:1), 1 h; ii. Et3N/CH2Cl2 (1:9), 2x 10 min; iii. Fmoc-Cit-OH, HOBt, HBTU, DIEA, DMF, 4 h (36%, by 
Fmoc determination, 2 steps); (c) i. piperidine/DMF (1:4), 2x 15 min; ii. Fmoc-Thr-OH, HOBT, HBTU, DIEA, DMF, 
5 h; iii. piperidine/DMF (1:4), 2x 15 min; iv. Boc-Gln-OH, HOBT, HBTU, DIEA, DMF, 4 h; (d) i. TFA/CH2Cl2 (1:1), 
1 h;  ii. Et3N/CH2Cl2 (1:9), 2x 10 min;  iii. butyric acid, HOBT, HBTU, DIEA, DMF, 4 h; iv. Fmoc-Val-OH, DIC, DMAP, 
CH2Cl2/DMF (9:1), 4x2 h (92% by Fmoc determination, 4 couplings); (e) i. piperidine/DMF (1:4), 2x 15 min; ii. 
Boc-mTyr(3-Br, 4-OMe)-OH, HOBT, HBTU, DIEA, DMF, 4.5 h; iii. TFA/CH2Cl2 (1:1), 1 h; iv. Et3N/CH2Cl2 (1:9), 2x 
10 min; v. Fmoc-Ile-OH, PyBrOP, DIEA, DMF, 24 h (73%, by Fmoc determination , 2 couplings); (f) i. 
piperidine/DMF (1:4), 2x 15 min; ii. Pd(PPh3)4, morpholine, CH2Cl2, 30 min; (g) PyBOP, HOBt, DIEA, DMF, 24 h; 
(h) i. NaIO4, OsO4 (0.1 M in t-BuOH), DABCO, H2O/THF (1:1), 20 h; ii. HPLC purification (3% overall yield). [115,118]  
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3.1.3 Biological evaluation of symplocamide A 
 
After the successful synthesis of symplocamide A, its biological properties were investigated. 
To this end, its reported chymotrypsin-inhibitory properties were verified. The inhibition 
assay was performed using a previously established assay.[126-128] In these measurements, 
the synthetic symplocamide A displayed a Ki value of 0.32 ± 0.09 μM which is in good 
accordance with the literature report (lit.[24]), IC50 = 0.38 ± 0.08 μM). Due to this potent 
inhibition, an attempt to co-crystallize symplocamide A with its target protease 
chymotrypsin was undertaken by the Groll group (TU München). Yet, all investigated 
conditions unfortunately failed to deliver a suitable crystal for x-ray structure 
determinations. Furthermore, the cross-reactivity of symplocamide A was tested in a trypsin-
inhibition assay; no inhibition of trypsin was detected.  
In the original publication of the symplocamide A isolation and structure elucidation, it was 
suggested that symplocamide A could act also as a proteasome inhibitor.[24] To test this 
hypothesis, two different proteasome inhibition assays, the first being a fluorescence-based 
enzyme assay and the second being an activity-based profiling assay, were performed with 
symplocamide A. In both assays no inhibition of the proteasome or one of its subunits was 
observed. This result is however not surprising if one is aware of the fact that despite its 
deceptive nomenclature, the chymotryptic subunit of the proteasome is structurally highly 
different from the serine protease chymotrypsin and that an inhibitor of this protease is not 
automatically prone to inhibit this subunit. In addition, Gerwick et. al. also reported a 
significant in vitro cytotoxicity of symplocamide A in two cancer cell lines (NCI H-460 
nonsmall lung cancer cells, IC50 = 40 nM; neuro-2A mouse neuroblastoma cells, IC50 = 
29 nM[24]). The attempt to reproduce this activity, however, failed, probably due to an 
alternative assay system.  
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3.2 Development and biological investigation of natural product-derived canonical-
conformation protease inhibitors 
 
The Ahp cyclodepsipeptides have been recognized as members of the class of canonical-
conformation serine protease inhibitors.[18] Originally, the canonical conformation was 
recognized as the inhibitory motif of several proteinaceous inhibitors and at least 18 non-
homologous families of serine protease inhibitors are known to adopt the canonical 
conformation.[17,18] For the plant-derived Bowman-Birk type inhibitors, extensive studies 
regarding the sequential preferences and a minimal sequence that is required to adopt the 
canonical conformation have been carried out.[18,20,22] During their studies on the structure 
and bioactivities of peptidic inhibitors derived from Bowman-Birk type inhibitors, 
Leatherbarrow et. al. became aware of the similarity of the conformation adopted by Ahp 
cyclodepsipeptides upon binding to a protease and the canonical conformation adopted by 
the BBI-derived inhibitors. Indeed, a detailed comparison of the binding conformations of 
the different inhibitors revealed that the Ahp cyclodepsipeptides along with other 
macrocyclic inhibitors of bacterial origin also adopt the canonical conformation, thereby 
representing a remarkable example of a convergent evolution.[18,129] The Ahp unit is 
therefore proposed as crucial for the bioactivity as it stabilizes the canonical conformation 
by participation in the hydrogen bonding and enhances the selectivity of the inhibitor by 
occupation of the S1’ subsite. Furthermore, the Ahp unit also occupies the region of the 
catalytic pocket in which the water molecule required for the hydrolysis of a peptidic 
substrate is commonly located. As a result, this water molecule is excluded from the 
enzyme, resulting in an increased hydrolytic stability of the inhibitor.[18,29] Consequently, Ahp 
cyclodepsipeptides represent lead structures for the design of small molecule analogs of the 
canonical-conformation serine protease inhibitors with the Ahp residue as central element 
to pre-arrange the cyclodepsipeptide into the canonical conformation. Despite the 
developed synthesis to Ahp cyclodepsipeptides, the installation of the Ahp residue into the 
cyclodepsipeptide structure is a laborious step. It would therefore be of interest to 
investigate if the Ahp residue is essential for achieving a canonical conformation or if 
synthetically easier accessible mimics can be designed.  
Consequently, the next step in this dissertation was to investigate if structurally simplified 
cyclodepsipeptides in which a natural amino acid replaces the Ahp unit under retention of 
the biological activity can be developed. After an adequate replacement for the Ahp unit had 
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been found, structure-activity analogs of the Ahp-mimicked peptides were synthesized to 
gain an in-depth insight into the mode of action and the structural determinants of these 
small molecule analogs of canonical-conformation inhibitors.  
 
3.2.1 Development of a solid-phase strategy towards simplified analogs of Ahp 
cyclodepsipeptides  
 
The new approach to simplified analogs of the Ahp cyclodepsipeptides required an 
alternative strategy for the solid phase assembly of the cyclodepsipeptides. In contrast to 
the solid-phase strategy for the synthesis of the Ahp cyclodepsipeptides, the synthesized 
cyclodepsipeptides were not cyclized on the resin but in solution. Therefore, a more straight-
forward solid-phase synthesis was possible (Fig. 59). Cyclization of the linear peptides was 
carried out prior to the cleavage of the remaining protecting groups. Since the resulting 
cyclodepsipeptides were expected to display a higher stability towards acidic conditions than 
the Ahp cyclodepsipeptides, the use of protecting groups that are cleaved by strong acidic 
conditions (e. g. a trityl amide protection for glutamine) was considered to be possible 
during the envisioned synthesis.  
2-chlorotrityl chloride resin was chosen as the solid support for this synthesis because it 
provides a reliable basis for the customary synthesis of peptides on solid phase. Regular 
Fmoc-based peptide chemistry can be carried out with this resin that is also compatible with 
palladium-mediated cleavage of allyl groups. Moreover, this resin allows to cleave peptides 
with weak acids from the solid support (leaving a free C-terminus) while the “standard” side 
chain protecting groups are maintained.[130] 
As the anchoring point to the solid phase, the P1 amino acid of the cyclodepsipeptide was 
chosen, enabling a combinatorial approach to different structure-activity analogs from one 
resin loaded with the selectivity-determining P1 amino acid. After the attachment of the P1 
amino acid, the P2 threonine residue was coupled to the resin, in analogy to the Ahp 
cyclodepsipeptide synthesis, without a protection of the side chain. After the coupling of the 
future P3 and P4 residues, the esterification was carried out under the conditions developed 
during the synthesis of the Ahp cyclodepsipeptides.[115,118] For the incorporation of the 
commercially not available N-methylated amino acids, the building block synthesis of the N-
methylated amino acids had to be adjusted to the different solid support. In the synthesis of 
Ahp cyclodepsipeptides on solid support, a Boc protecting group was used for these building 
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blocks. This protecting group is however not compatible with the acid labile 2-chlorotrityl 
chloride resin. The building block synthesis was therefore adapted to the new resin and 
instead of a Boc-protection, N-methyl amino acid derivatives with an Alloc-protection on the 
amino group were generated from the existing Boc protected derivatives. The Alloc group 
was removed during solid phase synthesis with the protocol developed by Vaz that was also 
used in the previous syntheses.[105] After the coupling of the N-methylated amino acid (or for 
structure-activity relationship studies an alternative amino acid on this position), a PyBrOP-
mediated coupling was again performed to couple the next amino acid on the secondary 
amine. The final step of the solid-phase synthesis was then the coupling of the amino acid 
candidate for the replacement of the Ahp residue (P1’ position). After the cleavage from the 
resin, the linear peptide was then cyclized in solution and the remaining protecting groups 
were cleaved. Finally, the resulting cyclodepsipeptide was purified by HPLC providing pure 
material for the further biological evaluation. (Fig.59, Fig. 60) 
 
 
 
Figure 59: Synthetic strategy towards the solid-phase synthesis of Ahp cyclodepsipeptide-derived canonical-
conformation analogs. P1, P3: amino acids occupying the S1 or the S3 subsite, respectively; R1: P4 amino acid 
(plus optional group); R2, R3: residues of the N-methylated analog or a substitution; R4: side chain of P2’ amino 
acid; A: side chain of the amino acid replacing the Ahp moiety. 
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3.2.2 Synthesis of SAR analogs of Ahp-mimicked cyclodepsipeptides 
 
This strategy allowed the synthesis of various simplified Ahp cyclodepsipeptide analogs 
(Fig. 60). For some cyclodepsipeptides, certain modifications of the synthesis route were 
necessary: For example, if serine was used as the Ahp replacement, for some analogs Boc-
Ser(Bzl)-OH was used as the building block during synthesis. The Boc group could be cleaved 
without removing the benzyl ether protection on the serine side chain prior to the 
cyclization. This was important as the benzyl ether protection needed to remain intact 
during the cyclization reaction in order to prevent side reactions during the 
macrolactamization. Cleavage of the benzyl protecting group, however, turned out to 
require rather harsh reaction conditions (resulting in the need of a high amount of palladium 
on active charcoal (up to 40% wt) and 10% of acetic acid and overnight reaction times to 
achieve a full cleavage of the benzyl ether). These reaction conditions, however, proved to 
be incompatible with some modified N-methyl tyrosine derivatives (for example with a 3-
bromo modification). Consequently, in these syntheses, Fmoc-Ser(Trt)-OH was used as the 
serine building block. For the cyclization of the linear depsipeptide, the following reaction 
conditions were used: As reagents, the combination of reagents established by Albericio et. 
al. during the synthesis of kahalalide F (i. e. PyBOP, DIEA) were used.[131] However, the 
procedure (low temperature, high dilution) was adapted from Shioiri’s didemnin 
synthesis.[132] These reaction conditions led to a full conversion of the linear peptide to the 
macrocycle without detectable side products (for example from an intermolecular coupling).  
Using these synthetic methodologies, a series of analogs of Ahp cyclodepsipeptides for the 
investigation of structure-activity relationships and evaluation of the structural determinants 
of the canonical conformation were synthesized (summarized in Figure 60 and Table 3). 
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Figure 60: Solid-phase synthesis of small molecule analogs of canonical-conformation β-(or γ-) hydroxy amino 
acid protease inhibitors derived from Ahp cyclodepsipeptides. Reagents and conditions (NOTE: for the 
individual reaction times t, refer to the experimental section): (a) i. P1 amino acid, DIEA, CH2Cl2, on; ii. 
CH2Cl2/MeOH/DIEA (17:2:1), 3x 5 min; (b) i. piperidine/DMF (1:4), 2x 15 min; ii. threonine building block, HOBt, 
HBTU, DIEA, DMF, t; (c) i. piperidine/DMF (1:4), 2x 15 min; ii. P3 amino acid; HOBt, HBTU, DIEA, DMF, t; iii. 
piperidine/DMF (1:4), 2x 15 min; iv. P4 amino acid; HOBt, HBTU, DIEA, DMF, t; (optional: v. piperidine/DMF 
(1:4), 2x 15 min; vi. butyric acid, HOBt, HBTU, DIEA, DMF, t); (d) Fmoc-Val-OH, DIC, DMAP, CH2Cl2/DMF (9:1), 4 x 
2 h; (e) i. piperidine/DMF (1:4), 2x 15 min; ii. N-methylated amino acid or analog; HOBt, HBTU, DIEA, DMF, t; iii. 
for Alloc protected derivatives: Pd(PPh3)4, morpholine, CH2Cl2, 30 min; for Fmoc-protected derivatives: 
piperidine/DMF (1:4), 2x 15 min; iv. P2
’ amino acid, for secondary amines: PyBrOP, DIEA, 24 h; for primary 
amines: HOBt, HBTU, DIEA, DMF, t; v. piperidine/DMF (1:4), 2x 15 min; vi. amino acid replacing Ahp, HOBt, 
HBTU, DIEA, DMF, t; (f) depending on N-terminal protection: for Boc-protected species: i. AcOH/TFE/CH2Cl2 
(1:1:3), 2 h; ii. HCl in dioxane (4 M) or TFA/TIS/CH2Cl2 (95:2.5:2.5); for Fmoc-protected species: i. 
piperidine/DMF (1:4); ii. AcOH/TFE/CH2Cl2 (1:1:3), 2 h; then for all species: iii. PyBOP, DIEA, 10 °C, 1 mM 
dilution, 2 d; iv. removal of remaining protecting groups (refer to experimental section); v. HPLC purification 
(overall yields: 1.0% to 12.3%, refer to experimental section). 
  
Results and Discussion 
107 
Table 3: analogs of Ahp cyclodepsipeptides synthesized for the investigation of structure-activity-relationships. 
 
compound 
 
 
P1 
 
P2 threonine 
 
P3 
 
R1 
 
R2 
 
R3 
 
R4 
 
A 
SAR-1 Cit L Gln But 3-Br,4-OMeTyr Me Ile Ser 
SAR-2 Cit L Gln But 3-Br,4-OMeTyr Me Ile Hse 
SAR-3 Cit L Gln But 3-Br,4-OMeTyr Me Ile Thr 
SAR-4 Cit L Gln But 4-OMeTyr Me Ile Ser 
SAR-5 Cit L Gln But Phe Me Ile Ser 
SAR-6 Cit L Gln But Phe H Ile Ser 
SAR-7 Cit L Gln But Pro - Ile Ser 
SAR-8 Cit D-allo Gln But Phe Me Ile Ser 
SAR-9 Cit L-allo Gln But Phe Me Ile Ser 
SAR-10 Leu L Thr Ala-But 3-ClTyr Me Thr Ser 
SAR-11 Leu L Thr Ala-But 3-ClTyr Me Thr Thr 
SAR-12 Leu L Thr Ala-But 3-ClTyr Me Thr Val 
 
 
3.2.3 Biological evaluation of the SAR analogs and elucidation of critical parameters for 
the canonical conformation 
 
After having synthesized a series of structure-activity analogs, a biological evaluation of the 
small molecule analogs was performed i) to identify adequate replacements for the Ahp unit 
and ii) to identify structural elements that have an influence on the molecule’s ability to 
adopt the canonical conformation. 
To this end, first analogs of symplocamide A (see section 3.1.2) were investigated.[115,118] 
The first three analogs were designed to test for suitable substitutions of the Ahp moiety. To 
this end, the focus was set on commercially available amino acids bearing a hydroxylated 
side chain (as the Ahp residue also features a hydroxyl group in the β-position). 
Consequently, three different symplocamide A analogs with serine, homoserine and 
threonine (SAR-1, SAR-2 and SAR-3, respectively) (Fig. 61) as replacement for the Ahp 
moiety were investigated. 
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Figure 61: A first set of SAR analogs for the evaluation of a suitable Ahp replacement. 
 
The replacement of the Ahp moiety with homoserine and threonine did not provide active 
compounds; the replacement of the Ahp unit with serine, however, provided a peptide that 
displayed a Ki of 3.8 μM in a chymotrypsin inhibition assay[126-128], indicating serine as a 
proper mimic of the Ahp moiety.  
With a proper Ahp mimic in hands, the structural determinants of the potent inhibition of 
the Ahp-mimicked cyclodepsipeptides were investigated. To this end, a first focus was set on 
the unusual 3-bromo-4-methyl N-methyl tyrosine residue that is located in the P3’ position of 
the inhibitor. In their studies of the BBI-derived peptides Leatherbarrow et. al. were able to 
identify the P3’ residue as the element that enforces the canonical conformation by forming 
a cis amide bond and thereby mimicking a β-turn element. In these BBI peptides, the P3’ 
residue is a conserved proline residue.[23] However, not only proline is known to enforce cis 
amide bonds, also N-methylated amino acids induce such cis-configured bonds.  
The first modification of the 3-bromo-4-methoxy N-methyl tyrosine residue was the 
replacement by a 4-methyl N-methyl tyrosine (SAR-4) moiety which had only a weak 
influence on the inhibitory potency of the inhibitor (resulting in a Ki of 4.8 μM). This indicates 
that the bromine modification of the aromatic residue has only a subtle influence on the 
overall inhibitory potency. In contrast to this, the replacement of the methoxy group by 
incorporation of N-methylated phenylalanine (SAR-5) resulted in a drastic loss of activity (Ki 
= 56.1 μM), emphasizing the importance of the methoxy substitution on the aromatic system 
(Fig. 62). Interestingly, also our structure-activity relationships demonstrate that a N-
methylated phenylalanine moiety on P3’ is much less active than for example a 4-methoxy 
tyrosine residue. However, several Ahp cyclodepsipeptides that display chymotrypsin 
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inhibitory activity feature an N-methylated phenylalanine residue are still among the most 
potent inhibitors.[24] This pinpoints that other amino acid residues in the sequence have a 
more important influence on bioactivity.  
For the present analogs, however, the influence of a methoxy substitution on the aromatic 
amino acid on the inhibitory potency cannot be denied.  
 
 
 
Figure 62: SAR analogs for the investigation of influence of the aromatic substitution. 
 
Next, the influence of the N-methyl modification on bioactivity was tested. The presence of 
an element forcing a peptide bond into a cis conformation in the P3’ position has been 
evaluated as a crucial element for the bioactivity of canonical inhibitors because the 
canonical conformation strictly requires a cis amide bond in this position. [23,133] To inspect 
the effect of the presence or absence of a cis conformation in the P3’ position for the present 
small molecule analogs of Ahp cyclodepsipeptides, two different analogs were investigated. 
First, and in total accordance with the results of Leatherbarrow et. al., the replacement of 
the N-methylated amino acid by a regular phenylalanine (SAR-6) was tested. This 
substitution resulted in a complete loss of bioactivity, thereby indicating the absence of the 
cis amide bond and simultaneously implicating its imperative presence in order to attain the 
canonical conformation. Furthermore, a replacement of the N-methylated amino acid with a 
proline (SAR-7) that is also able to enforce a cis amide bond resulted in a retention of the 
biological activity as SAR-7 displayed a Ki of 16.1 μM (Fig. 63).  
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Figure 63: SAR analogs for the investigation of the effect of a cis amide bond on the inhibitory potency.  
 
These results underline that also the Ahp-mimicked peptides act as small molecule analogs 
of canonical conformation inhibitors. Moreover, when comparing the inhibitory potencies of 
the proline Ahp-mimic SAR-7 (Ki = 16.1 μM) and the two closely related N-methylated mimics 
SAR-1 (Ki = 3.8 μM) and SAR-4 (Ki = 4.8 μM) that incorporate a substituted aromatic side chain 
a clear trend towards substituted N-methylated aromatic amino acids for this compound 
class can be observed. Interestingly, a similar trend is seen with the natural Ahp 
cyclodepsipeptides:[24] none of the 51 Ahp cyclodepsipeptides that have recently been 
summarized due to their potent S1 serine protease inhibition incorporate a proline in the P3’ 
position. Instead, in all cases a N-methylated aromatic amino acid is conserved in this 
position. This is quite remarkable as these unnatural N-methylated amino acids must be 
synthesized by the organism producing the respective Ahp cyclodepsipeptides. The 
conserved presence of these amino acids therefore indicates their significance for 
bioactivity.  
Thus, the identification of a suitable Ahp-mimic not only enabled the investigation of the 
crucial determinants for inhibition; these substances also indicate the substantial elements 
in Ahp cyclodepsipeptides for adopting the canonical conformation, i. e. the cis amide bond 
at the P3’ amino acid.  
Next, the influence of the stereochemistry of the threonine moiety that forms the 
depsipeptide bond and its effect on the inhibitory potency of the compounds was verified. 
The replacement of the natural (L)-threonine moiety in the N-methyl phenylalanine 
derivative with either (D)-allo-threonine (SAR-8) or (L)-allo-threonine (SAR-9) provided 
inactive compounds again (Fig. 64). While incorporation of a (D)-allo threonine residue could 
Results and Discussion 
111 
change the overall conformation of the macrocyclic ring system, the result with the (L)-allo-
threonine moiety is less clear.  
 
 
 
Figure 64: SAR analogs to study the effect of the threonine stereochemistry on the inhibitory potency.  
 
However, this result supports a hypothesis discussed by Leatherbarrow et. al. for the BBI-
derived inhibitors: in these peptides, a threonine residue in the P2 position is able to form a 
hydrogen bond to the P1’ serine moiety and thereby directs the aliphatic part of the 
threonine side chain towards a close contact with the imidazole part of the enzyme’s 
catalytic histidine. This contact is thought to interfere with a movement of the histidine that 
becomes necessary during the catalysis cycle and is proposed contribute to the inhibition of 
the protease.[18] 
This scenario should in principle also be possible for the Ahp cyclodepsipeptides as well as 
the generated Ahp-mimics because the orientation of the aliphatic part of the threonine side 
chain is restricted due to the ester bond of the side chain’s hydroxyl group. Hence, a 
different stereochemistry on the β-position of threonine would most probably result in a 
different orientation of the aliphatic part of the side chain, thereby preventing the contact to 
the histidine of the catalytic triad of the S1 serine protease and thus not impairing the 
mobility required for the cleavage of a substrate.  
It has to be noted, however, that the requirement of a flexible histidine residue has been a 
matter of highly controversial debate within the scientific community. Several groups have 
contributed to this debate, basing their argumentation either on structural data obtained 
from x-ray analysis of protein crystals or on data generated by in silico molecular dynamics 
experiments. For all models of serine protease catalysis, the general acid-base catalysis by 
the histidine residue is a commonly accepted concept. In the first step of the reaction, the 
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histidine acts as a general base by deprotonating the active site serine, thereby enabling the 
attack of the substrate and the formation of the first tetrahedral intermediate. In a later step 
of the cleavage reaction, histidine then acts as a general acid by donating a hydrogen to the 
amino leaving group. Afterwards, the histidine residue contributes to the deprotonation of 
the catalytic water molecule and finally donates a proton to the deprotonated serine in 
order to restore the enzyme to its active and free state. Some crucial questions concerning 
the progression of the reaction are however still unanswered. One of them is the 
reorganization of the reactive site after the formation of the first tetrahedral intermediate. 
This reorganization seems to be necessary because the histidine is positioned ideally to 
deprotonate the catalytic serine. However, this arrangement also catalyzes the back reaction 
of the first tetrahedral complex to the reactand complex, if the histidine moiety does not 
change its position, resulting in a lowered reaction rate. In a high resolution crystallographic 
study of acyl-enzyme structures, Radisky and coworkers were able to observe a slight out-of-
plane swiveling of the imidazole and a simultaneous movement of the serine moiety that 
results in a shift of the imidazole from its ideal deprotonation position into closer proximity 
of the amine leaving group and the catalytic water. A complete ring-flip is ruled out, the 
subtle changes described seems to suffice to drive forward the reaction.[134] In accordance 
with this report, Fodor et. al. describe the movement of the histidine as a subtle 12° change 
of a torsion angle and emphasize the economic nature of this movement that enables the 
imidazole to adapt to two different nucleophilic attackers that are 2 Å apart in the crystal 
structure.[135] In quantum mechanics and molecular mechanics calculations of the 
deacetylation step of serine proteases, Richards et. al. furthermore observed that during the 
progression of the reaction, the binding site rearranges to release the modified substrate. 
This has led to the overall conclusion that the ring mobility of the histidine side chain 
ensures a direction of the reaction towards the formation of the product because the 
mobility enables a concerted rearrangement of the catalytic site.[136,137]  
Concludingly, these different data support the hypothesis of subtle movements of the 
histidine residue during the catalysis cycle, a complete ring-flip of the histidine has however 
been ruled out.[134-138] The results obtained here for the Ahp-mimics with an altered 
threonine stereochemistry may serve as a humble contribution to the general debate. The 
loss of activity for these analogs indicates at least that an alteration in the prominent 
position of the inhibitor that is thought to interact with the histidine does indeed influence 
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the activity of the targeted protease. It can however not be ruled out that the unnatural 
threonine stereochemistry may however also induce an altered overall conformation of the 
macrocycles. 
With the previous encouraging results in hand, it was next evaluated if these results can also 
be transferred to a different member of the Ahp cyclodepsipeptides natural product class. If 
this were possible, the concept of Ahp mimicry could be considered as a global concept, 
thereby encouraging a further investigation of this type of small molecule serine protease 
inhibitors. The natural product chosen for this further investigation was the elastase 
inhibitor scyptolin A that displays a Ki of 0.16 μM against elastase and is one of two Ahp 
cyclodepsipeptide for which a crystal structure in complex with a target protease exists. 
Scyptolin A has been used in extensive enzyme inhibition and structural studies.[27,28] 
To identify first an Ahp mimic for scyptolin A, two different analogs incorporating serine 
(SAR-10) or threonine (SAR-11) as a replacement for the Ahp moiety were synthesized. Both 
compounds fortunately showed a potent bioactivity, with the threonine analog SAR-11 (Ki = 
5.0 μM) being even more potent than the serine analog SAR-10 (Ki = 19.1 μM) (Fig. 65).  
 
 
 
Figure 65: SAR analogs for the investigation of a possible Ahp mimicry in scyptolin A. 
 
The enhanced bioactivity of SAR-11 with the threonine moiety over the serine derivative 
SAR-10 is difficult to explain. A closer look however reveals two major different factors 
between the symplocamide A and the scyptolin A mimics. In symplocamide A, the P1 residue 
is citrulline while the P2’ residue is isoleucine. In the scyptolin A analogs, P1 is leucine and P2’ 
is threonine. Thus, the P1’ residue serine or threonine can form different additional 
interactions between the P1 and P2’ moieties that might have an influence on the overall 
efficiency to adopt the canonical conformation or the binding to the target protease.  
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The enhanced activity of SAR-11 compared to its serine analog SAR-10 could be explained 
with the higher sterical demand of the threonine methyl group that consequently locks the 
threonine in a state of decreased rotational freedom. As a result, the molecule does not lose 
as much more degrees of freedom (i. e. entropy) upon binding; hence, the binding of the 
inhibitor might be favored.  
In order to demonstrate the general requirement of a hydroxyl group in the side chain of the 
amino acid replacing the Ahp unit, a third scyptolin A analog that incorporated a valine (SAR-
12) instead of threonine was tested. This compound was again inactive in the enzyme 
inhibitory assay, demonstrating the critical role of a hydroxyl group in the side chain of the 
Ahp replacement.  
As an overview of the results of the structure-activity relationship studies the small molecule 
inhibitors evaluated in terms of their ability to adopt the canonical conformation and in 
terms of crucial elements for a potent inhibition are summarized in Table 4. 
 
Table 4: Summarized modifications of the mimics of Ahp cyclodepsipeptides and the resulting bioactivities. 
 
compound 
(mimic of) 
 
 
Ahp  
replacement 
 
further 
substitutions 
 
Ki 
SAR-1 (sym A) Ser - 3.8 μM 
SAR-2 (sym A) Hse - inactive 
SAR-3 (sym A) Thr - inactive 
SAR-4 (sym A) Ser 3-Br,4-OMe-mTyr→4-OMe-mTyr 4.8 μM 
SAR-5 (sym A) Ser 3-Br,4-OMe-mTyr→mPhe 56.1 μM 
SAR-6 (sym A) Ser 3-Br,4-OMe-mTyr→mPhe  inactive 
SAR-7 (sym A) Ser 3-Br,4-OMe-mTyr→Pro 16.1 μM 
 
SAR-8 (sym A) 
 
Ser 
3-Br,4-OMe-mTyr→mPhe 
 
L-Thr→D-allo-Thr 
 
inactive 
 
SAR-9 (sym A) 
 
Ser 
3-Br,4-OMe-mTyr→mPhe 
 
L-Thr→L-allo-Thr 
 
inactive 
SAR-10 (scyp A) Ser - 19.1 μM 
SAR-11 (scyp A) Thr - 5.0 μM 
SAR-12 (scyp A) Val - inactive 
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Overall, the present studies indicate that cyclodepsipeptides with an Ahp-mimicked moiety 
can also adopt a canonical conformation and thereby serve as potent S1 serine protease 
inhibitors. Despite their slightly reduced biological activities, their synthetically more facile 
access turns these mimics into highly interesting small molecules for performing protease 
research.  
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3.3 Synthesis and biological investigation of symplostatin 4  
3.3.1 Development of a synthetic strategy for a convergent synthesis of symplostatin 4 
and derivatives 
 
In a second project during this dissertation, chemical biology investigations of the natural 
product symplostatin 4[103,104] were performed. To this end, a total synthesis of the natural 
product as well as derivatives thereof was required. The derivatives of symplostatin 4 were 
designed to incorporate functionalities that enable an activity-based approach for the 
investigation of biological activities and target identification. In addition, structure-activity 
relationship studies were envisaged to investigate the influence of the methyl-
methoxypyrrolinone modification on the biological activity of symplostatin 4. To this end, an 
analog lacking the methyl-methoxypyrrolinone moiety was designed and derivatives for an 
activity-based approach were planned as well.  
To enable an activity-based approach during the chemical biology studies, different tags 
were planned to be attached to symplostatin 4 and its analog lacking the methyl-methoxy 
pyrrolinone. First, alkyne-modified derivatives were synthesized. Moreover, rhodamine and 
biotin tags were attached to these derivatives by a 1,3-dipolar Huisgen cycloaddition (click 
reaction) of the corresponding alkyne-modified derivatives.  
A rhodamine tag (or other fluorescent tags) allows a direct in-gel identification of labeled 
proteins by a read-out on a fluorescence scanner, whereas a biotin tag enables the 
identification of labeled enzymes by Western blotting. In addition, a biotin tag can be used 
to purify labeled enzymes with avidin- or streptavidin-based methods. A combination of the 
two tags is also possible by generating a so-called trifunctional probe[64] that incorporates a 
rhodamine and a biotin. These trifunctional probes provide the advantage of a direct 
visualization by fluorescence read-out combined with the possibility of an isolation and 
purification of labeled enzymes with just one probe. The downside of all tagged probes is 
however that, depending on the tag, the probes become quite bulky and their reaction in an 
assay may no longer resemble the behavior of the core molecule they were derived from. 
The attachment of a bulky tag can on the one hand prevent the binding to a target enzyme 
because the probe is sterically hindered. On the other hand it has also been observed that 
e. g. a rhodamine tag enhances the uptake of a probe in in vivo assays. A way to overcome 
the unwanted side effects of a tag attached to an activity-based probe is the use of probes 
that are modified to perform a click reaction after the labeling experiment.[139,140] The 
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structures of such probes resemble much more to the original molecules and therefore 
potentially display a more similar labeling pattern.  
In order to provide the highest flexibility in the future profiling experiments, symplostatin 4 
and its analog lacking the methoxy-methylpyrrolinone were therefore synthesized as alkyne-
modified, rhodamine-tagged, biotinylated and trifunctional versions (Fig. 66). 
 
 
 
Figure 66: Symplostatin 4 and derivatives for the investigation by an activity-based approach. A: symplostatin 4 
(Sym4, top) and its derivatives; B: symplostatin 4 analog lacking the methyl-methoxypyrrolinone (Sym4mmp→Ala, 
top) and its derivatives; C: tags attached to the alkyne-modified Sym4 and Sym4mmp→Ala derivatives by click 
reaction: rhodamine, rhodamine-biotin (trifunctional probe) and biotin (clockwise). 
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In order to gain a quick access to all envisioned derivatives, a convergent solution-phase 
synthesis starting from the crucial 4-(S)-amino-(E) pentenoic acid was planned initially. As 
only two of the building blocks (i. e. Boc-leucine and (S)-Hydroxyisocaproic acid) were 
commercially available, the other building blocks had to be generated for the synthesis. It 
was planned to synthesize the 4-(S)-amino-(E) pentenoic acid building block from Boc-
alanine by Wittig methodology. The building blocks required for the C-terminal modification 
should both be accessible from (L)-alanine. In analogy to the synthesis of symplocamide A, 
(S)-Hydroxyisocaproic acid would be coupled without a protection of the hydroxyl group due 
to its lower reactivity. The isoleucine building block bearing either the di-methylated amine 
or the methylated and alkyne-modified amine was planned to be synthesized starting from 
isoleucine (Fig. 67). 
 
 
 
Figure 67: Initial synthetic strategy for the synthesis of symplostatin 4 and derivatives based on sequential 
couplings. 
 
A first drawback of this strategy, however, was the observed difficult coupling of the methyl-
methoxypyrrolinone building block to the 4-(S)-amino-(E)-pentenoic acid. The synthesis of 
the precursor methyl pyrrolidine-2,4-dione proceeded smoothly using a protocol by Tønder 
et. al. which involved the coupling of Boc alanine with Meldrum’s acid followed by a 
rearrangement of the highly reactive intermediate to form the pyrrolidine-2,4-dione. The 
published introduction of an ethyl or a methyl group in order to obtain the methyl-
ethoxypyrrolinone or the methyl-methoxypyrrolinone, respectively, with KHMDS as the base 
and EtOTs or MeOTs however could not reproduced successfully.[141] Nevertheless, this 
Results and Discussion 
119 
circumstance could be overcome by using Mitsunobu conditions, as reported by Poncet et. 
al. (Fig.68).[142] 
 
 
 
Figure 68: Synthesis of the methyl-methoxypyrrolinone building block.[141,142] 
 
With the methyl-methoxypyrrolinone derivative in hands, the coupling to a second amino 
acid residue was first explored in a model reaction with alanine. Despite the use of a strong 
base (LHMDS) to deprotonate the secondary amine and a strong coupling reagent (PyBrOP), 
the coupling could not be achieved successfully. The difficult coupling could however be 
overcome by the strategy introduced by Poncet et. al. in their synthesis of dolastatin 15. 
Instead of synthesizing the benzyl-methoxypyrrolinone (as an element of dolastatin 15) 
moiety individually, they generated the pyrrolinone residue after coupling to the precursor 
amino acid phenylalanine, followed by a rearrangement of a highly reactive intermediate 
obtained after the coupling of Meldrum’s acid to the phenylalanine.[142] 
This methodology also seemed to suit to the synthesis of symplostatin 4 and its derivatives. 
Consequently, coupling of alanine methyl ester to the 4-(S)-amino-(E)-pentenoic acid 
building block the Sym4 as well as the Sym4mmp→Ala derivatives would allow its synthesis 
from a dipeptide building block (Fig. 69).  
 
 
 
Figure 69: New approach to the 4-(S)-amino-(E)-pentenoic acid modified with alanine methyl ester or the 
methyl-methoxypyrrolinone.  
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The synthesis of the isoleucine building block that features a di-methylation on its amino 
group however turned out to be more difficult than originally anticipated. While the 
protection of isoleucine as an allyl ester or a methyl ester proceeded as expected, the di-
methylation of the amine was complicated due to the high volatility of the resulting di-
methylated product. Several methods for the introduction of the two methyl groups by 
reductive amination were examined: a method using paraformaldehyde and formic acid in 
water[143] or just paraformaldehyde and formic acid[144], a combination of paraformaldehyde, 
sodium borohydride and sulfuric acid[145] and a combination of paraformaldehyde and 
sodium cyanoborohydride.[146] Despite great efforts, the desired di-methylated isoleucine 
building block could not be isolated in satisfying yields.  
This result, together with the already reconsidered approach to the synthesis of the 4-(S)-
amino-pentenoic acid modified either with alanine methyl ester or the methyl-
methoxypyrrolinone residue, called for the reconsideration of the sequential coupling 
strategy. Consequently, a new synthetic strategy consisting of the generation of an 
isoleucine-isocaproic acid depsipeptide which was subsequently modified N-terminally in 
order to obtain the di-methylated as well as the methylated and alkyne-modified variant was 
envisaged. The resulting depsipeptide fragments were then planned to be coupled to the 
different tripeptide fragments obtained from the C-terminal and N-terminal modification of 
4-(S)-amino-pentenoic acid (Fig.70). 
 
 
 
Figure 70: New fragment-based approach towards the synthesis of symplostatin 4 and derivatives.  
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3.3.2 Synthesis of symplostatin 4 and derivatives for the biological evaluation and target 
identification 
 
This alternative synthetic strategy required the synthesis of building blocks such as the 4-(S)-
amino-(E)-pentenoic acid moiety. This compound was readily synthesized from Boc-Ala-OH 
by adapting a protocol introduced by Pollini and coworkers.[147] In the first step, Boc-Ala-OH 
was converted to the Weinreb amide by reaction with DCC and N,O-dimethyl hydroxylamine. 
After a short work-up protocol, the resulting Weinreb amide was directly transformed to the 
aldehyde by reduction with LiAlH4. The aldehyde was then transformed directly to the α,β-
unsaturated methyl ester 37 by a Wittig reaction with methyl-2-
(triphenylphosphoranylidene)acetate. The desired 4-(S)-amino-(E)-pentenoic acid building 
block 37 was obtained after chromatographic work-up in a yield of 59% starting from Boc-
alanine. In the next step, this building block was deprotected and coupled with alanine 
methyl ester hydrochloride to obtain the dipeptide intermediate 38.  
38 was then converted to the tripeptides required for the synthesis of the Sym4 derivatives 
as well as for the Sym4mmp→Ala derivatives. To obtain the tripeptide for the Sym4 derivatives 
(i. e. the tripeptide with the methyl-methoxypyrrolinone residue), the dipeptide 38 was 
deprotected C-terminally using lithium hydroxide. The resulting free acid was then coupled 
with Meldrum’s acid to obtain a highly reactive enol intermediate that rearranges to form 
the pyrrolidine-2,4-dione upon refluxing in acetonitrile. The methylation was carried out 
under Mitsunobu conditions using DEAD, methanol and triphenylphosphine providing the 
methyl-methoxypyrrolinone-modified dipeptide 39 in 90% yield from the protected 
dipeptide 38.[142] The tripeptide 40 was accessed by sequential Boc deprotection and 
coupling with Boc leucine using HOBt/HBTU activation and acetonitrile as the solvent.[148] 
The tripeptide 40 was obtained in 85% yield.  
In order to access the Sym4mmp→Ala derivatives, the dipeptide 38 was coupled with Boc 
leucine in the next step. So, first the Boc group was removed using trifluoroacetic acid in 
dichloromethane and the free amine intermediate was then coupled with Boc leucine. The 
tripeptide 41 was obtained in 99% yield using the same coupling conditions as for the 
synthesis of the tripeptide 40 (Fig. 71). 
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Figure 71: Synthesis of the C-terminal tripeptides 40 and 41. Reagents and conditions: (a) N,O-
dimethylhydroxylamine hydrochloride, Et3N, DCC, CH2Cl2, rt, 1 h; (b) LiAlH4, Et2O, 0 °C, 20 min; (c) 
Ph3P=CHCOOMe, CH2Cl2, rt, o/n (59%, 3 steps); (d) LiOH, THF/MeOH/H2O (1.67:1:0.67), rt, 5 h; (e) H-Ala-OMe, 
HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, o/n (46%, 2 steps); (f) LiOH, THF/MeOH/H2O (1.67:1:0.67), rt, 5 h; (g) 2,2-
dimethyl-1,3-dioxane-4,6-dione, DMAP, EDC*HCl, CH2Cl2, -10 °C to rt, o/n; (h) CH3CN, reflux, 1 h; (i) Ph3P, 
MeOH, DEAD, THF, rt, o/n (90%, 4 steps); (j) TFA/CH2Cl2 (1:1), rt, 3 h; (k) Boc-Leu-OH, HOBt, HBTU, DIEA, CH3CN, 
0 °C to rt, o/n (85%, 2 steps); (l) TFA/CH2Cl2 (1:1), rt, 2 h; (m) Boc-Leu-OH, HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, 
o/n (99%, 2 steps). 
 
With the two C-terminal tripeptides in hands, the two different N-terminal depsipeptides 
were next synthesized. The synthesis for both depsipeptides started from (S)-2-hydroxy-
isocaproic acid which was first converted to its methyl ester using thionylchloride and 
methanol. The resulting methyl ester was directly submitted to the esterification reaction 
without a further purification because of its high volatility. The esterification with N-
methylated Boc isoleucine was carried out using DCC as the coupling reagent and DMAP as 
the additive to enhance the reaction rate and the depsipeptide 42 was obtained in a yield of 
55% from (S)-2-hydroxy-isocaproic acid. The moderate yield can be explained with the high 
volatility of the (S)-2-hydroxy-isocaproic acid methyl ester: during the removal of residual 
thionyl chloride via distillation under reduced pressure, a partial evaporation of the product 
also occurred.  
To obtain the two different depsipeptide building blocks, the depsipeptide 42 either needed 
to be modified with a methyl group (yielding depsipeptide 43) or with a propargyl group 
(yielding depsipeptide 44). The deprotection of 42 was again carried out using trifluoroacetic 
acid in dichloromethane. The di-methylated depsipeptide 43 was then obtained by reacting 
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the free secondary amine intermediate with methyl iodide in dimethylformamide using DIEA 
as the base; the desired compound 43 was obtained in a yield of 38%. In the case of the 
methyl and alkyne-modified depsipeptide 44, the free secondary amide was reacted with 
propargyl bromide in acetonitrile using DIEA as the base. The reaction was warmed to 80 °C 
and required an overnight reaction, providing the desired methyl- and alkyne-modified 
depsipeptide 44 in 63% yield (Fig. 72). 
 
 
 
Figure 72: Synthesis of the two depsipeptide fragments 43 and 44. Reagents and conditions: 
(a) SOCl2 (2 M in CH2Cl2), MeOH, 0 °C to rt, o/n; (b) Boc-NMeIle-OH, DMAP, DCC, CH2Cl2, 0 °C to rt, o/n (55%, 2 
steps); (c) TFA/CH2Cl2, rt, 2 h; (d) CH3I, DIEA, DMF, rt, 2 h (38%, 2 steps); (e) propargyl bromide (80% wt in 
toluene), DIEA, CH3CN, 80 °C, o/n (63%, 2 steps). 
 
With all four fragments in hands, the final assembly of the basic symplostatin 4 derivatives 
was initiated. To this end, the C-terminal depsipeptides were deprotected in order to obtain 
the free acid intermediates whereas the N-terminal Boc protecting group of the tripeptides 
needed to be cleaved. According to the original synthesis plan, the different fragments were 
then coupled using HOBt/HBTU activation in order to obtain the four different symplostatin 
4 derivatives (Fig. 73). After the reaction work-up, all derivatives with the exception of 
Sym4mmp→Ala were first purified by silica gel chromatography. The crude Sym4mmp→Ala and 
smaller fractions of the three other pre-purified compounds were also purified by HPLC in 
order to obtain highly pure material for the biological investigations.  
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Figure 73: Synthesis of the symplostatin 4 derivatives. Reagents and conditions: (a) LiOH, THF/MeOH/H2O 
(1.67:1:0.67), rt, 5 h; (b) TFA/CH2Cl2 (1:1), rt, 2 h; (c) HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, 5 h (91% (from 43) 
after silica gel chromatography, 51% after additional HPLC, 3 steps); (d) HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, 
o/n (39% (from 43) after HPLC, 3 steps); (e) HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, o/n (82% (from 44) after silica 
gel chromatography, 64% after additional HPLC, 3 steps); (f) HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, 5 h (73% 
(from 44) after silica gel chromatography, 53% after additional HPLC, 3 steps). 
 
With the two alkyne-modified derivatives ≡Sym4 and ≡Sym4mmp→Ala available, the additional 
derivatives modified with tags for the utilization in an activity-based approach were 
synthesized. The conditions for the click reaction were adapted from the conditions 
developed by Cravatt and coworkers for in vivo labeling.[139] However, the in vitro reactions 
carried out required an optimization of reaction conditions; in particular the amount of 
CuSO4 was increased greatly in order to achieve a good conversion of the starting material. 
The corresponding reactions were monitored by LC-MS and stopped upon sufficient product 
formation. The purification of the different products turned out to be rather tedious and 
required customized conditions: The rhodamine-modified derivatives Rh-Sym4 and Rh-
Sym4mmp→Ala were purified by AluOx chromatography; in the case of Rh-Sym4 a second 
chromatography was necessary to obtain pure material. For the purification of the 
trifunctional probes Tri-Sym4 and Tri-Sym4mmp→Ala and the biotinylated probes biotin-Sym4 
and biotin-Sym4mmp→Ala C18 silica gel (reversed phase silica gel) was tested as an alternative 
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stationary phase. In analogy to C18 HPLC purification an increasing gradient of acetonitrile in 
water was used and allowed their purification in a satisfying manner (Fig. 74).  
 
 
Figure 74: Synthesis of the different probes for the chemical biology investigations. Reagents and conditions: 
(b) Tag-N3, CuSO4 (aq. solution), TBTA (100 mM in DMSO), TCEP (100 mM in H2O), H2O, rt, reaction monitoring 
by LC-MS, chromatographic work-up. 
 
 
3.3.3 Biological investigation of symplostatin 4 in the model plant Arabidopsis thaliana 
3.3.3.1 First experiments using symplostatin 4 probes in Arabidopsis thaliana 
 
During a placement in the plant chemetics group of Dr. Renier van der Hoorn (MPI Cologne), 
the labeling of the A. thaliana proteome by symplostatin 4 and its derivatives was 
investigated by the means of ABPP. 
To establish a reliable and most of all reproducible labeling procedure, the conditions of the 
labeling reaction with the different probes needed to be evaluated prior to the actual 
experiments. In a first set of labeling experiments, the optimal pH for the labeling of A. 
thaliana leaf extracts with the rhodamine-labeled probes Rh-Sym4 and Rh-Sym4mmp→Ala was 
investigated. To this end, the leaf extracts were labeled at a constant probe concentration of 
5 μM at different pH values (pH 3.0 to 9.0; 0.5 steps). From these experiments, pH 8 was 
determined as the optimal pH for the labeling with the symplostatin 4 probes.  
A second set of experiments was aimed at the investigation of the concentration required 
for a well-detectable labeling. The experiment was carried out at pH 6 using different 
concentrations of the two probe molecules (0.2 to 10 μM; 0.2 steps to 1 μM, 2.0 steps to 10 
μM). Here, a difference between the two probe molecules became apparent: Rh-Sym4 
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showed a good labeling at 5 μM, while for Rh-Sym4mmp→Ala the highest concentration of 
10 µM was required to obtain a good labeling pattern.  
These preliminary experiments established the conditions for the future labeling 
experiments. Moreover, they were also revealed that a labeling of leaf extracts with the 
probes gives a quite indistinct labeling pattern, i. e. too many enzymes are labeled by the 
probes. Owing to this finding, the in vivo labeling of A. thaliana with the probes was 
investigated in order to potentially obtain a better labeling pattern. In these experiments, all 
6 differently-tagged probes (Rh-Sym4, Rh-Sym4mmp→Ala, biotin-Sym4, biotin-Sym4mmp→Ala, 
Tri-Sym4 and Tri-Sym4mmp→Ala) were investigated. Indeed, the labeling of A. thaliana cells 
did provide a clearer labeling pattern, thereby encouraging further in vivo experiments.  
Additionally, two different set-ups of leaf infiltration experiments were carried out to 
investigate the in vivo labeling of the A. thaliana leaves: In the first set-up, the leaves were 
infiltrated via their petioles. For each experiment, three leaves were carefully set into the 
well of a 24-well plate filled with a solution containing the respective probe. In this set-up, 
different mutants of A. thaliana were investigated, besides the regularly used Col-0 (wild-
type), the rd21, rA and aalp mutants were investigated. The incubation was carried out 
under the exclusion of light to prevent a decomposing of the fluorescent labels. Before the 
leaf extract was generated, the petioles were removed to ensure that only the in vivo 
labeling was determined and not an ex vivo labeling caused by a contamination of the 
extract.  
In the second set-up, the leaves were infiltrated with the different probes via the stomata on 
the reverse side of the leaf. Besides the Col-0 type, 4 different mutants (628oe, rd21, aalp 
and rA) were investigated. To achieve the infiltration, the probe solution was carefully 
applied by pressing a syringe (without a cannula) to the reverse side of a detached leaf and 
pressing down the plunger; a successful infiltration is thereby visualized by the slight 
darkening of the leaves resulting from the uptake of the liquid into the vascular system. 
After the incubation, the detached leaves were incubated under the exclusion of light on 
damp blotting paper in a Petri dish. After the incubation the infiltrated leaves were treated 
in order to obtain the leaf extract that was then analyzed. 
Unfortunately, none of the infiltration experiments provided a distinct labeling, although a 
repetition of the experiments would be highly desirable. 
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3.3.3.2 Identifying the target of symplostatin 4 in Arabidopsis thaliana 
 
With the preliminary results from the in vivo labeling experiments in hands, the next step in 
the investigation of symplostatin 4 and its derivatives was the identification of the targets 
labeled by Sym4 and the structure-activity analog Sym4mmp→Ala. To achieve this, Dr. Farnusch 
Kaschani from the van der Hoorn group used the click derivatives ≡Sym4 and ≡Sym4mmp→Ala 
in an in vivo labeling experiment with A. thaliana cells. The subsequent click experiment to 
tag the labeled enzymes with biotin and rhodamine was carried out with the Tri-azide 
reporter, following an established protocol.[149] After the click reaction the labeled enzymes 
were purified by avidin agarose beads (via the biotin tag). The enriched proteins were then 
separated by an SDS-PAGE and the bands were detected using a fluorescence scanner. The 
identification of the individual bands was carried out by nanoLC-MS/MS analysis after an in-
gel digestion of the individual bands (Fig. 75). 
 
 
 
Figure 75: Fluorescence scan of the SDS-PAGE-resolved enzymes labeled by ≡Sym4 and ≡Sym4mmp→Ala. For the 
target-ID, the individual bands were cut out, digested (trypsin) and the fragments detected by nanoLC-MS/MS 
(work by F. Kaschani). 
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The major target of Sym4 and Sym4mmp→Ala turned out to be the papain-like cysteine 
proteases RD21A and the homologous RD21B which are assigned to play a role in the plant 
immunity.[150] To a smaller extent, the protease RDL2 was also labeled by Sym4 and 
Sym4mmp→Ala. Moreover, these target identification experiments in the model plant A. 
thaliana showed no difference between the original natural product Sym4 and its analog 
Sym4mmp→Ala with the putatively important methyl-methoxypyrrolinone unit as both 
molecules labeled RD21 A and RD21B with the same intensity.  
 
3.3.4 Investigating the antimalarial activity of symplostatin 4 and target identification in 
Plasmodium falciparum 
 
After having investigated the labeling of the proteome of the model plant A. thaliana and 
having achieved the identification of the molecular target of symplostatin 4 in this model 
system, the molecular basis of the antimalarial activity of symplostatin 4[103] (i. e. the activity 
reported for the chemically identical gallinamide A[104]) was investigated. To this end, a 
collaboration with the group of Prof. Dr. Matthew Bogyo (Department of Pathology, 
Stanford University, CA) was initiated, aiming to study the effects of Sym4 and Sym4mmp→Ala 
on the malaria-causing parasite Plasmodium falciparum. From the structure of 
symplostatin 4 as well as from the preliminary studies of the labeling in A. thaliana which 
identified the cysteine protease RD21 as the target of Sym4, the hypothesis of parasital 
falcipains as the molecular target of Sym4 arose.  
In order to test this hypothesis, Dr. Edgar Deu Sandoval from the Bogyo group carried out 
several cell-based and activity-based assays. In a first cell-based assay the effect of Sym4 and 
Sym4mmp→Ala on malaria parasites in the erythrocytic cycle was investigated. To this end, a 
synchronized cell culture of P. falciparum D10 at ring stage was treated with different 
concentrations of Sym4 and Sym4mmp→Ala. The effect of the inhibitors was then visualized 
24 h after the treatment by Giemsa-stained thin blood smears. The cells treated with 0.1 μM 
Sym4 already showed a distinct swollen food vacuole phenotype which is observed 
characteristically when the proteases involved in the early stage of hemoglobin digestion are 
inhibited or differently disturbed (e. g. by a genetic knock-out) and is caused by the 
accumulation of undigested hemoglobin.[50,53,151] 
In contrast to this, the same effect was observed for Sym4mmp→Ala at a 100-fold higher 
concentration, indicating a significant difference between the two analogs. This difference 
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might stem from a decreased uptake of the probe to the food vacuole or it may be caused by 
a less specific binding to the target caused by the absence of the mmp unit.  
At high concentrations, however, both compounds seem to have a toxic effect on the 
parasite (Fig. 76). Importantly, at no tested concentration a lysis of the red blood cells was 
observed.  
 
 
 
Figure 76: Effect of Sym4 and Sym4mmp→Ala on P. falciparum D10 cells treated at ring stage with different 
concentrations of the probe. Significant phenotypes are indicated by arrows (work by E. Deu). 
 
These first results were already very encouraging and in addition, a clear difference between 
the two symplostatin 4 analogs was observed. Encouraged by these findings, the focus was 
then set on the investigation of the effect of symplostatin 4 on the replication of the 
parasite. Hence, a cell culture at 2% parasitemia was treated with different concentrations of 
the inhibitors for 75 h and after this time, the parasitemia was determined by flow 
cytometry.[152] Again, a clear difference between Sym4 and its analog Sym4mmp→Ala became 
apparent. The Sym4-treated cell culture displayed a potently inhibited parasite replication; 
the EC50 of Sym4 was in the low micromolar range (EC50 = 0.7 ± 0.2 μM). Sym4mmp→Ala on the 
other hand only displayed an EC50 of 27 ± 7 μM, thereby confirming the results of the 
previous phenotype assay (Fig. 77).  
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Figure 77: Investigation of the effects of Sym4 and Sym4mmp→Ala on parasite replication (work by E. Deu). 
 
With the results from the cell-based assays in hands that already indicated that one or more 
of the parasite’s food vacuole cysteine proteases i. e. falcipain 2, falcipain 2’ and falcipain 3 
(FP-2, FP-2’, FP-3)[50] may indeed be the target of Sym4, a focus was set on verifying this 
hypothesis by activity-based profiling experiments. In a first labeling experiment, Rh-Sym4 
and Rh-Sym4mmp→Ala were tested for their labeling of intact parasites (Fig. 78). Hence, 
purified schizonts were treated with the two different probes at a concentration of 10 μM. 
For Rh-Sym4, two strong bands in the 28 kDa region appeared, while for Rh-Sym4mmp→Ala 
only a very weak labeling in this region was detected. To investigate whether this labeling 
was caused by the respective probe or if it was just an artifact caused by the rhodamine tag, 
the experiment was also carried out in a competitive manner. To this end, the purified 
schizonts were pre-incubated with 10 μM of the non-tagged version and the click version of 
the respective rhodamine probe. Indeed, the bands in the 28 kDa region were sensitive to 
the pre-incubation with Sym4 and ≡Sym4, proving that the labeling was actually caused by 
the probe. Additionally, this experiment pinpointed to a clear difference between Sym4 and 
Sym4mmp→Ala that had already become apparent in the previous experiments. This 
impairment of bioactivity caused by the exchange of the mmp unit for the alanine methyl 
ester moiety can be explained either with a reduced uptake of the probe by the parasite or 
more likely, by a much less efficient binding of the compound to its targets. 
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Figure 78: Labeling of intact parasites with Rh-Sym4 and Rh-Sym4mmp→Ala. Purified schizonts were labeled with 
10 μM of the rhodamine-labeled probes for 1 h. For the competition experiments, the schizonts were pre-
incubated with the non-fluorescent probes Sym4 and ≡Sym4 or Sym4mmp→Ala and ≡Sym4mmp→Ala (10 μM), then 
the labeling with Rh-Sym4 or Rh-Sym4mmp→Ala was carried out for 1 h, the samples were boiled in loading buffer 
and the proteins were resolved by SDS-PAGE. The proteins were visualized by in-gel detection of fluorescence 
on a Typhoon scanner. (work of E. Deu) 
 
Since the labeling in the 28 kDa region was a strong indicator for the inhibition of FP-2, FP-2’ 
and FP-3 (referred to as FP-2/3) that are known to migrate in the 28 kDa region and are 
important factors for the development at the erythrocytic stages, a competitive ABPP 
experiment with Cy5-labeled DCG-04 and the probes Sym4 and Sym4mmp→Ala was carried out 
to test if Sym4 and Sym4mmp→Ala indeed target FP-2/3. While FP-2/3 are responsible for the 
digestion of hemoglobin and are expressed at later developmental stages, FP-1 is expressed 
during the phase of host invasion and is thought to play a crucial role in host cell 
invasion.[153,154] 
For the commonly used Cy5-DCG-04, the labeling pattern in P. falciparum is known and the 
targets have been identified. Thus, a competitive ABPP experiment can be used to identify if 
a small molecule probe is an inhibitor of the labeled enzymes.[153,154] 
The competitive ABPP experiment was carried out with P. falciparum D10 lysates that were 
pre-incubated with different concentrations of Sym4 or Sym4mmp→Ala for 30 min, then 1 μM 
of Cy5-DCG-04 was added and the labeling was stopped after 1 h by the addition of gel 
loading buffer. The labeled proteins were then resolved by SDS-PAGE and the fluorescence 
was detected by scanning the gel on a typhoon scanner. 
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For Sym4, the experiment revealed a low nanomolar (1.5 nM) inhibition of FP-2/3 as 
indicated by the disappearance of the DCG-04 bands, in addition, FP-1 was also inhibited but 
only at significantly higher concentrations (1.6 μM). The aminopeptidase DPAP-1 was not 
inhibited. In contrast to Sym4, the inhibition of FP-2/3 by Sym4mmp→Ala was much weaker; a 
reduced DCG-04 signal was detected starting from a concentration of 25 μM and an 
inhibition of FP-1 or DPAP-1 was not detected at all (Fig. 79). 
 
 
 
Figure 79: Competitive ABPP experiments with Cy5-DCG-04 and Sym4 or Sym4mmp→Ala. Sym4 potently inhibits 
FP-2/3 at a low nanomolar concentration (1.5 nM). (work of E. Deu) 
 
The competitive APBB experiments were carried out in the same manner with the click 
probes ≡Sym4 and ≡Sym4mmp→Ala that exhibited a similar labeling pattern as the unmodified 
probes, thereby indicating that in contrast to the C-terminal replacement of mmp by alanine 
methyl ester, the modification of the N-terminus did not influence the labeling behavior of 
the respective probe (Fig. 80). 
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Figure 80: Competitive ABPP experiments with Cy5-DCG-04 and ≡Sym4 or ≡Sym4mmp→Ala. ≡Sym4 also potently 
inhibits FP-2/3 at low nanomolar concentrations, similar to Sym4. It inhibits FP-1 above concentration of 25 µM. 
The derivative ≡Sym4mmp→Ala is a poor FP-2/3 inhibitor with no detectable inhibition of FP-1. (work of E. Deu)  
 
Since Sym4 turned out to be a highly potent inhibitor of FP-2/3, the parameters of inhibition 
were further investigated. Firstly, the kinetics of the inhibition as well as the mode of 
inhibition of FP-2 and FP-3 were investigated by determining the inhibition of substrate 
turnover for recombinant FP-2 and FP-3. This experiment revealed that Sym4 is an 
irreversible inhibitor of FP-2 and FP-3 and that Sym4 is approximately 10-fold more potent 
against FP-2 (ki = 58600 ± 1400 M-1s-1) than against FP-3 (ki = 7030 ± 250 M-1s-1). In summary, 
these assays performed for Sym4 revealed that Sym4 is one of the most potent FP-2/3 
inhibitors reported to date[155]. 
In a further evaluation of the inhibition parameters of Sym4, the inhibition of the parasite’s 
papain-like cysteine proteases by Sym4 was also determined in intact parasites. To this end, 
a parasite culture of P. falciparum was treated with different concentrations of Sym4 for 1 h 
then the RBCs were lysed with saponin, and the residual activity of the PLCPs in the parasite 
pellets was measured using Cy5-DCG-04 (Fig. 81). This assay revealed that Sym4 is a sub-
micromolar inhibitor of all falcipains in the intact parasites, preferentially inhibiting FP-2 (IC50 
= 8.5 ± 1.3 nM) over FP-3 (IC50 = 22 ± 8 nM) or FP-1(IC50 = 140 ± 23 nM).  
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Figure 81: Inhibition of PLCPs by Sym4 in intact parasite cells. (work of E. Deu) 
 
In summary, the overall antimalarial activity of Sym4 most likely results from a combined 
inhibition of FP-2 and FP-3 (and also to a certain extent of FP-1). It has to be noted that a 
lower concentration of Sym4 is required to cause a food vacuole defect (0.1 μM) than to 
actually kill the parasites (EC50 = 0.7 μM) indicating that the inhibition of FP-2 is sufficient to 
effect a disturbance of the hemoglobin digestion in the food vacuole, yet it is not sufficient to 
kill the parasite. [52] The antimalarial activity of Sym4 that results in a killing of the parasite is 
therefore most likely due to an inhibition of FP-3. The hemoglobinase activity of the 
falcipains has been suggested to be redundant, i. e. if FP-2 is inhibited, FP-3 is able to 
overtake its role in a rescue mechanism. FP-3 is, however, crucial for the survival of the 
parasite at a later developmental stage.[50] An evidence for this finding is provided by the fact 
that in knock-out experiments (that were also presented in the introduction of this work), a 
FP-2 knock-out indeed displays the prominent food vacuole defect but is yet viable, while an 
FP-3 knock-out could not be generated.[52] 
Moreover, the present studies indicate that derivatives of symplostatin 4 that feature the 
mmp group represent promising new lead structures for the design of antimalarial agents. In 
fact, the findings from this study indicate that an incorporation of this group into rationally-
designed small molecule inhibitors could significantly contribute to an enhancement of their 
biological activity.  
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4 Summary and Conclusions 
 
During this PhD project two different natural product protease inhibitors and analogs 
derived from these natural products were studied. Natural products are regarded as 
privileged structures that have emerged from evolution to exert a biological effect. 
Consequently, natural products are regarded as pre-validated compounds owing to their 
natural origin and they represent valuable lead structures in drug discovery.[1,3] Accordingly, 
the investigation of their chemical synthesis as well as the molecular basis of their biological 
activity are interesting scientific questions addressed in the field of chemical biology.  
 
4.1 Development of a general solid-phase synthesis for Ahp cyclodepsipeptides and 
synthesis of symplocamide A 
 
The class of Ahp cyclodepsipeptides is known for its specific and, most intriguingly, non-
covalent inhibition of S1 serine proteases and has been suggested as a target class in the 
investigation of serine protease inhibitors as drug targets.[25] 
At the beginning of this PhD project, only two tedious and highly specialized solution-phase 
syntheses of Ahp cyclodepsipeptides were published.[100-102]  
Consequently, the first goal of this thesis was the development of a more flexible synthesis 
approach to Ahp cyclodepsipeptides. This was accomplished by the development of a solid-
phase synthesis strategy for Ahp cyclodepsipeptides. These syntheses were based on a 
general Ahp precursor that enabled the anchoring to the solid phase as well as the 
installation of the critical Ahp residue in the cyclodepsipeptide structure (Fig. 82). 
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Figure 82: Retrosynthetic analysis of Ahp cyclodepsipeptides. A: The Ahp hemiaminal is formed spontaneously 
from an aldehyde precursor, if the cyclodepsipeptide framework is present. B: The aldehyde can be obtained 
by the oxidative cleavage of a masked glutamic aldehyde. The cyclization can be carried out as an on-resin 
macrolactamization; the esterification of the threonine side chain is a crucial step in the depsipeptide synthesis. 
C: The solid-phase synthesis starts from a suitable Ahp precursor that is coupled to the solid support via the 
carboxylic acid functionality incorporated its side chain. 
 
The development of a suitable Ahp precursor was a more demanding task than first 
anticipated. In fact, the final precursor structure was the result of tedious investigations and 
frequent reconsiderations. This precursor allowed the generation of a glutamic aldehyde on 
solid support via a dihydroxylation-glycol cleavage protocol based on the previous works of 
the Meldal group.[106-108] In fact, this cleavage procedure was used in this PhD thesis for the 
first time to generate an aldehyde upon cleavage from the solid phase and therefore extends 
the repertoire of solid-phase cleavage methods. The solid-phase cleavage, however, 
required the use of an alternative resin based on a polyethylene glycol core in place of the 
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commonly used polystyrene resins because polystyrene resins turned out to be incompatible 
to the employed reaction conditions. 
Finally, the Ahp cyclodepsipeptide symplocamide A was generated successfully with the 
newly developed synthetic strategy (Fig. 83)[115,118] The analytic data collected for synthetic 
symplocamide A corresponded well to the data published for the compound isolated from 
natural sources.[24] 
In addition to the spectral data, the biological activity of the synthetic symplocamide A was 
also validated. In a chymotrypsin inhibition assay the synthetic material proved to be as 
potent as the isolated compound, displaying a Ki of 0.32 ± 0.09 μM which is in good 
accordance with the literature report (lit.[24], IC50 = 0.38 ± 0.08 μM). The reported cytotoxicity 
against two cancer cell lines as well as a suggested putative proteasome inhibition, however, 
could not be confirmed for the synthetic material in the assays used here. 
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Figure 83: Total synthesis of symplocamide A.[115,118] Reagents and conditions: (a) i. EtOCOCl, Et3N, THF, -15 °C, 
1 h, ii. NaBH4, THF/H2O (1:1), -15 °C, 1 h, then rt, 6 h (84%); (b) TBDMSCl, imidazole, CH2Cl2, 0 °C to rt, o/n 
(95%); (c) Boc2O, DMAP, CH3CN, rt, 24 h (81%, b.r.s.m.); (d) 10% Pd/C, H2, EtOAc, rt, 2.5 h (99%); (e) i. Cs2CO3, 
MeOH; ii. allylbromide, DMF, rt, o/n (95%); (f) CuCl2*2H2O, acetone/H2O (95:5), reflux, 1 h (92%); (g) Dess-
Martin periodinane, CH2Cl2, rt, 1 h (84%); (h) i. Ph3P
+(CH2)3CO2H Br
-, LHMDS,THF, 0 °C, 55 min; ii. 15, THF, 0 °C to 
rt, o/n (64%). (i) i. amino NovaPEG resin, HOBt, HBTU, DIEA, CH2Cl2-DMF; ii. CH2Cl2/DIEA/Ac2O (3:1:1); iii. 
CH2Cl2/DIEA/Ac2O (3:1:1), 3h; (j) i. TFA/CH2Cl2 (1:1); ii. Et3N/CH2Cl2 (1:9); iii. Fmoc-Cit-OH, HOBt, HBTU, DIEA, 
DMF, 5h (30%, by Fmoc determination, 2 steps); iv. piperidine/DMF (1:4); v. Fmoc-Thr-OH, HOBt, HBTU, DIEA, 
DMF, 2h; vi. piperidine/DMF (1:4); vii. Fmoc-Gln(Trt)-OH, HOBt, HBTU, DIEA, DMF, 2h (88% by Fmoc 
determination, 2 couplings); viii. piperidine/DMF (1:4); ix. butyric acid, HOBt, HBTU, DIEA, DMF, 2h; (k) Fmoc-
Val-OH, DCC, DMAP, CH2Cl2/DMF (9:1); 79% by Fmoc determination, 2 couplings); (l) i. piperidine/DMF (1:4); ii. 
Fmoc-NMePhe-OH, HOBt, HBTU, DIEA, DMF, 2h; iii. piperidine/DMF (1:4); iv. Fmoc-Ile-OH, PyBrOP, DIEA, DMF, 
24h (60%, by Fmoc determination, 2 couplings); (m) i. piperidine, DMF; ii. Pd(PPh3)4, morpholine, CH2Cl2; iii. 
PyBOP, HOBt, DIEA, DMF; (n) OsO4, NaIO4, DABCO, t-BuOH, THF/H2O (3% overall yield).  
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4.2 Synthesis and biological evaluation of small molecule analogs of proteinaceous 
serine protease inhibitors adopting the canonical conformation 
 
Since the Ahp cyclodepsipeptides had only recently been recognized as inhibitors that adopt 
the canonical conformation and thereby belong to the larger class of small molecule analogs 
of canonical-conformation proteinaceous serine protease inhibitors[18], the question arose if 
the Ahp residue is truly essential to form a canonical conformation. Indeed, it became 
apparent during this project that the synthesis of tailor-made Ahp cyclodepsipeptides is 
doable but nevertheless laborious. Consequently, synthetically easier accessible Ahp-mimics 
were sought.  
To gain a quick and flexible access to the desired Ahp analogs, a new solid-phase synthesis 
was developed adapting some methodology from the previous synthesis of symplocamide A 
and using the specificity-determining P1 amino acid as the anchoring point to the solid 
phase. Such an approach should enable access to a multitude of inhibitors for one protease 
by a combinatorial approach (Fig. 84). 
 
 
 
Figure 84: General synthetic strategy for the synthesis of structure-activity analogs of Ahp cyclodepsipeptides, 
the residues are summarized in Table 5.  
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A first set of symplocamide A analogs then proved that the Ahp unit could indeed be 
replaced by the - also hydroxylated - amino acid serine. On the other hand the hydroxylated 
amino acids threonine and homoserine did not provide active compounds.  
The possibility of replacing the Ahp unit by serine then paved the way for the investigation of 
the elements that are required for the macrocycle to adopt the canonical conformation and 
thereby act as a non-covalent inhibitor of serine proteases. The different structure-activity 
analogs that were investigated are summarized in Table 5: 
 
Table 5: Structure-activity analogs investigated to determine the crucial elements for the adoption of the 
canonical conformation. 
 
compound 
(mimic of) 
 
 
Ahp  
replacement 
 
further 
substitutions 
 
Ki 
SAR-1 (Sym A) Ser - 3.8 μM 
SAR-2 (Sym A) Hse - inactive 
SAR-3 (Sym A) Thr - inactive 
SAR-4 (Sym A) Ser 3-Br,4-OMe-mTyr→4-OMe-mTyr 4.8 μM 
SAR-5 (Sym A) Ser 3-Br,4-OMe-mTyr→mPhe 56.1 μM 
SAR-6 (Sym A) Ser 3-Br,4-OMe-mTyr→mPhe  inactive 
SAR-7 (Sym A) Ser 3-Br,4-OMe-mTyr→Pro 16.1 μM 
 
SAR-8 (Sym A) 
 
Ser 
3-Br,4-OMe-mTyr→mPhe 
 
L-Thr→D-allo-Thr 
 
inactive 
 
SAR-9 (Sym A) 
 
Ser 
3-Br,4-OMe-mTyr→mPhe 
 
L-Thr→L-allo-Thr 
 
inactive 
SAR-10 (Scyp A) Ser - 19.1 μM 
SAR-11 (Scyp A) Thr - 5.0 μM 
SAR-12 (Scyp A) Val - inactive 
 
As already expected from the works of Leatherbarrow et. al.[23] the most crucial element for 
the adoption of the canonical conformation is an amino acid that supports the formation of 
a cis amide bond in the P3’ position. In the Ahp cyclodepsipeptides this residue is a 
conserved N-methylated aromatic amino acid[24], in the case of the BBI-derived inhibitors 
investigated by Leatherbarrow and coworkers, a proline is conserved.[23] For the present 
Ahp-mimicked cyclodepsipeptides, modified tyrosines in this position were superior to a 
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proline residue or an even less active analog with a N-methyl phenylalanine residue. The 
possibility to substitute the conserved N-methylated amino acid with a proline clearly 
demonstrates that these analogs of Ahp depsipeptides are truly canonical-conformation 
inhibitors that require the reinforcement of the cis amide bond in the P3’ position.  
Another structure element that was investigated and that has been suggested to play a role 
in the inhibition of serine proteases, is the threonine residue forming the depsipeptide 
linkage with the P4’ valine moiety. For the BBI inhibitors investigated by Leatherbarrow et. al. 
a threonine in the P2 position is able to form a hydrogen bond to the P1’ serine and thereby 
directs the aliphatic part of the threonine side chain towards a close contact with the 
imidazole part of the enzyme’s catalytic histidine. This contact is thought to interfere with a 
movement of the histidine that becomes necessary during the catalysis cycle and is 
proposed contribute to the inhibition of the protease.[18] Such a direction of the aliphatic 
part of the threonine side chain could indeed also be possible for Ahp cyclodepsipeptides 
and their structurally simplified analogs since the side chain is fixed by the ester bond and 
the direction of the methyl group is determined by the stereochemistry of the amino acid. 
Indeed, when the natural (L)-threonine residue was replaced by (D)-allo- or (L)-allo-
threonine the resulting analogs were inactive against chymotrypsin. It has to be noted, 
however, that the requirement of a flexible histidine is discussed controversially in the 
scientific community. The results obtained here may yet be a humble contribution to this 
debate, hinting that indeed a blocking of the histidine’s movement may interfere with the 
processing of the substrate and thereby contribute to the inhibitory mode-of-action. On the 
other hand, the loss of activity may also result from an overall altered conformation of the 
macrocycle.  
To finally prove that the concept of substituting the Ahp moiety in an Ahp cyclodepsipeptide 
with another amino acid is a global concept that affect other proteases than chymotrypsin, a 
different protease needed to be addressed. To achieve this, three different analogs of the 
natural product scyptolin A[27,28] were synthesized and tested for their inhibition of the 
target protease elastase. Fortunately, two of the three analogs were active against elastase, 
the expected serine analog and, surprisingly, also the analog with threonine as a 
replacement of the Ahp moiety.  
The third analog incorporating a valine as a replacement for the Ahp moiety was inactive 
against elastase, pinpointing the requirement of a hydroxyl group in the side chain of the 
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Ahp replacement. In the Ahp residue, the hydroxyl group plays a crucial role forming one of 
the two intramolecular hydrogen bonds with the peptidic backbone, thereby reinforcing the 
rigid structure of the molecule that contributes to the inhibitory potency. The present data 
indicate that also serine- and threonine analogs can form such hydrogen bonds, thereby 
stabilizing the canonical conformation.  
In summary, a general and flexible approach to the solid-phase combinatorial synthesis of 
Ahp cyclodepsipeptides was developed during this PhD work. The strategy was proven by 
the synthesis of the natural product symplocamide A which then served as starting point for 
the synthesis of more easily accessible analogs for structure-activity relationship studies. In 
these analogs the Ahp moiety was replaced by amino acids that are commercially available. 
For the synthesis of these analogs, a global, combinatorial solid-phase synthesis strategy was 
developed and several SAR analogs were synthesized. 
As a result of the structure-activity-relationship studies serine and threonine could be 
determined as adequate replacements of the Ahp moiety. Furthermore, the crucial 
determinants that are required to adopt the canonical conformation could be studied as well 
as the mode-of-inhibition using the newly developed Ahp-mimics. 
For future investigations, it would also be highly desirable to obtain a co-crystal structure or 
a NMR structure of one of the Ahp-mimicked analogs with their target protease in order to 
confirm the findings that so far are based only on enzyme inhibition assays. So far, all 
attempts to obtain a co-crystal structure with chymotrypsin or elastase were, however, not 
successful. 
Another aspect that would be worthwhile to investigate in future studies is the structural 
basis of the different inhibitory activities of threonine- and serine-mimics of scyptolin A. The 
substitution of the Ahp moiety in these compounds with threonine resulted in a more potent 
species than the respective serine analog. A possible explanation for this unexpected finding 
could be a hindered rotation (and thus pre-organization) of the threonine side chain. 
Inhibitor binding would therefore result in less entropy loss (in comparison to the respective 
serine analog), thereby the binding may be favored energetically. A possible explanation for 
the absence of this effect in the symplocamide A analogs could be that here the threonine 
side chain hydroxyl group may form a hydrogen bond with the side chain of citrulline; this 
arrangement however would prevent the formation of the intramolecular hydrogen bond 
that reinforces the conformation of the macrocycle. To prove this hypothesis, future 
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investigations are however required and could involve on the one hand the synthesis of 
further analogs incorporating different P1 residues or Ahp substitutions with more bulky side 
chain modifications. Finally, structural studies of the Ahp-mimics as well as the elucidation of 
the molecular binding mode via NMR or x-ray should provide the structural information 
required to prove the hypothesis. 
Overall, the newly developed small molecule analogs of proteinaceous serine protease 
inhibitors may serve as tools in chemical biology to investigate serine proteases, their mode 
of action and their inhibition; furthermore, they could also serve as leads for the 
development of potent, selective and most importantly non-covalent drugs directed against 
serine proteases. 
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4.3 Development of a convergent synthesis of symplostatin 4 and derivatives for the 
target identification and biological evaluation 
 
The second project that was carried out during this PhD thesis involved the investigation of 
the natural product symplostatin 4[103] that is also known by the name gallinamide A.[104] The 
interest in this natural product came from its molecular structure that consists of a 
prominent Michael acceptor system that has been recognized as a warhead for cysteine 
proteases and the rare C-terminal methoxy-methylpyrrolinone (mmp) residue as well as the 
interesting biological activities reported the compound. Consequently, symplostatin 4 
seemed to be a natural product that could be a useful tool in chemical biology investigations, 
for example after conversion into an activity-based probe. Furthermore, the role of the mmp 
unit could be investigated by replacing this moiety with another amino acid. 
To gain a quick access to symplostatin 4 (Sym4), an analog lacking the mmp moiety 
(Sym4mmp→Ala) and also derivatives of these substances that would function as probes in 
ABPP, a highly convergent, fragment-based synthesis was developed (Fig. 85). To enable a 
flexible conversion of Sym4 and Sym4mmp→Ala into suitable probes for ABPP, alkyne-modified 
versions of the two molecules were generated (≡Sym4 and ≡Sym4mmp→Ala). They were then 
converted either into activity-based probes by reaction with azide-modified tags by a 1,3-
dipolar Huisgen cycloaddition (click reaction) or used directly in a labeling and modified by a 
click reaction after the labeling. For the highest possible flexibility, rhodamine-, biotin- and 
trifunctional versions of both molecules were also generated (Fig. 86). 
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Figure 85: Convergent synthesis of symplostatin 4 and analogs. Reagents and conditions: (a) N,O-
dimethylhydroxylamine hydrochloride, Et3N, DCC, CH2Cl2, rt, 1 h; (b) LiAlH4, Et2O, 0 °C, 20 min; (c) 
Ph3P=CHCOOMe, CH2Cl2, rt, o/n (59%, 3 steps); (d) LiOH, THF/MeOH/H2O (1.67:1:0.67), rt, 5 h; (e) H-Ala-OMe, 
HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, o/n (46%, 2 steps); (f) LiOH, THF/MeOH/H2O (1.67:1:0.67), rt, 5 h; (g) 2,2-
dimethyl-1,3-dioxane-4,6-dione, DMAP, EDC*HCl, CH2Cl2, -10 °C to rt, o/n; (h) EtOAc, reflux, 1 h; (i) Ph3P, 
MeOH, DEAD, THF, rt, o/n (90%, 4 steps); (j) TFA/CH2Cl2 (1:1), rt, 3 h; (k) Boc-Leu-OH, HOBt, HBTU, DIEA, CH3CN, 
0 °C to rt, o/n (85%, 2 steps); (l) TFA/CH2Cl2 (1:1), rt, 2 h; (m) Boc-Leu-OH, HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, 
o/n (99%, 2 steps); (n) SOCl2 (2 M in CH2Cl2), MeOH, 0 °C to rt, o/n; (o) Boc-NMeIle-OH, DMAP, DCC, CH2Cl2, 0 °C 
to rt, o/n (55%, 2 steps); (p) TFA/CH2Cl2, rt, 2 h; (q) CH3I, DIEA, DMF, rt, 2 h (38%, 2 steps); (r) propargyl bromide 
(80% wt in toluene), DIEA, CH3CN, 80 °C, o/n (63%, 2 steps); (s) LiOH, THF/MeOH/H2O (1.67:1:0.67), rt, 5 h; (t) 
TFA/CH2Cl2 (1:1), rt, 2 h; (u) HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, 5 h (91% after silica gel chromatography, 51% 
after additional HPLC, 3 steps); (v) HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, o/n (39% after HPLC, 3 steps); (w) 
HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, o/n (82% after silica gel chromatography, 64% after additional HPLC, 3 
steps); (x) HOBt, HBTU, DIEA, CH3CN, 0 °C to rt, 5 h (73% after silica gel chromatography, 53% after additional 
HPLC, 3 steps).  
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Figure 86: Synthesis of the differently modified probes for ABPP. Reagents and conditions: (b) Tag-N3, CuSO4 
(aq. solution), TBTA (100 mM in DMSO), TCEP (100 mM in H2O), H2O, rt, reaction monitoring by LC-MS, 
chromatographic work-up. 
 
During a placement in the group of Dr. Renier van der Hoorn (MPI for Plant Breeding 
research, Cologne), symplostatin 4 and its derivatives were investigated for their labeling of 
the Arabidopsis thaliana proteome. In preliminary labeling experiments the optimal 
conditions for the in vivo labeling were established; additionally, some in vivo infiltration 
experiments were carried out, yet without remarkable results.  
The target identification for Sym4 and Sym4mmp→Ala was then carried out by Dr. Farnusch 
Kaschani, who was able to identify the papain-like cysteine proteases RD21A and RD21B as 
the major targets of Sym4 and Sym4mmp→Ala in A. thaliana by in vivo labeling of A. thaliana 
cells. RD21 has been assigned a role in the plant immune system.[150] Of note, a difference in 
the labeling pattern of Sym4 and Sym4mmp→Ala was not observed in these experiments 
(Fig. 87). 
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Figure 87: Fluorescence scan of the SDS-PAGE-resolved enzymes labeled in vivo by ≡Sym4 and ≡Sym4mmp→Ala. 
The labeling was carried out in vivo, followed by an in vitro click reaction with Tri-N3 and affinity purification of 
the labeled enzymes on agarose gel. After the resolution of the labeled enzymes, the individual protein bands 
were excised from the gel, digested with trypsin and analyzed by nanoLC-MS/MS. (work by F. Kaschani) 
 
Having successfully identified papain-like cysteine proteases as the targets of symplostatin 4 
in plant cells, the investigation of the antimalarial effect of symplostatin 4[104] was initiated 
under the hypothesis that the antimalarial activity might stem from an inhibition of the 
parasital falcipains. This project was carried out in collaboration with the group of Prof. Dr. 
Matthew Bogyo (Department of Pathology, Stanford University, CA); all experiments were 
carried out by Dr. Edgar Deu Sandoval. 
In a first, cell-based assay the effect of Sym4 and Sym4mmp→Ala on malaria parasites in the 
erythrocytic cycle became apparent: cells treated with 0.1 μM Sym4 showed a distinct 
swollen food vacuole phenotype which is related to a disturbance of the proteases involved 
in the early stage hemoglobin digestion.[50,53,151] In contrast to this, the cells had to be 
treated with a 100-fold higher concentration of Sym4mmp→Ala to observe the same effect, 
indicating a clear difference between the two analogs that might stem from either a 
decreased uptake of Sym4mmp→Ala or a less specific binding to the target enzyme(s) 
(Fig. 88, A). Importantly, at no applied concentration, a lysis of the red blood cells could be 
observed.  
After having studied the direct phenotypic effect of symplostatin 4 on the living parasite, the 
overall effect on parasite replication was investigated. This allows to evaluate if the effect 
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observed at an early stage of the parasite life cycle has an influence on the total 
development and replication (i. e. the progression of the disease). Hence, cell cultures at 2% 
parasitemia were treated with different concentrations of the inhibitors for 75 h and after 
this time, the parasitemia was determined by flow cytometry (Fig. 88, B).[152] Again, a clear 
difference between Sym4 and its analog Sym4mmp→Ala became apparent, thereby confirming 
the results of the previous phenotype assay.  
Since the results from the cell-based assays already indicated strongly that one or more of 
the parasite’s food vacuole cysteine proteases, i. e. falcipain 2, falcipain 2’ and falcipain 3 
(FP-2, FP-2’, FP-3)[50] as the targets of Sym4, a focus was set on verifying this hypothesis by 
activity-based profiling experiments. Firstly, Rh-Sym4 and Rh-Sym4mmp→Ala were tested for 
their labeling of intact parasites. Indeed, two strong bands in the 28 kDa region appeared for 
Rh-Sym4, while for Rh-Sym4mmp→Ala only a very weak labeling in this region could be 
detected. The bands were sensitive to a pre-incubation with Sym4 and ≡Sym4, indicating 
that the labeling is not an artifact caused by the rhodamine tag (Fig. 88, C). This labeling in 
the 28 kDa region was already a strong indicator for the inhibition of FP-2, FP-2’ and FP-3 
(referred to as FP-2/3) that are known to migrate in the 28 kDa region.[153,154] A competitive 
ABPP experiment with Cy5-labeled DCG-04 and the probes Sym4 and Sym4mmp→Ala was 
therefore carried out to test if Sym4 and Sym4mmp→Ala indeed labeled FP-2/3.  
Sym4 was revealed to be a nanomolar inhibitor (1.5 nM) of FP-2/3; in addition, FP-1 was also 
inhibited at higher concentrations (1.6 μM). The aminopeptidase DPAP-1 was not inhibited 
(Fig. 88, D). Sym4mmp→Ala on the other hand inhibited FP-2/3 only weakly (25 μM); an 
inhibition of FP-1 or DPAP-1 could not be detected at all. 
For the potent FP-2/3 inhibitor Sym4 the parameters of inhibition were then further 
investigated. A substrate turnover experiment with recombinant FP-2 and FP-3 revealed that 
Sym4 is an irreversible inhibitor of FP-2 and FP-3 and that it is approximately 10-fold more 
potent against FP-2 than it is against FP-3. In summary, the assays revealed Sym4 as one of 
the most potent FP-2/3 inhibitors reported to date.[155] The determination of the IC50 values 
for the different PLCPs revealed that Sym4 preferentially inhibits FP-2 over FP-3 and FP-1. 
Indeed, all falcipains are inhibited in the sub-micromolar range (Fig. 88, E). A summary of all 
biological activities of Sym4 and Sym4mmp→Ala is presented in Table 6.  
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Table 6: Summarized antimalarial activities of Sym4 and Sym4mmp→Ala. 
 
 
 
Sym4 
 
Sym4mmp→Ala 
food vacuole 
 defect observed at 
 
0.1 μM 
 
10 μM 
EC50  
(from replication assay) 
 
0.7 ± 0.2 μM 
 
27 ± 7 μM 
labeling of FP-2/3 in intact parasites at 10 μM strong weak 
FP-2/3 inhibition starting from (comp. assay) 1.5 nM 25 μM 
FP-1 inhibition starting from (comp. assay) 1.6 μM not observed 
ki(FP-2) / M-1s-1 58600 ± 1400 not determined  
ki(FP-2) / M-1s-1 7030 ± 250 not determined 
IC50(FP-2) 8.5 ± 1.3 nM not determined 
IC50(FP-3) 22 ± 8 nM not determined 
IC50(FP-1) 140 ± 23 nM not determined 
 
 
 
 
Figure 88: Summarized results of the investigation of the antimalarial activity of Sym4. A: food vacuole 
phenotype caused by Sym4 treatment of P. falciparum D10 at ring stage; B: effect of Sym4 treatment on 
replication of P. falciparum; C-E: ABPP experiments with Sym4 and ABPP analogs: labeling of intact parasite 
cells (C), competitive ABPP with Cy5-DCG-04 (D), competitive ABPP with Cy5-DCG-04 in order to determine IC50 
values (E). (work by E. Sandoval)  
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In summary, the overall antimalarial activity of Sym4 most likely results from a combined 
inhibition of FP-2 and FP-3 (and to a lesser extent FP-1). The food vacuole defect observed at 
an early stage of the parasital development is most likely caused by the inhibition of FP-2; 
the decreased replication (i. e. killing of the parasite) is in contrast most likely caused by the 
inhibition of FP-3 that has been demonstrated to be the determining factor for parasite 
survival.[52] 
In conclusion, the natural product symplostatin 4 has been studied in two different 
organisms. The targets of symplostatin 4 in A. thaliana have been identified to be the PLCPs 
RD21A and RD21B. For the labeling in the model plant, no difference in the labeling pattern 
between Sym4 and its analog lacking the putatively important mmp unit was observed.  
The antimalarial activity of symplostatin 4 was studied extensively, revealing Sym4 to be a 
highly potent inhibitor of the plasmodial falcipains. Here, a significant difference between 
Sym4 and Sym4mmp→Ala was observed. Sym4 may in the future serve as a lead structure for 
the development of new antimalarial drugs inhibiting the parasite’s falcipains; the different 
ABPP probes may furthermore be used for labeling experiments and investigation of 
different proteomes. 
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5 Zusammenfassung und Ausblick 
 
Im Rahmen dieser Dissertation wurden zwei unterschiedliche Naturstoffe, die als 
Proteaseinhibitoren wirken, sowie Analoga, die von diesen Naturstoffen abgeleitet wurden 
untersucht. Naturstoffe können aufgrund ihrer häufig vorhandenen Bioaktivität als 
privilegierte Strukturen betrachtet werden, die sich im Zuge der Evolution entwickelt haben. 
Deswegen können Naturstoffe als vor-validierte Substanzen angesehen werden, die bei der 
Suche nach neuen Wirkstoffen als wertvolle Leitstrukturen dienen können.[1,3] Die 
Untersuchung von Synthesewegen zur chemischen Darstellung von Naturstoffen als auch die 
Aufklärung der molekularen Basis ihrer Bioaktivität stellen somit interessante 
Fragestellungen dar, die im Themengebiet der Chemischen Biologie behandelt werden.  
 
5.1 Entwicklung einer allgemeinen Festphasen-Synthese von Ahp-Cyclodepsipeptiden 
und Synthese von Symplocamide A 
 
Die Naturstoffklasse der Ahp-Cyclodepsipeptide ist für ihre spezifische und bemerkenswerte 
nicht-kovalente Inhibierung der S1 Serinproteasen bekannt; dementsprechend wurden sie 
auch als wichtige Leitstruktur für die Entwicklung von Serinprotease-Inhibitoren z. B. zur 
Anwendung in der Wirkstoffforschung erkannt.[25] 
Zu Beginn dieser Dissertation waren lediglich zwei aufwändige und spezialisierte 
Lösungssynthesen von Ahp-Cyclodepsipeptiden bekannt[100-102], so dass die erste Aufgabe die 
Entwicklung eines flexibleren Synthesewegs für Ahp-Cyclodepsipeptide war. So sollte ein 
Zugang zu maßgeschneiderten Ahp-Cyclodepsipeptiden erhalten werden, um z. B. den 
Inhibitionsmodus besser im Detail studieren zu können. Verwirklicht wurde dieser Ansatz 
durch die Entwicklung einer Festphasensynthese-Strategie für die Ahp-Cyclodepsipeptide. 
Um diese Strategie zu verwirklichen, wurde dabei eine Ahp-„Vorstufe“ entwickelt, welche 
sowohl als Anker in der Festphasensynthese diente als auch zum geeigneten Zeitpunkt in 
einen Glutaminsäurealdehyd (als Vorstufe der Ahp-Gruppe) umgewandelt werden konnte. 
Erst die Entwicklung dieses Bausteins machte eine flexible Festphasensynthese von Ahp-
Cyclodepsipeptiden möglich (Abb. 89). 
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Abbildung 89: Retrosynthese der Ahp-Cyclodepsipeptide. A: Die Ahp-Hemiaminalstruktur bildet sich bei Ahp-
Cyclodepsipeptiden spontan aus einer Aldehyd-Vorstufe. B: Der Aldehyd wird durch die oxidative Abspaltung 
eines maskierten Glutaminsäurealdehyds erzeugt. Die Cyclisierung erfolgt an der festen Phase als 
Macrolaktamisierung; die Veresterung der Threoninseitenkette ist einer der grundlegenden Schritte der 
Depsipeptidsynthese. C: Die Festphasensynthese geht von einer geeigneten Ahp-Vorstufe aus, die über eine 
Säurefunktion am Harz verankert ist. 
 
Die Entwicklung einer geeigneten Ahp-Vorstufe stellte sich als eine anspruchsvollere 
Aufgabe dar, als der erste Anschein vermuten ließ. Die letztendlich verwendete Ahp-
Vorstufe wurde erst nach einer langen Entwicklungsarbeit erhalten und stellt das Resultat 
mühevoller Studien und häufiger Änderungen in der Syntheseplanung dar.  
Das Herzstück der Synthesestrategie ist die, im Rahmen der Ahp-Vorstufe, hier neu- 
entwickelte Abspaltungsmethode, bei welcher ein Glutaminsäurealdehyd über einen 
Dihydroxylierungs- und anschließenden Glykolspaltungsprozess erzeugt wird. Das Protokoll 
basiert dabei auf den vorhergehenden Arbeiten von Meldal et. al.,[106-108] als 
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Abspaltungmethode zur Generierung eines Aldehyds bei der Abspaltung wurde diese 
Reaktionssequenz hier jedoch zum ersten Mal eingesetzt und stellt somit eine Ergänzung 
zum Repertoire der Abspaltmethoden von der festen Phase dar. Um diese neuartige 
Abspaltmethode jedoch verwenden zu können, musste das für die Festphasen-Synthese 
verwendete Harz angepasst werden. Statt eines gebräuchlichen Polystyrol-Harzes, das sich 
unter den Abspaltbedingungen als nicht stabil erwiesen hatte, wurde bei dieser Methode ein 
Polyethylenglycol-Harz verwendet. 
Mithilfe der neuentwickelten Methodik konnte schließlich der Naturstoff Symplocamide A 
erfolgreich an der festen Phase synthetisiert werden (Abb. 90). Die analytischen Daten, die 
dabei für das synthetische Symplocamide A aufgenommen wurden, stimmten dabei sehr gut 
mit den Daten für den Naturstoff publizierten Werten überein.[24] 
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Abbildung 90: Totalsynthese von Symplocamide A.[115,118] Reagenzien und Reaktionsbedingungen: (a) i. 
EtOCOCl, Et3N, THF, -15 °C, 1 h, ii. NaBH4, THF/H2O (1:1), -15 °C, 1 h, dann RT, 6 h (84%); (b) TBDMSCl, Imidazol, 
CH2Cl2, 0 °C-RT, ü/N (95%); (c) Boc2O, DMAP, CH3CN, RT, 24 h (81%, b.r.s.m.); (d) 10% Pd/C, H2, EtOAc, RT, 2.5 h 
(99%); (e) i. Cs2CO3, MeOH; ii. Allylbromid, DMF, RT, ü/N (95%); (f) CuCl2*2H2O, Aceton/H2O (95:5), Rückfluss, 
1 h (92%); (g) Dess-Martin-Periodinan, CH2Cl2, RT, 1 h (84%); (h) i. Ph3P
+(CH2)3CO2H Br
-, LHMDS,THF, 0 °C, 55 
min; ii. 15, THF, 0 °C-RT, ü/N (64%). (i) i. Amino NovaPEG resin, HOBt, HBTU, DIEA, CH2Cl2/DMF (9:1); ii. 
CH2Cl2/DIEA/Ac2O (3:1:1); iii. CH2Cl2/DIEA/Ac2O (3:1:1), 3h; (j) i. TFA/CH2Cl2 (1:1); ii. Et3N/CH2Cl2 (1:9); iii. Fmoc-
Cit-OH, HOBt, HBTU, DIEA, DMF, 5h (30%, laut Fmoc-Bestimmung, 2 Stufen); iv. Piperidin/DMF (1:4); v. Fmoc-
Thr-OH, HOBt, HBTU, DIEA, DMF, 2h; vi. Piperidin/DMF (1:4); vii. Fmoc-Gln(Trt)-OH, HOBt, HBTU, DIEA, DMF, 2h 
(88% laut Fmoc-Bestimmung, 2 Kupplungen); viii. Piperidin/DMF (1:4); ix. Buttersäure, HOBt, HBTU, DIEA, DMF, 
2h; (k) Fmoc-Val-OH, DCC, DMAP, CH2Cl2/DMF (9:1); 79% laut Fmoc-Bestimmung, 2 Kupplungen); (l) i. 
Piperidin/DMF (1:4); ii. Fmoc-NMePhe-OH, HOBt, HBTU, DIEA, DMF, 2h; iii. Piperidin/DMF (1:4); iv. Fmoc-Ile-
OH, PyBrOP, DIEA, DMF, 24h (60%, laut Fmoc-Bestimmung, 2 Kupplungen); (m) i. Piperidin/DMF (1:4); ii. 
Pd(PPh3)4, Morpholin, CH2Cl2; iii. PyBOP, HOBt, DIEA, DMF; (n) OsO4, NaIO4, DABCO, t-BuOH, THF/H2O (3% 
Gesamtausbeute).  
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Neben den spektroskopischen Daten wurde auch die biologische Aktivität des synthetischen 
Symplocamide A validiert. In einem Inhibitionassay mit Chymotrypsin stellte sich die 
synthetische Substanz (Ki = 0.32 ± 0.09 μM) als ebenso potent wie der Naturstoff heraus 
(lit.[24], IC50 = 0.38 ± 0.08 μM). Die in der Originalpublikation festgestellte Zytotoxizität 
gegenüber zwei Krebszelllinien, sowie eine mögliche Inhibierung des Proteasoms durch 
Symplocamide A konnten jedoch in den, im Rahmen der Dissertation, verwendeten 
Testsystemen nicht festgestellt werden. 
 
5.2 Synthese und biologische Evaluierung von „Small-molecule”-Analoga proteinogener 
Serinproteaseinhibitoren mit kanonischer Konformation 
 
Trotz der bekannten Serinproteasehemmeigenschaften der Ahp-Cyclodepsipeptide wurde 
erst unlängst erkannt, dass auch diese Substanzen als Inhibitoren mit einer kanonischen 
Konformation wirken.[18] Sie werden somit zur Klasse der „Small-molecule“-Analoga 
proteinogener Serinproteaseinhibitoren gezählt. Dabei ist die kritische Rolle der Ahp-Einheit 
in der Stabilisierung der kanonischen Konformation bereits ausführlich untersucht worden. 
Dies führte zur Frage, ob diese Einheit jedoch durch eine andere Funktionalität unter 
Beibehaltung der Bioaktivität ersetzt werden kann. Dies ist insbesondere daher von 
Interesse, da im Verlauf der Dissertation klar wurde, dass mit der neu entwickelten 
Synthesestrategie zwar die Synthese maßgeschneiderter Ahp-Cyclodepsipeptide möglich ist, 
diese jedoch immer mehrstufige Synthesen einzelner Bausteine und eine sorgsame 
Festphasensynthese benötigen. Deshalb wurde nach einer Möglichkeit gesucht, die Ahp-
Einheit durch eine besser zugängliche, d. h. im besten Fall kommerziell erhältliche, 
Aminosäuren zu ersetzen. Im Anschluss an eine erfolgreiche Substitution der Ahp-Einheit 
sollten dann die kritischen Elemente für die Einnahme der kanonischen Konformation in 
diesen Ahp-Analoga untersucht werden. 
Für eine möglichst schnelle und flexible Synthese der geplanten Ahp-Analoga wurde eine 
neue Festphasensynthese entwickelt, die einen Teil der Methodik der vorangegangenen 
Synthese von Symplocamide A aufgreift. Als Anker an die feste Phase wurde die P1-
Aminosäure gewählt, da diese die Spezifität eines Inhibitors bestimmt und in einem 
kombinatorischen Ansatz viele Varianten eines Inhibitors zugänglich sind (Abb. 91).   
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Abbildung 91: Allgemeine Festphasen-Synthese zur Herstellung von Struktur-Wirkungsanaloga von Ahp-
Cyclodepsipeptiden. Die Reste R  und P sind in Tabelle 7 zusammengefasst.  
 
Mit einem ersten Satz von Symplocamide A-Analoga konnte dann zunächst der Beweis 
erbracht werden, dass die Ahp-Einheit durch die - ebenfalls hydroxylierte - Aminosäure Serin 
ersetzt werden kann. Zwei weitere Analoga, die die Aminosäuren Threonin und Homoserin 
enthielten, waren hingegen inaktiv im Inhibitionsassay.  
Die Substitution der Ahp-Einheit durch Serin ermöglichte dann die Untersuchung der 
Elemente, die zur Einnahme einer kanonischen Konformation essentiell sind. Die 
verschiedenen Analoga, mit denen diese Struktur-Wirkungsbeziehungen untersucht wurden 
sind in Tabelle 7 zusammengefasst. 
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Tabelle 7: Struktur-Wirkungsanaloga zur Auffindung der essentiellen Strukturelemente in der kanonischen 
Konformation. 
 
Substanz 
(abgeleitet von) 
 
 
Ahp-  
Substitution 
 
weitere 
Substitutionen 
 
Ki 
SAR-1 (Sym A) Ser - 3.8 μM 
SAR-2 (Sym A) Hse - inaktiv 
SAR-3 (Sym A) Thr - inaktiv 
SAR-4 (Sym A) Ser 3-Br,4-OMe-mTyr→4-OMe-mTyr 4.8 μM 
SAR-5 (Sym A) Ser 3-Br,4-OMe-mTyr→mPhe 56.1 μM 
SAR-6 (Sym A) Ser 3-Br,4-OMe-mTyr→mPhe  inaktiv 
SAR-7 (Sym A) Ser 3-Br,4-OMe-mTyr→Pro 16.1 μM 
 
SAR-8 (Sym A) 
 
Ser 
3-Br,4-OMe-mTyr→mPhe 
 
L-Thr→D-allo-Thr 
 
inaktiv 
 
SAR-9 (Sym A) 
 
Ser 
3-Br,4-OMe-mTyr→mPhe 
 
L-Thr→L-allo-Thr 
 
inaktiv 
SAR-10 (Scyp A) Ser - 19.1 μM 
SAR-11 (Scyp A) Thr - 5.0 μM 
SAR-12 (Scyp A) Val - inaktiv 
 
Wie bereits aufgrund der umfangreichen Arbeiten von Leatherbarrow et. al.[3] vermutet 
worden war, spielt insbesondere die Aminosäure in der P3‘-Position, welche eine cis-
Amidbindung eingehen muss, eine wichtige Rolle für die Einnahme der kanonischen 
Konformation. Bei Ahp-Cyclodepsipeptiden ist an dieser Stelle eine konservierte N-
methylierte aromatische Aminosäure zu finden[24], im Falle der von Leatherbarrow 
untersuchen Bowman-Birk-artigen Inhibitoren findet sich hier ein konserviertes Prolin.[23] 
Für die hier untersuchen Ahp-Analoga wurde eine deutliche Präferenz für methylierte 
Tyrosine gegenüber einem Prolin und einem, in seiner Aktivität drastisch herabgesetzten, 
N-Methylphenylalaninderivat festgestellt. Die Substitutionsfähigkeit der konservierten 
N-methylierten Aminosäure durch ein Prolin verifiziert dabei, dass es sich bei den hier 
hergestellten Analoga von Ahp-Cyclodepsipeptiden tatsächlich um Inhibitoren mit 
kanonischer Konformation handelt, da diese Konformation durch eine cis-Amidbindung in 
der P3‘-Position erzwungen wird. 
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Ein weiteres Strukturelement, dem eine Rolle bei der Inhibition von Serinproteasen 
zugeschrieben wird, ist der Threoninrest in P2-Position, mit dessen Seitenkette die 
Depsipeptidbindung zum P4‘-Valin hergestellt wird. In den von Leatherbarrow untersuchen 
BBI-Inhibitoren bildet ein Threonin in der P2-Position eine Wasserstoffbrücke mit dem Serin 
in der P1’-Position aus, wodurch der aliphatische Teil der Threoninseitenkette so dirigiert 
wird, dass er in einem engen Kontakt mit dem Imidazolrest des Histidins der katalytischen 
Triade steht. Dieser Kontakt steht im Verdacht, eine Bewegung des Imidazolrestes, die im 
Zuge des Katalysezyklus notwendig wird, zu blockieren und damit zur Inhibition 
beizutragen.[18] 
Eine ähnliche Dirigierung des aliphatischen Teils der Threoninseitenkette wäre auch für die 
Ahp-Cyclodepsipeptide denkbar, da die Seitenkette durch die Esterbindung fixiert ist und die 
Orientierung der Methylgruppe durch die Stereochemie der Aminosäure festgelegt wird.  
Tatsächlich waren die im Hinblick auf diese Hypothese hergestellten Analoga, in denen das 
natürliche (L)-Threonin durch (D)-allo- oder (L)-allo-Threonin ersetzt wurde, im 
anschließenden Enzymassay inaktiv. Es muss jedoch beachtet werden, dass die 
Notwendigkeit einer Bewegung des Histidins während der Katalyse immer noch höchst 
kontrovers diskutiert wird. Die hier gewonnenen Erkenntnisse stellen nichtsdestotrotz einen 
bescheidenen Beitrag zu dieser Debatte dar und geben zumindest einen Hinweis darauf, 
dass eine Blockierung des Histidins einen Einfluss auf die Prozessierung eines Substrats 
haben könnte und somit zur Inhibition beiträgt. Andererseits könnte der Verlust der Aktivität 
auch das Resultat einer veränderten Gesamtkonformation des Makrozyklus sein. 
Um abschließend zu zeigen, dass der Ersatz der Ahp-Einheit in einem Ahp-Cyclodepsipeptid 
nicht nur bei den bisher studierten Chymotrypsin-Inhibitoren funktioniert, sondern ein 
globaleres Konzept darstellt, sollte eine weitere Protease mit der entwickelten Methodik 
adressiert werden. Um dies zu bewerkstelligen, wurden drei Ahp-Analoga des Naturstoffs 
Scyptolin A[27,28] hergestellt und im Hinblick auf die Inhibition der Zielprotease Elastase 
getestet. Erfreulicherweise waren zwei der drei synthetisierten Analoga in dem Enzymassay 
aktiv. Neben dem erwarteten Serin-Analogon war überaschenderweise auch ein Analogon 
aktiv, in dem Threonin als Ahp-Ersatz verwendet wurde. In der Tat zeigte dieses Derivat 
sogar eine stärkere Aktivität als das Serin-Analogon. Im dritten Analogon war die Ahp-Einheit 
durch Valin ersetzt worden; diese Substanz war jedoch inaktiv, wodurch die Notwendigkeit 
einer Hydroxylfunktion in der Seitenkette der P1‘-Aminosäure unterstrichen wurde. Der 
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Hydroxylgruppe in Ahp wird eine wichtige Rolle bei der Inhibierung zugeschrieben, da sie 
eine der zwei intramolekularen Wasserstoffbrücken mit dem Peptidrückgrat bildet. Diese 
sind zur Festigung der rigiden macrocyclischen Struktur  erforderlich. Die vorliegenden Daten 
deuten darauf hin, dass auch bei den Ahp-Mimetika ein ähnliches System vorliegt.  
Zusammenfassend wurde im Rahmen dieser Dissertation ein allgemeiner und flexibler 
Ansatz zur Festphasensynthese von Ahp-Cyclodepsipeptiden entwickelt. Als Beweis für die 
Anwendbarkeit dieser neuen Strategie wurde der Naturstoff Symplocamide A synthetisiert. 
Symplocamide A diente dann als Ausgangspunkt für die Synthese besser zugänglicher 
Analoga für die Untersuchung von Struktur-Wirkungsbeziehungen. In diesen Analoga wurde 
die Ahp-Einheit durch kommerziell erhältliche Aminosäuren ersetzt; die Synthese erfolgte 
über einen allgemeinen, kombinatorischen Festphasenansatz. 
Die hydroxylierten Aminosäuren Serin und Threonin wurden zunächst als mögliche 
Substitutionen für die Ahp-Einheit bestimmt. Desweiteren wurden die kritischen Elemente 
identifiziert, die zur Einnahme der kanonischen Konformation notwendig sind und ein 
Einblick in den Mechanismus der Inhibition gewonnen. 
Im Rahmen weitergehender Untersuchungen der Ahp-Analoga wären zusätzliche Daten 
sowohl zur Struktur der Mimetika als auch zum Bindungsmodus mit der Protease höchst 
wünschenswert. Diese könnten z. B. durch eine Komplex-Kristallstruktur eines Analogons mit 
seiner Zielprotease oder alternativ über eine Strukturanalyse mittels NMR-Spektroskopie 
erhalten werden. Diese Daten würden dazu beitragen, die ausschließlich auf Studien der 
Enzyminhibierung basierenden Ergebnisse auf eine breitere Grundlage zu stellen. Alle 
Versuche solche strukturellen Daten zu erhalten (z. B. durch Ko-Kristallisation mit 
Chymotrypsin oder Elastase und anschließender Röntgenstrukturanalyse) blieben bisher 
jedoch leider erfolglos. 
Ein weiterer Aspekt, der Gegenstand weiterreichender Untersuchungen sein könnte, ist die 
Aufklärung der molekularen Basis der unterschiedlichen Bioaktivität Threonin und Serin-
substituierter Derivate von Scyptolin A. In der Tat war bei diesen Ahp-Mimetika das 
Threonin-Ahp-Mimetikum aktiver als die entsprechende Serin-Variante. Eine mögliche 
Erklärung hierfür könnte eine eingeschränkte Rotation der Seitenkette sein (und somit 
Präorganisation des Inhibitors), die einen geringeren Entropieverlust bei der Bindung an das 
Protein bewirkt. Interessanterweise wurde bei Symplocamide A dieser Effekt jedoch nicht 
beobachtet, was daran liegen könnte, dass in diesem Fall die Möglichkeit einer 
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Wasserstoffbrückenbindung zwischen der Hydroxylgruppe in der Threoninseitenkette mit 
der P1-Aminosäure Citrullin besteht, so dass die, für die Inhibition notwendige, 
Wasserstoffbrücke mit dem Peptidrückgrat nicht ausgebildet werden kann. Zur 
Unterstützung dieser Hypothese sind jedoch weitergehende Studien notwendig. Diese 
könnten z. B. mit weiteren Analoga, die unterschiedliche P1-Reste oder Ahp-Substitutionen 
mit sterisch anspruchsvolleren Seitenketten enthalten, durchgeführt werden; andererseits 
könnte auch eine NMR-Struktur der Inhibitoren in Lösung und eine Aufklärung des 
Bindungsmodus z. B. über eine Kristallstruktur für die bereits vorliegenden Analoga die 
erforderlichen strukturellen Informationen liefern. 
Insgesamt können die hier entwickelten „Small-molecule“-Analoga proteinogener 
Serinproteaseinhibitoren sicher einen Beitrag zur weitergehenden Untersuchung von 
Proteasen, ihrem Wirkmechanismus und ihrer Inhibition mit Methoden der Chemischen 
Biologie leisten. Desweiteren wäre auch ein Einsatz dieser Analoga als Leitstrukturen zum 
Auffinden potenter, selektiver und am wichtigsten nicht-kovalenter Wirkstoffe zur 
Hemmung von Proteasen denkbar. 
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5.3 Entwicklung einer konvergenten Synthese für Symplostatin 4 und Derivaten für die 
Target-Identifizierung und biologische Evaluierung 
 
Im Rahmen eines zweiten Projekts wurde der Naturstoff Symplostatin 4 (Sym4)[103] 
untersucht. Symplostatin 4 wurde aus einem marinen Organismus isoliert und ist identisch 
mit dem Naturstoff Gallinamid A, der potente anti-Malaria-Eigenschaften zeigt.[104] 
Symplostatin 4 enthält dabei zwei interessante Strukturelemente, die es zu einem wertvollen 
Werkzeug für biologische Untersuchung machen können: Zum einen enthält Symplostatin 4 
ein Michael-Akzeptorsystem, dass empfänglich für einen nukleophilen Angriff beispielsweise 
durch Cysteinproteasen ist, zum anderen ist es C-terminal mit einer ungewöhnlichen und 
seltenen Methoxy-Methylpyrrolinon-Gruppe (mmp) modifiziert. Neben der biologischen 
Aktivität von Sym4 sollte auch die Rolle der mmp-Einheit mit Hilfe eines Analogons, in dem 
die mmp-Einheit ersetzt wurde, untersucht werden. 
Um einen schnellen Zugang zu Symplostatin 4 (Sym4), einem Analogon ohne die mmp-
Einheit (Sym4mmp→Ala) und Derivaten dieser Verbindungen, die als ABPP-Sonden fungieren 
können, zu erhalten, wurde eine hochkonvergente, auf einer Fragmentkondensation 
basierende Synthese entwickelt. (Abb. 92). Um eine flexible Umwandlung von Sym4 und 
Sym4mmp→Ala zu Sonden für das ABPP zu ermöglichen, wurden zusätzlich Alkin-modifizierte 
Varianten der beiden Moleküle generiert (≡Sym4 und ≡Sym4mmp→Ala), die entweder im 
Rahmen einer 1,3-dipolaren Huisgen-Cycloaddition (Click-Reaktion) mit einer 
Reportereinheit modifiziert werden können oder direkt für ein Labeling eingesetzt und im 
Anschluss an dieses, im Rahmen einer Click-Reaktion, modifiziert werden können. Um die 
größtmögliche Flexibilität zu erreichen, wurden auf diesem Wege sowohl Rhodamin-, Biotin- 
als auch trifunktionale Versionen beider Moleküle hergestellt (Abb. 93). 
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Abbildung 92: Konvergente Synthese von Symplostatin 4 und Analoga. Reagenzien und Reaktionsbedingungen: 
(a) N,O-Dimethylhydroxylamin-Hydrochlorid, Et3N, DCC, CH2Cl2, RT, 1 h; (b) LiAlH4, Et2O, 0 °C, 20 min; (c) 
Ph3P=CHCOOMe, CH2Cl2, RT, ü/N (59%, 3 Stufen); (d) LiOH, THF/MeOH/H2O (1.67:1:0.67), RT, 5 h; (e) H-Ala-
OMe, HOBt, HBTU, DIEA, CH3CN, 0 °C-RT, ü/N (46%, 2 Stufen); (f) LiOH, THF/MeOH/H2O (1.67:1:0.67), RT, 5 h; 
(g) 2,2-Dimethyl-1,3-dioxan-4,6-dion, DMAP, EDC*HCl, CH2Cl2, -10 °C-RT, ü/N; (h) EtOAc, Rückfluss, 1 h; (i) Ph3P, 
MeOH, DEAD, THF, RT, ü/N (90%, 4 Stufen); (j) TFA/CH2Cl2 (1:1), RT, 3 h; (k) Boc-Leu-OH, HOBt, HBTU, DIEA, 
CH3CN, 0 °C-RT, ü/N (85%, 2 Stufen); (l) TFA/CH2Cl2 (1:1), RT, 2 h; (m) Boc-Leu-OH, HOBt, HBTU, DIEA, CH3CN, 
0 °C-RT, ü/N (99%, 2 Stufen); (n) SOCl2 (2 M in CH2Cl2), MeOH, 0 °C-RT, ü/N; (o) Boc-NMeIle-OH, DMAP, DCC, 
CH2Cl2, 0 °C-RT, ü/N (55%, 2 Stufen); (p) TFA/CH2Cl2, RT, 2 h; (q) CH3I, DIEA, DMF, RT, 2 h (38%, 2 Stufen); (r) 
Propargylbromid (80 Gew% in Toluol), DIEA, CH3CN, 80 °C, ü/N (63%, 2 Stufen); (s) LiOH, THF/MeOH/H2O 
(1.67:1:0.67), RT, 5 h; (t) TFA/CH2Cl2 (1:1), RT, 2 h; (u) HOBt, HBTU, DIEA, CH3CN, 0 °C-RT, 5 h (91% nach 
Kieselgelchromatographie, 51% nach zusätzlicher HPLC, 3 Stufen); (v) HOBt, HBTU, DIEA, CH3CN, 0 °C-RT, ü/N 
(39% nach HPLC, 3 Stufen); (w) HOBt, HBTU, DIEA, CH3CN, 0 °C-RT, ü/N (82% nach Kieselgelchromatographie, 
64% nach zusätzlicher HPLC, 3 Stufen); (x) HOBt, HBTU, DIEA, CH3CN, 0 °C-RT, 5 h (73% nach 
Kieselgelchromatographie, 53% nach zusätzlicher HPLC, 3 Stufen).  
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Abbildung 93: Synthese der unterschiedlich-modifizierten Sondenmoleküle für ABPP-Experimente. Reagenzien 
und Reaktionsbedingungen: (b) Tag-N3, CuSO4 (wässr. Lösung), TBTA (100 mM in DMSO), TCEP (100 mM in H2O), 
H2O, RT, Reaktionskontrolle mittels LC-MS, chromatographische Aufreinigung. 
 
Während eines Aufenthalts in der Gruppe von Dr. Renier van der Hoorn (MPI für 
Pflanzenzüchtungsforschung, Köln) wurden Symplostatin 4 und seine Derivate im Hinblick 
auf das Labeling des Proteoms der Modellpflanze Arabidopsis thaliana untersucht. Hierzu 
wurden zunächst die Reaktionsbedingungen für ein optimales in vivo-Labeling ermittelt. 
Anschließend durchgeführte Infiltrationsexperimente konnten jedoch keine 
weiterreichenden Ergebnisse liefern. 
Die Targetidentifizierung für Sym4 und Sym4mmp→Ala wurde dann von Dr. Farnusch Kaschani 
durchgeführt, der die Papain-artigen Cysteinproteasen (papain-like cysteine proteases-
PLCPs) RD21A und RD21B als Zielenzyme von Sym4 und Sym4mmp→Ala identifizieren konnte 
(Abb. 94). RD21 wird eine Beteiligung an der Immunantwort von Pflanzen zugeschrieben.[150] 
Bemerkenswerterweise konnte hier kein Unterschied zwischen Sym4 und seinem Derivat 
ohne die mmp-Einheit festgestellt werden. 
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Abbildung 94: Fluoreszenz-Scan der durch SDS-PAGE aufgetrennten Enzyme, die in vivo von ≡Sym4 und 
≡Sym4mmp→Ala markiert wurden. Das Labeling wurde in vivo ausgeführt, anschließend wurde in vitro eine Click-
Reaktion mit Tri-N3 durchführt und die markierten Enzyme wurden mittels Affintätschromatographie 
aufgereinigt. Nach der Auftrennung der Enzyme mittels SDS-PAGE wurden die Enzymbanden ausgeschnitten 
und ein Gelverdau mit Trypsin durchgeführt. Die Identifikation der markierten Enzyme erfolgte mittels nanoLC-
MS/MS. (F. Kaschani) 
 
Nach der erfolgreichen Identifizierung der molekularen Targets von Symplostatin 4 in 
Pflanzenzellen sollte auch der anti-Malaria-Effekt von Symplostatin 4, der für die chemisch 
identische Substanz Gallinamid A publiziert worden war,[104] untersucht werden. Diese 
Untersuchungen erfolgten in Zusammenarbeit mit der Gruppe von Prof. Dr. Matthew Bogyo 
(Department of Pathology, Stanford University, CA), sämtliche Experimente wurden dabei 
von Dr. Edgar Deu Sandoval durchgeführt.  
Im Rahmen eines ersten Zell-basierten Assays wurde zunächst der Effekt einer Behandlung 
von Malariaparasiten im erythrozytischen Zyklus mit Sym4 und Sym4mmp→Ala untersucht. Für 
Sym 4 zeigte sich dabei schon ab einer Konzentration von 0.1 μM der bekannte Defekt der 
Nahrungsvakuole. Ein solcher Effekt wird z. B. durch eine gestörte Aktivität der Proteasen, 
die im frühen erythrozytischen Zyklus für den Hemoglobinverdau zuständig sind, 
hervorgerufen.[50,53,151] Interessanterweise benötigte Sym4mmp→Ala eine 100-fach höhere 
Inhibitorkonzentration zum Hervorrufen eines vergleichbaren Effektes. Der hier klar zu 
beobachtende Unterschied zwischen den beiden Analoga kann dabei entweder mit einer 
verminderten Resorption von Sym4mmp→Ala oder einer schlechteren Bindung an die 
Zielprotease(n) erklärt werden (Abb. 95, A). Eine wichtige Nebenbeobachtung im Rahmen 
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dieses Experiments war, dass bei keiner der verwendeten Konzentrationen eine Lyse der 
roten Blutkörperchen auftrat. 
Im Anschluss an diese phänotypsiche Untersuchung wurde der Einfluss einer Symplostatin 4-
Behandlung auf die Replikation einer P. falciparum-Zellkultur untersucht, dies ist mit dem 
Fortschreiten der Malariainfektion im Wirt zu vergleichen. Um die Replikation unter 
Symplostatin 4-Einfluss zu studieren, wurden Zellkulturen mit 2% Parasitenbefall mit 
verschiedenen Konzentrationen von Sym4 und dem Analogon Sym4mmp→Ala behandelt und 
der Parasitenbefall nach 75 Stunden mittels Durchflusszytometrie bestimmt (Abb. 95, B).[152] 
Auch hier zeigte sich erneut ein klarer Unterschied in der Potenz der beiden Symplostatin 4-
Varianten, der den Trend des Phänotypen-Assays bestätigt.  
Die Ergebnisse der Zellassays hatten somit bereits einen indirekten Hinweis darauf gegeben, 
dass die parasitären Cysteinproteasen der Nahrungsvakuole, also Falcipain 2, Falcipain 2‘ 
sowie Falcipain 3 (FP-2, FP-2’, FP-3)[50] die Zielproteasen von Sym4 sein könnten. Dies sollte 
im Rahmen von ABPP-Experimenten verifiziert werden.  
Dazu wurde zunächst ein Labeling intakter Parasiten mit Rh-Sym4 und Rh-Sym4mmp→Ala 
durchgeführt. Dabei wurden für Rh-Sym4 zwei starke Banden im Bereich von 28 kDa 
beobachtet, bei Rh-Sym4mmp→Ala trat jedoch im gleichen Bereich lediglich ein schwaches 
Signal auf. Die Banden für Rh-Sym4 waren empfindlich gegenüber einer Präinkubation mit 
den Reporter-freien Versionen Sym4 und ≡Sym4. Dies deutete darauf hin, dass das Labeling 
tatsächlich durch die Funktionalität der Sonde und nicht durch die Rhodamineinheit 
verursacht wird (Abb. 95, C). 
Das im 28 kDa-Bereich beobachtete Labeling war bereits ein starkes Indiz dafür, dass 
tatsächlich FP-2, FP-2’ und FP-3 (bezeichnet als FP-2/3), die bekanntermaßen in diesem 
Bereich migrieren,[153,154] von Sym 4 inhibiert werden. Im Rahmen eines kompetitiven ABPP-
Experiments mit der Sonde Cy5-DCG-04 wurde diese Hypothese anschließend verifiziert. 
Hierzu wurde Sym4 als ein nanomolarer Inhibitor (1.5 nM) von FP-2/3 identifiziert, zusätzlich 
wurde bei höheren Konzentrationen (1.6 μM) auch FP-1 inhibiert. Die Aminopeptidase DPAP-
1 hingegen wurde nicht gehemmt (Abb. 95, D). Sym4mmp→Ala erwies sich lediglich als 
schwacher FP-2/3-Inhibitor (25 μM); weder FP-1 noch DPAP-1 wurden von Sym4mmp→Ala 
inhibiert. 
Für den hochpotenten FP-2/3-Inhibitor Sym4 wurden dann zusätzlich weitere Parameter der 
Inhibition bestimmt. Ein Experiment mit rekombinantem FP-2 und FP-3, in dem die 
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Substratumwandlung studiert wurde, zeigte erstens, dass Sym4 ein irreversibler Inhibitor 
von FP-2 und FP-3 ist und zweitens, dass FP-2 mit einer 10-fach größeren Potenz als FP-3 
inhibiert wird. Somit ist Sym4 einer der derzeit potentesten FP-2/3-Inhibitoren.[155] Die 
Bestimmung der IC50-Werte für die unterschiedlichen PLCPs zeigte zudem, dass Sym4 FP-2 
mit der höchsten Präferenz inhibiert, gefolgt von FP-3 und FP-1; dabei wurde für alle 
Zielproteasen eine sub-mikromolare Hemmung gemessen (Abb. 95, E). Die Ergebnisse der 
biologischen Untersuchungen sind in Tabelle 8 zusammengefasst.  
 
Tabelle 8: Zusammenfassung der Anti-Malaria-Aktivitäten von Sym4 und Sym4mmp→Ala. 
 Sym4 Sym4mmp→Ala 
Nahrungsvakuolendefekt 
 beobachtet ab 
 
0.1 μM 
 
10 μM 
EC50  
(aus Replikationsassay) 
 
0.7 ± 0.2 μM 
 
27 ± 7 μM 
Labeling von FP-2/3 in intakten Parasiten bei 10 μM stark schwach 
FP-2/3 Inhibition ab (kompet. Assay) 1.5 nM 25 μM 
FP-1 Inhibition ab (kompet. Assay) 1.6 μM nicht beobachtet 
ki(FP-2) / M-1s-1 58600 ± 1400 nicht bestimmt  
ki(FP-2) / M-1s-1 7030 ± 250 nicht bestimmt 
IC50(FP-2) 8.5 ± 1.3 nM nicht bestimmt 
IC50(FP-3) 22 ± 8 nM nicht bestimmt 
IC50(FP-1) 140 ± 23 nM nicht bestimmt 
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Abbildung 95: Zusammenfassung der anti-Malaria-Untersuchungen für Sym4. A: Nahrungsvakuolendefekt nach 
der Behandlung von P. falciparum D10 im Ringstadium mit  Sym4; B: Effekt einer Sym4-Behandlung auf die 
Replikation von P. falciparum; C-E: ABPP-Experimente mit Sym4 und ABPP-Analoga: Labeling intakter Parasiten 
(C), kompetitives ABPP mit Cy5-DCG-04 (D), kompetitives ABPP mit Cy5-DCG-04 zur Bestimmung der IC50-Werte 
(E). (E. Sandoval) 
 
Zusammenfassend ist festzustellen, dass die anti-Malaria-Aktivität von Sym4 
höchstwahrscheinlich aus einer kombinierten Inhibition von FP-2 und FP-3 (und in 
geringerem Maße auch FP-1) resultiert. Der Defekt der Nahrungsvakuole, der bereits in einer 
frühen Entwicklungsstufe des Parasiten beobachtet wird, hat seine Ursache dabei 
wahrscheinlich in der Inhibition von FP-2. Die verminderte Replikation (d. h. die Abtötung 
des Parasiten) wird am wahrscheinlichsten durch eine Inhibition von FP-3 verursacht. FP-3 
wird die wichtigste Rolle im Hinblick auf das Überleben und die Weiterentwicklung des 
Parasiten zugeschrieben.[52] 
Insgesamt wurde der Naturstoff Symplostatin 4 in zwei sehr unterschiedlichen Organismen 
studiert. Als Zielproteasen in A. thaliana konnten die PLCPs RD21A und RD21B identifiziert 
werden. Im Rahmen der Labeling-Experimente in der Modellpflanze konnte kein Unterschied 
zwischen Sym4  und Sym4mmp→Ala festgestellt werden.  
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Die anti-Malaria-Aktivität von Symplostatin 4 wurde eingehend studiert, dabei wurde Sym4 
als ein hochpotenter Inhibitor der parasitären Falcipaine identifiziert. Im Rahmen dieser 
Untersuchungen wurde ein klarer Unterschied in der Inhibitionspotenz zwischen Sym4 und 
Sym4mmp→Ala beobachtet.  
In Zukunft könnte Sym 4 als Leitstruktur bei der Suche nach Wirkstoffen gegen Malaria 
eingesetzt werden und darüber hinaus auch für das Profiling weiterer Proteome verwendet 
werden. 
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6 Experimental 
6.1 General methods and instruments 
 
Reagents  
Reagents were purchased from Acros, Senn Chemicals, Fluka, J.T. Baker, Merck, 
Novabiochem, Riedel de Haen, Iris, Roth or Sigma-Aldrich and were used without further 
purification. Anhydrous solvents in the highest available quality were purchased from the 
same suppliers.  
 
Thin layer chromatography (TLC)   
TLC was carried out on Merck aluminum pre-coated silica gel plates (20 × 20 cm, 60F254) 
using ultraviolet light irradiation at 254 nm or the following developing reagents. Eluents and 
Rf values are given in the respective experiment. Reversed-phase TLC was carried out on 
Merck aluminum pre-coated silica gel plates (60 RP-18 F254S) using ultraviolet light irradiation 
at 254 nm or the following developing reagents. 
Reagent A: 20 g of phosphomolybdic acid hydrate in 80 mL ethanol 
Reagent B: 1.5 g KMnO4, 10 g K2CO3 and 1.25 mL of 10% aq. NaOH in 200 mL water. 
 
Silica gel flash liquid chromatography  
Column chromatography purifications were performed with silica gel from Acros (particle 
size 35-70 μm). Reversed-phase chromatography was performed with LiChroprep RP-18 (40-
63µm) from Merck. 
 
Reversed-phase liquid chromatography - electrospray ionization mass spectrometry (LC-
MS)   
LC-MS analyses were performed on an HPLC system from Agilent (1200 series) with an 
Eclipse XDB-C18, 5 μm column from Agilent (peak detection at 210 nm) and a Thermo 
Finnigan LCQ Advantage Max ESI-Spectrometer. A linear gradient of solvent B (0.1% formic 
acid in acetonitrile) in solvent A (0.1% formic acid in water) was used at 1 mL/min flow rate. 
Gradient C18: 0 min / 10% B → 1 min / 10% B → 10 / 100% B → 12 min / 100% B → 15 min / 
10% B.  
Alternatively, a system consisting of an Agilent (1100 series) HPLC from Hewlett-Packard 
(peak detection at 210 nm) equipped with a CC 250/4 Nucleosil 120-5 C4 column from 
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Macherey-Nagel, connected to a Thermo Finnigan LCQ Advantage Max ESI-Spectrometer 
was used. A linear gradient of solvent B (0.1% formic acid in acetonitrile) in solvent A (0.1% 
formic acid in water) was employed at 1mL/min flow rate. 
Gradient C4: 0 min / 10% B → 1 min / 10% B → 10 min / 100% B → 12 min / 100% B → 15 
min / 10% B. 
 
Preparative reversed-phase high performance liquid chromatography (prep HPLC)   
Purification of the compounds was performed on a Varian HPLC system (Pro Star 215) with a 
VP 250/21 Nucleosil C18PPN-column from Macherey-Nagel and detection at 210 nm. 
Alternatively, a C4 column from Macherey-Nagel was used. Linear gradients of solvent B 
(0.1% TFA in acetonitrile) in solvent A (0.1% TFA in water) were applied at a 25 mL/min flow 
rate. 
 
Nuclear magnetic resonance spectroscopy (NMR)   
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Mercury 400 system 
(400 MHz for 1H- and 100 MHz for 13C-NMR), a Bruker Avance DRX 500 system (500 MHz for 
1H- and 126 MHz for 13C-NMR), a Varian Unity Inova 600 system (600 MHz for 1H- and 151 
MHz for 13C-NMR) or a Bruker Avance II 700 MHz system (700 MHz for 1H and 176 MHz for 
13C-NMR). 1H NMR spectra are reported in the following manner: chemical shifts (δ) in ppm 
calculated with reference to the residual signals of undeuterated solvent, multiplicity (s, 
singlet; d, doublet; t, triplet; dd, doublet of doublet; dt, doublet of triplet; m, multiplet; b, 
broad signal), coupling constants (J) in Hertz (Hz), and number of protons (H).  
 
High resolution mass spectrometry (HRMS)   
HRMS measurements were performed on a TRACE GC Ultra DFS (GC/EI) instrument from 
Thermo Scientific. Alternatively, an Accela/LTQ Orbitrap (LC/ESI) system from Thermo 
Scientific was used. 
 
Optical rotation 
Optical rotations were measured with a Polartronic HH8 polarimeter from Schmidt + 
Haensch. Concentrations c are given in g/100 mL, the solvent used is given with the 
respective data. 
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6.2 Solution synthesis of the Ahp precursors I and II 
 
(S)-Benzyl-2-(tert-butoxycarbonylamino)-5-hydroxypentanoate (2) 
 
Boc-(S)-glutamic acid benzyl ester (5.00 g, 14.8 mmol) was dissolved in anhydrous THF 
(60 mL) under an argon atmosphere and cooled to -15 °C in an ice-acetone cooling bath. 
Upon the successive addition of triethylamine (6.2 mL, 44.5 mmol, 3 eq.) and ethyl 
chloroformate (4.2 mL, 44.5 mmol, 3 eq.) a white precipitate formed. After the addition the 
reaction mixture was maintained at -15 °C for 1 h. Subsequently, sodium borohydride (2.24 
g, 59.3 mmol, 4 eq.) dissolved in water (60 mL) was carefully added to the reaction mixture 
at -15 °C resulting in the dissolution of the precipitate. After stirring at -15 °C for 1 further 
hour, the reaction mixture was allowed to warm to RT. A TLC check after 5 h indicated the 
complete consumption of the starting material.  
The reaction mixture was quenched with 1 M aq. KHSO4 solution (100 mL) and the aqueous 
phase was extracted with ethyl acetate (3x 100 mL). The combined organic extracts were 
washed with brine (150 mL), dried over Na2SO4 and evaporated to dryness. The crude 
material was purified by flash column chromatography (50% ethyl acetate in cyclohexane), 
affording (S)-benzyl-2-(tert-butoxycarbonylamino)-5-hydroxypentanoate (2). 
 
Yield: 4.03 g (12.5 mmol, 84%) as a pale yellow oil.  
TLC (50% ethyl acetate in cyclohexane): Rf = 0.36.  
[α]D
20 -2.3 (c 0.98 in CHCl3); (lit.[101],.[α]D -3.9 (c 1.0 in CHCl3)). 
1H NMR (400 MHz, CDCl3): δ 7.32-7.34 (m, 5 H), 5.10-5.19 (m, 2H), 4.29-4.34 (m, 1H), 3.58 (t, 
J = 6.20 Hz, 2H), 1.93-2.00 (m, 1H), 1.84-1.91 (m, 1H), 1.66-1.76 (m, 1H), 1.53-1.60 (m, 2H), 
1.41 (s, 9H).  
13C NMR (100 MHz, CDCl3): δ 172.6, 141.0, 135.3, 128.5, 128.4, 128.2, 79.8, 65.0, 61.8, 53.2, 
29.2, 28.2, 25.4.  
LC-MS: tR = 8.90 min (C18), m/z = 346(M+ + Na+, 30%), 224(M+ - Boc, 100). 
HRMS (EI): m/z calcd for C17H25O5N+ [M + H]+ 324.1805, found 324.1810. 
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(S)-1-Benzyl-5-methyl-2-(tert-butoxycarbonylamino)pentanedioate (3) 
 
Boc-(S)-Glu-OBn (5.00 g, 14.8 mmol) was dissolved in acetone and potassium carbonate 
(18.4 g, 133.4 mmol, 9 eq.) and methyl iodide (2.8 mL, 44.5 mmol, 3 eq.) were added at RT. 
Subsequently, the reaction mixture was heated to reflux. After 4 h a TLC reaction control 
indicated a complete conversion of the starting material. The reaction mixture was cooled to 
RT and quenched by addition of saturated aq. NH4Cl solution (120 mL). The aqueous phase 
was extracted with ethyl acetate (5x 150 mL) and the unified organic phases were dried over 
Na2SO4. 
After evaporation to dryness the crude product was purified by flash column 
chromatography (17% ethyl acetate in cyclohexane) affording pure (S)-1-benzyl-5-methyl-2-
(tert-butoxycarbonylamino)pentanedioate (3). 
 
Yield: 5.20 g mg (14.8 mmol, quant.) as a yellow oil.  
TLC (17% ethyl acetate in cyclohexane): Rf = 0.25. 
1H NMR (400 MHz, CDCl3): δ 7.32-7.38 (m, 5H), 5.17 (d, J = 2.4 Hz, 2H), 4.33-4-43 (m, 1H), 
3.66 (s, 3H), 2.31-2.45 (m, 2H), 2.15-2.23 (m, 1H), 1.91-2.01 (m, 1H), 1.42 (s, 9H).  
13C NMR (100 MHz, CDCl3): δ 173.1, 172.0, 155.3, 135.2, 128.6, 128.4, 128.2, 80.0, 67.2, 53.0, 
51.7, 30.0, 28.2, 27.7.  
LC-MS: tR = 10.00 min (C18), m/z = 252(M+ - Boc, 100%), 352.18 calcd for C18H26NO6+. 
 
(S)-1-Benzyl-5-methyl-2-(bis(tert-butoxycarbonylamino))pentanedioate (4) 
 
(S)-1-Benzyl-5-methyl-2-(tert-butoxycarbonylamino)pentanedioate (3, 5.06 g, 14.4 mmol) 
was dissolved in acetonitrile (150 mL) and transferred to a dry flask under an argon 
atmosphere. 4-(dimethylamino)pyridine (1.76 g, 14.4 mmol, 1 eq.) dissolved in acetonitrile 
(20 mL) and liquidified Boc anhydride (16.5 mL, 72.0 mmol, 5 eq.) were added to the solution 
successively at RT. During the addition of Boc anhydride, the color of the reaction solution 
changed from clear to yellow and during the progression of the reaction to a deep red. After 
stirring at RT for 20 h a TLC reaction control indicated a complete reaction.  
Water (150 mL) was added to the reaction solution and the aqueous phase was extracted 
with ethyl acetate (3x 250 mL); the sluggish phase separation was accelerated by the 
addition of small amounts of brine. The combined extracts were washed with 1 N HCl (300 
mL) and brine (4x 250 mL) and dried over Na2SO4 and evaporated to dryness. The crude 
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material was purified by flash column chromatography (17% ethyl acetate in cyclohexane to 
afford (S)-1-benzyl-5-methyl-2-(bis(tert-butoxycarbonylamino))pentanedioate (4). 
 
Yield: 6.35 g mg (14.1 mmol, 98%) as a colorless oil.  
TLC (17% ethyl acetate in cyclohexane): Rf = 0.24. 
1H NMR (400 MHz, CDCl3): δ 7.31-7.34 (m, 5H), 5.15 (d, J = 1.2 Hz, 2H), 4.96-4.99 (m, 1H), 
3.66 (s, 3H), 2.47-2.56 (m, 1H), 2.37-2.46 (m, 2H), 2.16-2.26 (m, 1H), 1.44 (s, 18H).  
13C NMR (100 MHz, CDCl3): δ 173.1, 170.1, 152.0, 135.6, 128.4, 128.1, 128.0, 83.3, 66.8, 57.5, 
51.6, 30.6, 27.9, 24.8.  
LC-MS: tR = 11.52 min (C18), m/z = 474(M+ + Na, 100%), 252(M+ - 2Boc, 70), 452.23 calcd for 
C23H34NO8+. 
 
(S)-1-Benzyl-2-(bis(tert-butoxycarbonylamino))-5-oxopenanoate (5) 
 
(S)-1-Benzyl-5-methyl-2-(bis(tert-butoxycarbonylamino))pentanedioate (4, 3.70 g, 8.19 
mmol) was dissolved in anhydrous toluene (82 mL, 0.1 M) under an argon atmosphere and 
the solution was cooled to -78 °C in a dry ice/acetone cooling bath. DIBAL-H (1 M in toluene, 
20.5 mL, 20.5 mmol, 2.2 eq.) was added dropwise over a period of 2 h at -78 °C and the 
reaction solution was stirred at -78 °C for another 2 h. The reaction was quenched by slow 
addition of a potassium-sodium-tartrate solution (60 mL) under vigorous stirring at -78 °C. 
The quenched reaction mixture was allowed to warm to ambient temperature, the phases 
were separated and the aqueous phase was extracted with DCM (2x 60 mL). The combined 
organic extracts were dried over Na2SO4 and the solvent was evaporated to dryness. The 
crude material was purified by flash column chromatography (20% ethyl acetate in 
cyclohexane) affording (S)-1-benzyl-2-(bis(tert-butoxycarbonylamino))-5-oxopenanoate (5). 
 
Yield: 918 mg (2.18 mmol, 27%) as a colorless oil.  
TLC (20% ethyl acetate in cyclohexane): Rf = 0.24. 
1H NMR (400 MHz, CDCl3): δ 9.77 (t, J = 0.8 Hz, 1H), 7.30-7-36 (m, 5H), 5.16 (d, J = 2.8 Hz, 2H), 
4.90-4.93 (m, 1H), 2.58-2.64 (m, 1H), 2.47-2.56 (m, 2H), 2.15-2.23 (m, 1H), 1.45 (s, 18H).  
13C NMR (100 MHz, CDCl3): δ 200.9, 170.1, 152.1, 145.3, 128.5, 128.2, 128.0, 83.4, 66.9, 57.5, 
40.5, 28.0, 22.2.  
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LC-MS: tR = 11.21 min (C18), m/z = 444(M+ + Na, 100%), 344(M+ - Boc + Na, 25), 422.22 calcd 
for C22H32NO7+. 
 
(S,E)-7-Benzyl-1-tert-butyl-6-(bis(tert-butoxycarbonylamino))-hept-2-enedioate (6) 
 
preparation of the ylide  
To prepare the ylide (2-tert-butoxy-2-oxoethyl)triphenylphosphonium chloride (2.50 g, 6.05 
mmol) was dissolved in 2 M NaOH (100 mL) and toluene (100 mL) was added. The resulting 
the biphasic reaction mixture was stirred vigorously at RT for 1 h. The phases were separated 
and the aqueous phase was extracted with toluene (1x 100 mL). The combined organic 
extracts were dried over Na2SO4. Evaporation to dryness then yielded the ylide as a white 
solid. 
Wittig reaction 
(S)-1-Benzyl-2-(bis(tert-butoxycarbonylamino))-5-oxopenanoate (5, 866 mg, 2.05 mmol) was 
dissolved in DCM (100 mL) and the ylide (1.55 g, 4.11 mmol, 2 eq.), prepared as described 
above, was added to the solution. The reaction mixture was stirred at RT overnight; after this 
time a TLC reaction control indicated a complete reaction. The reaction was quenched by the 
addition of water (80 mL). The phases were separated and the aqueous phase was extracted 
with ethyl acetate (2x 80 mL). The combined organic extracts were dried over Na2SO4 and 
the solvent was evaporated. The crude product was dissolved in a minimal amount of 
MeOH, mixed with silica gel and evaporated to dryness. This residue was submitted to flash 
chromatography purification (12.5 % ethyl acetate in cyclohexane) to afford (S,E)-7-benzyl-1-
tert-butyl-6-(bis(tert-butoxycarbonylamino))-hept-2-enedioate (6). 
 
Yield: 900 mg (1.73 mmol, 84%) as a pale yellow oil.  
TLC (12.5% ethyl acetate in cyclohexane): Rf = 0.30. 
1H NMR (400 MHz, CDCl3): δ 7.31-7.35 (m, 5H), 6.79-6.86 (m, 1H), 5.76 (d, J = 15.6 Hz, 1H), 
5.15 (d, J = 3.6 Hz, 2H), 4.87-4.91 (m, 1H) 2.22-2.36 (m, 3H) 2.05-2.11 (m, 1H) 1.47 (s, 9H), 
1.45 (s, 18H).  
13C NMR (100 MHz, CDCl3): δ 170.3, 167.8, 152.1, 146.2, 135.6, 128.5, 128.2, 128.0, 123.8, 
83.2, 80.1, 66.9, 57.7, 28.8, 28.1, 27.9.  
LC-MS: tR = 12.77 min (C18), m/z = 542(M+ + Na, 100%), 442(M+ - Boc + Na, 50), 520.29 calcd 
for C28H42NO8+.  
Experimental 
175 
(S,E)-7-(tert-Butoxy)-2-(bis-(tert-butoxycarbonylamino))-7-oxohept-5-enoic acid (7) 
 
Triethylsilane (354 μL, 2.23 mmol, 1.4 eq.), triethylamine (100 μL, 0.72 mmol, 0.45 eq.) and 
palladium(II) acetate (18 mg, 0.08 mmol, 0.05 eq.) were dissolved in anhydrous DCM (15 mL) 
in a dry flask under an argon atmosphere and stirred for 15 min. (S,E)-7-Benzyl-1-tert-butyl-
6-(bis(tert-butoxycarbonylamino))-hept-2-enedioate (6, 828 mg, 1.59 mmol) dissolved in 
anhydrous DCM (15 mL) and kept under an argon atmosphere was added dropwise to the 
reaction at RT. The resulting mixture was stirred overnight at ambient temperature. A TLC 
reaction control indicated a complete consumption of the starting material. The reaction 
mixture was quenched by the addition of sat. aq. NH4Cl (25 mL) and the aqueous phase was 
extracted with diethyl ether (2x 25 mL). The combined organic extracts were washed with 
brine (50 mL) and dried over Na2SO4. After evaporation to dryness the crude product was 
purified by flash column chromatography (gradient: 20% to 50% ethyl acetate in 
cyclohexane) affording (S,E)-7-(tert-butoxy)-2-(bis-(tert-butoxycarbonylamino))-7-oxohept-5-
enoic acid (7). 
 
Yield: 423 mg (0.98 mmol, 62%) as a colorless oil.  
TLC (50% ethyl acetate in cyclohexane): Rf = 0.24. 
1H NMR (400 MHz, CDCl3): δ 6.79-6.87 (m, 1H), 5.77 (d, J = 15.6 Hz, 1H), 4.91-4.94 (m, 1H), 
2.22-2.29 (m, 3H), 2.05-2.10 (m, 1H), 1.50 (s, 18H), 1.47 (s, 9H).  
13C NMR (100 MHz, CDCl3): δ 175.8, 165.8, 151.9, 146.1, 123.8, 83.5, 80.2, 57.4, 29.0, 287, 
28.1, 28.0.  
LC-MS: tR = 11.00 min (C18), m/z = 452(M+ + Na, 100%), 174(M+ - 2Boc - tBu, 100), 430.24 
calcd for C21H26NO8+. 
 
(S,E)-7-Allyl 1-tert-butyl-6-(bis(tert-butoxycarbonylamino))hept-2-enedioate (8)  
 
Synthesis from 7: (S,E)-7-(tert-Butoxy)-2-(bis-(tert-butoxycarbonylamino))-7-oxohept-5-enoic 
acid (7, 373 mg, 0.87 mmol) and cesium carbonate (283 mg, 0.87 mmol, 1 eq.) were 
dissolved in anhydrous MeOH (15 mL) and the mixture was evaporated to dryness. The 
resulting solid was then co-evaporated four times with toluene (15 mL) to obtain the cesium 
salt of 7 as a white solid. This cesium salt was suspended in DMF (20 mL) and allyl bromide 
(1.5 mL, 17.4 mmol, 20 eq.) was added at RT. The reaction mixture was stirred overnight at 
RT, the solvent was removed and the resulting yellowish solid was co-evaporated twice with 
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toluene (20 mL) to remove residual DMF. The crude product was purified by flash column 
chromatography (12.5% ethyl acetate in cyclohexane), yielding (S,E)-7-allyl 1-tert-butyl-6-
(bis(tert-butoxycarbonylamino))hept-2-enedioate (8). 
 
Yield: 310 mg (0.66 mmol, 76%) as a colorless oil. 
 
Synthesis from 15: (S)-Allyl-2-(bis(tert-butoxycarbonylamino))-5-oxopentanoate (15, 831 mg, 
2.24 mmol) was dissolved in dichloromethane and the ylide of (2-tert-butoxy-2-
oxoethyl)triphenylphosphonium chloride (prepared as described, 1.26 g, 3.36 mmol, 1.5 eq.) 
was added to the solution. The reaction mixture was stirred overnight at ambient 
temperature. Subsequently, the solvent was removed and the crude product was purified by 
flash column chromatography (12.5% ethyl acetate in cyclohexane), to afford (S,E)-7-allyl 1-
tert-butyl-6-(bis(tert-butoxycarbonylamino))hept-2-enedioate (8). 
 
Yield: 986 mg (2.10 mmol, 94%) as a colorless oil.  
TLC (12.5% ethyl acetate in cyclohexane): Rf = 0.23. 
1H NMR (400 MHz, CDCl3): δ 6.80-6.87 (m, 1H), 5.84-5.94 (m, 1H), 5.76 (d, J = 15.6 Hz, 1H), 
5.31 (dd, J = 1.6 Hz, 17.2 Hz, 1H), 5.21 (dd, J= 1.2 Hz, 9.2 Hz, 1H), 4.85-4.87 (m, 1H), 4.60-4.62 
(m, 2H), 2.21-2.32 (m, 3H), 2.04-2.10 (m, 1H), 1.49 (s, 18H), 1.47 (s, 9H).  
13C NMR (100 MHz, CDCl3): δ 170.2, 165.8, 152.1, 146.2, 131.7, 123.8, 118.1, 83.3, 80.1, 65.7, 
57.7, 28.7, 28.3, 28.1, 28.0.  
LC-MS: tR = 12.47 min (C18), m/z = 491(M+ + Na, 50%), 214(M+ - 2Boc - tBu, 100), 470.27 calcd 
for C24H40NO8+. 
 
(S,E)-7-(Allyloxy)-6-amino-7-oxohept-2-enoic acid (9) 
 
(S,E)-7-Allyl 1-tert-butyl-6-(bis(tert-butoxycarbonylamino))hept-2-enedioate (8, 43 mg, 0.09 
mmol) was dissolved in anhydrous DCM (1 mL) and trifluoroacetic acid (1 mL) was added to 
the solution at ambient temperature. A TLC reaction control after 4 h indicated a complete 
reaction. The solvent was removed and the resulting oil was co-evaporated twice with 
toluene (2 mL) to remove residual trifluoroacetic acid. The crude material was used directly 
in the next reaction without a further purification.  
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(S,E)-6-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-7-(allyloxy)-7-oxohept-2-enoic acid  (1) 
 
(S,E)-7-(Allyloxy)-6-amino-7-oxohept-2-enoic acid (9, 19 mg, 0.09 mmol) was dissolved in 
water (0.5 mL) and heated to 40 °C. To this solution, FmocCl (26 mg, 0.1 mmol, 1.1 eq.) 
dissolved in dioxane (1 mL) was added dropwise and the speed of the addition was adjusted 
to maintain a clear reaction solution. Saturated aq. NaHCO3 (0.5 mL) was added and the pH 
was determined 10 min after the addition, indicating a pH > 8. The resulting reaction mixture 
was stirred overnight at 40 °C. After cooling to RT, water (1 mL) was added to the reaction 
solution and the mixture was extracted with ethyl acetate (2 x 5 mL). Some ethyl acetate was 
added and the aqueous phase was adjusted to pH 1 by addition of 0.2 M HCl. The combined 
organic extracts were washed with 1 N HCl (2x 100 mL) and brine (100 mL) and dried over 
Na2SO4. After the evaporation of the solvent the crude product was purified by flash column 
chromatography (50 % ethyl acetate in cyclohexane) to yield (S,E)-6-(((9H-fluoren-9-
yl)methoxy)carbonylamino)-7-(allyloxy)-7-oxohept-2-enoic acid (1).  
 
Yield: 19 mg (0.04 mmol, 49%) as a white solid.  
TLC (50% ethyl acetate in cyclohexane): Rf = 0.11. 
1H NMR (400 MHz, CDCl3): δ 7.75-7.77 (m, 2H), 7.59-7.61 (m, 2H), 7.38-7.42 (m, 2H), 7.30-
7.33 (m, 2H), 7.00-7.06 (m, 1H), 5.84-5.96 (m, 2H), 5.37-5.39 (m, 1H), 5.25-5.32 (m, 1H), 
4.63-4.70 (m, 2H), 4.39-4.48 (m, 3H), 4.20-4.23 (m, 1H), 2.22-2.35 (m, 2H), 2.05-2.10 (m, 1H), 
1.79-1.88 (m, 1H) .  
13C NMR (100 MHz, CDCl3): δ171.6, 170.8, 155.8, 149.6, 143.6, 141.3, 131.2, 127.7, 127.1, 
125.0, 121.6, 120.0, 199.4, 67.0, 66.3, 53.4, 47.2, 31.0, 28.0.  
LC-MS: tR = 9.82 min (C18), m/z = 436(M+, 100%), 214(M+ - Fmoc, 35), 436.18 calcd for 
C25H25NO6+. 
 
(S)-Benzyl-2-(tert-butoxycarbonylamino)-5-(tert-butyldimethylsilyloxy)pentanoate (10) 
 
(S)-Benzyl-2-(tert-butoxycarbonylamino)-5-hydroxypentanoate (2, 3.92 g, 12.1 mmol) was 
dissolved in DCM (80 mL) and cooled to 0 °C. Imidazole (2.00 g, 30.3 mmol, 1.2 eq.) and tert-
butyldimethylsilyl chloride (2.19 g, 14.5 mmol , 2.5 eq.) were added to the solution 
successively. The reaction mixture was maintained at 0 °C for 1 h and then allowed to warm 
to RT overnight. Water was added to the reaction mixture, the phases were separated and 
the aqueous phase was extracted with ethyl acetate (3x 80 mL). The combined organic 
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extracts were washed with 1 M aq. KHSO4 solution (150 mL) and saturated aq. NaHCO3 
solution (150 mL), dried over Na2SO4 and evaporated to dryness. The crude product was 
purified by flash column chromatography (10% ethyl acetate in cyclohexane) to afford (S)-
benzyl-2-(tert-butoxycarbonylamino)-5-(tert-butyldimethyl-silyloxy)pentanoate (10). 
 
Yield: 5.05 g (11.5 mmol, 95%) as a yellow oil.  
TLC (10% ethyl acetate in cyclohexane): Rf = 0.35.  
[α]D
20 -5.8 (c 1.13 in CHCl3).  
1H NMR (400 MHz, CDCl3): δ 7.32-7.35 (m, 5H), 5.13-5.19 (m, 2H), 4.31-4,36 (m, 1H), 3.58-
3.61 (t, J = 6.05, 2H), 1.94-1.95 (m, 1H), 1.76-1.85 (m, 1H), 1.51-1.56 (m, 2H), 1.43 (s, 9H), 
0.88 (s, 9H), 0.03 (s, 6H). 
13C NMR (100 MHz, CDCl3): δ 172.6, 155.4, 135.5, 128.5, 128.3, 128,1, 79.6, 66.8, 62.2, 53.3, 
29.0, 28.3, 25.9, 18.3, -5.4 .  
LC-MS: tR = 13.31 min (C18), m/z = 460(M+ + Na+, 40%), 338(M+ - Boc, 100) 438.27 calcd for 
C23H40NO5Si+. 
HRMS (EI): m/z calcd for C23H40O5NSi+ [M + H]+ 438.2670, found 438.2670. 
 
(S)-Benzyl-2-(bis(tert-butoxycarbonyl)amino)-5-(tert-butyldimethylsilyloxy)-pentanoate 
(11) 
 
(S)-Benzyl-2-(tert-butoxycarbonylamino)-5-(tert-butyldimethylsilyloxy)pentanoate (10, 4.94 
g, 11.3 mmol) was dissolved in acetonitrile (80 mL). After the addition of 4-
(dimethylamino)pyridine (2.07 g, 16.9 mmol, 1.5 eq.) at RT, the mixture was stirred for 
10 min. Subsequently, liquidified Boc anhydride (13.0 mL, 56.5 mmol, 5 eq.) was added and 
the reaction mixture was stirred for 24 h at RT, thereby turning from a pale yellow color to 
bright red. The reaction was quenched by the addition of water (80 mL) and the aqueous 
phase was extracted with ethyl acetate (3x 80 mL); the sluggish phase separation was 
accelerated by the addition of brine in small portions. The combined organic extracts were 
washed with 1 M aq. HCl (150 mL) and brine (4x 150 mL), the solvent was removed. The 
crude mixture of product and unreacted starting material was purified by flash column 
chromatography (5% ethyl acetate in cyclohexane). First, (S)-benzyl-2-(bis(tert-
butoxycarbonyl)amino)-5-(tert-butyldimethylsilyloxy)pentanoate (11) eluted from the 
column, followed by the starting material 10. 
Experimental 
179 
Yield: 3.88 g (7.2 mmol, 64%, 81% b.r.s.m.) as a colorless oil.  
TLC (5% ethyl acetate in cyclohexane): Rf = 0.26.  
[α]D
20 -20.2 (c 1.26 in CHCl3). 
1H NMR (400 MHz, CDCl3): δ 7.31-7.33 (m, 5H), 5.11-5.18 (m, 2H), 4.88-4.92 (m, 1H), 3.61-
3.65 (dt, J = 6.40, 1.38 Hz, 2H), 2.12-2.14 (m, 1H), 1.91-2.01 (m, 1H), 1.54-1.61 (m, 2H), 1.44 
(s, 18H), 0.88 (s, 9H), 0.03 (s, 6H) .  
13C NMR (100 MHz, CDCl3): δ 170.7, 152.2, 135.7, 128.4, 128.0, 127.9, 82.9, 66.7, 62.6, 58.1, 
29.6, 27.9, 26.0, 25.9, 18.3, -5.3.  
LC-MS: tR = 11.29 min (C4), m/z = 1097(2M+ + Na+, 100%), 438(M+ - Boc, 35) 538.77 calcd for 
C28H48NO7Si+. 
HRMS (EI): m/z calcd for C56H94O14N2NaSi2+ [2M + Na]+ 1097.6136, found 1097.6141. 
 
(S)-2-(bis(tert-Butoxycarbonyl)amino)-5-(tert-butyldimethylsilyloxy)pentanoic acid (12) 
 
(S)-Benzyl-2-(bis(tert-butoxycarbonyl)amino)-5-(tert-butyldimethylsilyloxy)pentanoate (11, 
5.85 g, 10.9 mmol) was dissolved in ethyl acetate (80 mL) and transferred to a 2-neck round 
bottom flask equipped with a rubber septum and a stop-cock under an argon atmosphere. 
Palladium on activated charcoal (10%, 2.93 g, 5 %wt) was added in small portions at RT 
through a funnel that was flushed with ethyl acetate (70 mL in total) after each portion. The 
flask was equipped with a hydrogenation balloon and carefully flushed with hydrogen by 
opening the stop-cock from time to time. The hydrogenation was carried out for 2.5 h at RT, 
and the reaction mixture was filtered through a pad of Celite®, which was rinsed thoroughly 
with ethyl acetate (4x 100 mL). Evaporation to dryness afforded pure (S)-2-(bis(tert-
butoxycarbonyl)amino)-5-(tert-butyldimethylsilyloxy)-pentanoic acid (12). 
 
Yield: 4.84 g (10.8 mmol, 99%) as a white solid.  
[α]D
20 -19.8 (c 0.91 in CHCl3). 
1H NMR (400 MHz, CDCl3): δ 4.91-4.95 (m, 1H), 3.62-3.65 (dt, J = 6.30, 1.74 Hz, 2H), 2.11-2.20 
(m, 1H), 1.91-2.00 (m, 1H), 1.54-1.59 (m, 2H), 1.50 (s, 18H), 0.89 (s, 9H), 0.04 (s, 6H). 
13C NMR (100 MHz, CDCl3): δ 177.1, 152.0, 83.2, 62.5, 57.8, 29.5, 27.9, 26.1, 25.9, 18.3, -5.3.  
LC-MS: tR = 11.31 min (C18), m/z = 917(2M+ + Na+, 100%), 347(M+ - Boc, 20) 448.65 calcd for 
C21H42NO7Si+. 
HRMS (EI): m/z calcd for C42H82O14N2NaSi2+ [2M + Na]+ 917.5197, found 917.5191.  
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(S)-Allyl-2-(bis(tert-butoxycarbonyl)amino)-5-(tert-butyldimethylsilyloxy)-pentanoate (13) 
 
(S)-2-(bis(tert-Butoxycarbonyl)amino)-5-(tert-butyldimethylsilyloxy)pentanoic acid (12, 4.61 
g, 10.3 mmol) and cesium carbonate (3.36 g, 10.3 mmol, 1 eq.) were dissolved in anhydrous 
MeOH (40 mL). The solvent was evaporated and the resulting solid was co-evaporated twice 
with toluene (40 mL) to obtain the cesium salt of 12 as a white solid. This cesium salt was 
suspended in DMF (80 mL) and allyl bromide (17.4 mL, 206 mmol, 20 eq.) was added slowly 
at RT. The reaction mixture was stirred at RT overnight, the solvent was evaporated and the 
residue was co-evaporated twice with toluene (40 mL) to remove residual DMF. The crude 
material was purified by flash column chromatography (10% ethyl acetate in cyclohexane) to 
yield (S)-allyl-2-(bis(tert-butoxycarbonyl)amino)-5-(tert-butyldimethylsilyloxy)pentanoate 
(13). 
 
Yield: 4.75 g (9.7 mmol, 95%) as a pale yellow oil.  
TLC (5% ethyl acetate in cyclohexane): Rf = 0.13.  
[α]D
20 -20.1 (c 1.21 in CHCl3). 
1H NMR (400 MHz, CDCl3): δ 5.81-5.93 (m, 1H), 5.28-5.32 (dd, J = 17.20, 1.55 Hz, 1H), 5.18-
5.21 (dd, J = 10.50, 1.45 Hz, 1H), 4.86-4.88 (m, 1H), 4.58-4.60 (m, 2H), 3.60-3.64 (dt, J = 6.40, 
1.80 Hz, 2H), 2.12-2.21 (m, 1H), 1.89-1.96 (m, 1H), 1.54-1.60 (m, 2H), 1.48 (s, 9H), 0.87 (s, 
9H), 0.03 (s, 6H).  
13C NMR (100 MHz, CDCl3): δ 170.5, 152.1, 131.9, 117.9, 82.9, 65.5, 62.6, 58.1, 29.6, 27.9, 
26.2, 25.9, 18.3, -5.3.  
LC-MS: tR = 14.37 min, m/z = 510(M+ + Na+, 100%), 410(M+ - Boc + Na+, 80) 487.70 z calcd for 
C24H45NO7Si+. 
HRMS (EI): m/z calcd for C24H45O7NNaSi+ [M + Na]+ 510.2858, found 510.2860. 
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(S)-Allyl-2-(bis(tert-butoxycarbonyl)amino)-5-hydroxypentanoate (14) 
 
(S)-Allyl-2-(bis(tert-butoxycarbonyl)amino)-5-(tert-butyldimethylsilyloxy)pentanoate (13, 
4.63 g, 9.5 mmol) was dissolved in a solution of 5% water in acetone (100 mL) at RT. 
Copper(II) chloride dihydrate (81 mg, 0.5 mmol, 0.05 eq.) was added and the green-bluish 
reaction solution was heated to reflux; the color of the solution faded to a lighter green 
upon heating. A TLC check after 1 h indicated a complete conversion of the starting material. 
The solvent was evaporated to dryness and the crude product was purified by flash column 
chromatography (33% ethyl acetate in cyclohexane) to afford (S)-allyl-2-(bis(tert-
butoxycarbonyl)amino)-5-hydroxypentanoate (14). 
 
Yield: 3.27 g (8.7 mmol, 92%) as a colorless oil.  
TLC (33% ethyl acetate in cyclohexane): Rf = 0.26.  
[α]D
20 -30.2 (c 1.01 in CHCl3). 
1H NMR (400 MHz, CDCl3): δ 5.82-5.91 (m, 1H), 5.26-5.31 (dd, J = 17.20, 1.50 Hz, 1H), 5.17-
5.20 (dd, J = 10.50, 1.40 Hz, 1H), 4.85-4.89 (m, 1H), 4.57-4.59 (m, 2H), 3.62-3.65 (t, J = 6.40, 
2H), 2.17-2.26 (m, 1H), 1.87-1.97 (m, 1H), 1.57-1.64 (m, 2H), 1.46 (s, 18H). 
13C NMR (100 MHz, CDCl3): δ 170.5, 152.1, 131.7, 118.0, 83.1, 65.6, 62.1, 57.9, 29.3, 27.9, 
26.1.  
LC-MS: tR = 9.90 min (C18), m/z = 396(M+ + Na+, 100%), 295(M+ - Boc + Na+, 80), 173(M+ - 
2Boc, 70) 374.45 calcd for C18H32NO7+. 
HRMS (EI): m/z calcd for C18H31O7NNa+ [M + Na]+ 396.1990, found 396.1993. 
 
(S)-Allyl-2-(bis(tert-butoxycarbonyl)amino)-5-oxopentanoate (15) 
 
(S)-Allyl-2-(bis(tert-butoxycarbonyl)amino)-5-hydroxypentanoate (14, 1.60 g, 4.3 mmol) was 
dissolved in anhydrous DCM under an argon atmosphere. Dess-Martin´s periodinane (1.91 g, 
4.5 mmol, 1.05 eq.) was added in one portion at RT resulting in a slight warming of the 
reaction mixture. The reaction mixture was stirred at RT for 1.5 h, whereon a TLC check 
indicated the complete conversion of the starting material. The reaction mixture was 
quenched by addition of saturated aq. K2CO3 solution (60 mL), the phases were separated 
and the aqueous layer was extracted with ethyl acetate (3x 60 mL). The combined organic 
extracts were washed with brine (150 mL), dried over Na2SO4 and the solvent was 
evaporated.   
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The crude product was purified by flash column chromatography (17% ethyl acetate in 
cyclohexane) yielding (S)-allyl-2-(bis(tert-butoxycarbonyl)amino)-5-oxopentanoate (15) 
which was directly used in the next step. 
 
Yield: 1.34 g (3.6 mmol, 84%) as a colorless oil.  
TLC (17% ethyl acetate in cyclohexane): Rf = 0.23. 
[α]D
20 -26.2 (c 1.26 in CHCl3). 
 1H NMR (400 MHz, CDCl3): δ 9.75 (s, 1H), 5.83-5.92 (m, 1H), 5.27-5.32 (dd, J = 17.20, 1.50 Hz, 
1H), 5.18-5.21 (dd, J = 10.50, 1.40 Hz, 1H), 4.86-4.90 (m, 1H), 4.58-4.60 (m, 2H), 2.48-2.59 
(m, 3H), 2.13-2.20 (m, 1H), 1.47 (s, 18H). 
13C NMR (100 MHz, CDCl3): δ 200.8, 169.9, 152.0, 131.7, 118.2, 83.4, 65.7, 57.4, 40.4, 27.9, 
22.3.  
LC-MS: tR = 11.11 min (C18), m/z = 394(M+ + Na+, 80%), 294(M+ - Boc + Na+, 90) 372.20 calcd 
for C18H30NO7+. 
HRMS (EI): m/z calcd for C18H30O7N+ [M + H]+ 372.2017, found 372.2018. 
 
(S)-9-(Allyloxy)-8-(bis(tert-butoxycarbonyl)amino)-9-oxonon-4-enoic acid (16) 
 
3-(Carboxypropyl)triphenylphosphonium bromide (1.92 g, 4.5 mmol, 1.5 eq.) was suspended 
in anhydrous THF (20 mL) under an argon atmosphere. A 1 M lithium bis(trimethylsilyl)amide 
solution in THF (9.7 mL, 9.7 mmol, 3.25 eq.) was added within 40 min to the suspension at 
RT. The resulting dark red solution was stirred for additional 15 min at RT. The solution was 
then cooled to 0 °C and (S)-allyl-2-(bis(tert-butoxycarbonyl)-amino)-5-oxopentanoate (15, 
1.11 g, 3.0 mmol) dissolved in THF (20 mL) was added over 40 min. The reaction mixture was 
allowed to warm to room temperature. A TLC check after 4 h indicated a completed 
reaction.  
Subsequently, 2 M HCl was added to the reaction mixture until an acidic pH was obtained. 
The aqueous phase was extracted with ethyl acetate (3x 40mL) and the combined extracts 
were dried over Na2SO4. After evaporation of the solvent the crude mixture was purified by 
flash column chromatography (50% ethyl acetate in cyclohexane) affording (S)-9-(Allyloxy)-8-
(bis(tert-butoxycarbonyl)amino)-9-oxonon-4-enoic acid (16) in a 9:1 ratio (Z/E). 
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Yield: 824 mg (1.9 mmol, 64%) as a yellow oil.  
TLC (50% ethyl acetate in cyclohexane): Rf = 0.35.  
1H NMR (500 MHz, CDCl3): δ) 5.83-5.91 (m, 1H), 5.43-5.44 (t, J = 5.20 Hz 1H), 5.37-5.42 (dt, J 
= 11.10 Hz, 5.90 Hz, 1H), 5.27-5.31 (d, J = 16.20 Hz, 1H), 5.17-5.19 (d, J = 10.50 Hz, 1H), 4.83-
4.86 (m, 1H), 4.57-4.58 (d, J = 5.35 Hz, 2H), 2.28-2.40 (m, 4H), 2.11-2.19 (m, 2H), 2.02-2.06 
(m, 1H), 1.89-1.95 (m, 1H), 1.47 (s, 18H).  
13C NMR (126 MHz, CDCl3): δ 178.9, 170.5, 152.1, 131.8, 130.3, 130.0, 128.9, 128.4, 117.9, 
83.0, 65.6, 57.8, 33.9, 29.7, 29.5, 29.1, 27.9.  
LC-MS: tR = 10.73 min (C18), m/z = 486(M+ + 2Na+, 45%), 464(M+ + Na+, 45), 242(M+ - 2Boc, 
100) 442.24 calcd for C22H36NO8+ . 
HRMS (EI): m/z calcd for C22H36O8N+ [M + H]+ 442.2435, found 442.2436. 
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6.3 Synthesis of the N,O-dimethyl-3-bromotyrosine building block 29 
 
(S)-Methyl-3-(3-bromo-4-methoxyphenyl)-2-(tert-butoxycarbonyl(methyl)amino)-
propanoate (28) 
 
The starting material (S)-methyl-3-(3-bromo-4-methoxyphenyl)-2-(tert-butoxy-
carbonylamino)propanoate (27) was prepared in 3 steps following a literature procedure.[125] 
For methylation of the amine, sodium hydride (60% suspension in mineral oil, 187 mg, 4.7 
mmol, 1.2 eq.) was suspended in DMF (5 mL) and the suspension was stirred at ambient 
temperature. Methyl iodide (927 μL, 15.6 mmol, 4 eq.) and (S)-methyl-3-(3-bromo-4-
methoxyphenyl)-2-(tert-butoxy-carbonylamino)propanoate (27, 1.51 mg, 3.9 mmol) were 
dissolved in DMF (5 mL) and added to the sodium hydride suspension. The resulting clear 
reaction solution was stirred for 1 h at RT and the reaction was quenched by the slow 
addition of saturated aq. NH4Cl solution (10 mL). The aqueous phase was extracted with 
ether (3x 20 mL) and the combined organic extracts were washed with brine (2x 20 mL) and 
dried over Na2SO4. After evaporation to dryness the crude product was purified by flash 
column chromatography (33% ethyl acetate in cyclohexane) to afford (S)-methyl-3-(3-
bromo-4-methoxyphenyl)-2-(tert-butoxycarbonyl(methyl)amino)-propanoate (28). 
 
Yield: 1.41 g (3.5 mmol, 90%) as a colorless oil.  
TLC (33% ethyl acetate in cyclohexane): Rf = 0.54.  
[α]D
20 – 57.1 (c 0.93 in CHCl3).  
1H NMR (500 MHz, CDCl3): δ 7.35 (s, 1H) 7.01-7.10 (m, 1H), 6.78-6.80 (d, J = 8.4 Hz, 1H), 4.80 
(m, 0.5H), 4.50-4.51 (m, 0.5H) (Boc rotamers), 3.83 (s, 3H), 3.72 (s, 3H), 3.17-3.19 (m, 1H), 
2.87-2.96 (m, 1H), 2.70 (s, 3H), 1.33-1.37 (d, J = 20.2 Hz, 9H).  
13C NMR (126 MHz, CDCl3): δ (some peaks appear double due to Boc rotamers, for this case 
the second peak is given in parentheses) 171.5 (171.2), 155.7, 154.8 (154.6), 133.6 (133.5), 
131.2 (131.0), 129.0 (128.0), 111.9, 111,5 (111.3), 80.3 (80.0), 61.2, 56.2, 52.1, 34.2 (33.7), 
32.2 (32.0), 28.1.  
LC-MS: tR = 10.93 min (C18), m/z = 302(M+ - Boc, 100%). 
HRMS (EI): m/z calcd for C17H25O5NBr+ [M + H]+ 402.0911, found 402.0910, m/z calcd for 
C17H25O5N18Br+ [M + H]+ 404.0890, found 404.0889. 
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(S)-3-(3-Bromo-4-methoxyphenyl)-2-(tert-butoxycarbonyl(methyl)amino)propanoic acid 
(29) 
 
To a solution of (S)-methyl-3-(3-bromo-4-methoxyphenyl)-2-(tert-butoxycarbonyl-(methyl)-
amino)-propanoate (28, 1.30 g, 3.2 mmol) in THF (10 mL) and MeOH (6 mL), a solution of 
lithium hydroxide (155 mg, 6.5 mmol, 2 eq.) in water (4 mL) was added at ambient 
temperature. The reaction mixture was stirred for 5 h at RT. 1 M HCl was added to the 
reaction mixture until a pH of ~4 was reached. The solution was diluted with brine (20 mL) 
and DCM (20 mL). The phases were separated and the aqueous phase was extracted with 
DCM (1x 20 mL). The combined extracts were dried over Na2SO4 and the solvent was 
evaporated to dryness. The crude product was purified by flash column chromatography 
(10% MeOH in chloroform) to afford (S)-3-(3-bromo-4-methoxyphenyl)-2-(tert-
butoxycarbonyl(methyl)amino)propanoic acid (29). 
 
Yield: 985 mg (2.5 mmol, 78%) as white solid.  
TLC (10% MeOH in chloroform): Rf = 0.41. 
[α]D20 -44.3 (c 1.15 in CHCl3).  
1H NMR (500 MHz, CDCl3): δ 7.37-7.39 (d, J = 10.5 Hz, 1H), 7.04-7.13 (m, 1H), 6.81-6.83 (d, J = 
8.4 Hz, 1H), 4.74-4.75 (m, 0.5H), 4.61-4.62 (m, 0.5H) (Boc rotamers), 3.86 (s, 3H), 3.21-3.24 
(m, 1H), 2.91-3.05 (m, 1H), 2.69-2.76 (d, J = 32.2 Hz, 3H), 1.35-1.41 (d, J = 27.1 Hz, 9H).  
13C NMR (126 MHz, CDCl3): δ (some peaks appear double due to Boc rotamers, for this case 
the second peak is given in parentheses) 176.0 (175.8), 156.2, 154.8 (154.7), 133.7 (133.5), 
131.0 (130.8), 129.0 (128.9), 112.0, 111.7 (117.2), 80.8, 61.1 (60.4), 56.2, 34.0 (33.5), 33.1 
(32.3), 28.2 (28.1).  
LC-MS: tR = 9.45 min (C18), m/z = 288(M+ - Boc, 90%). 
HRMS (EI): m/z calcd for C16H23O5NBr+ [M + H]+ 388.0754, found 388.0756, m/z calcd for 
C16H23O5N18Br+ [M + H]+ 390.0734, found 390.0735. 
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6.4 Solid-phase syntheses  
6.4.1 General methods of the solid-phase syntheses 
 
Method A: Boc deprotection and neutralization 
 
The dry resin was transferred to a syringe reactor and swelled in an appropriate amount of 
DCM for 10 min. The solvent was removed and a freshly prepared solution of 50% 
trifluoroacetic acid in DCM was added. The resulting suspension was shaken for 5 min, the 
solution was removed, fresh TFA/DCM solution was added and the resulting suspension was 
shaken for 1 h. The resin was filtered off and washed with DCM (2x 1 min) and 2-propanol 
(2x 1 min). 
For neutralization, a 10% solution of triethyl amine in DCM was added to the resin and the 
resulting suspension was shaken for 10 min. This procedure was repeated once more, then 
the resin was washed alternately with DCM and 2-propanol (3x 1 min) and finally with DMF 
(2x 1 min). 
 
Method B: Fmoc deprotection 
 
A solution of 20% piperidine in DMF was added to the resin and the resulting suspension was 
shaken for 15 min. The solution was removed from the resin and the solid support was 
washed with DMF (5x 1 min). Fresh piperidine/DMF solution was added and the resulting 
suspension was shaken once more for 15 min. The solution was removed and the resin was 
washed alternately with MeOH and DCM (3x 1 min) and finally with DMF (5x 1 min). 
 
Method C: Allyl ester/Alloc deprotection 
 
In addition to the regular washing protocol performed after amino acid couplings, an 
additional washing protocol was required to prepare the resin for cleavage of an allyl 
ester/Alloc. The resin was washed with MeOH (2x 1 min), alternatingly with MeOH and DCM 
(2x 1 min), DMF (5x 1 min), NMP (5x 1 min), DCM (2x 1 min) and finally with diethyl ether (2x 
1 min). Subsequently, the resin was then dried under high vacuum (overnight for NovaPEG 
resin, 1 h for chlorotrityl resin).   
For the cleavage of the allyl ester or the Alloc group, the dried resin was transferred into a 
pear shaped flask under an argon atmosphere and was degassed under high vacuum for 
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15 min using an ultrasonication bath. The resin was washed with degassed DCM (3x 2 min) 
and during this washing step argon was bubbled through the suspension. After each washing 
step, the solvent was removed carefully using a cannula. After the last washing step, 
degassed DCM was added, followed by a solution of degassed morpholine (24 eq.) in 
degassed DCM. Again, argon was bubbled through the suspension for 2 min. Finally, 
Pd(PPh3)4 (0.25 eq.) dissolved in degassed DCM was added to the suspension and argon was 
again bubbled through the resulting suspension for 2 min. The reaction flask was 
subsequently placed on an orbital shaker and shaken gently for 30 min. 
The resin was removed carefully with a glass pipette and transferred to a syringe reactor to 
facilitate the washing steps. The resin was washed with DCM (3x 1 min), NMP (3x 1 min) and 
DCM (4x 1 min). This washing procedure was repeated once more. The washing procedure 
was then continued with DCM (3x 1 min), NMP (3x 1 min), a 0.02 M solution of Et2NCS2Na in 
NMP (3x 5 min), NMP (5x 1 min) and DMF (2x 1 min). 
 
Method D: Amino acid coupling 
 
The amino acid (4 eq.) was dissolved in an appropriate amount of DMF. Subsequently, HOBt 
(4 eq.), HBTU (3.5 eq.) and DIEA (3 eq.) were added to the amino acid solution and the 
resulting mixture was gently shaken for 1 min to pre-activate the amino acid. The solution 
was added to the resin, the resulting reaction suspension was shaken for an appropriate 
time (2 to 24 h, respective values are given in the experiment description). The reaction 
solution was discarded and the resin was washed with DMF (2x 1 min), alternatingly with 
MeOH and DCM (3x 1 min) and then again with DMF (5x 1 min). 
 
Method E: Esterification of the threonine sidechain 
 
For the esterification of the threonine sidechain, Fmoc-Val-OH (10 eq.), DIC (10 eq.) and 
DMAP (1 eq.) were dissolved in a 10% solution of DMF in DCM and added directly to the 
resin. The coupling was performed for 2 h and repeated 3 times in total. Between the 
individual couplings, the resin was washed with DMF (2x 1 min), alternatingly with MeOH 
and DCM (3x 1 min) and with DMF (2x 1 min). After the final coupling, the resin was then 
washed with DMF (2x min), alternatingly with MeOH and DCM (3x 1 min) and with DMF (5x 
1 min). 
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Method F: Fmoc determination 
 
A small aliquot of dry resin (~ 5 mg) was transferred into a 25 mL pear shaped flask and a 
freshly prepared 20% piperidine in DMF solution (5 mL) was added (in total 10 mL of the 
piperidine/DMF solution were prepared, either for dilution of the sample and as a reference 
blank for the UV measurement). The resulting suspension was shaken for 20 min. The resin 
was allowed to settle and the UV absorption of 1 mL of the cleavage solution or a dilution 
thereof (e.g 33%) was measured, using a Cary instrument type 100 Bio. The silica glass 
cuvettes had a thickness of 10 mm. The measurement was repeated at least 3 times.  
According to the formula  
 
[ ]gmmol
Fmd
VA
c /
⋅⋅⋅
⋅
=
ε
 
 
in which A is the absorption at 300.7 nm, V the total volume (here: 5 [mL]), ε the extinction 
coefficient (here: 780 [ml/mmol ·mm]), d the thickness of the cuvette (here: 10 [mm]), m the 
mass of resin in [g] and F the dilution factor (1, 1/3, 1/6, …), the loading of the resin was 
determined from the measurement of the absorption.  
 
Method G: Kaiser test 
 
A few beads were sampled into a small vial. 3 drops of a 5% solution of ninhydrine in 
ethanol, 2 drops of a 20% solution of phenole in ethanol and 3 drops of a 2% solution of aq. 
potassium cyanide (0.001 M) in pyridine were added and the resulting suspension was 
heated to 100 °C for 5 min. A blue solution and/or blue beads indicate the presence of 
primary amines. 
 
Method H: Chloranil test 
 
A few beads were sampled into a small vial. 2 drops of a 2% solution of acetaldehyde in DMF 
and 2 drops of a 2% solution of chloranil in DMF were added to the resin. The resulting 
suspension was allowed to stand for at 5-10 min at RT. Blue- to green-stained beads indicate 
the presence of secondary amines.  
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Method I: Cleavage from 2-chlorotrityl resin 
 
The dried resin was transferred to a fresh solid phase reactor and a solution of acetic acid/ 
trifluoroethanol/DCM (20%/20%/60%) was added. The mixture was shaken for 2 h at RT. 
After this time the solution containing the cleaved peptide was collected and the resin was 
washed once with the cleavage solution and with DCM (3x 2 min); these solutions were also 
collected. The solvent was removed and the remaining oil was co-evaporated twice with 
cyclohexane to remove residual acetic acid. 
 
Method J: full deprotection of cleaved peptides (removing Trt, Boc and t-Bu) 
 
The crude peptide was dissolved in trifluoroacetic acid/DCM/triisopropylsilane 
(95%/2.5%2.5%) (~1 mL) and stirred for 2 h at RT. The reaction mixture was added to cold 
ether resulting in the precipitation of the crude peptide. The suspension was centrifuged and 
the pellet was washed once with cold ether. After centrifugation the remaining pellet was 
dried by evaporation of the ether at RT and normal pressure.  
 
Method K: Hydrogenation to remove the benzyl ether protection on the serine sidechain 
 
The crude peptide was dissolved in EtOH (1 mL/100 mg crude peptide) and acetic acid (0.1 
mL/100 mg crude peptide) and transferred to a two-neck round bottom flask equipped with 
a stop-cock and a rubber septum under an argon atmosphere containing Pd/C catalyst (10 %, 
0.4 mg catalyst/mg crude product). The flask was equipped with a hydrogenation balloon 
and flushed with hydrogen by opening the stop-cock from time to time. The hydrogenation 
was carried out overnight at RT and the reaction mixture was filtered through a short pad of 
Celite® which was washed intensively with MeOH. The solvent was removed and the residue 
was dissolved in the minimal amount of ethyl acetate (and optionally a few drops of MeOH 
to enhance solubility). This solution was added to cold ether, resulting in the precipitation of 
the crude peptide. The suspension was centrifuged and the pellet was washed once with 
cold ether and dried after centrifugation. 
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6.4.2 Solid-phase synthesis of the symplocamide A model Ahp cyclodepsipeptide 19 
 
Coupling of (S)-9-(Allyloxy)-8-(bis(tert-butoxycarbonyl)amino)-9-oxonon-4-enoic acid (16) 
to NovaPEG amino resin 
 
NovaPEG amino resin (0.66 mmol/g, 1.00 g, 0.66 mmol) was transferred to a glass solid-
phase reactor under an argon atmosphere and swollen in a mixture of 10% anhydrous DMF 
in anhydrous DCM for 30 min under gentle shaking.  
(S)-9-(Allyloxy)-8-(bis(tert-butoxycarbonyl)amino)-9-oxonon-4-enoic acid (16, 706 mg, 1.60 
mmol, 2.4 eq.), HOBt (446 mg, 3.30 mmol, 5 eq.) and DIC (514 μL, 3.30 mmol, 5 eq.) were 
dissolved in a 10% mixture of anhydrous DMF in anhydrous DCM (10 mL) and stirred for 
20 min. This pre-activated solution was added to the pre-swollen resin and shaken for 24 h 
at RT. The reaction solution was removed and the resin was washed with DMF (2x 1 min), 
MeOH (2x 1 min) and DCM (2x 1 min). To eliminate remaining amino groups on the resin, a 
capping reaction was carried out. To this end, the resin was shaken with a mixture of acetic 
anhydride/DIEA/DCM (1:1:3) for 3 h and washed with DMF (2x 1 min), alternately with 
MeOH and DCM (3x 1 min) and finally with DMF (2 x 1 min). A Kaiser test performed 
according to method G then indicated the complete capping of all unreacted amines. 
The resin loaded with the Ahp precursor will be called NovaPEG-Ahp5COAll (17) in the 
following descriptions. 
 
Coupling of Fmoc-Cit-OH to NovaPEG-Ahp5-COAll (17) 
 
The resin 17 (0.66 mmol) was deprotected according to method A. The coupling of 
Fmoc-Cit-OH to the resin was performed using method D. The amounts of reagents used 
were: 
Fmoc-Cit-OH: 1.05 g, 2.64 mmol  
HOBt: 332 mg, 2.64 mmol  
HBTU: 877 mg, 2.31 mmol 
DIEA: 327 μL, 1.98 mmol.  
The coupling was performed for 5 h. A Kaiser test performed according to method G 
indicated a complete coupling reaction.  
  
Experimental 
191 
After the regular washing, an additional washing step was carried out using alternately 
anhydrous MeOH and DCM (3x 1 min) and finally anhydrous ether (3x 1 min). The resulting 
resin 18 was dried under high vacuum overnight. 
The Fmoc determination carried out with 6.4 mg of resin according to method F revealed a 
resin loading of 0.20 mmol/g (30%). 
 
Sequential coupling of Fmoc-Thr-OH and Fmoc-Gln(Trt)-OH to NovaPEG-Ahp5-COAll-Cit4-
Fmoc (18) 
 
NovaPEG-Ahp5-COAll-Cit4-Fmoc (18, loading of 0.20 mmol/g, 1.12 g, 0.22 mmol) was 
deprotected according to method B. The coupling of Fmoc-Thr-OH*H2O to the resin was 
performed using method D. The following amounts of reagents were used: 
Fmoc-Thr-OH*H2O: 322 mg, 0.90 mmol  
HOBt: 121 mg, 0.90 mmol  
HBTU: 298 mg, 0.78 mmol 
DIEA: 111 μL, 0.67 mmol.  
The coupling reaction was performed for 2 h. A Kaiser test performed according to method G 
indicated a complete coupling reaction.  
NovaPEG-Ahp5-COAll-Cit4-Thr3-Fmoc (0.20 mmol) was deprotected according to method B. 
The coupling of Fmoc-Gln(Trt)-OH to the resin was performed using method D. The amounts 
of reagents were: 
Fmoc-Gln(Trt)-OH: 547 mg, 0.90 mmol  
HOBt: 121 mg, 0.90 mmol  
HBTU: 298 mg, 0.78 mmol 
DIEA: 111 μL, 0.67 mmol.  
The coupling was performed for 2 h. A Kaiser test following method G indicated a complete 
coupling reaction.  
After the regular washing, an additional washing step was carried out using alternately 
anhydrous MeOH and DCM (3x 1 min) and finally anhydrous ether (3x 1 min). The resulting 
resin 19 was dried under high vacuum overnight. 
The Fmoc determination carried out with 5.1 mg of resin according to method F revealed a 
resin loading of 0.17 mmol/g (77%, 2 couplings).  
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Coupling of butyric acid to NovaPEG-Ahp5-COAll-Cit4-Thr3-Gln2(Trt)-Fmoc (19) and 
esterification of the threonine sidechain with Fmoc-Val-OH  
 
NovaPEG-Ahp5-COAll-Cit4-Thr3-Gln2(Trt)-Fmoc (19, loading of 0.17 mmol/g, 1.14 g, 0.20 
mmol) was deprotected according to method B. The coupling of butyric acid to the resin was 
performed using method D. The amounts of reagents were: 
butyric acid: 73 μL, 0.80 mmol 
HOBt: 108 mg, 0.80 mmol  
HBTU: 265 mg, 0.70 mmol 
DIEA: 99 μL, 0.60 mmol.  
The coupling reaction was performed for 2 h and a Kaiser test performed according to 
method G indicated a complete coupling reaction after this time.  
The esterification of the threonine sidechain was carried out following method E. The 
amounts of reagents used for this reaction were: 
Fmoc-Val-OH: 679 mg, 2.00 mmol, 10 eq. 
DIC: 312 μL, 2.00 mmol, 10 eq. 
4-(dimethylamino)pyridine: 24 mg, 0.2 mmol, 1 eq.  
After the washing protocol, the resin was washed additionally with anhydrous solvents: 
alternately MeOH and DCM (3x 1 min) and ether (3x 1 min). The resulting resin 20 was dried 
overnight under high vacuum. 
An Fmoc determination performed according to method F with 4.9 mg of resin gave a 
loading of 0.15 mmol/g (79%, 2 couplings). 
 
Sequential coupling of Fmoc-NMePhe-OH and Fmoc-Ile-OH to NovaPEG-Ahp5-COAll-Cit4-
Thr3(O-CO-Val8-Fmoc)-Gln2(Trt)-But1 (20) 
 
NovaPEG-Ahp5-COAll-Cit4-Thr3(O-CO-Val8-Fmoc)-Gln2(Trt)-But1 (20, loading of 0.15 
mmol/g, 1.07 g, 0.16 mmol) was deprotected according to method B. The coupling of Fmoc-
NMePhe-OH to the resin was performed using method D. The amounts of reagents were: 
Fmoc-NMePhe-OH: 199 mg, 0.64 mmol 
HOBt: 86 mg, 0.64 mmol  
HBTU: 213 mg, 0.56 mmol 
DIEA: 79 μL, 0.48 mmol. 
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The coupling was performed for 2 h. A Kaiser test performed according to method G 
indicated a complete coupling reaction. 
NovaPEG-Ahp5-COAll-Cit4-Thr3(O-CO-Val8-mPhe7-Fmoc)-Gln2(Trt)-But1 was deprotected 
according to method B. For the coupling of Fmoc-Ile-OH to the N-methylated amino acid, 
PyBrOP was used as the coupling reagent. The following reagents were dissolved in DMF, 
pre-activated for 1 min and then added to the resin. 
Fmoc-Ile-OH: 283 mg, 0.8 mmol, 5 eq. 
PyBrOP: 366 mg, 0.78 mmol, 4.9 eq. 
DIEA: 264 μL, 1.6 mmol, 10 eq. 
The coupling was performed for 24 h. A chloranil test performed according to method H 
indicated a complete coupling.  
After the regular washing, an additional washing protocol using anhydrous solvents was 
performed. The resin was washed alternately with MeOH and DCM (3x 1 min) and ether (3x 
1 min) and the resulting resin 21 was dried under high vacuum overnight.  
The following Fmoc determination with 4.9 mg of resin was carried out using method F 
revealed a loading of 0.088 mmol/g (60%, 2 couplings). 
 
Deprotection of NovaPEG-Ahp5-COAll-Cit4-Thr3(O-CO-Val8-mPhe7-Ile6-Fmoc)-Gln2(Trt)-
But1 (21) 
 
The Fmoc deprotection of NovaPEG-Ahp5-COAll-Cit4-Thr3(O-CO-Val8-mPhe7-Ile6-Fmoc)-
Gln2(Trt)-But1 (21, 0.088 mmol/g, 1.09 g, 0.096 mmol) was carried out using method B, the 
resin was then treated according to method C in order cleave the allyl ester protection. 
This procedure afforded the NovaPEG-Ahp5-COOH-Cit4-Thr3(O-CO-Val8-mPhe7-Ile6-NH2)-
Gln2-But1 (22) intermediate. 
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On resin macrolactamization of NovaPEG-Ahp5-COOH-Cit4-Thr3(O-CO-Val8-mPhe7-Ile6-
NH2)-Gln2(Trt)-But1 (22) 
 
HOBt (104 mg, 0.77 mmol, 8 eq.) and DIEA (190 μL, 1.15 mmol, 12 eq.) were dissolved in 
DMF and added to resin 22. The resin was shaken for 1 min and a solution of PyBOP (171 mg, 
0.38 mmol, 4 eq.) in DMF was added to the resin, which was shaken for 24 h. 
The resin was washed with DMF (2x 1 min), alternatingly with MeOH and DCM (3x 1 min), 
DMF (5x 1 min), DCM (2x 1 min) and finally with ether (3x 1 min) and the resin was dried 
under high vacuum for 1 h. A Kaiser test according to method G indicated a complete 
reaction.  
 
Oxidative cleavage from the resin to obtain Ahp peptide 24 
 
Sodium periodate (205 mg, 0.96 mmol, 10 eq.) and DABCO (54 mg, 0.48 mmol, 5 eq.) were 
suspended in water (8 mL), sonificated briefly and added to resin 23 (0.096 mmol). The resin 
was allowed to stand in this mixture for 10 min, then THF (8 mL) was added and the resulting 
suspension was shaken for 2 min. Subsequently, a 0.1 M solution of osmium tetroxide in tert-
butanol (59 μL, 0.005 mmol, 0.05 eq.) was added to the suspension, which was shaken for 
20 h. 
The cleavage solution was collected and quenched with an aq. saturated sodium 
metabisulfite solution. The resin was washed with a 1:1 (v/v) solution of THF/water (5x 
20 mL) and the washing phases were added to the sodium metabisulfite solution. The 
phases in this solution were allowed to separate and the aqueous phase was extracted with 
ethyl acetate (5x 80 mL). The combined organic extracts were dried over Na2SO4 and the 
solvent was evaporated. The resulting crude mixture was re-dissolved in ethyl acetate (1 mL) 
followed by transfer of the whole reaction mixture to cold ether, thereby causing the crude 
product to precipitate as a white solid. The precipitate was centrifuged at 4 °C; the 
supernatant removed and fresh cold ether was added. The suspension was sonificated 
briefly and centrifuged again at 4 °C, the supernatant was removed and the precipitate was 
allowed to dry.  
The crude product (58 mg) was purified by preparative HPLC using a preparative C4 column 
and a linear gradient starting from 10% acetonitrile in H2O to yield 3.1 mg (2.6 μmol, 1.2%) 
of Ahp cyclodepsipeptide 24 as a white solid. 
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1H NMR (600 MHz, DMSO-d6): δ 8.48 (d, J = 8.5 Hz, 1H), 8.27 (s, 1H), 8.04 (d, J = 7.8 Hz, 1H), 
7.73 (d, J = 9.2 Hz, 1H), 7.65 (d, J = 9.4 Hz, 1H), 7.34 (d, J = 9.1 Hz, 1H), 7.24-7.28 (m, 5H), 
7.16-7.20 (m, 15H), 6.09 (bs, 1H), 5.92 (bs, 2H), 5.15-5.17 (m, 1H), 4.93-4.92 (m, 1H), 4.66-
4.67 (m, 1H), 4.44-4.45 (m, 1H), 4.43-4.44 (m, 1H), 4.39-4.41 (m, 1H), 4.32-4.33 (m, 1H), 
4.24-4.23 (m, 1H), 3.76-3.75 (m, 1H), 3.51 (s, 3H), 3.10-3.06 (m, 2H), 3.02 (s, 1H), 2.92 (d, J = 
5.6 Hz, 1H), 2.37-2.39 (m, 1H), 2.14-2.09 (m, 3H), 2.03-2.00 (m, 2H), 1.99-1.96 (m, 2H), 1.86-
1.84 (m, 2H), 1.72-1.75 (m, 2H), 1.69-1.64 (m, 2H), 1.52-1.56 (m, 4H), 1.29 – 1.27 (m, 2H), 
1.23 (s, 3H), 1.21-1.22 (m, 5H), 0.88-0.84 (m, 3H), 0.75 (d, J = 6.8 Hz, 3H), 0.61 (d, J = 3.1 Hz, 
3H), -0.25 (d, J = 6.4 Hz, 1H);  
LC-MS: tR = 9.91 min, m/z = 1207(M+ + Na+,100%), 1185 (M+ - H+, 20) 1185.63 calcd for 
C64H85N10O12+. 
 
6.4.3 Solid-phase synthesis of symplocamide A  
 
Coupling of (S)-9-(Allyloxy)-8-(bis(tert-butoxycarbonyl)amino)-9-oxonon-4-enoic acid (16) 
to NovaPEG amino resin 
 
NovaPEG amino resin (0.66 mmol/g, 1.00 g, 0.66 mmol, 1 eq.) was transferred to a glass 
solid-phase reactor under an argon atmosphere and swelled in anhydrous DCM (20 mL) for 
1 h. (S)-9-(Allyloxy)-8-(bis(tert-butoxycarbonyl)amino)-9-oxonon-4-enoic acid (16, 729 mg, 
1.65 mmol, 2.5 eq.), HOBt (357 mg, 2.64 mmol, 4 eq.), HBTU (877 mg, 2.31 mmol, 3.5 eq.) 
and anhydrous DIEA (327 μL, 1.98 mmol, 3 eq.) were dissolved in a solution of 10% 
anhydrous DMF in anhydrous DCM (15 mL) under an argon atmosphere and pre-activated 
for 30 min at RT. The solvent was removed from the resin and re-suspended in a 10% DMF in 
DCM solution (15 mL) and shaken gently for 10 min. The pre-activated amino acid solution 
was added to the resin and the resulting suspension was shaken for 24 h. 
The reaction solution was removed and the resin was washed with DMF (2x 1 min), MeOH 
(2x 1 min) and DCM (2x 1 min). A capping step was subsequently performed to block 
unreacted amines. To this end, a solution of DCM, DIEA and acetic anhydride (3:1:1, (v/v/v)) 
was added to the resin and the resulting suspension was shaken for 2 h. After removal of the 
solution, a fresh capping solution was added and the resin was again shaken for 2 h. The 
resin was washed with DMF (5x 1 min), alternately with MeOH and DCM (3x 1 min) and 
finally with DMF (2x 1 min). The subsequent Kaiser test performed according to method G 
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indicated the complete capping of all unreacted amines. The resulting resin is named as 
NovaPEG-Ahp5COAll (30) in the following.  
 
Coupling of Fmoc-Cit-OH to NovaPEG-Ahp5COAll (30) 
 
The resin 30 (0.66 mmol) was deprotected following method A. The coupling of Fmoc-Cit-OH 
to the resin was performed according to method D. The amounts of reagents were:  
Fmoc-Cit-OH: 1.05 g, 2.64 mmol  
HOBt: 357 mg, 2.64 mmol  
HBTU: 877 mg, 2.31 mmol 
DIEA: 327 μL, 1.98 mmol.  
The coupling reaction was performed for 4 h. After the regular washing, an additional 
washing procedure consisting of washing alternately with anhydrous MeOH and DCM (3x 
1 min) and finally anhydrous ether (3x 1 min) was performed. The resin was then dried 
under high vacuum overnight. 
A Kaiser test according to method G indicated a quantitative coupling.  
The loading of the resulting NovaPEG-Ahp5COAll-Cit4-Fmoc resin (31) was measured as 
described in method F using 5.8 mg of resin and revealed a resin loading of 0.24 mmol/g 
(36% loading yield, 2 couplings). 
 
Sequential coupling of Fmoc-Thr-OH and Boc-Gln-OH to NovaPEG-Ahp5COAll-Cit4-Fmoc 
(31) 
 
NovaPEG-Ahp5COAll-Cit4-Fmoc (31, loading of 0.24 mmol/g, 1.12 g, 0.27 mmol) was 
deprotected according to method B. The coupling of Fmoc-Thr-OH to the resin was 
performed using method D. The amounts of reagents used for the coupling were:  
Fmoc-Thr-OH*H2O: 388 mg, 1.08 mmol  
HOBt: 146 mg, 1.08 mmol  
HBTU: 359 mg, 0.95 mmol 
DIEA: 134 μL, 0.81 mmol. 
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The coupling was performed for 5 h. The Kaiser test performed following method G 
remained negative, thereby indicating a complete conversion of 31 to NovaPEG-Ahp5COAll-
Cit4-Thr3-Fmoc. 
NovaPEG-Ahp5COAll-Cit4-Thr3-Fmoc (0.27 mmol) was deprotected following to method B. 
The coupling of Boc-Gln-OH to the resin was carried out using method D. The amounts of 
reagent were:  
Boc-Gln-OH: 266 mg, 1.08 mmol  
HOBt: 146 mg, 1.08 mmol  
HBTU: 359 mg, 0.95 mmol 
DIEA: 134 μL, 0.81 mmol. 
The coupling was performed for 4 h. The Kaiser test performed according to method G 
indicated a complete conversion to NovaPEG-Ahp5COAll-Cit4-Thr3-Gln2-Boc (32). 
 
Coupling of butyric acid (But-OH) to NovaPEG-Ahp5COAll-Cit4-Thr3-Gln2-Boc (32) and 
esterification of the threonine sidechain with Fmoc-Val-OH 
 
The deprotection of NovaPEG-Ahp5COAll-Cit4-Thr3-Gln2-Boc (32, 0.27 mmol) was 
performed according to method A. The coupling of butyric acid to the resin was achieved 
following method D. The amounts of reagents were:  
But-OH: 99 μL, 1.08 mmol  
HOBt: 146 mg, 1.08 mmol  
HBTU: 359 mg, 0.95 mmol 
DIEA: 134 μL, 0.81 mmol. 
The coupling was performed for 4 h. The Kaiser test carried out according to method G 
indicated a complete conversion of 32 to NovaPEG-Ahp5COAll-Cit4-Thr3-Gln2-But1. 
The esterification of the threonine sidechain with Fmoc-Val-OH was carried out according to 
method E using the following amounts of reagents: 
Fmoc-Val-OH: 916 mg, 2.70 mmol, 10 eq. 
4-(dimethylamino)pyridine: 33 mg, 0.27 mmol, 1 eq. 
N,N’-diisopropylcarbodiimide: 421 μL, 2.70, 10 eq. 
After the washing step an additional washing step consisting of washing alternately with 
anhydrous MeOH and DCM (3x 1 min) and anhydrous ether (3x 1 min) was performed. The 
resin was dried under high vacuum overnight.  
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The loading of NovaPEG-Ahp5COAll-Cit4-Thr3(O-CO-Val8-Fmoc)-Gln2-But1 (33) was 
measured as described in method F using 6.8 mg of resin, revealing a resin loading of 0.22 
mmol/g (92%, 4 couplings). 
 
Sequential coupling of N-Boc-N-Methyl-3-bromomethyltyrosine (Boc-mTyr(3-Br,4-OMe)-
OH) (29) and Fmoc-Ile-OH to NovaPEG-Ahp5-COAll-Cit4-Thr3(O-CO-Val8-Fmoc)-Gln2-But1 
(33) 
 
NovaPEG-Ahp5COAll-Cit4-Thr3(O-CO-Val8-Fmoc)-Gln2-But1 (33, 0.22 mmol/g, 1.19 g, 
0.26 mmol) was deprotected following method B. The coupling of Boc-mTyr(3-Br,4-OMe)-OH 
to the resin was carried out using method D. The amounts of reagents used for this reaction 
were:  
Boc-mTyr(3-Br,4-OMe)-OH (29): 396 mg, 1.02 mmol  
HOBt: 138 mg, 1.02 mmol  
HBTU: 339 mg, 0.89 mmol 
DIEA: 126 μL, 0.77 mmol. 
The coupling was performed for 4.5 h. The Kaiser test performed following method G 
indicated a complete conversion to NovaPEG-Ahp5-COAll-Cit4-Thr3(O-CO-Val8-mTyr7(3-
Br,4-OMe)-Boc)-Gln2-But1. 
The deprotection of NovaPEG-Ahp5-COAll-Cit4-Thr3(O-CO-Val8-mTyr7(3-Br,4-OMe)-Boc)-
Gln2-But1 (0.26 mmol) was performed according to method A. The coupling of Fmoc-Ile-OH 
to the resin was carried out using PyBrOP as the coupling reagent. The following reagents 
were dissolved in DMF, pre-activated for 1 min and then added to the resin.  
Fmoc-Ile-OH: 451 mg, 1.28 mmol, 5 eq.  
PyBrOP: 583 mg, 1.25 mmol, 4.9 eq.  
DIEA: 421 μL, 2.55 mmol, 10 eq. 
The coupling was performed for 24 h. After the coupling, the resin was washed with DMF (2x 
1 min), alternately with MeOH and DCM (3x 1 min), DMF (5x 1 min), alternately with 
anhydrous MeOH and DCM (3x 1 min) and finally with anhydrous ether (3x 1 min). 
Subsequently, the resin was dried under high vacuum overnight. The chloranil test according 
to method H remained negative, indicating a complete conversion to NovaPEG-Ahp5-COAll-
Cit4-Thr3(O-CO-Val8-mTyr7(3-Br,4-OMe)-Ile6-Fmoc)-Gln2-But1 (34) 
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The loading of NovaPEG-Ahp5-COAll-Cit4-Thr3(O-CO-Val8-mTyr7-(3-Br,4-OMe)-Ile6-Fmoc)-
Gln2-But1 (34) was measured as described in method F using 5.0 mg of resin, revealing a 
loading of 0.16 mmol/g (73%, 2 couplings). 
 
Full deprotection of NovaPEG-Ahp5-COAll-Cit4-Thr3(O-CO-Val8-mTyr7-(3-Br,4-OMe)-Ile6-
Fmoc)-Gln2-But1 (34) 
 
The final Fmoc deprotection of 34 (0.16 mmol/g, 1.27 g, 0.20 mmol) was performed 
according to method B and the resulting resin was then treated according to method C in 
order to cleave the allyl ester protection. 
This procedure then afforded the NovaPEG-Ahp5-COOH-Cit4-Thr3(O-CO-Val8-mTyr7-(3-Br,4-
OMe)-Ile6-NH2)-Gln2-But1 (35) intermediate. 
 
On resin macrolactamization of NovaPEG-Ahp5-COOH-Cit4-Thr3(O-CO-Val8-mTyr7-(3-Br, 4-
OMe)-Ile6-NH2)-Gln2-But1 (35) 
 
To the fully deprotected intermediate resin 35 (0.20 mmol), a solution of HOBt (216 mg, 1.60 
mmol, 8 eq.) and DIEA (397 μL, 2.40 mmol, 12 eq.) in DMF was added and the resulting 
suspension was shaken 1 min for pre-activation. A solution of PyBOP (357 mg, 0.80 mmol, 
4 eq.) in DMF was added and the resulting reaction mixture was shaken for 24 h. 
The resin was washed with DMF (2x 1 min), alternately with MeOH and DCM (3x 1 min), 
DMF (5x 1 min), DCM (2x 1 min) and finally with diethyl ether (2x 1 min). The resin was then 
dried under high vacuum for 1 h, resulting in resin 36. A Kaiser test following method G 
indicated a complete reaction. 
 
Oxidative cleavage of resin 36 to symplocamide A 
 
Sodium periodate (428 mg, 2.00 mmol, 10 eq.) and DABCO (112 mg, 1.00 mmol, 5 eq.) were 
suspended in water (8 mL), sonificated briefly and added to resin 36 (0.20 mmol). The resin 
was allowed to swell in this mixture for 10 min, after which THF (8 mL) was added and the 
resulting suspension was shaken for 2 min. Subsequently, a 0.1 M solution of osmium 
tetroxide in tert-butanol (123 μL, 0.01 mmol, 0.05 eq.) was added to the suspension, which 
was shaken for further 20 h. 
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The cleavage solution was collected and quenched with an aq. saturated sodium 
metabisulfite solution (100 mL). The resin was washed with a 1:1 (v/v) solution of THF/water 
(5x 20 mL), the washing phases were added to the sodium metabisulfite solution. The phases 
in this solution were allowed to separate and the aqueous phase was extracted with ethyl 
acetate (5x 80 mL). The combined organic extracts were dried over Na2SO4 and the solvent 
was evaporated. The resulting crude mixture was re-dissolved in ethyl acetate (1 mL) and a 
few drops of trifluoroacetic acid were added, followed by transfer of the whole reaction 
mixture to cold ether, thereby causing the crude product to precipitate as a white solid. The 
precipitate was centrifuged at 4 °C; the supernatant removed and fresh cold ether was 
added. The suspension was sonificated briefly and centrifuged again at 4 °C, then the 
supernatant was removed and the precipitate was allowed to dry.  
 
The crude product (65 mg) was purified by preparative HPLC (0 min / 10% B → 3 min / 10% B 
→ 15 min / 32% B → 40 min / 45% B → 41 min / 100% B → 51 min / 100% B) to afford 8.4 
mg (8 μmol, 3%) symplocamide A as a light yellow glass. 
[α]D
20 -21.7 (c 0.06 in MeOH). 
1H NMR (600 MHz, DMSO-d6): δ 8.49 (d, J = 8.65 Hz, 1H), 8.05 (d, J = 7.30 Hz, 1H), 7.82 (d, J = 
8.95 Hz, 1H), 7.66 (d, J = 9.00 Hz, 1H), 7.34 (d, J = 9.25 Hz, 1H), 7.31 (bs, 1H), 7.20 (d, J = 7.15 
Hz, 1H), 7.03 (d, J = 8.40 Hz, 1H), 6.74 (bs, 1H), 6.13 (bs, 1H), 5.97 (bs, 1H), 5.51 (m, 1H), 5.37 
(bs, 2H), 5.06 (d, J = 11.80 Hz, 1H), 4.93 (bs, 1H), 4.65 (m, 1H), 4.48-4.49 (m, 1H), 4.44 (m, 
1H), 4.37-4.39 (m, 2H), 4.25 (m, 1H), 3.77 (s, 1H), 3.22-3.24 (m, 1H), 2.94 (m, 1H), 2.77-2.80 
(m, 1H), 2.74 (s, 3H), 2.57-2.61 (m, 1H), 2.16-2.17 (m, 2H), 2.12 (t, J = 6.75 Hz, 2H), 2.04-2.06 
(m, 1H), 1.98-2.01 (m, 2H), 1.78-1.80 (m, 1H), 1.73-1.75 (m, 4H), 1.53 (m, 2H), 1.46 (m, 1H), 
1.24 (m, 2H), 1.21 (d, J = 5.50 Hz, 2H), 1.10 (m, 2H), 0.87 (m, 6H), 0.76 (d, J = 6.20 Hz, 3H), 
0.63 (m, 3H), -0.14 (d, J = 5.50 Hz, 3H). 
13C NMR (151 MHz, DMSO-d6): δ 174.4, 174.0, 172.5, 172.4, 170.3, 169.8, 169.5, 169.3, 
169.3, 158.1, 154.6, 129.8, 128.1, 126.5, 116.5, 111.2, 74.1, 72.05, 63.0, 60.6, 56.4, 54.9, 
54.3, 52.5, 52.2, 49.0, 37.2, 36.6, 35.2, 33.1, 32.9, 31.7, 31.4, 30.3, 28.9, 28.8, 28.7, 26.7, 
25.2, 22.2, 19.4, 18.8, 17.8, 17.8, 13.9, 13.7, 10.4. 
LC-MS: tR = 7.35 min, m/z = 1053(M+ + H+,75%), 1035 (M+ - H2O, 100). 
HRMS (ESI): m/z calcd for C46H72O13N10Br + [M + H]+ 1051.4458, found 1051.4463, m/z calcd 
for C46H72O13N1081Br + [M + H]+ 1053.4438, found 1053.4446.  
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6.4.4 Synthesis of structure-activity analogs of Ahp cyclodepsipeptides 
6.4.4.1 Synthesis of SAR-1 and SAR-2: (1: Ahp→Ser, 2: Ahp→Hse) 
 
Loading of Fmoc-Cit-OH onto 2-chlorotrityl resin 
 
2-chlorotrityl resin (1.6 mmol/g, 1.20 g, 1.92 mmol) was transferred to a glass solid-phase 
reactor under an argon atmosphere. To the resin was added a solution of Fmoc-Cit-OH 
(917 mg, 2.30 mmol, 1.2 eq.) and DIEA (2.12 mL, 7.68 mmol, 4.0 eq.) in DCM (15 mL) and the 
resin was shaken gently at RT overnight. The resin was capped with a solution of 
DCM/MeOH/DIEA (85%/10%/5%) which was applied 3x 5 min. The resin was washed with 
DMF (2x 1 min), alternatingly with MeOH and DCM (3x 1 min), DMF (3x 1 min) and finally 
with DCM (3x 1 min). After drying under high vacuum, the loading of the resin was 
determined according to method F and the loading was determined to 0.62 mmol/g (39%). 
The resulting resin was used for the syntheses of SAR-1, SAR-2, SAR-4, SAR-6, SAR-7, SAR-8 
and SAR-9. 
 
Coupling of Fmoc-Thr-OH, Fmoc-Gln(Trt)-OH and butyric acid 
 
The dried resin (0.62 mmol/g, 520 mg, 0.32 mmol) was transferred into a solid-phase syringe 
reactor for the subsequent couplings. 
The resin was deprotected prior to every coupling according to method B. 
The amino acids were coupled using the protocol described in method D. 
A Kaiser test following the protocol in method G was performed after each coupling. 
The following amounts of reagents and coupling times were used for the respective 
couplings: 
HOBt: 173 mg, 1.28 mmol 
HBTU: 425 mg, 1.12 mmol 
DIEA: 160 μL, 0.96 mmol. 
 
Fmoc- Thr-OH*H2O: 460 mg, 1.28 mmol 
The coupling was performed for 2 h, the Kaiser test performed after the coupling remained 
negative, indicating a complete coupling. 
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Fmoc-Gln(Trt)-OH: 782 mg, 1.28 mmol 
The coupling was performed for 2 h, after which the Kaiser test turned positive. The required 
double coupling was performed as an overnight reaction using the same amounts of 
reagents again. The Kaiser test performed after this coupling remained negative. 
 
butyric acid: 117.5 μL, 1.28 mmol 
The coupling was performed for 5 h, after which the Kaiser test remained negative, thereby 
indicating a complete coupling. 
 
Esterification with Fmoc-Val-OH 
 
The esterification of the threonine side chain was performed following method E, using the 
following amounts of reagents: 
Fmoc-Val-OH: 1.09 g, 3.20 mmol  
diisopropyl carbodiimide: 499 μL, 3.20 mmol  
(4-dimethylamino)pyridine: 39 mg, 0.32 mmol.  
 
Coupling of Alloc-(Br,OMe)-mTyr-OH, Fmoc-Ile-OH and Fmoc-Ser(Trt)-OH (SAR-1) or Fmoc-
Hse(Trt)-OH (SAR-2) 
 
The resin was deprotected prior to the coupling according to method B. 
The coupling with Alloc-(Br,OMe)-mTyr-OH was carried out using the following amounts of 
reagents and following method D: 
HOBt: 173 mg, 1.28 mmol 
HBTU: 425 mg, 1.12 mmol 
DIEA: 160 μL, 0.96 mmol. 
Alloc-(Br,OMe)-mTyr-OH: 476 mg, 1.28 mmol. 
 
The Kaiser test performed according to method G remained negative after a coupling time of 
6 h. The washing and subsequent removal of the Alloc group was then carried out as 
described in method C. The following amounts of reagents were used for the deprotection 
reaction: 
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morpholine: 672 μL, 7.68 mmol 
Pd(PPh3)4: 92 mg, 0.08 mmol. 
 
The subsequent coupling with Fmoc-Ile-OH was carried out using the following amounts of 
reagents: 
PyBrOP: 731 mg, 1.57 mmol, 4.9 eq. 
DIEA: 529 μL, 3.2 mmol, 10 eq. 
Fmoc-Ile-OH: 565 mg, 1.60 mmol, 5.0 eq. 
 
The coupling was performed for 24 h, the resin was washed as described in method D after 
the coupling. Additionally, the resin was washed with DCM (3x 1 min) and ether (3x 1 min) 
and dried under high vacuum for 1 h. 
The chloranil test carried out after 24 h of coupling remained negative, thereby indicating a 
complete reaction. 
After drying, the resin was divided into three equal portions (0.62 mmol/g, 0.11 mmol each) 
and transferred to fresh solid-phase syringe reactors. 
 
The coupling with Fmoc-Ser(Trt)-OH or Fmoc-Hse(Trt)-OH was performed as a double 
coupling as described in method D using the following amounts of reagents: 
HOBt: 60 mg, 0.44 mmol 
HBTU: 146 mg, 0.39 mmol 
DIEA: 55 μL, 0.33 mmol  
 
SAR-1: Fmoc-Ser(Trt)-OH: 251 mg, 0.44 mmol 
SAR-2: Fmoc-Hse(Trt)-OH: 257 mg, 0.44 mmol 
 
After a reaction time of 2x 2 h, a Kaiser test performed according to method G remained 
negative for both sequences. 
After removal of the Fmoc group according to method B the resins were additionally washed 
with DCM (2x 1 min) and ether (3x 1 min) and dried under high vacuum for 1 h. 
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Cleavage from the solid phase  
 
The peptides were cleaved from the resins according to method I and the ether precipitation 
yielded 200 mg of crude peptide for SAR-1 and 100 mg for SAR-2. 
 
Cyclization of the linear peptide and removal of the trityl protecting groups 
 
The cyclization was carried out analogously for both peptides; the respective amounts of 
reagents are given in brackets. 
The crude peptide (SAR-1: 200 mg, 200 μmol / SAR-2: 100 mg, 100 μmol) was dissolved in 
precooled DMF (190 mL / 90 mL) and cooled to 10 °C. DIEA (198 μL, 1200 μmol, / 99 μL, 600 
μmol, 6.0 eq.) was added and the flasks containing the reaction solutions were placed on an 
orbital shaker and shaken gently. PyBOP (312 mg, 600 μmol / 156 mg, 300 μmol, 3.0 eq.) 
dissolved in pre-cooled DMF (10 mL) was added and the mixture was gently shaken at 10 °C 
for 2 d. After this time, the solvent was removed and the residue was co-evaporated twice 
with toluene. The remaining crude mixture was dissolved in a minimal amount of ethyl 
acetate (and optionally a few drops of MeOH to enhance solubility). This solution was added 
to cold ether, resulting in the precipitation of the crude peptide. The suspension was 
centrifuged and the pellet was washed once with cold ether, centrifuged and dried 
subsequently. 
The trityl protecting groups were removed as described in method J. 
The crude peptides were purified by preparative HPLC using a preparative C18 column and a 
linear gradient of acetonitrile in H2O, starting from 10% acetonitrile. 
After the purification the solvent was removed and the products were lyophilized. 
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SAR-1: 
Yield: 4.60 mg (4.5 μmol, 4.1%) as a white powder. 
1H NMR (600 MHz, DMSO-d6) δ 8.52 (d, J = 6.6 Hz, 1H), 8.48 (d, J = 7.6 Hz, 1H), 8.02 (d, J = 7.9 
Hz, 1H), 7.99 (dd, J = 8.0, 3.4 Hz, 1H), 7.46 (d, J = 2.0 Hz, 1H), 7.30 (s, 1H), 7.15 (d, J = 8.3 Hz, 
1H), 7.04-7.01 (m, 2H), 6.79 (bs, 2H), 5.93 (bs, 1H), 5.29-5.23 (m, 3H), 4.64-4.61 (m, 1H), 
4.48-4.44 (m, 1H), 4.33-4.30 (m, 1H), 4.24-4.20 (m, 2H), 4.13-4.09 (m, 2H), 3.79 (s, 3H), 3.60 
(dd, J = 10.5, 5.5 Hz, 1H), 3.53 (dd, J = 10.6, 6.8 Hz, 1H), 3.23 (dd, J = 14.1, 6.5 Hz, 1H), 3.03-
3.00 (m, 3H), 2.73 (dd, J = 14.1, 7.9 Hz, 1H), 2.69 (s, 3H), 2.14-2.06 (m, 8H), 1.85-1.83 (m, 1H), 
1.75-1.72 (m, 4H), 1.53-1.49 (m, 4H), 1.12 (d, J = 6.5 Hz, 3H), 0.88-0.83 (m, 3H), 0.82-0.79 (m, 
6H), 0.70 (t, J = 7.4 Hz, 3H), 0.39 (d, J = 6.2 Hz, 3H). 
LC-MS: tR = 7.43 min (C18), m/z = 1027.47(M+ + H+, 100%), 1027.43 calcd for C44H70BrN10O13+. 
 
SAR-2: 
Yield: 1.10 mg (1.1 μmol, 1.0%) as a white powder. 
1H NMR (600 MHz, DMSO-d6) δ 8.66 (d, J = 8.5 Hz, 1H), 8.43 (d, J = 8.2 Hz, 1H), 8.39 (d, J = 8.8 
Hz, 1H), 8.12 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 2.0 Hz, 1H), 7.45 (d, J = 2.0 Hz, 1H), 7.18 (s, 1H), 
7.09 (s, 1H), 7.01 (s, 1H), 6.83 (bs, 2H), 5.93 (bs, 1H), 5.42 (bs, 2H), 5.12-5.09 (m, 1H), 4.54-
4.53 (m, 1H), 4.49-4.48 (m, 1H), 4.34-4.33 (m, 1H), 4.29-4.28 (m, 1H), 4.26-4.24 (m, 1H), 
4.22-4.21 (m, 1H), 3.81 (s, 3H), 3.11-3.08 (m, 5H), 3.03 (s, 3H), 2.62-2.61 (m, 1H), 2.39 (dd, J = 
3.7, 1.9 Hz, 1H), 2.12-2.06 (m, 10H), 1.74-1.72 (m, 1H), 1.52-1.46 (m, 8H), 0.95 (d, J = 7.0 Hz, 
3H), 0.86-0.83 (m, 3H), 0.81-0.79 (m, 6H), 0.70-0.66 (m, 3H), 0.59-0.57 (m, 3H). 
LC-MS: tR = 6.23 min (C18), m/z = 1041.33(M+ + H+, 100%), 1041.44 calcd for C45H72BrN10O13+. 
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6.4.4.2 Synthesis of SAR-3 (Ahp→Thr)  
 
Loading of Fmoc-Cit-OH onto 2-chlorotrityl resin 
 
2-chlorotrityl resin (1.6 mmol/g, 250 mg, 0.40 mmol) was transferred to a glass solid-phase 
reactor under an argon atmosphere. To the resin was added a solution of Fmoc-Cit-OH 
(182 mg, 0.48 mmol, 1.2 eq.) and DIEA (264 μL, 7.68 mmol, 4.0 eq.) in DCM (6 mL) and the 
resin was shaken gently at RT overnight. The resin was capped with a solution of 
DCM/MeOH/DIEA (85%/10%/5%) which was applied 3x for 5 min. The resin was washed 
with DMF (2x 1 min), alternatingly with MeOH and DCM (3x 1 min), DMF (3x 1 min) and 
finally with DCM (3x 1 min). After drying under high vacuum, the loading of the resin was 
determined according to method F, revealing a loading of 0.46 mmol/g (29 %). 
 
Coupling of Fmoc-Thr-OH, Fmoc-Gln(Trt)-OH and butyric acid 
 
The dried resin (0.36 mmol/g, 342 mg, 0.16 mmol) was transferred to a solid-phase syringe 
reactor for the subsequent couplings. 
The resin was deprotected prior to every coupling according to method B. 
The amino acids were coupled using the protocol described in method D. 
A Kaiser test following the protocol in method G was performed after each coupling. 
The following amounts of reagents and coupling times were used for the respective 
couplings: 
HOBt: 87 mg, 0.64 mmol 
HBTU: 213 mg, 0.56 mmol 
DIEA: 79 μL, 0.48 mmol. 
 
Fmoc-Thr-OH*H2O: 87 mg, 0.64 mmol 
The coupling was performed for 2 h, the Kaiser test performed after the coupling remained 
negative, indicating a complete coupling. 
 
Fmoc-Gln(Trt)-OH: 391 mg, 0.64 mmol 
The coupling was performed as an overnight reaction, after which the Kaiser test remained 
negative, indicating a complete coupling. 
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butyric acid: 59 μL, 0.64 mmol 
The coupling was performed for 4 h, after which the Kaiser test remained negative for both 
reactions, indicating a complete coupling. 
 
Esterification with Fmoc-Val-OH 
 
The esterification of the threonine side chain was performed following method E, using the 
following amounts of reagents: 
Fmoc-Val-OH: 543 mg, 1.60 mmol  
diisopropyl carbodiimide: 249 μL, 1.60 mmol  
(4-dimethylamino)pyridine: 20 mg, 0.16 mmol.  
 
Coupling of Alloc-(Br,OMe)-mTyr-OH, Fmoc-Ile-OH and Fmoc-Thr(tBu)-OH 
 
The resin was deprotected prior to the coupling according to method B. 
The coupling with Alloc-(Br,OMe)-mTyr-OH was carried out using the following amounts of 
reagents and following method D: 
HATU: 266 mg, 0.8 mmol, 5 eq. 
DIEA: 263 μL, 1.60 mmol, 10 eq. 
Alloc-(Br,OMe)-mTyr-OH: 238 mg, 0.64 mmol, 4 eq. 
 
The Kaiser test performed according to method G remained negative after a coupling time of 
24 h. The washing and subsequent removal of the Alloc group was carried out as described 
in method C. The following amounts of reagents were used for the deprotection reaction: 
morpholine: 336 μL, 3.84 mmol 
Pd(PPh3)4: 46 mg, 0.04 mmol. 
 
The subsequent coupling with Fmoc-Ile-OH was carried out using the following amounts of 
reagents: 
PyBrOP: 365 mg, 0.78 mmol, 4.9 eq. 
DIEA: 263 μL, 1.60 mmol, 10 eq. 
Fmoc-Ile-OH: 283 mg, 0.80 mmol, 5.0 eq. 
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The coupling was performed for 24 h, the resin was washed as described in method D after 
the coupling. The chloranil test carried out according to method H after the 24 h coupling 
remained negative, thereby indicating a complete coupling. 
The coupling with Fmoc-Thr(tBu)-OH was performed for 6 h as described in method D using 
the following amounts of reagents: 
HOBt: 87 mg, 0.64 mmol 
HBTU: 213 mg, 0.56 mmol 
DIEA: 79 μL, 0.48 mmol. 
Fmoc-Thr(tBu)-OH: 254 mg, 0.64 mmol 
A Kaiser test performed according to method G remained negative for both sequences. 
After removal of the Fmoc group according to method B the resin was washed additionally 
with DCM (2x 1 min) and ether (3x 1 min) and dried under high vacuum for 1 h. 
 
Cleavage from the solid phase 
 
The peptide was cleaved from the resin according to method I, the ether precipitation 
yielded 160 mg of the crude peptide. 
 
Cyclization of the linear peptide and removal of the trityl protecting groups 
 
The crude peptide (160 mg, 117 μmol) was dissolved in pre-cooled DMF (110 mL) and cooled 
to 10 °C. DIEA (116 μL, 702 μmol, 6.0 eq.) was added to the solution and the flask containing 
the reaction solution was placed on an orbital shaker and shaken gently. PyBOP (183 mg, 
351 μmol, 3.0 eq.) dissolved in pre-cooled DMF (10 mL) was added and the reaction mixture 
was gently shaken at 10 °C for 2 d. The solvent was removed and the residue was co-
evaporated twice with toluene. The remaining crude mixture was dissolved in the minimal 
amount of ethyl acetate (and optionally a few drops of MeOH to enhance solubility). This 
solution was added to cold ether, resulting in the precipitation of the crude peptide. The 
suspension was centrifuged and the pellet was washed once with cold ether, centrifuged 
and dried subsequently. 
The trityl protecting groups were removed as described in method J. 
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The crude peptide was purified by preparative HPLC using a preparative C18 column and a 
linear gradient of acetonitrile in H2O, starting from 10% acetonitrile. After the purification 
the solvent was removed and the product was lyophilized. 
 
SAR-3: 
Yield: 3.54 mg (3.4 μmol, 2.1%) as a white powder. 
1H NMR (500 MHz, DMSO-d6) δ 8.57 (d, J = 6.3 Hz, 1H), 8.28 (d, J = 7.5 Hz, 1H), 8.02 (d, J = 3.4 
Hz, 1H), 8.00 (d, J = 2.5 Hz, 1H), 7.47 (d, J = 2.0 Hz, 1H), 7.30 (s, 1H), 7.20 (s, 1H), 7.10 (s, 1H), 
7.00 (d, J = 3.5 Hz, 1H), 6.80 (bs, 2H), 5.92 (bs, 1H), 5.20-5.16 (m, 1H), 5.11 (bs, 2H), 4.60-4.55 
(m, 1H), 4.46-4.43 (m, 1H), 4.31-4.26 (m, 3H), 4.19 – 4.15 (m, 1H), 4.10-4.05 (m, 1H), 3.88 (d, 
J = 3.0 Hz, 1H), 3.79 (s, 3H), 2.94-2.91 (m, 3H), 2.77-2.72 (m, 2H), 2.68 (s, 3H), 2.12-2.06 (m, 
9H), 1.54-1.48 (m, 8H), 1.12 (d, J = 6.5 Hz, 3H), 0.97-0.94 (m, 3H), 0.87-0.83 (m, J = 7.4 Hz, 
6H), 0.78 (d, J = 6.8 Hz, 3H), 0.68 (t, J = 7.1 Hz, 3H), 0.56 (d, J = 5.7 Hz, 3H). 
LC-MS: tR = 7.63 min (C18), m/z = 1041.40(M+ + H+, 100%), 1041.44 calcd for C45H72BrN10O13+. 
 
6.4.4.3 Synthesis of SAR-4 and SAR-7: (4: Ahp→Ser, Br,OMe-mTyr→OMe-mTyr, 7: 
Ahp→Ser, Br,OMe-mTyr→Pro ) 
 
Coupling of Fmoc-Thr-OH, Fmoc-Gln(Trt)-OH and butyric acid 
 
The dried resin (0.62 mmol/g, 520 mg, 0.32 mmol) was transferred into a solid-phase syringe 
reactor for the subsequent couplings. 
The resin was deprotected prior to every coupling according to method B. 
The amino acids were coupled using the protocol described in method D. 
A Kaiser test following the protocol in method F was performed after each coupling. 
The following amounts of reagents and coupling times were used for the respective 
couplings: 
HOBt: 173 mg, 1.28 mmol 
HBTU: 425 mg, 1.12 mmol 
DIEA: 160 μL, 0.96 mmol. 
 
Fmoc- Thr-OH*H2O: 460 mg, 1.28 mmol 
The coupling was performed for 2 h, the Kaiser test performed after the coupling remained 
negative, indicating a complete coupling.  
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Fmoc-Gln(Trt)-OH: 782 mg, 1.28 mmol 
The coupling was performed for 2 h, after which the Kaiser test remained negative, 
indicating a complete coupling. 
 
butyric acid: 117.5 μL, 1.28 mmol 
The coupling was performed as an overnight reaction, after which the Kaiser test remained 
negative, indicating a complete coupling. 
 
Esterification with Fmoc-Val-OH 
 
The esterification of the threonine side chain was performed according to method E, using 
the following amounts of reagents: 
Fmoc-Val-OH: 1.09 g, 3.20 mmol  
diisopropyl carbodiimide: 499 μL, 3.20 mmol  
(4-dimethylamino)pyridine: 39 mg, 0.32 mmol.  
After the regular washing protocol, the resin was additionally washed with DCM (3x 1 min) 
and ether (3x 1 min) and dried under high vacuum for 1 h. The dried resin was then divided 
into four equal portions and transferred into fresh solid-phase syringe reactors. 
 
Sequential coupling of Alloc-(Br,OMe)-mTyr-OH (SAR-4) or Fmoc-Pro-OH (SAR-7), Fmoc-Ile-
OH and Boc-Ser(OBzl)-OH 
 
The resin (0.62 mmol/g, 0.08 mmol) was deprotected prior to every coupling according to 
method B. 
The following two couplings were carried out using the given amounts of reagents according 
to method D: 
HOBt: 43 mg, 0.32 mmol 
HBTU: 106 mg, 0.28 mmol 
DIEA: 40 μL, 0.24 mmol. 
 
SAR-4: Alloc-(Br,OMe)-mTyr-OH: 119 mg, 0.32 mmol. 
SAR-7: Fmoc-Pro-OH: 108 mg, 0.32 mmol. 
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For SAR-4 the Kaiser test performed according to method G remained negative after a 
coupling time of 3 h. The washing and subsequent removal of the Alloc group was carried 
out as described in method C. The following amounts of reagents were used for the 
deprotection reaction: 
morpholine: 168 μL, 1.92 mmol 
Pd(PPh3)4: 23 mg, 0.02 mmol. 
 
For SAR-7 the Kaiser test following the protocol of method G was performed after 3 h 
coupling and indicated an incomplete coupling. A double coupling was performed for 2 h 
using the same amounts of reagents, which resulted in a negative Kaiser test. The removal of 
the Fmoc protection was carried out following the protocol described in method B.  
The subsequent coupling with Fmoc-Ile-OH was carried out in the same manner for both 
sequences using the following amounts of reagents: 
PyBrOP: 175 mg, 0.39 mmol, 4.9 eq. 
DIEA: 132 μL, 0.8 mmol, 10 eq. 
Fmoc-Ile-OH: 141 mg, 0.40 mmol, 5.0 eq. 
 
The coupling was performed for 24 h, the resins were washed as described in method D after 
the coupling.   
 
For SAR-4, the chloranil test carried out with the protocol of method H was positive, 
indicating an incomplete coupling. The required double coupling was performed using the 
same amounts of reagents again, the reaction time was 4 h, after which the chloranil test 
remained negative. 
 
For SAR-7 the chloranil test carried out after the 24 h coupling remained negative, thereby 
indicating a complete coupling. 
The coupling with Boc-Ser(OBzl)-OH was performed as described in method D as an 
overnight reaction using the following amounts of reagents: 
HOBt: 43 mg, 0.32 mmol 
HBTU: 106 mg, 0.28 mmol 
DIEA: 40 μL, 0.24 mmol  
Boc-Ser(OBzl)-OH: 95 mg, 0.32 mmol.  
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The Kaiser test performed as described in method G remained negative for both sequences, 
thereby indicating a complete coupling. Additionally, after the regular washing protocol the 
resins were washed with DCM (2x 1 min) and ether (3x 1 min) and dried under high vacuum 
for 1 h. 
 
Cleavage from the solid phase and deprotection 
 
The peptides were cleaved from the resins according to method I. The Boc and trityl 
protecting groups were removed using the protocol described in method J; the ether 
precipitation yielded 60 mg of crude peptide for both sequences. 
 
Cyclization of the linear peptide and removal of the benzyl ether protection 
 
The crude peptides (60 mg, 60 μmol) were dissolved in pre-cooled DMF (50 mL) and the 
solutions were maintained at 10 °C. DIEA (59.5 μL, 360 μmol, 6.0 eq.) was added and the 
flasks containing the reaction solutions were placed on an orbital shaker and shaken gently. 
PyBOP (94 mg, 180 μmol, 3.0 eq.) dissolved in pre-cooled DMF (10 mL) was added and the 
mixtures was gently shaken at 10 °C for 2 d. The solvent was removed and the residue was 
co-evaporated twice with toluene. The remaining crude mixtures were dissolved in a 
minimal amount of ethyl acetate (and optionally a few drops of MeOH to enhance 
solubility). The resulting solutions were added to cold ether, resulting in the precipitation of 
the crude peptide. The suspension was centrifuged and the pellet was washed once with 
cold ether and dried subsequently, yielding 150 mg of crude product for each sequence. 
The benzyl group was removed from the crude cyclized peptides with the hydrogenation 
performed following method K. 
An LC-MS analysis carried out after the hydrogenation indicated that the hydrogenation for 
SAR-4 had also resulted in the removal of the aromatic bromine besides the cleavage of the 
benzyl group. 
The crude peptides were then purified by preparative HPLC using a preparative C18 column 
and a linear gradient of acetonitrile in H2O, starting from 10% acetonitrile. 
After the purification the solvent was removed and the products were lyophilized. 
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SAR-4: 
Yield: 2.90 mg (3.1 μmol, 3.8%) as a white powder. 
1H NMR (600 MHz, DMSO-d6) δ 8.56 (d, J = 6.6 Hz, 1H), 8.47 (d, J = 7.7 Hz, 1H), 8.01-7.99 (m, 
2H), 7.29 (s, 1H), 7.17 (d, J = 5.9 Hz, 1H), 7.15-7.12 (m, 2H), 6.85-6.81 (m, 2H), 6.79 (bs, 2H), 
5.92 (bs, 1H), 5.37 (bs, 2H), 5.26-5.23 (m, 1H), 4.64-4.61 (m, 1H), 4.48-4.43 (m, 1H), 4.33-4.29 
(m, 2H), 4.23-4.20 (m, 2H), 4.12-4.10 (m, 1H), 3.69 (s, 3H), 3.60-3.58 (m, 1H), 3.29-3.27 (m, 
1H), 3.25-3.23 (m, 1H), 2.95-2.91 (m, 4H), 2.69 (s, 3H), 2.15-2.05 (m, 8H), 1.85-1.81 (m, 1H), 
1.53-1.48 (m, 4H), 1.27-1.23 (m, 4H), 1.10 (d, J = 6.5 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H), 0.82-0.79 
(m, 6H), 0.72 (t, J = 7.4 Hz, 3H), 0.43 (d, J = 6.3 Hz, 3H). 
LC-MS: tR = 7.79 min (C18), m/z = 947.53(M+ + H+, 100%), 947.52 calcd for C44H71N10O13+. 
 
SAR-7: 
Yield: 4.85 mg (5.7 μmol, 7.1%) as a white powder. 
1H NMR (600 MHz, DMSO-d6) δ 8.48 (d, J = 8.4 Hz, 1H), 8.09-8.05 (m, 2H), 7.81 (d, J = 9.2 Hz, 
1H), 7.30 (bs, 2H), 6.96 (d, J = 5.0 Hz, 1H), 6.78 (bs, 1H), 6.59 (d, J = 6.7 Hz, 1H), 5.97 (bs, 2H), 
5.24-5.20 (m, 1H), 4.66-4.64 (m, 1H), 4.47-4.45 (m, 1H), 4.41-4.39 (m, 1H), 4.34-4.31 (m, 1H), 
4.27-4.25 (m, 1H), 4.23-4.20 (m, 2H), 3.66-3.62 (m, 1H), 3.56-3.49 (m, 3H), 3.44-3.41 (m, 1H), 
2.94 (t, J = 6.8 Hz, 2H), 2.26-2.22 (m, 1H), 2.19-2.14 (m, 1H), 2.13-2.08 (m, 4H), 2.01-1.96 (m, 
1H), 1.94-1.91 (m, 1H), 1.89-1.84 (m, 2H), 1.80-1.75 (m, 2H), 1.73-1.68 (m, 2H), 1.54-1.49 (m, 
2H), 1.47-1.43 (m, 2H), 1.37-1.32 (m, 2H), 1.13 (d, J = 6.3 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H), 
0.84-0.81 (m, 3H), 0.81-0.78 (m, 9H). 
LC-MS: tR = 6.90 min (C18), m/z = 853.47(M+ + H+, 100%), 853.48 calcd for C38H65N10O12+. 
 
6.4.4.4 Synthesis of SAR-5 (simplified SymA analog, Ahp→Ser, Br,OMe-mTyr→mPhe) 
 
Loading of Fmoc-Cit-OH onto 2-chlorotrityl resin 
 
2-chlorotrityl resin (1.6 mmol/g, 500 mg, 0.80 mmol) was transferred to a glass solid-phase 
reactor under an argon atmosphere. To the resin was added a solution of Fmoc-Cit-OH 
(382 mg, 0.96 mmol, 1.2 eq.) and DIEA (529 μL, 3.2 mmol, 4.0 eq.) in DCM (6 mL). The resin 
was shaken gently at RT overnight and capped with a solution of DCM/MeOH/DIEA 
(85%/10%/5%) which was applied 3x for 5 min. After the capping step, the resin was washed 
with DMF (2x 1 min), alternatingly with MeOH and DCM (3x 1 min), DMF (3x 1 min) and 
Experimental 
214 
finally with DCM (3x 1 min). After drying under high vacuum for 1 h, the loading of the resin 
was determined according to method F, revealing a loading of 0.33 mmol/g (20%). 
 
Coupling of Fmoc-Thr-OH, Fmoc-Gln(Trt)-OH and butyric acid 
 
The dried resin (0.33 mmol/g, 700 mg, 0.23 mmol) was transferred to a solid-phase syringe 
reactor for the subsequent couplings. 
The resin was deprotected prior to every coupling according to method B. 
The amino acids were coupled using the protocol described in method D. 
A Kaiser test following the protocol in method G was performed after each coupling. 
The following amounts of reagents and coupling times were used for the respective 
couplings: 
HOBt: 125 mg, 0.92 mmol 
HBTU: 307 mg, 0.81 mmol 
DIEA: 115 μL, 0.69 mmol. 
 
Fmoc-Thr-OH: 315 mg, 0.92 mmol 
The coupling was performed for 2 h, after which the Kaiser test remained positive. A double 
coupling was performed for additional 2 h, using the same amounts of reagents. The Kaiser 
test performed after this second coupling was negative, indicating a complete coupling. 
 
Fmoc-Gln(Trt)-OH: 564 mg, 0.92 mmol 
The coupling was performed for 2 h, after which a Kaiser test remained positive. A double 
coupling was performed for additional 2 h, using the same amounts of reagents. The Kaiser 
test performed after this second coupling was negative, indicating a complete coupling. 
 
butyric acid: 85 μL, 0.92 mmol 
The coupling was performed for 4 h, after which the Kaiser test remained positive. A double 
coupling was performed overnight, using the same amounts of reagents. The Kaiser test 
performed after this second coupling was negative, indicating a complete coupling. 
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Esterification with Fmoc-Val-OH 
 
The esterification of the threonine side chain was performed following method E, using the 
following amounts of reagents: 
Fmoc-Val-OH: 781 mg, 2.30 mmol 
diisopropyl carbodiimide: 358 μL, 2.30 mmol  
(4-dimethylamino)pyridine: 28 mg, 0.23 mmol.  
 
After the regular washing steps, the resin was washed additionally with DCM (3x 1 min) and 
ether (3x 1 min) and dried under high vacuum for 1 h. 
An Fmoc determination performed according to method F revealed a loading of 0.33 mmol/g 
(quant.). 
 
Coupling of Fmoc-NMePhe, Fmoc-Ile-OH and Boc-Ser(OBzl)-OH 
 
The dried resin (0.33 mmol/g, 835 mg, 0.23 mmol) was transferred into a fresh solid phase 
syringe reactor for the subsequent couplings. 
The resin was deprotected prior to every coupling according to method B. 
Fmoc-NMePhe-OH (371 mg, 0.924 mmol) was coupled using method D and the same 
amounts of coupling reagents as in the prior couplings. 
A Kaiser test following the protocol of method F was performed after an overnight coupling 
and indicated an incomplete coupling. The double coupling was performed for 4 h using the 
same amounts of reagents and this time the Kaiser test remained negative.   
The coupling to the N-methylated amino acid required different coupling reagents. A 
solution of Fmoc-Ile-OH (406 mg, 1.15 mmol, 5.0 eq.), PyBrOP (525 mg, 1.13 mmol, 4.9 eq.) 
and DIEA (380 μL, 2.30 mmol, 10.0 eq.) in DMF was added to the resin, which was then 
shaken for 24 h. The washing steps were performed according to method D. A chloranil test 
performed following the protocol described in method H indicated a complete coupling.  
The coupling with Boc-Ser(OBzl)-OH (273 mg, 0.924 mmol) was performed overnight 
following the protocol of method D. Additionally, after the regular washing protocol the 
resin was washed with DCM (2x 1 min) and ether (3x 1 min) and dried under high vacuum for 
1 h.  
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Cleavage from the solid phase and deprotection 
 
The peptide was cleaved from the resin according to method I. The Boc and trityl protecting 
groups were removed using the protocol described in method J, the ether precipitation 
yielded 300 mg of crude peptide. 
 
Cyclization of the linear peptide and removal of the benzyl ether protection 
 
The crude peptide (150 mg, 147 μmol) was dissolved in DMF (140 mL) and cooled to 2 °C. 
DIEA (144 μL, 876 μmol, 6.0 eq.) and PyBOP (228 mg, 441 μmol, 3.0 eq.) were added and the 
mixture was stirred at 2 °C for 2 d. After this time the solvent was removed and the residue 
was co-evaporated twice with toluene. The remaining crude mixture was dissolved in a 
minimal amount of ethyl acetate (and optionally a few drops of MeOH to enhance 
solubility). This solution was added to cold ether, resulting in the precipitation of the crude 
peptide. The suspension was centrifuged and the pellet was washed once with cold ether 
and dried subsequently. 
The benzyl group was removed from 200 mg of crude cyclized peptide; the hydrogenation 
was performed following method K. 
The crude peptide was purified by preparative HPLC using a preparative C18 column and a 
linear gradient of acetonitrile in H2O, starting from 10% acetonitrile. After the purification 
the solvent was removed and the product was lyophilized. 
 
SAR-5: 
Yield: 9.19 mg (10 μmol, 4.4%) as white powder. 
1H NMR (600 MHz, DMSO-d6) δ 8.55 (d, J = 6.8 Hz, 1H), 8.46 (d, J = 7.7 Hz, 1H), 7.99 (m, 3H), 
7.63 (d, J = 8.6 Hz, 1H), 7.29-7.22 (m, 5H), 6.78 (bs, 1H), 5.94 (bs, 1H), 5.34 (t, J = 7.2 Hz, 1H), 
5.26 (bs, 2H), 4.63 (m, 1H), 4.45 (m, 1H), 4.34-4.29 (m, 2H), 4.26-4.17 (m, 2H), 4.15-4.09 (m, 
1H), 3.61 (dd, J = 10.6, 5.6 Hz, 1H), 3.54 (dd, J = 10.5, 6.7 Hz, 1H), 3.34 (dd, J = 14.0, 7.1 Hz, 
1H), 3.04-2.99 (m, 1H), 2.93 (t, J = 6.7 Hz, 2H), 2.75 (dd, J = 14.3, 7.7 Hz, 1H), 2.71 (s, 3H), 
2.17-2.05 (m, 8H), 1.76-1.72 (m, 1H), 1.54-1.44 (m, 8H), 1.10 (d, J = 6.5 Hz, 3H), 0.87-0.84 (m, 
3H), 0.81-0.79 (m, 6H), 0.71 (t, J = 7.4 Hz, 3H), 0.36 (d, J = 6.2 Hz, 3H). 
LC-MS: tR = 7.74 min (C18), m/z = 917.47(M+ + H+, 100%), 917.51 calcd for C43H69N10O12+. 
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6.4.4.5 Synthesis of SAR-6: (Ahp→Ser, Br,OMe-mTyr→Phe) 
 
Coupling of Fmoc-Thr-OH, Fmoc-Gln(Trt)-OH and butyric acid 
 
The dried resin (0.62 mmol/g, 260 mg, 0.16 mmol) was transferred into a solid-phase syringe 
reactor for the subsequent couplings. 
The resin was deprotected prior to every coupling according to method B. 
The amino acids were coupled using the protocol described in method D. 
A Kaiser test following the protocol in method G was performed after each coupling. 
The following amounts of reagents and coupling times were used for the respective 
couplings: 
HOBt: 86 mg, 0.64 mmol 
HBTU: 212 mg, 0.56 mmol 
DIEA: 40 μL, 0.48 mmol. 
 
Fmoc- Thr-OH*H2O: 230 mg, 0.64 mmol 
The coupling was performed for 2 h; the Kaiser test performed after the coupling remained 
negative, indicating a complete coupling. 
 
Fmoc-Gln(Trt)-OH: 391 mg, 0.64 mmol 
The coupling was performed for 2 h, after which the Kaiser test performed according to 
method G remained negative, thereby indicating a complete coupling. 
 
butyric acid: 58.7 μL, 0.64 mmol 
The coupling was performed as an overnight reaction, after which the Kaiser test remained 
negative, thereby indicating a complete coupling. 
 
Esterification with Fmoc-Val-OH 
 
The esterification of the threonine side chain was performed following method E, using the 
following amounts of reagents: 
Fmoc-Val-OH: 543 mg, 1.60 mmol  
diisopropyl carbodiimide: 250 μL, 1.60 mmol  
(4-dimethylamino)pyridine: 20 mg, 1.60 mmol.   
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After the regular washing protocol, the resin was washed additionally with DCM (3x 1 min) 
and ether (3x 1 min) and dried under high vacuum for 1 h. The dried resin was then divided 
into two equal portions and transferred into fresh solid-phase syringe reactors. 
 
Coupling of Fmoc-Phe-OH, Fmoc-Ile-OH and Boc-Ser(OBzl)-OH 
 
The resin (0.62 mmol/g, 0.08 mmol) was deprotected prior to every coupling according to 
method B. 
The following two couplings were carried out using the following amounts of reagents and 
according to method D: 
HOBt: 43 mg, 0.32 mmol 
HBTU: 106 mg, 0.28 mmol 
DIEA: 40 μL, 0.24 mmol. 
 
Fmoc-Phe-OH: 124 mg, 0.32 mmol 
A Kaiser test following the protocol of method G was performed after a 2 h coupling time 
and indicated an incomplete coupling; the subsequent double coupling was performed 
overnight using the same amounts of reagents. The Kaiser test performed after this second 
coupling remained negative.   
 
Fmoc-Ile-OH: 113 mg, 0.32 mmol. 
The coupling was performed as an overnight reaction, the Kaiser test performed after the 
reaction was positive. The required double coupling required was performed using the same 
amounts of reagents, the reaction time was 4 h, after which the Kaiser test remained 
negative.  
 
For the coupling with Boc-Ser(OBzl)-OH the amounts of reagents were adjusted regarding 
the previous incomplete couplings. The coupling was performed as described in method D 
for 5 h using the following amounts of reagents: 
HOBt: 65 mg, 0.48 mmol, 6.0 eq. 
HBTU: 159 mg, 0.42 mmol, 5.3 eq. 
DIEA: 60 μL, 0.36 mmol, 4.5 eq. 
Boc-Ser(OBzl)-OH: 142 mg, 0.48 mmol, 6.0 eq.  
Experimental 
219 
The Kaiser test performed as described in method G remained negative, thereby indicating a 
complete coupling. Additionally, after the regular washing protocol, the resin was 
furthermore washed with DCM (2x 1 min) and ether (3x 1 min) and dried under high vacuum 
for 1 h. 
 
Cleavage from the solid phase and deprotection 
 
The peptide was cleaved from the resin according to method I. The Boc and trityl protecting 
groups were removed using the protocol described in method J; the ether precipitation 
yielded 100 mg of crude peptide. 
 
Cyclization of the linear peptide and removal of the benzyl ether protection 
 
The crude peptide (100 mg, 98 μmol) was dissolved in pre-cooled DMF (90 mL) and cooled to 
10 °C. DIEA (96 μL, 584 μmol, 6.0 eq.) was added and the flask containing the reaction 
solution was placed on an orbital shaker and shaken gently. PyBOP (152 mg, 292 μmol, 3.0 
eq.) dissolved in pre-cooled DMF (10 mL) was added and the reaction mixture was gently 
shaken at 10 °C for 2 d. After this time the solvent was removed and the residue was co-
evaporated twice with toluene. The remaining crude mixture was dissolved in a minimal 
amount of ethyl acetate (and optionally a few drops of MeOH to enhance solubility). This 
solution was added to cold ether, resulting in the precipitation of the crude peptide. The 
suspension was centrifuged and the pellet was washed once with cold ether and dried 
subsequently, yielding 220 mg of crude product. 
The benzyl group was removed from the crude cyclized peptide and the hydrogenation was 
performed according to method K. 
The crude peptide was purified by preparative HPLC using a preparative C18 column and a 
linear gradient of acetonitrile in H2O, starting from 10% acetonitrile.  
After the purification the solvent was removed and the product was lyophilized. 
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SAR-6: 
Yield: 8.87 mg (9.8 μmol, 12.3%) as a white powder. 
1H NMR (600 MHz, DMSO-d6) δ 8.39 (d, J = 6.0 Hz, 1H), 8.26 (s, 1H), 8.04 (d, J = 7.8 Hz, 1H), 
7.85 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 7.3 Hz, 1H), 7.36 (d, J = 9.0 Hz, 1H), 7.26-7.24 (m, 3H), 
7.20-7.16 (m, 2H), 6.76 (bs, 2H), 5.96 (bs, 2H), 5.66 (d, J = 6.6 Hz, 1H), 5.11-5.09 (m, 1H), 
4.67-4.65 (m, 1H), 4.52-4.49 (m, 1H), 4.45-4.42 (m, 1H), 4.31-4.27 (m, 2H), 4.11-4.08 (m, 1H), 
3.97-3.93 (m, 1H), 3.69-3.64 (m, 2H), 3.26 (d, J = 3.8 Hz, 1H), 3.23 (d, J = 3.4 Hz, 1H), 2.96 (t, J 
= 6.7 Hz, 1H), 2.76-2.70 (m, 2H), 2.13-2.06 (m, 8H), 1.88-1.85 (m, 1H), 1.81-1.77 (m, 1H), 
1.70-1.66 (m, 1H), 1.53-1.47 (m, 3H), 1.43-1.37 (m, 3H), 1.17 (d, J = 6.5 Hz, 3H), 0.96 (d, J = 
6.6 Hz, 3H), 0.85-0.82 (m, 6H), 0.61 (t, J = 7.3 Hz, 3H), 0.53 (d, J = 6.9 Hz, 3H). 
LC-MS: tR = 7.47 min (C18), m/z = 903.47(M+ + H+, 100%), 903.49 calcd for C42H67N10O12+. 
 
6.4.4.6 Synthesis of SAR-8 and SAR-9 (8: Ahp→Ser, Br,OMe-mTyr→mPhe, L-Thr→D-allo-
Thr; 9: Ahp→Ser, Br,OMe-mTyr→mPhe, L-Thr→L-allo-Thr) 
 
Coupling of Fmoc-protected D- or L-allo-Thr-OH, Fmoc-Gln(Trt)-OH and butyric acid 
 
Two portions of dried resin (0.62 mmol/g, 130 mg, 0.08 mmol) were transferred into 
individual solid-phase syringe reactors for the subsequent couplings. 
The resins were deprotected prior to every coupling according to method B. 
The amino acids were coupled using the protocol described in method D. 
A Kaiser test following the protocol in method G was performed after each coupling. 
The following amounts of reagents and coupling times were used for the respective 
couplings: 
HOBt: 43 mg, 0.32 mmol 
HBTU: 106 mg, 0.28 mmol 
DIEA: 40 μL, 0.24 mmol. 
 
SAR-8: Fmoc-D-allo-Thr-OH: 109 mg, 0.32 mmol 
SAR-9: Fmoc-L-allo-Thr-OH: 109 mg, 0.32 mmol 
 
The coupling was performed for 2 h, the Kaiser test performed after the coupling remained 
negative for both reactions, indicating a complete coupling. 
The following couplings were performed for both peptide sequences in the same manner.  
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Fmoc-Gln(Trt)-OH: 195 mg, 0.32 mmol 
The coupling was performed for 2 h, after which the Kaiser test remained negative for both 
reactions, indicating a complete coupling. 
 
butyric acid: 29.4 μL, 0.32 mmol 
The coupling was performed as an overnight reaction, after which the Kaiser test remained 
negative for both reactions, indicating a complete coupling. 
 
Esterification with Fmoc-Val-OH 
 
The esterification of the threonine side chain was performed following method E, using the 
following amounts of reagents for both sequences: 
Fmoc-Val-OH: 272 mg, 0.80 mmol 
diisopropyl carbodiimide: 125 μL, 0.80 mmol  
(4-dimethylamino)pyridine: 10 mg, 0.08 mmol.  
 
Coupling of Fmoc-NMePhe, Fmoc-Ile-OH and Boc-Ser(OBzl)-OH 
 
The resins were deprotected prior to every coupling according to method B. 
Fmoc-NMePhe-OH (128 mg, 0.32 mmol, 4.0 eq.) was coupled using method D. 
A Kaiser test following the protocol in method G was performed after a 2 h coupling time 
and indicated an incomplete coupling. The required double coupling was performed 
overnight using the same amounts of reagents, resulting in a negative Kaiser test.   
The coupling to the N-methylated amino acid was performed using PyBrOP activation. To the 
resins was added a solution of Fmoc-Ile-OH (141 mg, 0.40 mmol, 5.0 eq.), PyBrOP (183 mg, 
0.39 mmol, 4.9 eq.) and DIEA (132 μL, 0.8 mmol, 10.0 eq.) in DMF and the resulting 
suspensions were shaken for 24 h. The washing steps were performed according to method 
D. A chloranil test performed following the protocol described in method H turned positive 
for both sequences. The coupling was repeated using the same amounts of reagents and a 
coupling time of 4 h after which the chloranil test remained negative.  
For the coupling with Boc-Ser(OBzl)-OH the amounts of reagents were adjusted in light of 
the previous incomplete couplings. The coupling was performed as described in method D 
for 5 h using the following amounts of reagents: 
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HOBt: 65 mg, 0.48 mmol, 6.0 eq. 
HBTU: 159 mg, 0.42 mmol, 5.3 eq. 
DIEA: 60 μL, 0.36 mmol, 4.5 eq. 
Boc-Ser(OBzl)-OH: 142 mg, 0.48 mmol, 6.0 eq. 
 
The Kaiser test performed as described in method G remained negative for both sequences, 
thereby indicating a complete coupling. Additionally, after the regular washing protocol the 
resins were washed with DCM (2x 1 min) and ether (3x 1 min) and dried. 
 
Cleavage from the solid phase and deprotection 
 
The peptides were cleaved from the resins according to method I. The Boc and trityl 
protections were removed using the protocol described in method J; the ether precipitation 
yielded 100 mg of crude peptide for each sequence. 
 
Cyclization of the linear peptide and removal of the benzyl ether protection 
 
The crude peptides (100 mg, 98 μmol) were dissolved in pre-cooled DMF (90 mL) and cooled 
to 10 °C. DIEA (96 μL, 584 μmol, 6.0 eq.) was added and the flasks containing the reaction 
solutions were placed on an orbital shaker and shaken gently. PyBOP (152 mg, 292 μmol, 3.0 
eq.) dissolved in pre-cooled DMF (10 mL) was added and the mixtures were shaken gently at 
10 °C for 2 d. After this time the solvent was removed and the residues were co-evaporated 
twice with toluene. The remaining crude mixtures were dissolved in a minimal amount of 
ethyl acetate (and optionally a few drops of MeOH to enhance solubility). The solutions were 
added to cold ether, resulting in the precipitation of the crude peptides. The suspensions 
were centrifuged and the pellet was washed once with cold ether, centrifuged and dried 
subsequently, yielding 220 mg of crude product for each sequence. 
The benzyl group was removed from the crude cyclized peptides; the corresponding 
hydrogenation was performed following method K. 
The crude peptides were purified by preparative HPLC using a preparative C18 column and a 
linear gradient of acetonitrile in H2O, starting from 10% acetonitrile. 
After the purification the solvent was removed and the products were lyophilized. 
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SAR-8: 
Yield: 2.70 mg (2.9 μmol, 3.7%) as a white powder. 
1H NMR (600 MHz, DMSO-d6) δ 8.61 (d, J = 9.7 Hz, 1H), 8.48 (d, J = 9.9 Hz, 1H), 8.21 (d, J = 6.4 
Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.92-7.87 (m, 2H), 7.26-7.23 (m, 2H), 7.21-7.18 (m, 3H), 6.78 
(bs, 1H), 5.88 (bs, 1H), 5.37 (bs, 2H), 5.29-5.23 (m, 1H), 5.02-5.00 (m, 1H), 4.50-4.47 (m, 1H), 
4.38-4.35 (m, 1H), 4.26-4.22 (m, 1H), 4.15-4.10 (m, 1H), 4.08-4.04 (m, 1H), 3.95-3.92 (m, 1H), 
3.60-3.56 (m, 1H), 3.52-3.49 (m, 1H), 3.11-3.08 (m, 1H), 3.02-3.01 (m, 1H), 2.93-2.88 (m, 3H), 
2.71 (s, 3H), 2.10 (m, 8H), 1.86-1.81 (m, 2H), 1.76-.73 (m, 3H), 1.50 (m, 4H), 1.15 (d, J = 6.6 
Hz, 3H), 0.88-0.84 (m, 6H), 0.75-0.72 (m, 3H), 0.67-0.64 (m, 3H), 0.52 (d, J = 6.7 Hz, 3H). 
LC-MS: tR = 7.77 min (C18), m/z = 917.47(M+ + H+, 100%), 917.51 calcd for C43H69N10O12+. 
SAR-9: 
Yield: 2.70 mg (5.2 μmol, 6.5%) as a white powder. 
1H NMR (600 MHz, DMSO-d6) δ 8.62 (d, J = 6.6 Hz, 1H), 8.59 (d, J = 9.4 Hz, 1H), 8.42 (d, J = 9.4 
Hz, 1H), 8.31 (d, J = 8.6 Hz, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.38 (s, 1H), 7.27-7.25 (m, 3H), 7.21-
7.18 (m, 2H), 6.88 (bs, 2H), 5.90 (bs, 1H), 5.09-5.06 (m, 1H), 4.52-4.48 (m, 1H), 4.42-4.39 (m, 
1H), 4.35-4.32 (m, 1H), 4.27-4.24 (m,  1H), 4.21-4.19 (m, 1H), 4.08-4.05 (m, 2H), 3.82 (bs, 2H), 
3.51 (dd, J = 10.8, 4.5 Hz, 1H), 3.43 (dd, J = 10.7, 6.8 Hz, 1H), 3.23 (dd, J = 14.0, 6.8 Hz, 1H), 
3.03- 3.00 (m, 1H), 2.91-2.89 (m, 2H), 2.83 (dd, J = 13.9, 7.7 Hz, 1H), 2.72 (s, 3H), 2.16-2.11 
(m, 4H), 2.10-2.06 (m, 4H), 1.82-1.77 (m, 2H), 1.74-1.72 (m, 2H), 1.69-1.66 (m, 1H), 1.52-1.47 
(m, 4H), 1.13 (d, J = 6.3 Hz, 3H), 0.90 (d, J = 6.6 Hz, 3H), 0.85-0.82 (m, 3H), 0.67-0.63 (m, 6H), 
0.48 (d, J = 6.6 Hz, 3H). 
LC-MS: tR = 7.79 min (C18), m/z = 917.47(M+ + H+, 100%), 917.51 calcd for C43H69N10O12+. 
 
6.4.4.7 Synthesis of SAR-10, SAR-11 and SAR-12: (Scyptolin A analogs; 10: Ahp→Ser, 11: 
Ahp→Thr, 12: Ahp→Val) 
 
Loading of Fmoc-Leu-OH onto 2-chlorotrityl resin 
 
2-chlorotrityl resin (1.6 mmol/g, 750 mg, 1.20 mmol) was transferred to a glass solid-phase 
reactor under an argon atmosphere. To the resin was added a solution of Fmoc-Leu-OH (509 
mg, 1.44 mmol, 1.2 eq.) and DIEA (794 μL, 4.80 mmol, 4.0 eq.) in DCM (15 mL) and the resin 
was shaken gently at RT overnight. The resin was capped using a solution of 
DCM/MeOH/DIEA (85%/10%/5 %) which was applied 3x for 5 min. The resin was washed 
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with DMF (2x 1 min), alternatingly with MeOH and DCM (3x 1 min), DMF (3x 1 min) and 
finally with DCM (3x 1 min). After drying under high vacuum, the loading of the resin was 
determined according to method F, revealing a loading of 0.83 mmol/g (52%). 
 
Coupling of Fmoc-Thr-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH and butyric acid 
 
The dried resin (0.83 mmol/g, 580 mg, 0.48 mmol) was transferred into a solid-phase syringe 
reactor for the subsequent couplings. 
The resin was deprotected prior to every coupling according to method B. 
The amino acids were coupled using the protocol described in method D. 
A Kaiser test following the protocol in method G was performed after each coupling. 
The following amounts of reagents and coupling times were used for the respective 
couplings: 
HOBt: 259 mg, 1.92 mmol 
HBTU: 638 mg, 1.68 mmol 
DIEA: 238 μL, 1.44 mmol. 
 
Fmoc-Thr-OH*H2O: 690 mg, 1.92 mmol 
The coupling was performed for 2 h; the Kaiser test performed after the coupling remained 
negative, indicating a complete coupling. 
 
Fmoc-Thr(tBu)-OH: 763 mg, 1.92 mmol 
The coupling was performed as an overnight reaction; the Kaiser test performed after this 
time remained negative. 
 
Fmoc-Ala-OH: 598 mg, 1.92 mmol 
The coupling was performed for 3 h; the Kaiser test performed after the coupling remained 
negative, indicating a complete coupling. 
 
butyric acid: 117.5 μL, 1.28 mmol 
The coupling was performed as an overnight reaction, after which the Kaiser test remained 
negative, thereby indicating a complete coupling. 
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Esterification with Fmoc-Val-OH 
 
The esterification of the threonine side chain was performed as described in method E, using 
the following amounts of reagents: 
Fmoc-Val-OH: 1.63 g, 4.80 mmol  
diisopropyl carbodiimide: 748 μL, 4.80 mmol  
(4-dimethylamino)pyridine: 54 mg, 0.48 mmol.  
 
Coupling of Alloc-(Cl, O(TBDMS))-mTyr-OH, Fmoc-Thr(tBu)-OH and Fmoc-Ser(tBu)-OH (SAR-
10), Fmoc-Thr(tBu)-OH (SAR-11) or Fmoc-Val-OH (SAR-12) 
 
The resin was deprotected prior to the coupling according to method B. 
The coupling with Alloc-(Br,OMe)-mTyr-OH was carried out using the following amounts of 
reagents and following method D: 
HOAt: 130 mg, 0.96 mmol, 2.0 eq. 
HATU: 800 mg, 2.40 mmol, 5.0 eq. 
DIEA: 793 μL, 4.80 mmol, 10 eq.  
Alloc-(Cl,O(TBDMS))-mTyr-OH: 532 mg, 1.24 mmol, 2.6 eq. 
 
The Kaiser test performed according to method G remained negative after a coupling time of 
24 h. The washing and subsequent removal of the Alloc group was carried out as described 
in method C. The following amounts of reagents were used for the deprotection reaction: 
morpholine: 1070 μL, 11.5 mmol 
Pd(PPh3)4: 139 mg, 0.12 mmol. 
 
The subsequent coupling with Fmoc-Thr(tBu)-OH was carried out using the following 
amounts of reagents: 
PyBrOP: 1.10 g, 2.35 mmol, 4.9 eq. 
DIEA: 793 μL, 4.80 mmol, 10 eq. 
Fmoc-Thr(tBu)-OH: 954 mg, 2.40 mmol, 5.0 eq. 
 
The coupling was performed for 24 h; the resin was washed as described in method D after 
the coupling. Additionally, the resin was washed with DCM (3x 1 min) and ether (3x 1 min) 
and dried under high vacuum for 1 h.  
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The chloranil test carried out according to the protocol described in method H after the 24 h 
coupling remained negative, thereby indicating a complete coupling. 
After drying the resin was divided into three equal portions (0.83 mmol/g, 0.16 mmol each) 
and transferred to fresh solid-phase syringe reactors. 
 
The coupling with Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH or Fmoc-Val-OH was performed as a 
double coupling as described in method D using the following amounts of reagents: 
HOBt: 87 mg, 0.64 mmol 
HBTU: 213 mg, 0.56 mmol 
DIEA: 79 μL, 0.48 mmol. 
SAR-10: Fmoc-Ser(tBu)-OH: 245 mg, 0.64 mmol 
SAR-11: Fmoc-Ser(tBu)-OH: 254 mg, 0.64 mmol 
SAR-11: Fmoc-Val-OH: 217 mg, 0.64 mmol 
 
After a reaction time of 2x 2 h, a Kaiser test performed according to method G remained 
negative for all of the three sequences. 
After removal of the Fmoc group according to method B the resins were additionally washed 
with DCM (2x 1 min) and ether (3x 1 min) and dried under high vacuum for 1 h. 
 
Cleavage from the solid phase  
 
The peptides were cleaved from the resins according to method I, the ether precipitation 
yielded 114 mg of crude peptide for SAR-10, 136 mg for SAR-11 and 182 mg for SAR-12. An 
LC-MS control indicated that the TBDMS protection had been cleaved, probably during the 
cleavage from solid phase. 
 
Cyclization of the linear peptide and removal of the tBu protecting groups 
 
The cyclization was carried out in the same manner for all three peptides, the respective 
amounts of reagents are given in brackets. 
The crude peptide (SAR-10: 114 mg, 100 μmol / SAR-11: 136 mg, 118 μmol / SAR-12: 182 
mg, 166 μmol) was dissolved in pre-cooled DMF (90 mL / 110 mL / 160 mL) and cooled to 
10 °C. DIEA (99 μL, 600 μmol, / 117 μL, 708 μmol / 165 μL, 996 μmol, 6.0 eq.) was added and 
the flasks containing the reaction solutions were placed on an orbital shaker and shaken 
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gently. PyBOP (156 mg, 300 μmol / 184 mg, 354 μmol / 259 mg, 498 μmol, 3.0 eq.) dissolved 
in pre-cooled DMF (10 mL) was added and the mixture was gently shaken at 10 °C for 2 d. 
After this time the solvent was removed and the residue was co-evaporated twice with 
toluene. The remaining crude mixture was dissolved in a minimal amount of ethyl acetate 
(and optionally a few drops of MeOH to enhance solubility). This solution was added to cold 
ether, resulting in the precipitation of the crude peptide. The suspension was centrifuged 
and the pellet was washed once with cold ether and dried subsequently. 
The tBu protecting groups were removed as described in method J. 
The crude peptides were purified by preparative HPLC using a preparative C18 column and a 
linear gradient of acetonitrile in H2O, starting from 10% acetonitrile. 
After the purification the solvent was removed and the products were lyophilized. 
 
SAR-10: 
Yield: 2.41 mg (2.5 μmol, 1.6%) as a white powder. 
1H NMR (700 MHz, DMSO-d6) δ 10.01 (s, 1H), 8.45 (d, J = 8.1 Hz, 1H), 8.04-8.00 (m, 2H), 7.80 
(d, J = 4.9 Hz, 1H), 7.72-7.70 (m, 1H), 7.69-7.66 (m, 1H), 7.22 (d, J = 2.0 Hz, 1H), 7.16 (s, 1H), 
7.09 (s, 1H), 7.02 (s, 1H), 5.30-5.26 (m, 1H), 5.21-5.17 (m, 1H), 4.70-4.66 (m, 1H), 4.64-4.60 
(m, 1H), 4.53-4.50 (m, 1H), 4.39-4.35 (m, 3H), 4.31-4.28 (m, 2H), 4.22-4.20 (m, 1H), 4.07 (bs, 
1H), 4.01 (bs, 1H), 3.97-3.94 (m, 1H), 3.83-3.80 (m, 1H), 3.79-3.77 (m, 1H), 3.78 (bs, 1H), 
3.12-3.11 (m, 1H), 2.70 (s, 3H), 2.41-2.39 (m, 1H), 2.09 (t, J = 7.3 Hz, 2H), 2.02-1.97 (m, 1H), 
1.85-1.83 (m, 2H), 1.52-1.49 (m, 2H), 1.07 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.2 Hz, 3H), 0.87-
0.84 (m, 15H), 0.82 (d, J = 7.2 Hz, 3H), 0.75 (d, J = 6.5 Hz, 3H). 
LC-MS: tR = 7.12 min (C18), m/z = 955.47(M+ + H+, 100%), 945.45 calcd for C43H68ClN8O14+. 
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SAR-11: 
Yield: 2.23 mg (2.3 μmol, 1.4%) as a white powder. 
1H NMR (700 MHz, DMSO-d6) δ 10.00 (s, 1H), 8.49 (d, J = 7.4 Hz, 1H), 8.42 (d, J = 6.4 Hz, 1H), 
8.01 (d, J = 7.5 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.25 (d, J = 1.8 Hz, 1H), 
7.16 (s, 1H), 7.09 (s, 1H), 7.02 (s, 1H), 6.99 (d, J = 8.3 Hz, 1H), 5.- 5.22 (m, 1H), 5.21-5.19 (m, 
1H), 4.92-4.90 (m, 1H), 4.69-4.66 (m, 1H), 4.62-4.59 (m, 1H), 4.55-4.52 (m, 1H), 4.39-4.35 (m, 
2H), 4.34-4.31 (m, 1H), 4.29-4.26 (m, 1H), 4.23-4.20 (m, 1H), 4.18-4.16 (m, 1H), 4.10 (bs, 1H), 
3.95 (bs, 1H), 3.86 (bs, 1H), 3.11-3.09 (m, 1H), 3.03-3.00 (m, 1H), 2.70 (s, 3H), 2.41-2.39 (m, 
1H), 2.08 (t, J = 7.2 Hz, 2H), 1.86-1.85 (m, 2H), 1.74-1.72 (m, 1H), 1.53-1.48 (m, 2H), 1.20 (d, J 
= 7.1 Hz, 3H), 1.01 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 6.3 Hz, 3H), 0.87-0.83 (m, 15H), 0.79 (d, J = 
6.6 Hz, 3H), 0.75 (d, J = 6.3 Hz, 3H). 
LC-MS: tR = 7.33 min (C18), m/z = 969.47(M+ + H+, 100%), 969.47 calcd for C44H70ClN8O14+. 
 
SAR-12: 
Yield: 7.04 mg (7.3 μmol, 4.5%) as a white powder. 
1H NMR (700 MHz, DMSO) δ 9.99 (s, 1H), 8.66 (s, 1H), 8.06-8.01 (m, 2H), 7.88 (d, J = 8.6 Hz, 
1H), 7.76 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.26 (d, J = 1.6 Hz, 1H), 7.22 (s, 1H), 7.14 
(s, 1H), 7.07 (s, 1H), 5.18-5.14 (m, 1H), 5.10-5.05 (m, 1H), 4.63-4.59 (m, 1H), 4.59-4.54 (m, 
1H), 4.40-4.35 (m, 2H), 4.33-4.30 (m, 1H), 4.27-4.25 (m, 1H), 4.23-4.12 (m, 3H), 4.02 b(s, 1H), 
3.93 (bs, 1H), 3.18-3.14 (m, 1H), 3.13-3.09 (m, 1H), 3.06-3.02 (m, 1H), 2.68 (s, 3H), 2.57-2.54 
(m, 1H), 2.12-2.07 (m, 3H), 1.88-1.83 (m, 2H), 1.53-1.48 (m, 2H), 1.14 (d, J = 6.5 Hz, 3H), 1.08 
(d, J = 6.0 Hz, 3H), 1.01 (d, J = 6.2 Hz, 3H), 0.93 (d, J = 6.3 Hz, 3H), 0.88-0.84 (m, 6H), 0.81 (d, J 
= 6.8 Hz, 6H), 0.79 (d, J = 6.6 Hz, 3H), 0.76 (d, J = 6.1 Hz, 3H), 0.71 (d, J = 6.8 Hz, 3H). 
LC-MS: tR = 7.04 min (C18), m/z = 967.40(M+ + H+, 100%), 967.49 calcd for C45H72ClN8O13+. 
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6.5 Synthesis of symplostatin 4 and analogs 
6.5.1 Synthesis of the building blocks for Symplostatin 4 and its derivatives 
 
(S,E)-Methyl-4-((tert-butoxycarbonyl)amino)pent-2-enoate (37) 
 
N,O-Dimethylhydroxylamine hydrochloride (1.07 g, 11.0 mmol, 1.1 eq.) was suspended in 
DCM (50 mL). Triethylamine (1.53 mL, 11.0 mmol, 1.1 eq.) and Boc-Ala-OH (1.89 g, 10.0 
mmol) were added and the resulting solution was stirred until it became clear. Finally, 
dicyclohexylcarbodiimide (2.27 g, 11.0 mmol, 1.1 eq.) was added and the reaction mixture 
was stirred for 1 h. After this period the reaction mixture was filtered through a pad of 
Celite® and the solvent was removed. 
The resulting white solid was suspended in ether (50 mL) and cooled in an ice bath. LiAlH4 
(417 mg, 11.0 mmol, 1.1. eq.) was added in one portion and the resulting mixture was stirred 
for 20 min at 0 °C. The reaction was quenched by addition of 1 M KHSO4 solution, the 
resulting mixture was filtered through a pad of Celite® and the solvent was removed. 
The resulting colorless oil was dissolved in DCM (100 mL) and methyl-2-
(triphenylphosphoranylidene)acetate (5.02 g, 15.0 mmol, 1.5 eq.) was added. The reaction 
mixture was stirred at RT overnight. 
The solvent was removed and the crude product was purified by flash column 
chromatography (33 % ethyl acetate in cyclohexane) yielding (S,E)-methyl-4-((tert-
butoxycarbonyl)amino)pent-2-enoate (37). 
 
Yield: 1.35 g (5.88 mmol, 59 %) as a pale yellow oil.  
TLC (33 % ethyl acetate in cyclohexane): Rf = 0.47.  
1H NMR (500 MHz, CDCl3): δ 6.81 (dd, J = 15.70, 4.90 Hz, 1H), 5.83 (dd, J = 15.70, 1.70. Hz, 
1H), 4.68 (m, 1H), 4.32(bs, 1H), 3.66(s, 3H), 1.37(s, 9H), 1.20(d, J = 7.00 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 166.93, 155.07, 149.90, 119.80, 79.79, 51.68, 47.17, 28.47, 
20.35.  
LC-MS: tR = 9.11 min (C18), m/z = 229 (M+, 15 %). 
HRMS (ESI): m/z calcd for C11H20NO4+ [M + H]+ 230.1387, found 230.1388. 
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(S)-Methyl-2-((S,E)-4-((tert-butoxycarbonyl)amino)pent-2-enamido)propanoate (38) 
 
(S,E)-Methyl-4-((tert-butoxycarbonyl)amino)pent-2-enoate (37, 700 mg, 3.05 mmol) was 
dissolved in a mixture of THF (5 mL) and MeOH (3 mL), then lithium hydroxide (146 mg, 6.11 
mmol, 2.0 eq.) in water (2 mL) was added and the reaction mixture was stirred for 5 h at RT. 
After this time the reaction mixture was acidified to pH = 4 by addition of 1 N HCl and then 
diluted by the addition of brine (25 mL) and DCM (25 mL). The phases were separated and 
the aqueous phase was extracted once with DCM (25 mL). The organic phases were unified 
and the solvent was evaporated to dryness. 
The remaining white solid was suspended in acetonitrile (25 mL) and alanine methylester 
hydrochloride (482 mg, 3.66 mmol, 1.2 eq.) was added. The suspension was cooled in an ice 
bath and DIEA (1.60 mL, 9.76 mmol, 3.2 eq.), HOBt (412 mg, 3.05 mmol, 1.0 eq.) and HBTU 
(1.16 g, 3.05 mmol, 1.0 eq.) were added consecutively. The reaction was allowed to warm to 
RT and stirred overnight. 
The solvent was removed and the residue was taken up in ethyl acetate (100 mL), washed 
with 0.5 M aq. KHSO4 solution (2x 20 mL), saturated aq. NaHCO3 solution (2x 20 mL) and 
brine (2x 20 mL), dried over Na2SO4 and evaporated to dryness. 
The crude product was purified by flash column chromatography (66 % ethyl acetate in 
cyclohexane, to afford pure (S)-methyl-2-((S,E)-4-((tert-butoxycarbonyl)amino)pent-2-
enamido)propanoate (38). 
 
Yield: 424 mg (1.41 mmol, 46 %) as white solid. 
TLC (50 % ethyl acetate in cyclohexane): Rf = 0.22.  
1H NMR (400 MHz, MeOD): δ 6.70 (dd, J = 15.50, 5.40 Hz, 1H), 6.04 (dd, J = 15.50, 1.40 Hz, 
1H), 4.45 (q, J = 7.30 Hz, 1H), 4.10 (q, J = 7.10 Hz, 1H), 3.71 (s, 3H), 1.44 (s, 3H), 1.39 (d, J =  
7.30 Hz, 3H), 1.24 (d, J = 7.00 Hz, 3H). 
13C NMR (101 MHz, MeOD): δ 174.82, 168.10, 157.70, 147.41, 122.90, 80.39, 61.69, 52.89, 
28.88, 21.01, 20.48, 17.51, 14.59.  
LC-MS: tR = 8.05 min (C18), m/z 600 (2M+, 100 %), ,323 (M+ +Na+, 50) 300 (M+, 60). 
HRMS (ESI): m/z calcd for C14H25N2O5+ 301.1758, found 301.1758. 
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tert-Butyl((S,E)-5-((S)-3-methoxy-2-methyl-5-oxo-2,5-dihydro-1H-pyrrol-1-yl)-5-oxopent-3-
en-2-yl)carbamate (39) 
 
(S)-Methyl-2-((S,E)-4-((tert-butoxycarbonyl)amino)pent-2-enamido)propanoate (38, 250 mg, 
0.83 mmol) was dissolved in a mixture of THF (1.7 mL) and MeOH (1 mL) and lithium 
hydroxide (40 mg, 1.66 mmol, 2.0 eq.) in water (0.65 mL) was added. The resulting reaction 
mixture was stirred for 5 h at RT. The reaction mixture was acidified to pH = 4 by the 
addition of 1 N HCl and then diluted by the addition of brine (10 mL) and DCM (10 mL). The 
phases were allowed to separate and the aqueous phase was extracted once with DCM 
(10 mL). The organic phases were unified and the solvent was evaporated to dryness. 
The resulting white solid was dissolved with 4-(dimethyl)aminopyridine (254 mg, 2.08 mmol, 
2.5 eq.) and 2,2-dimethyl-1,3-dioxane-4,6-dione (132 mg, 0.91 mmol, 1.1 eq.) in DCM (10 
mL) and the mixture was cooled to -10 °C. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(191 mg, 1.00 mmol, 1.2 eq.) dissolved in DCM (5 mL) was added to the mixture over a 
period of 30 min and after the complete addition the reaction was allowed to warm to RT 
and stirred overnight.  
The solvent was removed and the residue was taken up in ethyl acetate. The organic phase 
was washed with 0.5 M KHSO4 solution (2x 10 mL), dried over Na2SO4 and evaporated to 
dryness. 
The remaining bright yellow oil was dissolved in acetonitrile (20 mL) and heated to reflux for 
1 h. The solvent was evaporated and the resulting yellow oil was dissolved in THF (10 mL). 
Triphenylphoshine (262 mg, 1.00 mmol, 1.2 eq.) and MeOH (40.5 μL, 1.00 mmol, 1.2 eq.) 
were added to this solution. Diethylazodicarboxylate (40 % in toluene, 458 μL, 1.00 mmol, 
1.2 eq.) was added dropwise to the mixture, which remained light orange after complete 
addition. The reaction was stirred at RT overnight. The solvent was removed and the crude 
mixture was purified by flash column chromatography (2 % MeOH in DCM) to afford tert-
butyl((S,E)-5-((S)-3-methoxy-2-methyl-5-oxo-2,5-dihydro-1H-pyrrol-1-yl)-5-oxopent-3-en-2-
yl)carbamate (39). 
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Yield: 240 mg (0.74 mmol, 90 %) as a light yellow solid.  
TLC (2 % MeOH in DCM): Rf = 0.37.  
1H NMR (400 MHz, CDCl3): δ 7.34 (dd, J = 15.50, 6.10 Hz, 1H), 6.94 (dd, J = 14.80, 5.10 Hz, 
1H), 4.97 (s, 1H), 4.69 (m, 1H), 4.39 (m, 1H) 3.80 (s, 3H) , 1.42 (s, 3H) 1.38 (s, 9H) 1.23 (d, J = 
7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 180.78, 169.87, 164.45, 155.14, 149.65, 121.87, 93.09, 79.63, 
58.85, 55.79, 47.45, 28.48, 20.50, 17.20.  
LC-MS: tR = 9.41 (C18), m/z = 671 (2M+ +Na+, 100 %), 548 (2M+ -Boc, 85), 325 (M+ +H+, 75). 
HRMS (ESI): m/z calcd for C16H25N2O5+ 325.1758, found 325.1760. 
 
tert-Butyl((S)-1-(((S,E)-5-((S)-3-methoxy-2-methyl-5-oxo-2,5-dihydro-1H-pyrrol-1-yl)-5-
oxopent-3-en-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (40) 
 
tert-Butyl((S,E)-5-((S)-3-methoxy-2-methyl-5-oxo-2,5-dihydro-1H-pyrrol-1-yl)-5-oxopent-3-
en-2-yl)carbamate (39, 390 mg, 1.30 mmol) was dissolved in DCM (3 mL) and trifluoroacetic 
acid (3 mL) was added. The reaction mixture was stirred for 3 h at RT. The solvent was 
evaporated and the remaining oil was co-evaporated twice with toluene to remove residual 
trifluoroacetic acid.  
The resulting white solid was suspended in acetonitrile (10 mL) and Boc-Leu-OH (130 mg, 
0.61 mmol, 1.1 eq.) was added. The suspension was cooled in an ice bath and DIEA (291 μL, 
1.76 mmol, 3.2 eq.), HOBt (82 mg, 0.61 mmol, 1.1 eq.) and HBTU (332 mg, 0.61 mmol, 
1.1 eq.) were added successively. The reaction was allowed to warm to RT and then stirred 
overnight. 
The solvent was removed and the residue was taken up in ethyl acetate (40 mL), washed 
with 0.5 M KHSO4 solution (2x 10 mL), saturated aq. NaHCO3 solution (2x 10 mL) and brine 
(2x 10 mL). After drying over Na2SO4 the solvent was evaporated to dryness. 
The crude product was purified by flash column chromatography (66 % ethyl acetate in 
cyclohexane) affording tert-butyl((S)-1-(((S,E)-5-((S)-3-methoxy-2-methyl-5-oxo-2,5-dihydro-
1H-pyrrol-1-yl)-5-oxopent-3-en-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (40). 
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Yield: 209 mg (0.47 mmol, 85 %) as a white solid.  
TLC (66 % MeOH in DCM): Rf = 0.50. 
1H NMR (400 MHz, MeOD): δ 7.38 (dd, J = 15.6, 2.1 Hz, 1H), 6.96 (dd, J = 15.5, 5.2 Hz, 1H), 
5.20 (s, 1H), 4.63 (m, 2H), 4.14 (m, 1H), 3.92 (s, 3H), 1.74-1.67 (m, 2H), 1.64-1.40 (m, 2H), 
1.44 (s, 9H), 1.31 (d, J = 6.9 Hz, 3H), 1.23 (m, 3H), 0.98-0.93 (m, 6H). 
13C NMR (101 MHz, MeOD): δ 182.91, 175.08, 171.62, 165.75, 157.77, 150.05, 123.19, 93.77, 
80.46, 68.16, 61.57, 59.95, 56.98, 54.46, 28.86, 26.03, 23.68, 17.52, 14.63.  
LC-MS: tR = 9.74 min (C18), m/z = 438 (M+ +H+, 100 %), 338 (M+ -Boc, 40). 
HRMS (ESI): m/z calcd for C22H36N3O6+ 438.2599, found 438.2599. 
 
(6S,9S,14S,E)-Methyl-6-isobutyl-2,2,9,14-tetramethyl-4,7,12-trioxo-3-oxa-5,8,13-
triazapentadec-10-en-15-oate (41) 
 
(S)-Methyl-2-((S,E)-4-((tert-butoxycarbonyl)amino)pent-2-enamido)propanoate (38, 390 mg, 
1.30 mmol) was dissolved in DCM (5 mL), trifluoroacetic acid (5 mL) was added and the 
reaction mixture was stirred at RT for 2 h. The solvent was evaporated and the remaining oil 
was co-evaporated twice with toluene to remove residual trifluoroacetic acid.  
The resulting white foamy solid was suspended in acetonitrile (10 mL) and Boc-Leu-OH 
(292 mg, 1.37 mmol, 1.1 eq.) was added. The suspension was cooled in an ice bath and DIEA 
(716 μL, 4.33 mmol, 3.3 eq.), HOBt (185 mg, 1.37 mmol, 1.1 eq.) and HBTU (520 mg, 
1.37 mmol, 1.1 eq.) were added. The reaction was allowed to warm to RT and stirred 
overnight. 
After this time the solvent was removed and the residue was taken up in ethyl acetate (100 
mL), washed with 0.5 M KHSO4 solution (2x 20 mL), saturated NaHCO3 solution (2x 20 mL) 
and brine (2x 20 mL). After drying over Na2SO4 the solvent was removed. 
The crude product was purified by flash column chromatography (66 % ethyl acetate in 
cyclohexane, affording (6S,9S,14S,E)-methyl-6-isobutyl-2,2,9,14-tetramethyl-4,7,12-trioxo-3-
oxa-5,8,13-triazapentadec-10-en-15-oate (41). 
 
Yield: 529 mg (1.28 mmol, 99 %) as a white solid. 
TLC (66 % MeOH in DCM): Rf = 0.27.  
1H NMR (400 MHz, MeOD): δ 6.69 (dd, J = 15.4, 5.7 Hz, 1H), 6.06 (t, J = 15.7 Hz, 1H), 4.59 (m, 
1H), 4.47 (m, 1H), 4.10 (m, 1H), 3.71 (s, 3H), 1.69 (m, 1H), 1.52 (m, 2H), 1.44 (s, 9H), 1.39 (d, J 
= 7.3 Hz, 3H), 1.29 (d, J = 6.5 Hz, 3H), 0.94 (m, 6H).  
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13C NMR (101 MHz, MeOD): δ 175.19, 174.67, 167.82, 157.96, 146.18, 123.64, 80.67, 54.73, 
52.88, 47.27, 42.49, 38.78, 28.87, 26.05, 23.68, 22.00, 17.60.  
LC-MS: tR = 9.14 min (C18), m/z = 436 (M+ +Na+, 40 %), 314 (M+ -Boc, 40 %). 
HRMS (ESI): m/z calcd for C20H36N3O6+ 414.2599, found 414.2602. 
 
(2S,3S)-(S)-1-Methoxy-4-methyl-1-oxopentan-2-yl-2-((tert-butoxycarbonyl)-
(methyl)amino)-3-methylpentanoate (42) 
 
(S)-(-)2-Hydroxyisocaproic acid (500 mg, 3.78 mmol) was dissolved in MeOH (20 mL) and 
cooled in an ice bath. Thionyl chloride (685 μL, 9.45 mmol, 2.5 eq.) was slowly added from a 
2 M solution in DCM (4.8 mL). The reaction mixture was allowed to warm to RT and stirred 
overnight. The solvent was removed carefully due to the high volatility of the intermediate 
methyl ester. 
The remaining light yellow oil was dissolved in DCM (20 mL) and Boc-NMeIle-OH (927 mg, 
3.78 mmol, 1.0 eq.) and 4-(dimethyl)aminopyridine (46 mg, 0.38 mmol, 0.1 eq.) were added. 
The mixture was cooled in an ice bath and stirred for 5 min. Dicyclohexylcarbodiimide 
(840 mg, 4.07 mmol, 1.1 eq.) was added in one portion and the reaction mixture was 
allowed to warm to RT and stirred overnight. 
The urea side product was filtered off and the solvent was removed. The residual solid was 
taken up in DCM (50 mL) and filtered once again. The organic phase was washed with 0.5 M 
HCl (2x 25 mL) and saturated aq. NaHCO3 solution (2x 25 mL) and dried over Na2SO4. 
The solvent was evaporated to dryness and the crude mixture was purified by flash column 
chromatography (12.5 % ethyl acetate in cyclohexane) to yield (2S,3S)-(S)-1-methoxy-4-
methyl-1-oxopentan-2-yl-2-((tert-butoxycarbonyl)-(methyl)amino)-3-methylpentanoate (42). 
 
Yield: 771 mg (2.06 mmol, 55%) as a colorless oil.  
TLC (12.5% ethyl acetate in cyclohexane): Rf = 0.39.  
1H NMR (500 MHz, CDCl3): δ 4.48 (m, 1H), 4.17 (m, 1H), 3.63 (s, 3H), 2.75 (s, 3H), 1.91 (m, 
1H), 1.39 (s 14H), 1.02 (m, 3H), 0.84 (m, 6H).  
13C NMR (126 MHz, CDCl3): δ 173.01, 170.84, 155.70, 79.86, 71.74, 58.04, 52.04, 39.99, 
38.24, 28.47, 25.21, 23.10, 21.78, 15.63, 11.71.  
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(2S,3S)-(S)-1-Methoxy-4-methyl-1-oxopentan-2-yl2-(dimethylamino)-3-methyl-pentanoate 
(43) 
 
(2S,3S)-(S)-1-Methoxy-4-methyl-1-oxopentan-2-yl-2-((tert-butoxycarbonyl)(methyl)-amino)-
3-methylpentanoate (42, 400 mg, 1.07 mmol) was dissolved in DCM (5 mL) and 
trifluoroacetic acid was added. The reaction mixture was stirred for 2 h at RT. The solvent 
was evaporated and the remaining oil was co-evaporated twice with toluene to remove 
residual trifluoroacetic acid. 
The resulting pale yellow oil was dissolved in DMF (5 mL) and methyl iodide (79 μL, 1.26 
mmol, 1.2 eq.) and DIEA (531 μL, 3.21 mmol, 3.0 eq.) were added. The reaction mixture was 
stirred for 2 h, whereupon a TLC indicated a completed reaction. 
The reaction mixture was quenched with saturated aq. NH4Cl solution (5 mL) and extracted 
with ether (3x 30 mL). The unified organic phases were washed with brine (2x 30 mL) and 
dried over Na2SO4. Removal of the solvent afforded (2S,3S)-(S)-1-methoxy-4-methyl-1-
oxopentan-2-yl2-(dimethylamino)-3-methyl-pentanoate (43) without further purification. 
 
Yield: 118 mg (0.41 mmol, 38%) as a colorless oil.  
1H NMR (400 MHz, CDCl3): δ 5.15 (dd, J = 9.1, 4.4 Hz, 1H), 4.52 (s, 1H), 3.73 (s, 3H), 3.61 (s, 
6H), 2.35 (dd, J = 14.0, 7.0 Hz, 1H), 1.79 (m, 3H), 1.65 (m, 2H), 1.08 (m, 3H), 0.91 (dd, J = 14.9, 
6.2 Hz, 9H). 
13C NMR (101 MHz, CDCl3): δ 169.96, 166.08, 77.75, 72.99, 53.12, 39.70, 33.51, 29.17, 24.64, 
23.05, 21.71, 16.65, 12.21.  
LC-MS: tR = 7.93 min, m/z = 288 (M+ + H+, 10 %). 
HRMS (ESI): m/z calcd for C15H30NO4+ 288.2169, found 288.2170. 
 
(2S,3S)-(S)-1-Methoxy-4-methyl-1-oxopentan-2-yl-3-methyl-2-(methyl(prop-2-yn-1-
yl)amino)pentanoate (44) 
 
(2S,3S)-(S)-1-Methoxy-4-methyl-1-oxopentan-2-yl-2-((tert-butoxycarbonyl)(methyl)-amino)-
3-methylpentanoate (42, 357 mg, 0.95 mmol) was dissolved in DCM (5 mL) and 
trifluoroacetic acid was added. The reaction mixture was stirred for 2 h at RT. The solvent 
was evaporated and the remaining oil was co-evaporated twice with toluene to remove 
residual trifluoroacetic acid. 
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The resulting pale yellow oil was dissolved in acetonitrile (10 mL) and propargyl bromide 
(80%wt in toluene, 125 μL, 1.12 mmol, 1.2 eq.) and DIEA (471 μL, 2.85 mmol, 3.0 eq.) were 
added. The reaction mixture was heated to 80 °C and stirred at this temperature overnight. 
The reaction mixture was allowed to cool to RT, quenched with saturated aq. NH4Cl solution 
(5 mL) and extracted with ether (3x 30 mL). The unified organic phases were washed with 
brine (2x 30 mL) and dried over Na2SO4. After evaporation to dryness, the crude mixture was 
purified by flash column chromatography (50 % ethyl acetate in cyclohexane) to afford 
(2S,3S)-(S)-1-methoxy-4-methyl-1-oxopentan-2-yl-3-methyl-2-(methyl(prop-2-yn-1-
yl)amino)pentanoate (44). 
 
Yield: 186 mg (0.60 mmol, 63%) as a light yellow oil.  
1H NMR (400 MHz, CDCl3): δ 4.97 (dd, J = 9.8, 4.0 Hz, 1H), 3.69 (s, 3H), 3.34 (ddd, J = 54.4, 
16.9, 2.0 Hz, 2H), 3.12 (d, J = 9.8 Hz, 1H), 2.37 (s, 3H), 2.18 (t, J = 2.3 Hz, 1H), 1.78 (m, 3H), 
1.61 (m, 2H), 1.17 (m, 1H), 0.89 (m, 12H). 
13C NMR (101 MHz, CDCl3): δ 171.35, 171.26, 80.16, 72.52, 71.04, 70.09, 52.31, 43.46, 40.00, 
38.23, 33.65, 25.30, 24.68, 23.28, 21.48, 15.46, 10.65. 
LC-MS: tR =12.49 min m/z = 312 (M+ + H+, 100 %). 
 
6.5.2 Synthesis of symplostatin 4 and derivatives from the C-terminal and N-terminal 
peptides 
 
Synthesis of symplostatin 4 (Sym4)  
 
(2S,3S)-(S)-1-Methoxy-4-methyl-1-oxopentan-2-yl2-(dimethylamino)-3-methyl-pentanoate 
(43, 118 mg, 0.41 mmol) was dissolved in a mixture of THF (1.6 mL) and MeOH (1 mL) and 
lithium hydroxide (20 mg, 0.82 mmol, 2.0 eq.) in water (0.65 mL) was added. The resulting 
reaction mixture was stirred for 5 h at RT. The reaction mixture was acidified by addition of 
1 M aq. HCl to pH 4 and diluted by the addition of DCM (5 mL) and brine (5 mL). The phases 
were separated and the water phase was extracted with DCM (2x 5 mL). The organic phases 
were combined and evaporation to dryness yielded the free acid, which was used directly for 
the following coupling. 
To obtain the free amine, tert-butyl((S)-1-(((S,E)-5-((S)-3-methoxy-2-methyl-5-oxo-2,5-
dihydro-1H-pyrrol-1-yl)-5-oxopent-3-en-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate 
(40, 170 mg, 0.39 mmol, 0.95 eq.) was dissolved in DCM (5 mL). trifluoroacetic acid (5 mL) 
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was added and the reaction mixture was stirred at RT for 2 h. The solvent was evaporated 
and the resulting oil was co-evaporated twice with toluene to remove residual trifluoroacetic 
acid. 
For the peptide coupling the free acid and the free amine were dissolved separately in 
acetonitrile (6 mL) and cooled in an ice bath. The solution containing the amine was added 
to the acid solution and HOBt (55 mg, 0.41 mmol, 1.0 eq.), HBTU (156 mg, 0.41 mmol, 1.0 
eq.) and DIEA (214 μL, 1.30 mmol, 3.2 eq.) were added successively. The reaction was 
allowed to warm to RT and followed by LC-MS analysis. A sample taken after 5 h indicated 
no further conversion, so the reaction was worked up. 
The solvent was removed and the residue was taken up in ethyl acetate (100 mL). The 
organic phase was washed with 0.5 M aq. KHSO4 solution (2x 10 mL), saturated aq. NaHCO3 
solution (2x 10 mL) and brine (2x 10 mL) and dried over Na2SO4. After removal of the solvent 
the crude product was purified by flash column chromatography (50 % ethyl acetate in 
cyclohexane) yielding symplostatin 4 (Sym4). 
For a further purification, 96 mg of the pre-purified Sym4 (210 mg in total, 91 %) were 
purified by preparative HPLC (0 min / 10% B → 3 min / 10% B → 30 min / 45% B → 32 min / 
50% B → 33 min / 100% B → 43 min / 100% B) to afford symplostatin 4 (Sym4).  
 
Yield: 48.8 mg (82.3 μmol, 20 %, 51 % in total) as a white powder.  
TLC (50% ethyl acetate in cyclohexane): Rf = 0.24. 
1H NMR (600 MHz, CD3CN): δ 7.34-7.29 (m, 1H), 6.89-6.85 (m, 1H), 5.09 (s, 1H), 5.08 (m, 1H), 
4.59-4.55 (m, 2H), 4.38-4.31 (m, 1H), 3.86 (s, 1H), 3.13-3.08 (s, 1H) 2.91 (s, 6H), 2.18-2.13 (m, 
1H), 1.82-1.73 (m, 2H), 1.70-1.64 (m, 1H), 1.63-1.53 (m, 4H), 1.42 (d,  J = 6.6 Hz, 3H), 1.40-
1.36 (m, 1H), 1.24 (d, J = 7.0 Hz, 3H), 1.00-0.88 (m, 18H). 
13C NMR (151 MHz, CD3CN): δ 182.25, 172.28, 171.00, 170.19, 166.96, 164.99, 149.49, 
123.06, 93.79, 75.83, 72.54, 60.03, 56.57, 52.99, 47.09, 42.05, 41.83, 41.22, 34.41, 27.32, 
25.54, 25.29, 23.51, 23.34, 21.97, 21.83, 20.13, 17.44, 14.58, 11.82.  
LC-MS: tR = 7.39 min (C18), m/z = 616 (M+ +Na+, 30 %) 593 (M+ +H+, 100). 
HRMS (ESI): m/z calcd for C31H53N4O7+ 593.3909, found 592.3895. 
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Synthesis of a symplostatin 4 analog lacking the mmp unit (Sym4mmp→Ala)   
 
(2S,3S)-(S)-1-Methoxy-4-methyl-1-oxopentan-2-yl2-(dimethylamino)-3-methyl-pentanoate 
(43, 49 mg, 0.17 mmol) was dissolved in a mixture of THF (1.6 mL) and MeOH (1 mL), then 
lithium hydroxide (8 mg, 0.34 mmol, 2.0 eq.) dissolved in water (0.65 mL) was added and the 
reaction mixture was stirred for 5 h at RT. After this time the reaction mixture was acidified 
by addition of 1 M HCl to pH 4 and diluted with DCM (10 mL) and brine (10 mL). The phases 
were separated and the organic phase was extracted with DCM (2x 10 mL). Evaporation to 
dryness afforded the free acid, which was directly used in the following coupling. 
To obtain the free amine (6S,9S,14S,E)-methyl-6-isobutyl-2,2,9,14-tetramethyl-4,7,12-trioxo-
3-oxa-5,8,13-triazapentadec-10-en-15-oate (41, 78 mg, 0.25 mmol, 1.5 eq.) was dissolved in 
DCM (3 mL) and trifluoroacetic acid (3 mL) was added. The reaction mixture was stirred for 
2 h at RT. The solvent was evaporated and the resulting oil was co-evaporated twice with 
toluene to remove residual trifluoroacetic acid. 
For the peptide coupling the free acid and the free amine were dissolved separately in 
acetonitrile (5 mL) and cooled in an ice bath. The amine solution was added to the solution 
containing the acid; then HOBt (24 mg, 0.18 mmol, 1.1 eq.), HBTU (68 mg, 0.18 mmol, 1.1 
eq.) and DIEA (93 μL, 0.56 mmol, 3.2 eq.) were added successively. After the addition of the 
reagents the reaction was allowed to warm to RT and stirred overnight. 
The solvent was removed and the residue was taken up in ethyl acetate (50 mL). The organic 
phase was washed with 0.5 M aq. KHSO4 solution (2x 10 mL), saturated aq. NaHCO3 solution 
(2x 10 mL) and brine (2x 10 mL) and dried over Na2SO4. After evaporation of the solvent the 
crude product (49 mg) was purified by preparative HPLC (0 min / 10% B → 3 min / 10% B → 
32 min / 50% B → 33 min / 100% B → 43 min / 100% B) to afford symplostatin 4 lacking the 
mmp unit (Sym4mmp→Ala).  
 
Yield: 37.5 mg (65.9 μmol, 39 %) as a white powder.  
1H NMR (600 MHz, CD3CN): δ 7.51 (d, J = 7.6 Hz, 1H), 7.04 (d, J = 6.0 Hz, 1H), 6.79 (d, J = 7.9 
Hz, 1H) 6.65 (dd, J = 15.5, 4.9 Hz, 1H), 5.98 (dd, J = 15.5, 1.6 Hz), 5.09-5.07 (m, 1H), 4.54-4.48 
(m, 1H), 4.43-4.38 (m, 1H), 4.33-4.28(m, 1H), 3.89-3.87 (m, 1H), 3.66 (s, 3H), 2.91 (s, 6H), 
2.18-2.14 (m, 1H), 1.81-1.73 (m, 2H), 1.67-1.54 (m, 5H), 1.42-1.37 (m, 1H), 1.35 (d, J = 7.3 Hz, 
3H), 1.21 (d, J = 7.0 Hz, 3H), 0.98-0.97 (m, 3H), 0.96-0.91 (m, 12H), 0.89 (d, J = 6.4 Hz, 3H). 
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13C NMR (151 MHz, CD3CN): δ 174.34, 172.16, 170.39, 167.03, 166.15, 145.75, 123.22, 76.09, 
72.60, 53.09, 52.84, 49.25, 46.78, 41.75, 41.41, 41.19, 34.43, 27.39, 25.57, 25.31, 23.45, 
23.31, 21.86, 20.19, 17.76, 14.48, 11.89.  
LC-MS: tR = 6.68 min (C18)  m/z = 591 (M+ +Na+, 50 %), 569 (M+ +H+, 100). 
HRMS (ESI): m/z calcd for C29H53N4O7+ 569.3909, found 569.3894. 
 
6.5.3 Synthesis of tagged symplostatin 4 derivatives 
 
Synthesis of an alkyne-tagged symplostatin 4 derivative (≡Sym4)  
 
(2S,3S)-(S)-1-Methoxy-4-methyl-1-oxopentan-2-yl-3-methyl-2-(methyl(prop-2-yn-1-
yl)amino)pentanoate (44, 86 mg, 0.28 mmol) was dissolved in a mixture of THF (1.6 mL) and 
MeOH (1 mL) and lithium hydroxide (13 mg, 0.55 mmol, 2.0 eq.) in water (0.65 mL) was 
added. The resulting reaction mixture was stirred for 5 h at RT. After this time the reaction 
mixture was acidified by addition of 1 M HCl to pH 4 and diluted by the addition of DCM (10 
mL) and brine (10 mL). The phases were allowed to separate and the organic phase was 
extracted with DCM (2x 10 mL). Evaporation to dryness afforded the free acid, which was 
directly used for the following coupling. 
To obtain the free amine tert-butyl((S)-1-(((S,E)-5-((S)-3-methoxy-2-methyl-5-oxo-2,5-
dihydro-1H-pyrrol-1-yl)-5-oxopent-3-en-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate 
(40, 109 mg, 0.25 mmol, 0.9 eq.) was dissolved in DCM (5 mL) and trifluoroacetic acid (5 mL) 
was added. The resulting reaction mixture was stirred for 2 h at RT. The solvent was 
removed and the remaining oil was co-evaporated twice with toluene to remove residual 
trifluoroacetic acid. 
For the peptide coupling the free acid and the free amine were dissolved separately in 
acetonitrile (5 mL) and cooled in an ice bath. The solution containing the amine was added 
to the acid solution and then HOBt (35 mg, 0.26 mmol, 0.9 eq.), HBTU (99 mg, 0.26 mmol, 
0.9 eq.) and DIEA (136 μL, 0.83 mmol, 3.0 eq.) were added successively. The reaction was 
allowed to warm to RT and stirred overnight. 
The solvent was evaporated and the residue was taken up in ethyl acetate (50 mL). The 
organic phase was washed with 0.5 M aq. KHSO4 solution (2x 10 mL), saturated aq. NaHCO3 
solution (2x 10 mL) and brine (2x 10 mL) and dried over Na2SO4. After evaporation to dryness 
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the crude product was purified by flash column chromatography (50 % ethyl acetate in 
cyclohexane) yielding the symplostatin 4 click derivative (≡Sym4). 
For a further purification, 55 mg of the pre-purified ≡Sym4 (127 mg in total, 82 %) was 
purified by preparative HPLC (0 min / 10% B → 3 min / 10% B → 13 min / 45% B → 48 min / 
85% B → 55 min / 100% B → 63 min / 100% B) to afford symplostatin 4 click derivative 
(≡Sym4).  
 
Yield: 36.2 mg (58.7 μmol, 23 %, 64 % in total) as a white powder. 
TLC (50% ethyl acetate in cyclohexane): Rf = 0.34. 
1H NMR (600 MHz, CD3CN): δ 7.34-7.29 (m, 1H), 7.11 (d, J = 7.0 Hz, 1H), 6.91-6.86 (m, 1H), 
6.81 (d, J = 8.2 Hz, 1H), 5.09 (s, 1H), 5.05-5.03 (m, 1H), 4.59-4.56 (m, 2H), 4.38-4.32 (m, 1H), 
3.86 (s, 3H), 3.81 (s, 2H), 3.62-3.59 (m, 1H), 2.77 (s, 1H), 2.69 (s, 1H), 2.05-1.99 (m, 1H), 1.79-
1.74 (m, 2H), 1.70-1.65 (m, 1H), 1.63-1.55 (m, 4H),1.42 (d, J = 6.6 Hz, 3H), 1.32-1.27 (m, 1H), 
1.24 (d, J = 7.0 Hz, 3H), 0.95-0.88 (m, 18H). 
13C NMR (151 MHz, CD3CN): δ 182.24, 172.23, 170.95, 170.64, 168.86, 164.91, 149.47, 
123.06, 93.78, 77.89, 74.85, 70.61, 60.03, 56.56, 52.82, 52.64, 47.08, 44.90, 42.08, 41.45, 
39.45, 34.32, 26.82, 25.56, 25.28, 23.52, 21.93, 21.88, 20.16, 20.05, 17.43, 15.32, 11.38.  
LC-MS: tR = 10.76 min, m/z = 639 (M+ +Na+, 100 %), 617 (M+ + H+, 30 %). 
HRMS (ESI): m/z calcd for C33H53N4O7+ 617.3909, found 617.3896. 
 
Synthesis of a alkyne-tagged Sym4mmp→Ala derivative (≡Sym4mmp→Ala)  
 
(2S,3S)-(S)-1-Methoxy-4-methyl-1-oxopentan-2-yl-3-methyl-2-(methyl(prop-2-yn-1-
yl)amino)pentanoate (44, 100 mg, 0.32 mmol) was dissolved in a mixture of THF (1.6 mL) and 
MeOH (1 mL) and lithium hydroxide (15 mg, 0.64 mmol, 2.0 eq.) in water (0.65 mL) was 
added. The reaction mixture was stirred for 5 h at RT and the reaction mixture was acidified 
by addition of 1 M HCl to pH 4. DCM (10 mL) and brine (10 mL) were added, the phases were 
separated and the organic phase was extracted with DCM (2x 10 mL). Evaporation to dryness 
afforded the free acid, which was used directly for the following coupling. 
To obtain the free amine (6S,9S,14S,E)-methyl-6-isobutyl-2,2,9,14-tetramethyl-4,7,12-trioxo-
3-oxa-5,8,13-triazapentadec-10-en-15-oate (41, 100 mg, 0.32 mmol, 1.0 eq.) was dissolved in 
DCM (3 mL) and trifluoroacetic acid (3 mL) was added. The resulting reaction mixture was 
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stirred for 2 h at RT. The solvent was evaporated and the resulting oil was co-evaporated 
twice with toluene to remove residual trifluoroacetic acid. 
For the peptide coupling the free acid and the free amine were dissolved separately in 
acetonitrile (5 mL) and cooled in an ice bath. The amine solution was added to the solution 
containing the acid; then HOBt (43 mg, 0.32 mmol, 1.0 eq.), HBTU (121 mg, 0.32 mmol, 1.0 
eq.) and DIEA (131 μL, 1.01 mmol, 3.2 eq.) were added successively. The reaction mixture 
was warmed to RT and then stirred for further 5 h. 
The solvent was removed and the residue was taken up in ethyl acetate (50 mL). The organic 
phase was washed with 0.5 M aq. KHSO4 solution (2x 10 mL), saturated aq. NaHCO3 solution 
(2x 10 mL) and brine (2x 10 mL) and dried over Na2SO4. The solvent was removed and the 
crude product was purified by flash column chromatography (50 % ethyl acetate in 
cyclohexane) yielding the Sym4mmp→Ala click derivative (≡Sym4mmp→Ala). 
For a further purification, 66 mg of the pre-purified ≡Sym4mmp→Ala (139 mg in total, 73 %) 
was purified by preparative HPLC (0 min / 10% B → 3 min / 10% B → 13 min / 45% B → 48 
min / 85% B → 55 min / 100% B → 63 min / 100% B) to afford the Sym4mmp→Ala click 
derivative (≡Sym4mmp→Ala).  
 
Yield: 35.2 mg (59.5 μmol, 19 %, 53 % in total) as a white powder. 
TLC (50% ethyl acetate in cyclohexane): Rf = 0.14. 
1H NMR (600 MHz, CD3CN): δ 7.15 (bs, 1H), 6.95 (bs, 1H), 6.76 (bs, 1H), 6.66-6.61 (m, 1H), 
5.96-5.91 (m, 1H), 5.03-5.01(m, 1H), 4.54-4.48 (m, 1H), 4.43-4.39 (m, 1H), 4.34-4.30 (m, 1H), 
3.76 (s, 2H), 3.66 (s, 3H), 3.56-3.54 (m, 1H), 2.74 (s, 1H), 2.65 (s, 3H), 2.01-1.99 (m, 1H), 1.79-
1.74 (m, 2H), 1.69-1.65 (m, 1H), 1.64-1.58 (m, 2H), 1.57-1.53 (m, 2H), 1.35 (d, J = 7.3 Hz, 3H), 
1.30-1.25 (m,, 1H), 1.22-1.20 (m, 3H), 0.94-0.91 (m, 15H), 0.89 (d, J = 6.5 Hz, 3H). 
13C NMR (151 MHz, CD3CN): δ 173.33, 171.21, 169.94, 168.41, 165.01, 144.71, 144.63, 
122.23, 80.56, 76.43, 73.74, 69.64, 57.89, 51.85, 48.21, 45.79, 43.85, 40.84, 40.70, 40.41, 
40.39, 38.41, 33.33, 25.73, 24.57, 24.31, 22.55, 22.43, 20.93, 19.21, 16.87, 16.80, 14.46, 
10.31.  
LC-MS: tR = 9.87 min, m/z = 615 (M+ +Na+, 100 %), 593 (M+ +H+, 50). 
HRMS (ESI): m/z calcd for C31H53N4O7+ 593.3909, found 593.3895. 
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Synthesis of a rhodamine-labeled symplostatin 4 derivative (Rh-Sym4) 
 
≡Sym4 (1.14 mg, 1.85 μmol) and rhodamine azide (1 mg, 1.85 μmol, 1.0 eq.) were dissolved 
in water (400 μL) and tris(2-carboxyethyl)phosphine (TCEP, 100 mM aq. solution, 4.6 μL, 0.46 
μmol, 0.25 eq.), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 100 mM solution in 
DMSO, 9.3 μL, 0.93 μmol, 0.5 eq.) and CuSO4 (5 mM aq. solution, 92 μL, 0.46 μmol, 0.25 eq.) 
were added subsequently. The resulting reaction solution was stirred at RT overnight under 
exclusion of light. 
The solvent was removed in a nitrogen stream and the crude product was purified by 
column chromatography (AluOx, 12.5 % MeOH in chloroform). This work-up yielded impure 
Rh-Sym4, and was purified further by a second chromatographic purification (AluOx, 12.5 % 
MeOH in chloroform) to yield pure Rh-Sym4.  
 
Yield: 0.5 mg (0.43 μmol, 23 %) as a pink solid. 
LC-MS: tR = 8.55 min, m/z = 1157 (M+ +H+, 100 %), 1179 (M+ +Na+, 80). 
HRMS (ESI): m/z calcd for C63H85N10O11+ 1157.6394, found 1157.6411. 
 
Synthesis of a rhodamine-labeled symplostatin 4 derivative lacking the mmp unit (Rh-
Sym4mmp→Ala) 
 
≡Sym4mmp→Ala (1.30 mg, 1.85 μmol) and rhodamine azide (1 mg, 1.85 μmol, 1.0 eq.) were 
dissolved in water (400 μL) and tris(2-carboxyethyl)phosphine (TCEP, 100 mM aq. solution, 
4.6 μL, 0.46 μmol, 0.25 eq.), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 100 mM 
solution in DMSO, 9.3 μL, 0.93 μmol, 0.5 eq.) and CuSO4 (5 mM aq. solution, 92 μL, 0.46 
μmol, 0.25 eq.) were added subsequently. The reaction solution was stirred at RT overnight 
under exclusion of light. 
The solvent was removed in a nitrogen stream and the crude product was purified by 
column chromatography (AluOx, 12.5 % MeOH in chloroform to yield pure Rh-Sym4mmp→Ala.  
 
Yield: 1.4 mg (1.24 μmol, 67 %) as a pink solid. 
LC-MS: tR = 8.55 min, m/z = 1133 (M+ +H+, 30 %), 1155 (M+ +Na+, 75). 
HRMS (ESI): m/z calcd for C61H85N10O11+ 1133.6394, found 1157.6404. 
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Synthesis of a trifunctional symplostatin 4 derivative (Tri-Sym4) 
 
≡Sym4 (1.4 mg, 1.95 μmol, 1.05 eq.) and “Tri-azide” (2 mg, 1.85 μmol, 1.0 eq.) were 
dissolved in water (400 μL), then tris(2-carboxyethyl)phosphine (TCEP, 100 mM aq. solution, 
4.6 μL, 0.46 μmol, 0.25 eq.), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 100 mM 
solution in DMSO, 9.3 μL, 0.93 μmol, 0.5 eq.) and CuSO4 (5 mM aq. solution, 92 μL, 0.46 
μmol, 0.25 eq.) were added successively. The reaction solution was stirred at RT overnight 
under exclusion of light. A LC-MS control performed after this time indicated that only a 
small amount of product had formed; consequently, the same amounts of the click reagents 
(TCEP, TBTA and CuSO4) were added again to the solution which was then stirred for further 
24 h. Although product had formed, a large quantity of starting material was still present. 
Thus, another 100 μL of a 1 M CuSO4 solution and 10 μL of the TCEP solution were added and 
the reaction was stirred for another 24 h. After this time, the LC-MS control indicated a 
complete reaction. 
The solvent was removed in a nitrogen stream and the crude product was purified by 
column chromatography (C18 silica gel, gradient starting from 30 % acetonitrile in H2O) to 
yield pure Tri-Sym4.  
 
Yield: 0.92 mg (0.54 μmol, 29 %) as a pink solid. 
LC-MS: tR = 8.21 min, m/z calcd for C89H128N15O16S+ 1696.12, found 848.87 (100%, M2+). 
 
Synthesis of a trifunctional symplostatin 4 derivative lacking the mmp unit (Tri-
Sym4mmp→Ala) 
 
≡Sym4mmp→Ala (1.4 mg, 1.95 μmol, 1.05 eq.) and “Tri-azide” (2 mg, 1.85 μmol, 1.0 eq.) were 
dissolved in water (400 μL), then tris(2-carboxyethyl)phosphine (TCEP, 100 mM aq. solution, 
4.6 μL, 0.46 μmol, 0.25 eq.), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 100 mM 
solution in DMSO, 9.3 μL, 0.93 μmol, 0.5 eq.) and CuSO4 (5 mM aq. solution, 92 μL, 0.46 
μmol, 0.25 eq.) were added successively. The reaction solution was stirred at RT overnight 
under exclusion of light. A LC-MS control performed after this time indicated that only a 
small amount of product had formed; consequently, the same amounts of the click reagents 
(TCEP, TBTA and CuSO4) were added again to the solution and the resulting mixture was 
stirred for further 24 h. Although the desired product was formed, a large quantity of 
starting material was still present. To overcome this, 100 μL of a 1 M CuSO4 solution and 
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10 μL of the TCEP solution were added again and the reaction was stirred for another 24 h. 
After this time, the LC-MS control indicated a complete reaction. 
The solvent was removed in a nitrogen stream and the crude product was purified by 
column chromatography (C18 silica gel, gradient starting from 30 % acetonitrile in H2O) to 
yield pure Tri- Sym4mmp→Ala.  
 
Yield: 1.41 mg (0.84 μmol, 45 %) as a pink solid. 
LC-MS: tR = 8.43 min, m/z calcd for C86H178N16O16S+ 1673.09, found 837.07 (100%, M2+). 
 
Synthesis of a biotinylated symplostatin 4 derivative (biotin-Sym4) 
 
≡Sym4 (2.2 mg, 2.96 μmol, 1.05 eq.) and biotin azide (1 mg, 2.82 μmol, 1.0 eq.) were 
dissolved in water (500 μL), then tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 
100 mM solution in DMSO, 14.1 μL, 1.41 μmol, 0.5 eq.), tris(2-carboxyethyl)phosphine (TCEP, 
100 mM aq. solution, 7.1 μL, 0.71 μmol, 0.25 eq.), and CuSO4 (1 M solution, 141 μL, 141 μmol, 
50 eq.) were added successively. The resulting reaction solution was stirred at RT for 3 d. A 
LC-MS control performed after this time indicated a complete reaction. 
The solvent was removed in a nitrogen stream and the crude product was purified by 
column chromatography (C18 silica gel, gradient starting from 30 % acetonitrile in H2O) to 
afford pure biotin-Sym4.  
 
Yield: 0.67 mg (0.69 μmol, 24 %) as a white solid. 
LC-MS: tR = 9.21 min, m/z calcd for C48H79N10O9S+ 971.57, found 971.53 (100%). 
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Synthesis of a biotinylated symplostatin 4 derivative lacking the mmp unit (biotin-
Sym4mmp→Ala) 
 
≡Sym4mmp→Ala (2.1 mg, 2.96 μmol, 1.05 eq.) and biotin azide (1 mg, 2.82 μmol, 1.0 eq.) were 
dissolved in water (500 μL), then tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 
100 mM solution in DMSO, 14.1 μL, 1.41 μmol, 0.5 eq.), tris(2-carboxyethyl)phosphine (TCEP, 
100 mM aq. solution, 7.1 μL, 0.71 μmol, 0.25 eq.), and CuSO4 (1 M solution, 141 μL, 141 μmol, 
50 eq.) were added successively. The resulting reaction solution was stirred at RT for 3 d. A 
LC-MS control performed after this time indicated a complete reaction. 
The solvent was removed in a nitrogen stream and the crude product was purified by 
column chromatography (C18 silica gel, gradient starting from 30 % acetonitrile in H2O) to 
afford pure biotin-Sym4.  
 
Yield: 1.22 mg (1.29 μmol, 46 %) as a white solid. 
LC-MS: tR = 8.93 min, m/z calcd for C46H49N10O9S+ 947.57, found 947.24 (100%). 
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6.6 Activity-based protein profiling experiments 
6.6.1 General methods 
 
Plant material 
 
Arabidopsis thaliana ecotype Columbia plants were grown in a growth chamber at 24 °C 
(day)/20 °C (night) under a 12-h light regime. For the manufacturing of leaf extracts 4 to 6 
week old rosette leaves were chosen.[156] 
 
Protein extraction from A. thaliana leaves 
 
Two rosette leaves were transferred into a 1.5 mL Eppendorf tube and 100 μL of water were 
added. The leaves were grinded and the grinder was rinsed with water (900 μL in total). The 
extract was then cleared by centrifugation (1 min at 16000 g).[156] 
 
Labeling of A. thaliana leaf extracts 
 
The labeling was carried out with 100 μL of leaf extract. 8 μL of buffer (50 mM sodium 
acetate for pH<6.5 and 50 mM 2-amino-2-(hydroxymethyl)-1,3-propandiol for pH>6.5) and 2 
μL of 100 mM DTT (2 mM final concentration) were added. This solution was then incubated 
with 4.5 μL of the respective probe solution (100 mM stock in DMSO for 5 μM final 
concentration, 200 mM stock in DMSO for 10 μM final concentration) for 3 h under the 
exclusion of light with gentle agitation. 
The labeling was stopped by the addition of 4X SDS-PAGE loading buffer (20 μL) and heating 
of the sample to 95 °C for 5 min. The proteins were separated by SDS-PAGE and visualized 
using a Typhoon scanner in case of the fluorescent probes. For the Western blotting of the 
biotinylated probes, the proteins were transferred onto polyvinylidene fluoride membranes 
after SDS-PAGE separation and detected using streptavidin-horseradish-peroxidase (HRP).  
For competitive ABPP experiments, the protein extract was pre-incubated with competitor 
(11 μM) for 30 min, then the probe (5 μM) was added and the labeling was carried out as 
described. 
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In vivo labeling of A. thaliana cell culture 
 
The cell cultures (A. thaliana,ecotype Landsberg[157]) were weekly subcultured in medium 
(3% w/v sucrose, 0.5 mg/L naphthalene acetic acid, 0.05 mg/L 6-benzylaminopurine (BAP)) 
and 4.4 g MS Gamborg B5 vitamins (Duchefa, http://www.duchefa.com), pH 5.7. Before the 
labeling experiment, the medium of a 7-day old cell culture was replaced by fresh 
medium.[149] 
Labeling experiments were carried out using 300 μL of cell culture solution for each 
experiment; the solution was transferred to a 24-well microtiter plate. To this solution was 
added DTT (6 μL, 2 mM final concentration). In case of a competitive experiment, the cell 
culture was pre-incubated with competitor (15 μL, 25 μM final concentration) for 30 min, 
then the probe (13.5 μL, 5 μM final concentration (100 μM stock) or 13.5 µL, 10 μM final 
concentration (200 μM stock)) was added and the labeling was carried out for 1 h under the 
exclusion of light with gentle agitation. After the labeling, the cells were washed 3 - 5 times 
with medium that was carefully removed after each washing step, avoiding to remove cells 
as well. After the final washing step, 150 μL cell-containing solution were removed and 
transferred to a 1.5 mL Eppendorf tube where the cells were grinded. The solution was 
cleared by centrifugation (5 min at 16000 g), then 100 μL of the supernatant were 
transferred to a fresh Eppendorf tube and the reaction was stopped by addition of 20 μL 4X 
SDS-PAGE loading buffer and heating the sample to 95 °C for 5 min. The proteins were 
separated by SDS-PAGE and visualized using a Typhoon scanner in case of the fluorescent 
probes. For the Western blotting of the biotinylated probes, the proteins were transferred 
onto polyvinylidene fluoride membrane after SDS-PAGE separation and detected using 
streptavidin-horseradish-peroxidase (HRP).  
 
6.6.2 Infiltration experiments 
 
Infiltration of A. thaliana leaves via their petioles 
 
The infiltration experiments were carried out in 24-well microtiter plates. Each well was 
filled with 500 μL of probe solution (2 μM/water), then three leaves with intact petioles were 
carefully inserted into the well with the leaves leaning against the walls of the well. The 
incubation was carried out at ambient temperature for 1 h; subsequently, the leaves were 
removed from the well. The petioles were detached and the leaves were transferred into an 
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Eppendorf tube containing a metal bead, then 300 μL of water were added and the leaves 
were grinded. After addition of 200 μL of water the extract was cleared by centrifugation 
(5 min at 16000 g) and 100 μL of supernatant were transferred to a fresh Eppendorf tube. 
The reaction was stopped by addition of 20 μL of 4X SDS-PAGE loading buffer and heating to 
95 °C for 5 min. 
The proteins were separated by SDS-PAGE and visualized using a Typhoon scanner in case of 
the fluorescent probes. For the Western blotting of the biotinylated probes, the proteins 
were transferred onto polyvinylidene fluoride membrane after SDS-PAGE separation and 
detected using streptavidin-horseradish-peroxidase (HRP).  
 
Infiltration of A. thaliana leaves via their stomata 
 
The infiltration of A. thaliana leaves via the stomata on the reverse side of the leaf was 
carried out while the leaves were still attached to the plant. To achieve the infiltration, the 
probe solution (2 μM/water, 500 μL per sample) was carefully applied by pressing a syringe 
(without a cannula) to the reverse side of a detached leaf and pressing down the plunger; a 
successful infiltration is visualized by the slight darkening of the leaves resulting from the 
uptake of the liquid into the vascular system. After the infiltration the infiltrated leaf was 
detached and incubated on a damp blotting paper in a petri dish. Each experiment was 
carried out with three leaves that were combined in the latter extraction. The infiltrated 
leaves were incubated for 2 h under the exclusion of light.  
After this time, the leaves were transferred into an Eppendorf tube containing a metal bead, 
then 300 μL of water were added and the leaves were grinded. After addition of 200 μL of 
water, the extract was cleared by centrifugation (5 min at 16000 g) and 100 μL of 
supernatant were transferred to a fresh Eppendorf tube, the reaction was stopped by 
addition of 20 μL of 4X SDS-PAGE loading buffer and heating to 95 °C for 5 min. 
The proteins were separated by SDS-PAGE and visualized using a Typhoon scanner in case of 
the fluorescent probes. For the Western blotting of the biotinylated probes, the proteins 
were transferred onto polyvinylidene fluoride membrane after SDS-PAGE separation and 
detected using streptavidin-horseradish-peroxidase (HRP). 
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8 Appendix 
 
Abbreviations 
 
The amino acids were abbreviated according to the 1-letter or 3-letter code recommended by the 
IUPAC-IUB joint commission on biochemical nomenclature (compare: Pure Appl. Chem. 1984, 56, 
595-624.) 
A. thaliana Arabidopsis thaliana 
aa  amino acid(s) 
ABP  activity-based probe 
ABPP  activity-based protein profiling 
Ac   acyl- 
Acm  acetamidomethyl- 
AcOH  acetic acid 
ACT  artemisinin combination therapy 
Ahp  3-amino-6-hydroxy-2-piperidone 
AIDS  acquired immunodeficiency syndrome 
Alloc  allyloxycarbonyl- 
aq.  aqueous 
ASPP  active site peptide profiling 
b  broad signal (NMR) 
BBI  Bowman-Birk inhibitor 
Bn  benzyl- 
Boc  tert-butoxycarbonyl- 
Bz/Bzl  benzyl- 
Cbz  benzyloxylcarbonyl- 
CID  collision-induced dissociation 
Cit  citrulline 
d   doublet 
Da  Dalton 
DABCO  1,4-Diazobicyclo[2.2.2]octane 
DCC  N,N’-Dicyclohexyl carbodiimide 
DCM  dichloromethane 
dd  doublet of doublets 
Ddm  4,4-dimethoxydiphenylmethyl- 
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DEAD   Diethyl azodicarboxylate 
DHA  dihydroartemisinin 
DHFR  dihydrofolate reductase 
DHPS  dihydropteroate synthetase 
DIAD  diiso-propyl azodicarboxylate 
DIBAL-H diiso-butyl aluminum hydride 
DIC/DIPCDI N,N’-Diisopropyl carbodiimide  
DIEA  N,N’-Diisopropylethylamine 
DMAP  4-Dimethylamino pyridine 
DMF  dimethyl formamide 
DMPU  1,3-Dimethyltetrahydropyrimidin-2(1H)-one 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DPPA  Diphenylphosphorylazide 
dr  diastereomeric ratio 
dt  doublet of triplets 
EDC  1-Ethyl-3-(3’-dimethylaminopropyl)carbodiimide 
eq.  equivalent(s) 
ESI  electrospray ionization 
Et  ethyl- 
EtOAc  ethyl acetate 
EtOH  ethanol 
FDPP  Pentafluorophenyl diphenylphosphinate 
Fmoc  9-fluorenylmethoxy carbonyl- 
FP-1/-2/-3 falcipain-1/-2/-3 
h  hour(s) 
HATU  2-(1H-Azabenzotriazole-1-yl)1,1,3,3-tetramethylaminium hexafluorophosphate 
HBTU  2-(1H-Benzotriazole-1-yl)1,1,3,3-tetramethylaminium hexafluorophosphate 
HIV   human immunodeficiency virus  
HOAt  1-Hydroxy-7-azabenzotriazole 
HOBt  N-Hydroxybenzotriazole 
HOSu  N-Hydroxysuccinimide 
HPLC  high pressure liquid chromatography 
HRMS  high resolution mass spectrometry 
HRP  horseradish peroxidase 
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Hse  homoserine 
Hz  Hertz 
iBu  iso-butyl- 
ICAT  isotope-coded affinity tags 
iPr  iso-propyl- 
IRS  indoor residual spraying 
ITN  insecticide-treated net 
J  coupling constant 
k  kilo- 
KHMDS  Potassium bis(trimethylsilyl)amide  
Ki  dissociation constant 
ki  rate of inactivation 
KO  knock-out 
LC-MS  liquid chromatography mass spectrometry 
LHMDS  Lithium bis(trimethylsilyl)amide 
m  multiplet 
M  molar 
MALDI  matrix-assisted laser desorption ionization 
Me  methyl- 
MeOH  methanol 
MHz  Megahertz 
min  minute(s) 
mL  milliliter(s) 
mRNA  messenger ribonucleic acid 
Ms  mesyl- 
MS  mass spectrometry 
Mu  morpholine urea 
MudPIT multidimensional protein identification technology 
N  normal 
NaHMDS Sodium bis(trimethylsilyl)amide 
nm  nanometer 
NMP  N-Methylpyrrolidone 
NMR  nuclear magnetic resonance 
N-Pipu  N-Methylpiperazyl urea 
o/n  overnight 
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P. falciparum Plasmodium falciparum 
PCR  polymerase chain reaction 
PEG   polyethylene glycol 
Pet  2-(pyridyl)ethyl- 
Piv  pivaloyl- 
PLCP  papain-like cysteine protease 
pNZ  para-nitrobenzyloxycarbonyl- 
ppm  parts per million 
Py  pyrrole- 
PyBOP  Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate 
PyBrOP  Bromo-tris-pyrrolidino-phosphonium hexafluorophosphate 
quant.  quantitative 
RBC  red blood cell  
RCM  ring closing metathesis 
rt/RT  room temperature 
s  singlet 
SAR  structure-activity relationship 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel eletrophoresis 
Sharpless AA Sharpless asymmetric aminohydroxylation 
Sharpless AD Sharpless asymmetric dihydroxylation 
SP  sulfadoxine-pyrimethamine 
sp.  species 
spp.  species pluralis 
SPPS  solid-phase peptide synthesis 
t  triplet 
TBS/TBDMS tert-butyl dimethylsilyl- 
TBTA  Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
tBu  tert-butyl 
tBuOH  tert-butanol 
TCEP  Tris(2-chloroethyl)phosphate 
TEA  triethylamine  
Tf  triflyl- 
Tfa  trifluoroacetyl- 
TFA  Trifluoroacetic acid 
TFE  Trifluoro ethanol 
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THF  tetrahydrofuran  
TIS  Triisopropyl silane 
TLC  thin layer chromatography 
TLR9  toll-like receptor 9 
TMSE  trimethylsilyl ethyl- 
TNF-α  tumor necrosis factor α 
TOF  time of flight 
Trt  trityl-, triphenylmethyl- 
Ts  tosyl- 
UNDP  United Nations Development Program 
UNICEF  United Nations (International) Children’s (Emergency) Fund 
UV   ultraviolet 
WHO  World Health Organizaztion 
WT  wild-type 
Z  benzyloxylcarbonyl-    
°C  degrees Celsius  
2DE  2-dimensional gel electrophoresis 
δ  chemical shift 
ε  extinction coefficient 
μ  micro- 
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Hiermit erkläre ich an Eides statt, dass ich die vorliegende Dissertation selbständig verfasst 
habe und alle dafür verwendeten Quellen und Hilfen kenntlich gemacht habe. Darüber 
hinaus wurden keine weiteren Quellen oder Hilfsmittel verwendet. 
 
 
Zudem erkläre ich, dass diese Dissertation weder in der gegenwärtigen noch in einer 
anderen Form an der Technischen Universität Dortmund oder an einer anderen Hochschule 
im Zusammenhang mit einer staatlichen oder akademischen Prüfung bereits vorgelegt 
worden ist.  
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Summary 
 
The objective of this dissertation was the synthesis and biological evaluation of natural product 
protease inhibitors as well as derivatives thereof. 
For the natural product class of 3-amino-6-hydroxy-2-piperidone(Ahp) cyclodepsipeptides that are 
known as non-covalent inhibitors of serine proteases, a solid-phase synthesis could be developed. 
The established solid-phase strategy thereby enables the synthesis of tailor-made Ahp 
cyclodepsipeptides. The synthesis is based on the use of a general Ahp precursor molecule, which 
was generated by a solution phase synthesis. It furthermore includes an esterification on solid phase, 
as well as a solid-phase macrolactamization and features a novel protocol for the generation of an 
aldehyde upon cleavage from the solid support. As a proof-of-principle for the synthesis strategy, the 
chymotrypsin inhibitor symplocamide A was synthesized successfully and was then analyzed 
regarding its biological activity. 
Next, simplified analogs of Ahp cyclodepsipeptides in which the Ahp residue was mimicked by other 
amino acids were synthesized, using symplocamide A as the lead structure. These studies aimed to 
investigate if a mimicry of the Ahp unit under retention of the canonical conformation is possible. 
The canonical conformation was first discovered and studied for proteinaceous serine protease 
inhibitors. Only recently, peptidic analogs of these inhibitors were examined for the adoption of the 
canonical inhibition. In this context, the Ahp cyclodepsipeptides were also suggested to mediate 
inhibition by the adoption of a canonical conformation. 
In this dissertation, it could firstly be demonstrated that the Ahp unit can be replaced by 
commercially available amino acid under retention of the biological activity. Furthermore, the critical 
determinants for the adoption of the canonical conformation could be defined and an insight into 
the molecular basis of an efficient inhibition was gained. 
 
In an alternative project, a convergent solution synthesis for the natural product symplostatin 4 was 
developed, enabling a flexible access to modified derivatives. Especially the synthesis of probes for 
the examination of symplostatin 4 by activity-based protein profiling was possible in a simplified 
manner by a 1,3-dipolar Huisgen cycloaddition of propargyl-modified derivatives with azide-modified 
reporter molecules.  
By the use of the chemical biology methodology of activity-based protein profiling, the direct targets 
of symplostatin 4 in the model plant Arabidopsis thaliana were identified, being the cysteine 
proteases RD21A and RD21B. In addition, the direct target being responsible for the antimalarial 
activity of symplostatin 4 was investigated. Experiments with the malaria parasite Plasmodium 
falciparum then distinguished symplostatin 4 as a nanomolar inhibitor of the parasital cysteine 
proteases falcipain 2 and 3 that are responsible for the hemoglobin digestion and have been 
recognized as target enzymes for alternative malaria chemotherapy. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
